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ABSTRACT
Two groups of essential fatty acids (n-6 and n-3) are needed in a healthy human diet. 
Current advice suggests an optimal ratio of about 4:1 for these polyunsaturated fatty 
acids (PUFAs) in the diet but in Western countries it is usually 10-20:1. The n-3 
PUFAs are synthesized in photosynthetic organisms from where they move up the food 
chain. Fish in particular, are a rich source of twenty and twenty two carbon n-3 PUF As 
which are particularly effective for humans. Fish oils have been shown to be beneficial 
in a variety of chronic inflammatory diseases. However, fish stocks are under threat. 
Therefore, fish farming has increased recently and offers some opportunities for viable 
sources of n-3 PUFAs, especially since disposal of fish farm waste is expensive and 
environmentally problematic.
In this project, we investigated trout (Oncorhynchus mykiss) as a potential source of n-3 
PUFAs. The lipid composition of different tissues was analysed by combinations of 
TEC and GLC. This work identified the differences between various individual tissues 
and pin-pointed those with high eicosapentaenoic (EPA) and docosahexaenoic acid 
(DHA) content. Two possible industrial lipid extraction methods were compared with a 
standard laboratory procedure. These studies included a comparison of yields for offal 
which had been stored for various times. The rendering method, although not as 
efficient as the laboratory procedure (Garbus), was concluded to allow oil yield for 
nutraceutical development although tissues could not be stored for greater than two days 
without compromised quality. Finally, oil extracts from trout (containing 2.5% EPA 
and 10.5% DHA) were tested in a model system (bovine cartilage explants) as treatment 
for osteoarthritis. The trout oil preparation significantly reduced cytokine-induced 
glycosaminoglycan release indicating a protective action. However, it was not as 
effective as pure EPA or DHA. Moreover, the trout oil preparation was not able to 
reduce mRNA levels of inflammatory genes (e.g., COX-2, IL-6, ADAMTS-4, -5 and 
MMP-3) which were lowered by pure EPA or DHA supplementation. We conclude that 
trout waste is a viable source of n-3 PUFAs for nutraceutical development but that 
processing will probably be needed to produce a dietary supplement with potent anti­
inflammatory properties.
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CHAPTER 1 
General Introduction
1
1.1 ARTHRITIS
Arthritis is a generic term that refers to the destruction of cartilage in joints. 
Inflammation of the joints together with tenderness, swelling, stiffness, restriction of 
movement and warmth accompany arthritic diseases. There are over 200 diseases 
which may lead to arthritis, including gout, synovitis, rheumatoid and osteoarthritis.
1.1.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is chronic, multi-system, inflammatory condition affecting 
the peripheral synovial joints leading to inflammation and swelling coupled with 
destruction of articular cartilage. The specific trigger for the development of RA is 
still elusive but it is considered to have an autoimmune basis and, in some cases, a 
genetic component (Buch and Emery, 2002).
RA is classified by inflammation of the synovium and infiltration of the synovium 
with immune cells, namely activated T-lymphocytes, macrophages and B- 
lymphocytes (Reines, 2004). Continued proliferation of the synovium gives rise to a 
granulated membrane, the pannus, which covers the surface of articular cartilage 
(Rayman and Callaghan, 2006). Inflammatory cells invade the pannus which 
facilitates the invasion of articular cartilage by these cells, thus promoting articular 
cartilage destruction (Rowan, 2001). The T-lymphoctyes (which some consider to be 
the initiator cells of RA (Panayi, 1993b)) together with the macrophages, mast cells 
and B-lymphocytes (in addition to elevated levels of cytokines) erode and degrade the 
articular cartilage resulting in loss of mobility, swelling, deformity and pain (Panayi, 
1993b). Synovitis may reduce for short periods before re-appearing and it is believed 
that chronic destruction of the joint occurs during the inflammatory episodes (Panayi, 
1993a). Lesions which develop in the joint are permeated with macrophages and 
antibody-secreting B-lymphocytes which enter the synovium. These cells, together 
with synoviocytes, give rise to new blood vessels contributing to the development of 
the pannus. The erosion of cartilage is thought to be primarily due to altered 
chondrocyte metabolism coupled with cytokine-and prostanoid-mediated induction of 
destructive enzymes such as matrix metalloproteinases and aggrecanases (Calder and 
Zurier, 2001).
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1. 1.2 Osteoarthritis
Osteoarthritis (OA) is one of the most common conditions associated with aging 
populations across the Western world (section 1.1.3). Affecting millions of people, 
this complex disease stems from both biomechanical and biochemical aetiology and is 
a leading cause of morbidity and disability. Once difficult to define, this degenerative 
disease of aging populations is now defined as “a degenerative disease of joints 
resulting from wear of the articular cartilage. Both mechanical and biological events 
destabilize the normal coupling of degradation and synthesis of articular cartilage 
chondrocytes, extracellular matrix (ECM), and subchondral bone (Fig. 1.1). OA may 
be initiated by multiple factors, including genetics, development, metabolic and 
traumatic events. Ultimately, osteoarthritic diseases are manifested by morphologic, 
biochemical, molecular and biomechanical changes of both cells and matrix which 
lead to softening, fibrillation, ulceration, loss of articular cartilage, sclerosis and 
ebumation of subchondral bone, osteophytes and subchondral cysts. When clinically 
evident, osteoarthritic diseases are characterized by joint pain, tenderness, limitation 
of movement, crepitus, occasional effusion and variable degrees of inflammation 
without systemic effects*’ (Goldberg and Kuettner, 1994).
Fig. 1.1: Schematic representation of (a) normal joint, (b) mild osteoarthritic
joint and (c) severe osteoarthritic joint. Osteoarthritis (OA) of the joint 
results in cartilage depletion and progressive inflammation.
(a) Norm al (b) Mild OA (c) Severe OA
1.13 Prevalence of Osteoarthritis
Due to increases in life expectancies the burden of OA on medical and public health 
systems has increased exponentially. It is estimated that in England and Wales alone
1.3 -  1.75 million people are known sufferers o f OA whilst in France it is believed 
that approximately 6 million cases of OA are diagnosed annually (Reginster, 2002). 
In the USA. a report published in 1997 by the American Centre for Disease Control 
and Prevention estimated that 43.3 million persons were afflicted with arthritis and it 
supported predications that over the next decade 60 million people will be diagnosed 
including 11.6 million people whose activity will become severely limited due to 
arthritic disease (Centre for Disease Control and Prevention, 2001).
A recent review concluded that 21% of the US population had doctor-diagnosed 
arthritis which included an estimated 27 million people suffering chronic clinical OA 
(Helmick et al., 2007; Lawrence et al., 2007). The burden of this disease is not solely 
restricted to prevalence and quality of life. The costs associated with OA are 
increasing astronomically, placing extra pressure on government health and medical 
systems. The economic burden o f such a multi-factorial and far reaching disease 
takes both direct (hospitals, drugs, medical costs etc) and indirect (chronic and short­
term disability, mortality) expenses into consideration. It is believed that for countries 
including the USA, Canada, the UK, France and Australia costs incurred by 
musculoskeletal disorders, particularly OA, are 1 -  2.5% of the gross national product 
(March and Bachmeier, 1997). A study conducted in 2003 revealed that in the USA 
alone costs incurred by OA are estimated to range from $3.4 to $13.2 billion per year 
(Lubeck, 2003). In 1998, the combined costs of OA to the UK NHS Executive were 
estimated to be £569 million, although the overall cost in the UK was in excess of £1 
billion (Scott et al., 1998). Due to the disabling effects of OA and the economic 
burden caused by this disease there is huge interest in prevention and treatment of 
OA. Nutritional intervention, for example by glucosamine, hyaluronate and fish oil 
supplementation is one such area of research.
Before the pathogenesis and development of OA is discussed (section 1.3) a review of 
joint morphology and composition is given.
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1.2 JOINT MORPHOLOGY AND COMPOSITION
1.2.1 Articular Cartilage
Articular cartilage is a unique form of connective tissue found at the end of the 
diarthrodial bones (Fig. 1.2). It plays an important role in synovial joints due to its 
ability to absorb water and compress under pressure, therefore allowing friction-free 
movement and, hence, preventing wear and tear of the joint (Kuettner, 1992). The 
ECM of articular cartilage is composed of an intricate network of collagen fibers 
intersected with a high concentration of aggregating proteoglycans along with other 
minor matrix proteins (Hardingham and Bayliss, 1990). The collagen fibers are 
responsible for the high tensile strength whilst the high concentration of 
proteoglycans determine the compressive nature of articular cartilage (Buckwalter and 
Mankin. 1998).
Chondrocytes are the main cells found in articular cartilage. They are embedded in 
the ECM and are responsible for the maintenance and synthesis of the components of 
the ECM (Rowan, 2001). As a member of the connective tissue family, articular 
cartilage is unique in that it contains no nerve, blood or lymphatic supply and lacks 
the presence of separating basement membranes (Kuettner, 1992). Due to the absence 
of a blood supply, nutrients are delivered by diffusion via the synovial fluid 
(synthesised by fibroblasts) (Rowan, 2001).
Fig- 1-2: The metacarphangeal joint is outlined below. The cartilage found at
the end of long bones is termed articular cartilage and it functions to 
allow friction free movement and joint compressibility.
cartilageArticular
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1.2.1.1 Articular Cartilage Zones
Articular cartilage may appear homogenous but it is actually organised in terms of 
both structure and composition. The structural and cellular components of articular 
cartilage can be divided into four identifiable zones. These include the superficial 
(tangential) zone; middle (transitional) zone; radial (deep) zone and a region of 
calcified cartilage and these zones are classified depending on depth from the surface 
(Tsou et al., 2006) (Fig. 1.3). Each zone can be further divided into three regions, the 
pericellular, territorial and the inter-territorial region.
The pericellular region is the immediate area surrounding the chondrocyte membrane 
and is rich in proteoglycans and hyaluronic acid with a low collagen fiber content 
(Kuettner, 1992). The territorial region is an extension of the pericellular matrix. 
Here thin collagen fibers encapsulate chondrocytes or chondrons (groups of 
chondrocytes) in a basket-like fashion to provide protection for the cells. The inter- 
territorial region is furthest from the chondrocyte and the highest levels of 
proteoglycan and collagen fibrils are located here (Newman, 1998). As seen from the 
organisation o f the zones and compartments, the ECM of articular cartilage varies in 
terms o f collagen, proteoglycan and water concentrations and the chondrocytes vary 
with regard to shape and orientation.
1.2.1.2 The Superficial Zone
The superficial (tangential) zone is located at the surface and is bathed in synovial 
fluid. It is the thinnest of all four zones but provides the greatest tensile strength 
making it extremely important in combatting the compressive forces during joint 
loading (Poole et al., 2001). Collagen fibrils tend to run parallel to each other and the 
articular surface. The proteoglycan, aggrecan, concentration is lowest in this zone 
although other minor leucine-rich proteoglycans such as decorin and biglycan are 
found in abundance here (Newman, 1998). Chondrocytes found here are flat and 
ovoid in shape and tend to run parallel with collagen fibrils (Aigner and McKenna, 
2002). Chondrocytes found in the superficial zone synthesise a multi-functional 
domain proteoglycan protein known as the superficial zone protein (SZP) (Kuettner 
and Cole, 2005). The SZP is unique to chondrocytes of the superficial zone and is not
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secreted by chondrocytes found in deeper zones, though it is also produced by 
synovial cells and plays an important role in joint lubrication (Poole et al., 2001). It is 
also known to possess potential growth-promoting, cytoprotective and matrix-binding 
properties (Flannery et al.. 1999).
1.2.13 The Middle Zone
The largest compartment of articular cartilage is the middle (transitional) zone. It is 
also the area furthest away from the chondrocyte. The middle zone is much thicker 
than the superficial zone and it contains most of the proteoglycans and collagen 
fibrils. These are organised along lines which enable articular cartilage to perform its 
mechanical role (Newman, 1998).
1.2.1.4 The Radial Zone
Chondrocytes o f the radial (deep) zone are spherical in shape and are organised into
vertical columns. They are also the most metabolically-active chondrocytes found in 
articular cartilage, even more so than those found in the superficial zone (Temenoff 
and Mikos, 2000). The collagen fibers found here have the largest diameter and are 
organised into upright columns perpendicular to the cartilage surface. Proteoglycan 
content is high in the radial zone whereas water is at its lowest (Buckwalter et al., 
2005; Tsou et al., 2006). The radial zone is separated from the region o f calcified 
cartilage by a thin basophile line, the tidemark.
1.2.1.5 Region of Calcified Cartilage
A thin region of calcified cartilage separates the subchondral bone from the soft 
cartilage. Chondrocytes located here are much smaller than those found elsewhere in 
articular cartilage and possess little or no endoplasmic reticulum and Golgi apparatus 
(Temenoff and Mikos, 2000). Within some areas of this region, the chondrocytes 
appear to be fully surrounded by the calcified matrix and, hence, have very low 
metabolic activity (Buckwalter and Mankin, 1998).
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Fig- 1-3= Articular cartilage is divided in four distinct zones, the superficial 
(tangential) zone; middle (transitional) zone: radial (deep) zone and the 
region of calcified cartilage.
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1.2.2 Chondrocytes
Chondrocytes, the architects of articular cartilage, are derived from the mesenchymal 
stem cells found in the bone marrow. During development, these spheroidal-shaped 
cells produce and secrete components of the ECM, collagen fibrils, proteoglycans and 
non-collagenous proteins organising them into a highly ordered structure in order to 
expand and remodel the articular surface. However, in mature cartilage, they do not 
substantially change matrix volume but replace degraded matrix macromolecules, 
maintaining its integrity (Muir, 1995). Their metabolic activity differs in relation to 
their zonal location, with cells of the middle zone having a greater concentration of 
synthetic organelles and, hence, greater metabolic activity. Chondrocytes in the 
region of calcified cartilage possess few or no synthetic organelles and have a very 
low rate of metabolic activity (Buckwalter and Mankin, 1998). In addition to 
synthetic organelles, chondrocytes may possess lipid and glycogen stores and 
secretory vesicles. They may also possess cilia radiating from the cell surface. These 
cilia are thought to be involved in determining mechanical changes in the ECM 
(Buckwalter and Mankin, 1998; Temenoff and Mikos, 2000).
8
Chondrocytes lack cell to cell contact. Occasionally they exist as clusters of cells, 
chondrons. As articular cartilage is non-vascularised the cells obtain their nutrients 
via diffusion through the ECM from the synovial fluid. As a consequence of the 
avascular nature of cartilage, chondrocytes are able to withstand low oxygen 
concentrations and rely on anaerobic metabolism to fulfill their energy needs (Muir, 
1995). Chondrocytes are very much dependent on the ECM and, in turn, the 
components and integrity of the ECM are dependent on chondrocyte function. Hence, 
a symbiotic relationship exists where chondrocytes are responsible for matrix 
synthesis and turnover, whilst the matrix state directly affects chondrocyte function. 
These cells receive electrical, mechanical and physicochemical signals from the ECM 
and respond by adjusting their metabolic state to suit the matrix needs (Huber et al., 
2000).
1.23 The Extracellular Matrix
The ECM of articular cartilage is composed o f a tangled network of collagen fibers of 
varying length and diameter. Entrapped within these fibers exists the hydrated 
proteoglycan, aggrecan. The collagen fibrils are responsible for providing the tensile 
strength whereas the proteoglycans, mainly aggrecan, provide the compressibility for 
cartilage. The ECM is organised into three different zones depending on depth from 
surface, and also into specific regions defined by distance from chondrocytes or 
chondrons. All components of the ECM are produced by the chondrocytes (Dudhia, 
2005; Ottani et al., 2001). The various components of the ECM are discussed below.
1.23.1 Collagens of the Extracellular Matrix
Collagen, a fibrous protein which is a principal component of connective tissues is 
found in tendons, bones, teeth, cartilage, skin and blood vessels. It is the single most 
abundant protein found in mammals (~30% of total proteins) (Burgeson and Nimni, 
1992). The high tensile strength of collagen allows such activities as running, 
jumping or other activities that put severe stress on a joint. In higher vertebrates, 
there are at least 27 types of collagens which are the products of ~40 genes (Eyre, 
2004).
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Synthesis of collagen begins with a precursor molecule termed procollagen. These 
precursor molecules possess several N- and C- terminal peptides which are processed 
in the ECM by post-translational modification. The resulting molecule, collagen, is 
then integrated into the ECM (Burgeson and Nimni, 1992). Each collagen molecule 
is composed of three intertwined polypeptide chains which are about 100 amino acids 
in length. These intertwined chains give rise to a left-handed a-helix. Each collagen 
molecule is composed of the repeating amino acid sequence of glycine-X-Y, where X 
is frequently proline and Y, hydroxyproline. The amino acid 5-hydroxylysine is also 
present. This amino acid sequence is unique to the collagen three-dimensional 
structure and physical properities. Proline and hydroxyproline compose of -30%  of 
the residues o f collagen. It is interesting to note that both 4-hydroxyproline and 5- 
hydroxylysine are formed from proline by the action of two enzymes (propyl 
hydroxylase and lysyl hydroxylase) after collagen polypeptides have already been 
synthesised. These hydroxylation processes are known as post-translational 
modifications of collagen (Brodsky and Persikov, 2005; Engel and Prockop, 1991; 
Prockop and Kivirikko, 1995; van der Rest and Garrone, 1991).
The triple helix of collagen is not as traditional a structure as a-helices or P-pleated 
sheets. This structure is formed as a result of the unique amino acid sequence. 
Within the triple helix every third residue faces the centre of the structure. As 
mentioned, the glycine-X-Y sequence is unique to collagen and it is the glycine 
residues in contact with the centre of the helix that confers this structure as this is the 
only amino acid residue which will fit. Therefore, this amino acid sequence is 
conserved for physical and functional reasons. There are approximately 3.3 residues 
per turn o f each of these helices (Muir, 1995; Prockop and Kivirikko, 1995).
Another effect of the ‘stacking’ of the glycine residues along the centre of the 
collagen molecule is the generation of hydrogen bonding which contributes further to 
the molecule stability. The N-H of each glycine residue lies adjacent to each X 
(proline) residue and, hence, hydrogen bonds can form (Engel and Prockop, 1991; van 
der Rest and Garrone, 1991).
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There are several different forms o f collagen found within articular cartilage, collagen 
types II, IX, X, XI, and VI. However, it is collagen type II which is the predominant 
form.
l i J i  Collagen Type II
Type II collagen comprises approximately 90% o f adult articular cartilage. Type II is 
part o f the fibril-forming collagen family (i.e. a class I collagen molecule) (Kuettner, 
1992). This class o f molecules contains large triple helical domains with about 1000 
amino acids (Prockop and Kivirikko, 1995). Type II collagen is composed of three 
identical a l  polypeptide chains which compose a 300 nm long triple helix (Mendler et 
al.f 1989). It is synthesised as procollagen and before it is incorporated into the ECM 
to form fibrils and the non-collagenous extensions are removed (van der Rest and 
Garrone, 1991). As suggested by its family name (fibril-forming), type II is the main 
fibril-forming collagen found in articular cartilage. It integrates within the ECM and 
forms fibrils. Fibril thickness and density change in accordance with location within 
the ECM. For example, thicker fibrils are found in the deeper layers whereas finer 
fibrils are located close to the surface (Hall, 1983; Mayne, 1989). The tensile strength 
of articular cartilage is attributed to type II collagen which is also necessary for 
maintaining the volume and shape o f the tissue. Covalent intermolecular crosslinks 
formed between collagen fibrils also increase tensile strength (Kuettner, 1992).
U J J  Other Collagens of Articular Cartilage
The remaining 10% of collagen within articular cartilage is composed of several 
different types of genetically distinct collagens, types IX, X, XI and, to a much lesser 
extent, VI.
Type IX collagen is a class III collagen molecule, (fibril-associated collagens with 
interrupted triple helices (FACIT)). This collagen does not form fibrils itself but 
attaches to the surface o f pre-existing fibrils o f type II collagen. The short triple 
helical domains, interrupted by short noncollagenous domains, characterise type IX 
collagen (Vaughan et al., 1985). The globular regions are thought to attribute more 
flexibilty to the molecule. Since type IX collagen possesses both collagenous
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domains and covalently-bound GAGs it has been considered that it mediates contact 
between the collagens and proteoglycans (Bruckner et al., 1985; Muller-Glauser et 
al., 1986).
Type X collagen is a macrofibril-associated collagen synthesised by chondrocytes 
located in the region o f calcified cartilage (Schmid and Conrad, 1982). It is found in 
the pericellular region and belongs to a family o f network-forming collagens 
(Habuchi et al., 1985). Though as yet unclear, it is thought that collagen type X may 
play a role in structural support o f long bones through the process of calcification 
(Grant, 2007).
Type XI collagen, another minor constitutent o f articular collagens, is localised on or 
within macrofibrils formed by type II collagens. It belongs to the same family as type 
II collagen (fibril-forming family). Interactions between collagen type XI and 
proteoglycans have also been documented and it is thought that these interactions may 
influence proteoglycan distribution in cartilage (Mayne, 1989; Smith et al., 1985).
Type VI is a member o f the beaded-filament forming collagen. The three a chains 
contain short triple helices and the remainder o f the molecule is composed of large N- 
terminal and C-terminal globular domains (Jander et al., 1984). Type VI collagen 
forms microfibrils in the pericellular region and it is believed that it may play a role in 
chondrocyte attachment to the ECM (Engel et a l , 1985; Jander et al., 1984; Poole et 
aL, 1988).
1.2.4 Glvcosaminoglvcans
Glycosaminoglycans (GAGs) consist of linear chains o f repeating disaccharides units. 
Each disaccharide consists o f one hexosamine (D-galactosamine or D-glucosamine), 
which can be N-acetylated or N-sulphated, and one uronic acid (D-glucuronic acid, 
GlcA or L-iduronic acid, IdoA) or neutral hexose (D-galactose, Gal) (Vynios et al., 
2002). GAG chains possess either sulphate or carboxylate groups which confer a high 
negative charge to these molecules, a property which has great importance in the 
ECM, where GAG chains have a high affinity for water, thereby allowing articular 
cartilage the ability for reversible deformation (Dudhia, 2005; Kuettner, 1992).
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In the ECM o f articular cartilage, GAGs are covalently linked to proteoglycans, major 
macromolecules o f the ECM. Proteoglycans have important structural functions (as 
seen in the ECM) but can also be found on the cell surface where they have a variety 
o f roles varying from cell differentiation and tissue morphogenesis (perlecan, a 
basement membrane proteoglycan) to cell proliferation (heparan and heparan 
sulphate) and matrix organisation (aggrecan, decorin and biglycan) (Iozzo, 1998; 
Schwartz, 2000). The diversity of function is thought to be due to the multitude of 
GAG side chains (GAG type, size, composition and structural domain arrangement). 
There are five GAGs known to occur in articular cartilage, 1) hyaluronate, 2) 
chondroitin sulphate, 3) dermatan sulphate, 4) keratan sulphate; 5) heparin and 
heparan sulphate. All GAGs are sulphated to different degrees except for 
hyaluronate, which is not sulphated and is not found covalently linked to a core 
protein (Schwartz, 2000). Fig. 1.4 outlines the structures of the main GAGs found in 
articular cartilage.
ygr 1-4: Chemical structures o f the major glycosaminoglycans found in
articular cartilage.
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NHCOCH,
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1.2.4.1 Hyaluronate
Hyaluronate (HA) is distinct from all other GAGs in that it is not sulphated and is not 
attached to a core protein. However, structurally it is similar to other GAGs and 
consists o f repeating disaccharides o f N-acetylglucosamine and glucuronic acid 
(Kakehi et a l,  2003). Even though HA can be regarded as the simplest GAG, it can 
have molecular weights from 105 -  107 kDa. The highest concentrations of this large, 
negatively-charged molecule are found in the ECM of connective tissues. In the 
ECM, HA provides the backbone for the predominant aggregating proteoglycan, 
aggrecan, via binding o f a link protein (Laurent and Fraser, 1992). HA is synthesised 
by hyaluronan synthase in the plasma membrane. This is in contrast to all other 
GAGs which are synthesised by enzymes located in the Golgi apparatus (Vynios et 
a l , 2002). HA is not unique to connective tissues. It can also be found in most 
tissues and fluids. As well as interacting with aggregating proteoglycans, it possesses 
other functions as diverse as a role in tissue morphogenesis, angiogenesis and the 
cancer cell microenvironment.
1.2.4.2 Chondroitin Sulphate
Chondroitin sulphate (CS) is composed o f 30-50 repeating disaccharides o f N- 
acetylgalactosamine and glucuronic acids in a (5-1-3 linkage. It can be sulphated on 
either the 4 or 6 position giving rise to chondroitin-4-sulphate or chondroitin-6- 
sulphate (Hay, 1991). CS plays an important role within the ECM of articular 
cartilage. Due to its arrangement within the joint (i.e. attached to aggrecan) each 
negative molecule o f CS repels the other, creating space between each neighbouring 
CS molecule. This space is filled with water which absorbs shock when pressure is 
applied to the joint. When pressure is removed, the negative charge confers the 
ability for the joint to return to its original shape (Bali et a l, 2001).
1.2.43 Dermatan Sulphate
Dermatan sulphate (DS) is similiar to CS except it contains iduronic acid instead of 
glucuronic acid. The disaccharide is often sulphated in position 2 of iduronic acid and 
position 4 o f N-acetylgalactosamine. In contrast to CS and keratan sulphate, DS
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monomers are usually smaller and do not bind to HA to form large aggregates but 
self-associate to form relatively small but unstable aggregates (Laurent and Fraser, 
1992).
1.2.4.4 Keratan Sulphate
Keratan sulphate (KS) is a linear molecule composed of p-1-3 linked N- 
acetylgalactosamine disaccharide units. These units are sulphated to different degrees 
on the sixth carbon o f either glucosamine or galactose residues (Lindahl et al., 1996). 
Within the ECM, KS binds to aggrecan in a similiar fashion to CS. The combined 
effect o f both CS and KS binding to aggrecan influences the resistance of articular 
cartilage to compressive forces (Roughley, 2001).
12.4.5 Heparin and Heparan Sulphate
Heparin (Hep) and heparan sulphate (HS) differ from other GAGs in terms o f their 
different repeating disaccharides. Due to their structural similarity Hep and HS are 
often confused but the difference in these GAGs lies in their degree o f sulphation. 
Hep is believed to be more heavily sulphated (approximately 70% N-sulfation) whilst 
HS is thought to contain approximately 50% or less N-sulphation (Volpi, 2006). 
They are both composed to D-glucuronate-2-sulphate (or iduronate-2-sulphate) and 
N-sulpho-D-glucosamine-6-sulphate connected via a -1-4 linkage (Vynios et al., 
2002). Hep is known to possess the highest charge density compared to any known 
biological molecule and exhibits diverse biological functions including antithrombotic 
activity (Powell et al., 2004). HS is commonly found on the cell surface as well as 
the ECM and is believed to interact with other ECM molecules as well as growth 
factors, viruses and proteins (Bemfield et al., 1999).
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1.2.5 Proteoglycans
Proteoglycans are a diverse group o f heterogenous complexes of macromolecular 
glycoconjugates consisting o f various glycoaminoglycans (GAGs) covalently-bound 
to a protein core (Huber et al., 2000). They are widely distributed throughout the 
ECM of connective tissues or associated with the cell surface where they have the 
potential to bind to other cellular or matrix components (Schwartz, 2000). 
Functionally, proteoglycans are quite diverse with roles ranging from modulation of 
growth and growth-factor activities, biological lubrication, matrix organisation and 
cell adhesion (Iozzo, 1998). Aggregating proteoglycans are those which have the 
potential to form large aggregates via non-covalent interactions with the GAG, HA. 
O f these aggregating proteoglycans, aggrecan, is the best studied. Initially thought to 
be a cartilage-specific proteoglycan, it was later identified in the aorta, cornea and 
tendon (Huber et a l , 2000).
1.2.5.1 Aggrecan
Aggrecan is the main proteoglycan present in cartilage, accounting for 90% of the 
proteoglycan content o f  articular cartilage. It is a multi-domain proteoglycan with 
distinctly characterised functional regions (Caterson et al., 2000). It is composed of 
globular domains with intervening heavily sulphated and glycosated regions. There 
are three distinct globular domains, G l, G2 and G3. The G1 domain located at the N- 
terminal o f the molecule has a high affinity for HA and binds non-covalently to HA. 
This permits the formation o f large aggregates. A link protein is also bound here and 
this aggrecan-HA-link protein interaction stabilises the molecule (Dudhia, 2005) (Fig. 
1.5).
The Gl and G2 domains are separated by the interglobular domain (IGD). The 
function o f this IGD region is still relatively unknown (Kiani et al., 2002). Within 
this highly conserved IGD there are two specific sites for aggrecan cleavage. These 
sites are located at the following peptide bonds, Asn34I-Phe342 and Glu373-Ala374. 
Cleavage o f these sites compromises the functional and structural integrity o f the
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cartilage matrix. Matrix metalloproteinases (MMPs) and the ‘A Disintegrin and 
Metalloproteinase with Thrombospondin Motifs’ (ADAMTS) are responsible for this 
cleavage which is seen in osteoarthritic tissue (Caterson et al., 2000). (See section 
1.13).
The G2 domain, which is unique to aggrecan, is homologous to the tandem repeats 
found in the G l domain. The function of G2 is still relatively unknown but there is 
evidence suggesting it may play a role in inhibiting the secretion of aggrecan before it 
has undergone GAG substitution by the Golgi (Luo et al., 1996).
The area between the G2 and G3 domain is where the majority of GAG side chains, 
CS and KS attach. As the attachment o f CS and KS is unique to aggrecan (as is the 
G2 domain), there is a hypothesis that the G2 domain may influence GAG binding 
(Dudhia, 2005). CS tends to bind nearer the C-terminal of the molecule whereas the 
KS is found nearer the N-terminal (Hardingham and Bayliss, 1990). The C-terminal 
is located in the G3 domain. This region is very different from both the Gl and G2 
domains but it is highly conserved among species (Iozzo, 1998).
The major role o f aggrecan lies in distributing load in weight-bearing joints. The 
association o f aggrecan with HA and link protein as well as the GAG side chains (CS 
and KS) allows the formation o f aggregates. The high negative charge conferred on 
aggrecan by the GAG side chains (CS and KS) allows these aggregates to be hydrated 
allowing reversible osmotic swelling o f the tissue. When the joint is at rest the 
aggregates are fully hydrated but when stress is placed on the joint the osmotic 
pressure is depleted and water is essentially ‘squeezed’ out of the joint and the weight 
is distributed evenly (Watanabe, 2004; Watanabe et a l , 1998) (Fig. 1.6).
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Fig. 1.5: Schematic drawing of aggrecan structure. The three globular domains
are identified (Gl, G2 and G3) as well as the interglobular domain 
(IGD). The glycosaminoglycan (GAG) side chains are outlined: KS, 
keratan sulphate; CS. chondroitin sulphate 1 and 2 and the carboxy- 
terminal at the third globular domain (G3). The domain sturcture of 
the link protein is also outlined. This is similiar to the Gl domain of 
aggrecan. In order to form aggregates the aggrecan binds to 
hyaluronate via a link protein which functions to stabilise this 
interaction. Blue, CS side chains; red, KS side chains; yellow, O- 
linked oligosaccharides; green, N-linked oligosaccharides.
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1.2.5.2 Small Leucine-Rich Proteoglycans
Within the ECM of articular cartilage exist other minor proteoglycan components 
known as small leucine-rich proteoglycans (SLRPs). These were coined ‘non- 
aggregating’ proteoglycans due to their inability to interact with HA. Decorin, 
biglycan and fibromodulin compose this group of SLRPs. These are all characterised 
by a central domain containing leucine-rich repeats with small cysteine-clusters at 
each end. They also possess DS within their structure (Hardingham and Fosang, 
1992).
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Decorin and biglycan are normally found throughout the life cycle in articular 
cartilage. However with age, biglycan is seen to undergo proteolytic cleavage of the 
amino terminal resulting in loss of the DS side chains. Decorin, located in the 
interterritorial matrix, is normally found ‘decorating’ the surface of collagen and is 
known to contain either CS or DS as side chains (Iozzo, 1998).
Biglycan, on the other hand, is normally situated in the pericellular matrix and does 
not interact with collagen fibrils (Iozzo, 1998; Roughley, 2001). Its precise function 
is still under investigation. Fibromodulin is known to possess up to four KS side 
chains and, like decorin, it can adorn the surface of collagen fibrils. It is thought to 
play a role in regulation of collagen fibril diameter (Knudson and Knudson, 2001).
19
Fig. 1.6: Diagrammatic representation of the macrofibrillar collagen network
and aggrecan superaggregate with hyaluronic acid (HA). CS, 
chondroitin sulphate; KS, keratan sulphate; DS, dermatan sulphate; 
HA, hyaluronate (Poole et al., 2001).
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13  PATHOGENESIS AND DEVELOPM ENT OF OSTEOARTHRITIS
OA is a degenerative joint disease which involves not only the progressive loss of 
cartilage but also affects the synovium, joint capsule and underlying bone. The 
disease involves loss of articular cartilage integrity coupled with remodelling and 
thickening/hardening (sclerosis) of the subchondral bone, development of bone cysts 
and osteophytes together with inflammation o f the synovial joint resulting in pain, 
restriction of movement and joint deformity (Hedbom and Hauselmann, 2002). In an 
osteoarthritic joint, a number of catabolic processes override any repair processes 
resulting in overall degradation of articular cartilage (Aigner and McKenna, 2002). 
The development o f OA occurs in specific stages although the sequence of each stage 
is still unclear. These include perturbation of the bone, cartilage zone and matrix 
destruction. In the early stages of OA the surface becomes rough with surface 
irregularities becoming more obvious. As surface changes become more pronounced, 
fibrillation of the superficial zone o f articular cartilage is initiated and this continues 
into the deeper zones until the subchondral bone is visible. Joint inflammation is 
present throughout the progression of the disease (Aigner and McKenna, 2002; 
Buckwalter et al., 2001; Kuettner and Cole, 2005).
Continued wear o f the subchondral bone reduces the bone into a hard, ivory-like mass 
by a process o f ebumation. Here bone hypertrophy occurs with the development of 
osteophytes (projections of bone). In conjunction with the fibrillation of cartilage, the 
cartilage matrix is degraded due to improper matrix metabolism by a series of 
enzymes and the condition is exacerbated by the action of cytokines due to joint 
inflammation. The presence of cells associated with the immune system, 
macrophages, monocytes and neutrophils, results in the over-expression of IL-lp, IL- 
6 and TNF-a (Gueme et al., 1990; Sarzi-Puttini et al., 2005). Such cytokines are 
thought be responsible for matrix destruction in cartilage and are believed to be 
involved in the inflammation seen in OA (section 1.3.2).
Loss of the main proteoglycan, aggrecan and reduction in integrity of the collagen 
network is thought to be mediated by an upregulation of catabolic enzymes. The 
enzymes belong to the metalloproteinase family of which there are two distinct types.
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Aggrecan destruction, which is believed (though not confirmed) to occur prior to 
collagen depletion, is mediated by members o f the ADAMTS family (Dudhia, 2005) 
(see section 1.3.1).
Collagen is responsible for forming the highly organised fibrillar network o f the ECM 
and, hence, its destruction during the pathogenesis of OA is detrimental to joint 
integrity. Due to the action of a second class o f matrix proteinases, the MMPs which 
are upregulated in arthritic disease, a progressive loss of collagen, most especially 
type 11, results in the collapse o f the ECM (Caterson et a l , 2000) (see section 1.3.1).
Loss o f proteoglycan and the collagen networks o f the ECM are the principal factors 
involved in OA. However, chondrocytes are also implicated in disease pathogenesis. 
In the early stages o f OA, chondrocyte metabolism is increased in an attempt to repair 
the ECM. However, catabolism o f the ECM over-rides any attempt at repair and, as 
disease progresses, chondrocytes release increased amounts of catabolic proteins and 
inflammatory cytokines (Goldring, 2000). In late stage OA, chondrocyte metabolism 
becomes mis-directed and often contributes to matrix degradation and down- 
regulation o f anabolic pathways necessary for repair, before cell death (Goldring and 
Goldring, 2007).
13.1 Proteoglycan and Collagen Degradation
The loss o f aggrecan from the ECM is one o f the earliest pathophysiological 
hallmarks o f OA (Hughes et a l , 1998). Cartilage degradation involves proteolytic 
cleavage o f both aggrecan and collagen (Pratta et a l , 2003). Depletion of 
proteoglycan is due to an increased rate o f aggrecan degradation which can be 
attributed to proteolytic cleavage within the IGD located between the Gl and G2 
globular domains of aggrecan (Amer et a l , 1998). Degradation of aggrecan leads to 
increased concentrations o f GAGs (KS and CS) in the synovial fluid.
Two related enzyme families are responsible for degradation of proteoglycan, the 
MMPs and the ADAMTS proteinases. The MMPs are zinc-dependent enzymes and, 
collectively, they can degrade all components o f the ECM (Rowan, 2001). MMPs are
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inhibited by tissue inhibitors of metalloproteinases (TIMPs) and a fine balance 
between MMPs and the TIMPs determine whether matrix components are catabolised 
or not. A disruption o f this balance, as seen in OA gives rise to destruction o f the 
ECM (Cawston, 1998) O f the MMP family several collagenases exist, MMP-1 
(interstitial collagenase/collagenase-1), MMP-8 (neutrophil collagenase) and MMP- 
13 (collagenase-3) and all can aggressively degrade collagens of the ECM. Another 
important member o f the MMP family is MMP-3 which is responsible for activation 
of the other collagenases (Woessner and Nagase, 2000).
The other proteinase family involved in ECM degradation are the aggrecanases 
(ADAMTSs). Though multiple members o f the aggrecanases family exist it is 
believed that the two main members responsible for the cleavage of aggrecan and loss 
of matrix integrity (although research continues) are ADAMTS-4 and -5 
(aggrecanases-1 and -2, respectively) (Abbaszade et al., 1999; Flannery, 2006; 
Tortorella et a l , 1999). Though not strictly MMPs, the ADAMTS members may be 
inhibited by high concentrations o f TIMPS (Rowan, 2001).
These two enzyme systems (MMPs and aggrecanases) have specific aggrecan 
cleavage sites within the IGD o f the aggrecan molecule (Hughes et a l , 1998). In 
humans, the aggrecanases cleave aggrecan in the IGD at the peptide bond Glu373 -  
Ala374 whilst the MMPs cleave at Asn341 -  Phe342 (Flannery et a l , 1992; Sandy et a l , 
1992). Cleavage results in removal o f the GAG side chains from the N-terminal 
hyaluronan-binding G l domain and loss o f aggrecan into synovial fluid. Evidence 
indicates that the aggrecanases are responsible for primary cleavage of the aggrecan 
IGD during cartilage degradation, while cleavage o f the Asn341 -  Phe342 by the MMPs 
can occur as a late event in cartilage degeneration (Caterson et a l , 2000).
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13.2 Inflammation and Cvtokines
Cytokines are soluble proteins that function as chemical messengers between cells 
and are believed to be involved in almost all biological process including cell growth, 
differentiation, inflammation, tissue repair/remodelling and immune response. By 
acting in either an autocrine or a paracrine manner, cytokines exert either pro- or anti­
inflammatory effects (Buch and Emery, 2002) and oftentimes work synergistically. 
With regard to arthritic disease, two specific cytokines have received particular 
investigation, 1L-1 and TNF-a. Both IL-1 and TNF-a stimulate a pro-inflammatory 
response in cells which, in turn, leads to the upregulation of catabolic and proteolytic 
enzymes (e.g. MMPs and aggrecanases), as well as chemotaxis together with T- and 
B- cell activation (Wood, 2006). However, IL-1 and TNF-a are not the only 
cytokines implicated in RA. IL-6, -8, -10, -11, -13 and -17 as well as macrophage- 
granulocyte colony-stimulating factor (GM-CSF) may also contribute. Lower levels 
of IL-2, -3, -12, oncostatin M and leukaemia inhibitory factor (LIF) have also been 
detected in the synovial fluid o f arthritic patients (Rowan, 2001).
Some cytokines have anti-inflammatory properties (IL-4, -10) but, in the case of OA, 
the pro-inflammatory cytokines are thought to be present in greater concentrations 
than the anti-inflammatory cytokines resulting in little protection from the latter. 
Little, if  any, o f  the chondro-protective cytokine, IL-4 is usually detected (Kardel et 
al., 2003; Rowan, 2001). Eicosanoids are another series o f pro-inflammatory 
mediators involved in the pathogenesis and progression o f OA (see section 1.5.1.1).
Before the effects o f n-3 PUFAs on the pathogenesis, progression and possible 
treatment o f OA are discussed (section 1.6) a review of n-3 PUFA chemistry is 
outlined (section 1.4).
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1.4 n-3 POLYUNSATURATED FATTY ACIDS
PUFAs are an unsaturated class o f fatty acids which contain more than one double 
bond in their carbon chain. The two main families of PUFAs are the n-6 and n- 3 
PUFAs and it is the position o f the first double bond within the hydrocarbon chain 
that gives the n-6 and n-3 PUFAs their name and properties. The n-6 PUFAs have 
their first double bond on the sixth carbon o f the methyl (non-carboxyl) end o f the 
fatty acid molecule whereas in an n-3 PUFA the first double bond is located at the 
third carbon from the non-carboxyl end. PUFAs are usually methylene-interrupted 
meaning that there is at least one intervening carbon between the carbons involved in 
a double bond. The most important PUFAs in health and nutrition are 18:2 n-6 
linoleic acid and 18:3 n-3 a-linolenic acid together with their respective very long 
chain derivatives 20:4 n-6 AA, 20:5 n-3 EPA and 22:6 n-3 DHA which play 
important roles in human health and disease (Gurr et al., 2002).
De novo synthesis o f fatty acids occurs in the mammalian cell cytosol and consists of 
a cyclic series o f reactions which ‘build-up’ the acyl chain by the addition o f two 
carbon units (Gurr et al., 2002). Using the multi-functional proteins acetyl-CoA 
carboxylase and fatty acid synthase conversion o f acetyl-Coenzyme-A to 
palmitic/stearic acids is achieved (Benyon, 1998). Despite the ability o f mammals to 
adequately produce saturated fatty acids, the diet provides an abundant supply. 
Elongation and desaturation enzyme systems exist to insert double bonds at certain 
positions in the acyl chain to yield unsaturated fatty acids. However, mammals lack 
the necessary enzymes to yield the simplest members o f the two main PUFA families, 
n-6 linoleic acid (18:2) and n-3 a-linolenic acid (18:3). Due to the inability o f 
mammals to generate these PUFAs both 18:2 n-6 and 18:3 n-3 are classified as 
essential fatty acids (EFAs) (Cunnane, 2003).
In contrast to mammals, plants possess the necessary desaturases to convert the 18:0 
fatty acid (stearic acid) to both 18:2 n-6 and 18:3 n-3 (Fig. 1.7). As 18:2 n-6 and 18:3 
n-3 are EFAs they need to be provided by the diet. Essentiality o f both these fatty 
acids was determined in 1927-1930 when experimental animals fed a semi-purified 
fat-free diet suffered impaired growth, scaliness o f the skin, water retention, retarded 
growth, infertility and reproductive failure. These symptoms were reversed when the
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EFAs were introduced to the diet (Burr and Burr, 1930; Evans and Burr, 1927). 
However, it should be mentioned that the term EFAs has come under review due to 
the hypothesis that certain non-EFA may be essential (termed conditionally essential) 
during certain periods o f development (for review see Cunnane, 2003). One such 
example is the case o f the saturated fatty acid, palmitic acid (16:0) for which there is 
evidence that it is required for normal expression of hedgehog proteins (e.g. sonic 
hedgehog) during embryonic development (and hence, could be seen as being 
conditionally essential during this period) (Chamoun et al., 2001). Despite this 
ongoing debate, both 18:2 n-6 and 18:3 n-3 are considered the classical EFAs and 
need to be provided by the diet.
Conversion o f stearic acid (18:0) to linolenic acid (18:3 n-3) via oleic 
acid (18:1 n-9) and linoleic acid (18:2 n-6) by the action of specific 
desaturase enzymes (A9, A12 and A15).
Although 18:2 n-6 and 18:3 n-3 cannot be synthesized de novo, mammals can further 
metabolise them to their longer chain polyunsaturated fatty acids (PUFA) derivatives, 
arachidonic acid (AA) (n-6) and eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) (n-3) by the action of desaturases and elongases (Fig. 1.8). In mammals, 
the pathway o f desaturation and elongation occurs primarily in the liver. However, 
despite possessing the ability to convert the 18 carbon precursors to the longer chain 
derivatives the efficiency of this pathway is particularly low and it is also affected by 
the preferential P-oxidation o f 18 carbon fatty acids (Cunnane, 2003; Gurr et al., 
2002). Therefore, the n-3 PUFAs, EPA and DHA, are often also considered EFAs.
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The same enzymes are used in the metabolism o f both the n-6 and n-3 fatty acids, 
hence, competition exits between the two families. The enzymes involved in the 
conversion o f 18 carbon fatty acids favour the more unsaturated fatty acid, 18:3 n-3, 
but as 18:2 n-6 is more common in the diet there is more conversion of 18:2 n-6 to 
AA (Calder, 2004; Simopoulos, 2002a; Simopoulos, 1995). It is the generation and 
consumption o f large quantities o f n-6 fatty acids and the relative lack of n-3 fatty 
acids that have, in part, given rise to the extensive research on the role of n-3 and n-6 
fatty acids in the diet and the resulting implications on health and disease.
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Fig. 1.8: Conversion of linoleic (18:2 n-6) and linolenic acids (18:3 n-3) fatty
acids to their respective very long chain derivatives arachidonic acid 
(20:4 n-6), eicosapentaenoic acid (EPA, 20:5 n-3) and
docosahexaenoic acid (DHA, 22:6 n-3).
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1.4.1 Balance of Essential PUFAs
Millions of years ago, when the human genome was being established the dietary ratio 
of n-6/n-3 fatty acids was thought to be approximately 1 (Simopoulos, 2002). During 
this stage of human development the diet consisted primarily of green leafy 
vegetables, fish, lean meats, fruits, berries and honey, meaning that it contained equal 
levels of n-3 and n-6 PUFAs (Simopoulos, 2002). However, since the arrival of the 
agricultural revolution dramatic changes have occurred in terms of the types and
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quantities of foods consumed by humans and a large change in the n-3/n-6 ratio of 
dietary PUFAs has occurred. Despite the inherent changes of the diet the human 
genetics have not changed. The spontaneous mutation rate for nuclear DNA is 
thought to be 0.005% per million years. Therefore, not enough time has elapsed for 
the genome to have mutated in accordance with the drastic dietary changes 
(Simopoulos, 2002a). Therefore, this imbalance can be implicated in disease 
development.
With the development of technology which allowed cereal grains to become staple 
foods within the global food chain there has been a dramatic impact on the ratio of n- 
6/n-3 PUFAs. Cereal grains are a relatively recent addition to the human diet and 
cause great deviation from man’s original diet (which was consumed when the 
genome was being established) (Simopoulos, 1995). Cereal grains are a major source 
of n-6 PUFAs and contain little or no n-3 PUFAs or antioxidants. Moreover, most 
plant oils have much more n-6 than n-3 PUFAs. Therefore, excessive intake of 
cereals and plant oils reduces the n-3/n-6 fatty acid ratio (Simopoulos, 2002a).
The current consensus on Western type diets is that they are abundant in n-6 PUFAs 
but deficient in n-3 PUFAs. In Western countries, dietary ratios are believed to be as 
high as 15-20/1 (n-6/n-3) (Crawford, 1968; Simopoulos, 1998) although a recent 
report by the NHANES committee suggest that improvements are gradually being 
made with a reported ratio of 10/1 in some countries (Griffin et al., 2006; Sanders et 
al., 2006). Current advice suggests that ratios of 3 -  4/1 are desirable (Kris-Etherton 
et al., 2001). Excessive amount of n-6 PUFAs, a high n-6/n-3 ratio and a deficiency 
of n-3 PUFAs can promote the pathogenesis of many diseases, especially 
cardiovascular disease (CVD) and chronic inflammatory diseases. The n-6 PUFAs 
exert pro-inflammatory effects whereas the n-3 PUFAs are thought to express 
inhibitory effects on a range of cells involved in inflammation, particularly the 
immune cells, and have less-inflammatory properties (Calder, 2003; Sardesai, 1992a; 
Simopoulos, 2002b). CVD and chronic inflammatory dieseases such as arthritis, are a 
major cause of ill-health and mortality in the developed world.
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High dietary intakes o f n-6 PUFAs mean that the PUFA components of the 
phospholipids in cell membranes are mainly composed of the n-6 PUFA, AA (20:4 
n-6). AA is metabolised by enzyme systems to produce eicosanoids which are active 
mediators o f the immune system (section 1.5.1). The eicosanoids derived from AA 
are biologically-active in small quantities and, if  they are formed in large amounts, 
they encourage the formation o f thrombus and atheromas; allergic and inflammatory 
disorders, and the proliferation o f cells. Previous research has proven that the n-6 
derived eicosanoids are several times more biologically potent than the n-3 derived. 
One classic example is that o f the inflammatory response invoked by leukotriene B4 
(n-6 derived). Leukotriene B4 (n-6 PUFA derived) is believed to be 10 times more 
aggressive in promoting an inflammatory attack compared to leukotriene B5 (an n-3 
PUFA-derived) (Calder, 2002). Due to this evidence, several investigators including 
Kris-Etherton et al. (2001), have concluded that a diet rich in n-6 PUFAs shifts the 
physiological state to one that is “pro-inflammatory (prothrombotic and 
proaggregatory, with increases in blood viscosity, vasopasm and vasoconstriction and 
decreases in bleeding time)”. A reduction in bleeding is seen in most aspects of CVD 
from patients with hypocholesterolemia, myocardial infarction and diabetes.
Chronic inflammatory dieseases, such as CVD, are characterised by the formation of 
increased amounts o f thromboxane A2, leukotriene B4, IL-1 p, IL-6 and TNF-a 
(Mehra et al., 2005). Unsurprising, increases in these mediators has been correlated 
with high intakes o f n-6 PUFAs. By increasing the intake of n-3 PUFAs a balance of 
the n-6/n-3 ratio is achieved with beneficial effects particularly with regard to immune 
cells and inflammatory response (von Schacky, 2007). Such effects are achieved by 
the incorporation o f EPA and DHA into cellular membranes at the expense of AA 
and, therefore, the production o f less-inflammatory prostanoids (Grimble, 1998; 
Simopoulos, 2002b). In view of this, assessment of the role of fat quality and the 
balance o f n-6/n-3 PUFAs is o f considerable importance.
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1.4.2 Biological Properties of Polyunsaturated Fattv Acids
The two classes o f EFA (n-3 and n-6) are metabolically and functionally distinct, and 
often have opposing physiological functions (Simopoulos, 2002a). Dietary EFAs can 
be converted directly or indirectly into a class of twenty carbon oxygenated 
derivatives collectively known as eicosanoids. Eicosanoids are a group of chemical 
messengers which act locally and include prostaglandins (PG), thromboxanes (TX), 
leukotrienes (LT), lipoxins, hydroperoxyeicosatetraenoic acids (HPETE) and 
hydroxyeicosatetraenoic acids (HETE) (Bowman and Russell, 2000). They are potent 
regulators o f cell function and act locally in tissues in which they are formed and are 
rapidly converted to their inactive form (Kinsella et al., 1990). A new series of 
bioactive lipid compounds is currently being elucidated, the resolvins, docosatrienes 
and neuroprotectins. These compounds are produced from both EPA and DHA and 
possess potent immunoregulatory and anti-inflammatory actions (Serhan et al., 2004a; 
2004b) (see section 1.5.3).
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‘ANTF-INFLAMMATORY EFFECTS OF n-3 PUFAs
An abundance o f scientific evidence indicates a role for n-3 PUFA in combating 
inflammation. In particular, a-linolenic acid (ALA), EPA and DHA have been 
extensively investigated over the last two decades and evidence now exists that the 
type o f fat in the diet has a major impact on inflammation and other areas of immune 
function. It should be noted that the term ‘ anti ’ -inflammatory is used loosely as many 
n-3 PUFA-derived mediators of inflammation are mildly-inflammatory rather than 
strictly ‘anti’-inflammatory.
Investigation into the diets of Greenland Eskimos prompted speculation that a 
component o f their diet may have protective properties due to their low incidence of 
CVD and other autoimmune and inflammatory disorders. It was concluded that, 
despite the high fat content o f the diet, intakes o f n-3 PUFAs were particularly high 
and offered protection again CVD and other inflammatory disease (Bang et a l , 1971; 
Bang and Dyerberg, 1980).
High levels o f n-3 PUFAs were also observed in Japan where a low incidence of CVD 
is also found (Kromann and Green, 1980). Data indicated that it was the type of fat 
consumed which demonstrated protection again CVD and gave rise to an abundance 
of studies investigating the protective effects of n-3 PUFAs. More recently, the 
GISSI study (Italian Group for the Study o f Streptokinase in Myocardial Infarction 
(Gruppo Italiano per lo Studio della Streptochinasi nellTnfarto Miocardico)) reported 
a significant reduction (45%) in sudden death in >11,000 patients with CVD, when 
taking almost a gram o f n-3 PUFA per day (Marchioli et al., 2002). Such reports led 
to extensive research using animal models, tissue culture and human studies which 
complemented the original observational studies.
From this research, some o f the mechanisms by which n-3 PUFAs exert protective 
anti-inflammatory effects have been elucidated (Fig. 1.9). The main mechanisms 
identified include, the generation o f active metabolites (e.g. eicosanoids, resolvins, 
docosatrienes) (Calder, 2003); effects on inflammatory gene expression (e.g. 
cyclooxygenase-2) (Calder, 2005); modulation o f inflammatory cytokine production 
(e.g. TNF-a) (Simopoulos, 2002b) and influence over adhesion molecule expression
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(e.g. E-selectin) (Calder, 1998). The effect o f n-3 PUFAs on adhesion molecule 
expression is not a parameter examined in this project and, therefore, will not be 
discussed further.
Fig. 1.9: Mechanisms by which polyunsaturated fatty acids (PUFAs) may affect
immune cell function.
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1.5.1 Cvcloorvgenase
Cyclooxygenase (COX), otherwise known as prostaglandin endoperoxide H synthase 
(PGHS), was initially purified from sheep seminal vesicles and was finally cloned in 
the late 1980s (DeWitt and Smith, 1988; Tanabe and Tohnai, 2002; Vane et al., 
1998). There are two known isoforms o f COX, although recent developments have 
presented evidence o f the existence o f a third isoform, COX-3 as well as two smaller 
COX-1 derived proteins (partial COX-1 or PCOX-1 proteins) (Chandrasekharan et 
al., 2002). COX-3 is an acetaminophen-sensitive splice variant o f COX-1 which was 
first identified in canine tissues but its function is still relatively unknown (Dogne et 
al., 2005).
COX enzymes are heme-containing proteins which possess both oxygenase and 
peroxidase activity (Smith et al., 1996). The oxygenase and peroxidase sites are both 
physically and functionally separate (Smith et al., 1996). The COX enzymes are 
membrane-bound and located on the endoplasmic reticulum (ER) membrane, the 
nuclear envelope or, in some cases, the plasma membrane. Thus, they exist in various 
locations within the same cell (Spencer et al., 1999). It has been suggested that the 
prostaglandins produced in different locations function via two different classes of 
receptor systems (Lim et al., 1999; Smith et al., 2000). For example the 
prostaglandins produced by ER-bound COX are thought to both exit the cell and exert 
their function through G-protein coupled receptors which are linked to different 
cytoplasmic cell signalling pathways (Negishi et al., 1995).
COX-1 is a constitutive enzyme expressed at a constant level in many mammalian 
cells. It is thought to function in ‘housekeeping’ events via prostaglandin formation. 
Maintenance o f mucosal epithelium in the stomach, regulation o f kidney function and 
vascular homeostasis are some of the normal physiological events COX-1 derived 
prostaglandins appear to regulate (Spencer et al., 1999; Vane et al., 1998). COX-2 is 
considered the inducible isoform as it is induced by a range o f mitogenic agents such 
as cytokines (Bagga et al., 2003; Tanabe and Tohnai, 2002). However, the labelling 
of COX-1 as constitutive and COX-2 as inducible is somewhat o f an over-
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simplification as COX-1 levels vary during development and some organs (brain, 
testes) constitutively express low levels o f COX-2 (Smith et a l , 1996). It is believed 
that expression o f COX-2 in response to stimuli increases and decreases rapidly. 
Fagan and Goldberg (1986) estimated the half life o f COX-2 in skeletal muscle is less 
than 4 minutes which indicates that enzyme turnover is tightly regulated. COX-2 
plays important roles in disease pathology. It is implicated in diseases ranging from 
arthritis (Martel-Pelletier et a l , 2003) to colon cancer (Eberhart et a l , 1994) and 
Alzheimer's disease (Hoozemans et a l , 2001; Hoozemans and O'Banion, 2005; 
T zcn g e ta l , 2005).
The isolation and characterisation o f the COX enzymes established them as targets for 
non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen 
(Fig. 1.10). NSAIDs function by acetylating amino acid residues (Ser530 in COX-1 
and Ser516 in COX-2) near the active site o f the COX enzyme. Acetylation results in 
a conformational change in enzyme structure therefore preventing the cyclic 
oxygenation o f AA and, thus, preventing eicosanoid production (Fiorucci et a l , 2003; 
Mamett, 2002; Smith et a l , 1996). NSAIDs have the ability to inhibit both COX 
isoforms as these proteins are very similar in both structure and catalytic activity 
(60% homology) (Vane et a l , 1998). However, one o f the most common NSAIDs, 
aspirin, is known to be a more potent inhibitor o f COX-1 (10 -  100 fold) relative to 
COX-2 (Smith et a l, 1996). This is due to the substrate channel of the COX-2 
isoform being larger and more flexible due to the presence of arginine and valine 
which are smaller and less bulky than the histidine and isoleucine found at the same 
positions (513 and 523 respectively) in the COX-1 isoform. Aspirin acetylated 
inhibition o f COX-2 occurs at Ser516 whilst the selective COX-2 inhibitors target the 
hydrophobic channels surrounding the active site (Botting et al., 2006).
There are currently two types of NSAIDs (a) classical NSAIDs (pre-1995) and (b) 
selective COX-2 inhibitors (Smith et a l , 2000). Once the pharmacological 
mechanism o f acetyl-salicylic acid (aspirin) had been elucidated and its effects on 
COX-1 and COX-2 demonstrated, the development of classical NSAIDs ensued. As 
outlined earlier, COX-1 is constitutively expressed and plays important roles in 
normal physiological events, such as maintenance of gastric lining. Classical 
NSAIDs inhibit both COX-1 and -2 but, in spite of their anti-inflammatory effects,
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they also give rise to toxicity issues (Wallace, 2006). Toxicity from NSAIDs includes 
the development o f ulcers and/or other serious gastrointestinal complications as the 
prostaglandins necessary for gastric mucosal integrity are no longer formed due the 
inhibition o f COX-1 (DeWitt, 1999).
The toxicity issues associated with classical NSAIDs together with the emergence o f 
information regarding the difference in the active sites of COX-1 and -2 paved the 
way for the development o f selective COX-2 inhibitors. As selective COX-2 
inhibitors do not inhibit COX-1 it was believed that the risks for gastrointestinal 
toxicity would be much lower compared to the classical NSAIDs (DeWitt, 1999). 
However, selective COX-2 inhibitors were not problem-free. Several of these drugs 
(e.g. rofecoxib, celecoxib and valdecoxib), developed for the treatment of OA and 
acute-pain conditions, were withdrawn from the market following six placebo- 
controlled studies (e.g. VIGOR study) which reported increased cardiovascular risks 
(myocardial infractions, stroke and congestive heart failure) (Davies and Jamali, 
2004; Scheen, 2004). One o f these placebo-controlled studies which investigated the 
potential reduction in GI complications with the selective COX-2 inhibitor, rofecoxib, 
compared to classical NSAIDs reported a 4-fold increase in cardiovascular risk. 
Subsequently, rofecoxib was removed from the market by Merck & Co. Other studies 
carried out also reported no significant increase in gastrointestinal safety with 
selective COX-2 inhibitors compared to the classical NSAIDs (e.g. CLASS study) 
(for review see James et al., 2007).
IA1.1 Eicosanoid Production and Polyunsaturated Fattv Acids
Eicosanoids are twenty carbon oxygenated derivatives derived from both the n-3 and 
n-6 family o f PUFAs. The production o f specific categories of eicosanoids is 
governed by fast-acting and quickly inactivated enzyme systems (Bowman and 
Russell, 2001). This group of short-lived lipid derivatives possess potent biological 
activity and link PUFAs to inflammation (Calder, 2005). They act locally in either an 
autocrine or a paracrine fashion, influencing numerous biological processes including 
inflammation (Gil, 2002).
36
Two membrane-bound enzyme systems are responsible for the formation of 
eicosanoids, the COXs and specific lipoxygenases (LOX) (the P450 oxygenase 
system also plays a role but this is not discussed further) (section 1.5.2). Precursors 
for eicosanoid synthesis are the unesterified PUFAs, AA and EPA (Sardesai, 1992b). 
Initiation of eicosanoid synthesis begins with mobilization of PUFAs found in the 
cellular membrane by the action o f phospholipases (mainly phospholipase A2). The 
phospholipases themselves are stimulated in a number of ways such as mechanical 
stimuli or by peptides and other chemical mediators of inflammation such as 
complement Csa (Gil, 2002). The amounts and types of eicosanoids produced 
depends on a number of factors including, availability of the substrate (PUFA), 
activities o f phospholipases and the various fast-acting COX, LOX or P450 enzyme 
systems. The cell type and the nature o f the stimulus will also influence the 
eicosanoids produced (Calder, 1998).
Inflammatory cells typically contain a high proportion of the n-6 PUFAs, mainly AA 
and a low proportion o f the n-3 PUFAs, especially EPA (Calder, 2005). Thus, AA is 
the primary substrate for eicosanoid synthesis. Metabolism of PUFAs to eicosanoids 
is mainly initiated by phospholipase A2 cleaving off PUFAs from the sn-2 position of 
a phospholipid molecule, such as phosphatidylcholine (PC) (Calder, 1998). However, 
increasing the levels o f n-3 PUFAs consumed in the diet reduces the n-6 PUFA levels 
in cellular membranes, (i.e. AA is replaced by EPA, which is a competing substrate 
for the COX and LOX systems) (Robinson et al., 2001; Robinson and Field, 1998; 
Wallace et al., 2001). Eicosanoids produced from EPA may exert the same effects as 
those from AA but possess much less potency. Hence, they are deemed to have ‘anti­
inflammatory' effects because they will reduce the amount of inflammation (Calder 
and Grimble, 2002). Regardless o f whether the initial PUFA substrate is n-6 or n-3, 
the same families o f eicosanoids are produced -  the prostaglandins (PGs), 
thromboxanes (TXs) and leukotrienes (LTs), only the series differs (section 1.5.1.2).
The first step in the formation o f many o f the aforementioned eicosanoid families is 
the oxygenation o f the precursor PUFA by the COX enzyme system. The 
cyclooxygenation occurs in a hydrophobic channel in the enzyme core and combines 
the precursor PUFA with two molecules of oxygen to yield prostaglandin G2 (PGG2). 
PGG2 is then quickly reduced to the endoperoxide, PGH2 , from which the classical
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PGs, TXs or prostacyclins can be produced (Gurr et al., 2002; Smith et a l 2000; 
Smith et al., 1996; Vane et al., 1998). The resulting eicosanoids exit the cell via a 
carrier-mediated process to activate prostanoid G-protein-linked prostanoid receptors 
or may interact with nuclear receptors (Chan et al., 1998; Lim et al., 1999; Ushikubi 
etal., 1998) (Fig. 1.10).
1.5.1.2 Prostaglandins and Thromboxanes
Prostaglandin (PGs) and thromboxanes (TXs) are potent mediators of inflammation 
and, due to their transient nature, they have extremely short half lives, generally in the 
realm o f seconds (Funk, 2001). Depending on the cell type where they are produced 
they can induce different responses in either an autocrine or a paracrine fashion. 
PGE2 is probably the best studied o f all the eicosanoids and it has many pro- 
inflammatory effects ranging from fever onset and the induction of pain and odema 
caused by other stimulatory agents such as histamine. It has also been demonstrated 
to suppress lymphocyte proliferation, natural killer cell activity and inhibit the 
production o f IL-2 and interferon-y (INF-y). It has also been demonstrated to promote 
immunoglobulin E production by B-lymphocytes (Calder, 2002; Fantone et al., 1980; 
Kunkel et al., 1979). It is believed that PGE2 exits the cell via facilitated transport 
through the prostaglandin transporter (PGT) which belongs to the organic anion 
transporter polypeptide family. The PGTs belong to three clusters within a distinct 
subfamily o f the G protein-coupled receptor (GPCR) superfamily (Funk, 2001).
Of the thromboxanes (TXs), TXA2 is the best documented. It is formed from the 
endoperoxide, PGH2 via the action o f thromboxane synthase. Roles for TXA2 include 
vasoconstriction, vasodilation and platelet aggregation. It is also a smooth muscle 
mitogen. The production o f TXA2 is increased during the development o f 
artherogenesis and its biosynthesis and biological activities are now being 
investigated as therapeutic targets in the treatment o f this disease (Dogne et al., 2005).
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Fig. 1.10: Synthesis of eicosanoids from arachidonic acid and inhibition by
NSAIDs. The metabolic cascade indicates prostaglandin (PG), 
thromboxane (TXA2 ) and prostacyclin (PGI2 ) generation from 
arachidonic acid via the cyclooxygenase (COX) enzyme system.
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1.5.2 Lipoxygenase
Lipoxygenases (LOX) are a group of enzymes which function in the biosynthesis of a 
group of inflammatory and cell signalling mediators, the leukotrienes and lipoxins 
(Prigge et a l , 1997). This family of lipid peroxidising enzymes is widely distributed 
throughout both the plant and animal kingdom. They have also been identified in 
lower marine organisms such as sea-urchins and starfish (Kuhn and Thiele, 1999). 
Up until the mid 1970s it was assumed that LOX enzymes were only to be found in 
the plant kingdom. Most of the early research into these enzymes was done on the 
soyabean LOX-1 and some other plant isoforms (Kuhn et al., 2005). It was not until 
the 1970s that the presence of LOX in mammalian cells was established. Two 
important studies led to a resurgence of research in the LOX field. Hamberg and
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Samuelsson (1974) documented the formation of 12-hydroxyeicosa-5,8,10,14- 
tetraenoic acid (12-HETE) from human thrombocytes whilst they were incubated with 
exogenous AA. Another important study was carried out in 1974 which identified the 
presence of 15-LOX in rabbit reticulocytes. This isoform was capable of oxidising 
membrane phospholipids to active metabolites (Schewe et a l, 1986).
Since then. 18 different LOX sequences have been determined representing seven 
different isoforms studied in seven mammalian species. Among the species studied, 
mice appear to have the greatest diversity o f LOX enzymes. It is thought that the 
current six different isoforms established in mice is set to expand further over the 
coming years (Kuhn and Thiele, 1999).
Initially, much mystery surrounded the mechanistic action (Fig. 1.11) of the LOX 
enzymes. However, it is now accepted that the reaction takes place in three 
consecutive steps: (a) stereo-selective removal of hydrogen from a bisallylic 
methylene forming a carbon-centred fatty acid radical; (b) rearrangement of the fatty 
acid radical from a cis-cis methylene interrupted radical to a trans cis-conjugated 
diene and (c) insertion of molecular dioxygen (peroxidation) resulting in the 
formation o f an oxygen-centred fatty acid radical (Gurr et al., 2002; Ivanov et al., 
2005). LOX metabolism gives rise to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) 
which rapidly undergoes dehydration coupled with isomerization of double bonds to 
yield the parent leukotriene, LTA4 .
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Fig. 1.11: Mechanism of lipoxygenase (LOX) action from a trienoic precursor
unsaturated fatty acid (adapted from Kuhn and Thiele, 1999).
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As mentioned, leukotrienes and lipoxins are the end products of LOX metabolism. 
However, they are produced by different isomers of LOX enzymes. The three main 
isoforms are: 5-LOX, 12-LOX and 15-LOX. In mammals, the LOXs are named in 
terms of their positional specificity of AA oxygenation (i.e. the carbon number which 
they oxygenate) (Ivanov et al., 2005). Despite the substrate selectivity of the LOX 
enzymes (the PUFAs must possess a minimum of two cis double bonds interrupted by 
a methylene group) other PUFAs can act as substrates in LOX metabolism, for 
example, EPA (Gurr et al., 2002). Also, the 15-LOX (see section 1.5.2.3) may use 
both free and esterified PUFAs, and perhaps, even more complex lipid assemblies 
such as lipoproteins (Brinckmann et a l 1998; Calder, 2002).
41
1.5.2.1 5-Lipoxvgenase
5-LOX is a non-heme iron dioxygenase located in either the nucleus or cytosol 
depending on the type of cell. The initiation of 5-LOX metabolism of AA begins with 
changes in cytosolic calcium in response to stimulation of the cell (e.g. trauma, 
bums). This mobilises phospholipase A2 which cleaves phospholipid PUFAs from 
their sn-2 position. The free AA is then metabolised to produce the leukotrienes 
(Flamand et al., 2006). When AA is metabolised by 5-LOX another important 
molecule, 5-LOX activating protein (FLAP), is necessary for the generation of the 
common precursor of all leukotrienes, LTA4 . FLAP is an 18 kDa protein bound to the 
nuclear membrane and plays an important role in the cellular regulation of 5-LOX- 
activity (it appears unique to the 5-LOX isoform) (Miller et al., 1990). Its importance 
is derived from the fact that it acts in ‘presenting’ the activated AA to 5-LOX for 
metabolism (Dixon et al., 1990; Wenzel, 2003; Yokomizo et al., 2001). The early 
precursor of all leukotrienes, LTA4 , is an unstable allylic epoxide (a cyclic ether with 
only three ring atoms) and it undergoes rapid transformation (hydrolysis, conjugation 
to gluthatione or transcellular metabolism to generate bioactive eicosanoids) to yield 
the other leukotrienes. For example, LTC4  is produced by gluthatione conjugation of 
LTA4  whereas hydrolysis of LTA4  produces LTB4  (Flamand et al., 2006). Fig. 1.12 
outlines conversion of LTA4  into the functional leukotrienes.
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Fig. 1.12: Conversion of leukotriene A4 into leukotriene B4 and the cysteinyl
leukotrienes C4, D4 and E4.
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1.5.2.2 12-Lipoxvgenase
12-LOX oxygenates AA at carbon-12. There are two major locations of this isoform, 
‘platelet 12-LOX’ and ‘leukocyte 12-LOX’. The most notable difference between 
these two isoforms is due to their substrate selectivity -  platelet 12-LOX can only 
metabolise AA to produce 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (12- 
HPETE) whereas leukocyte 12-LOX can generate both 12- and 15-HPETEs from a 
variety of PUFAs (Yoshimoto and Yamamoto, 1995).
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1.5.23 15-Lipoxvgenase
15-LOX is primarily found in the cytosol but increases in cytosolic calcium 
concentrations results in binding of 15-LOX to intracellular membranes (Brinckmann 
et al., 1998). This isoform was initally identified in the rabbit reticulocytes and has 
the ability to oxygenate esterified polyenoic PUFAs whilst they are still present in the 
phospholipids of the cell membrane (Kuhn et al., 2005). Metabolism of AA by 15- 
LOX results in the oxygenation of AA at carbon-15 to produce 15-hydroperoxy-
5,8,1 LI3-eicosatetraenoic acid (Gurr et al., 2002). Several lines of evidence 
implicate 15-LOX in cell development and differentiation (Kuhn and Thiele, 1999). 
It is believed that actions o f the generated lipoxins (see section 1.5.2.4) antagonize 
many of the responses o f leukotrienes (and possibly other mediators) and that they 
represent effective inhibitors o f inflammation (Badr et al., 1989; Brady et al., 1990; 
Papayianni et al., 1996).
1.5.2.4 Leukotrienes and Lipoxins
Leukotrienes and lipoxins, together with prostaglandins, thromboxanes and 
prostacyclins, are major constituents of the biologically-potent mediators of 
inflammation, the eicosanoids. Leukotrienes are a powerful class of eicosanoids 
synthesised from PUFAs by various cells including mast cells, basophils and 
macrophages. The leukotrienes play a major role in inflammation, for example the 
cysteinyl-containing leukotrienes (LTC4, LTD4 and LTE4) produced by glutathione 
conjugation from LTA4 are potent bronchoconstrictors in the lung, are known to 
increase the permeability of post-capillary venules and stimulate the secretion of 
mucus (Samuelsson et al., 1987) (Fig. 1.13). LTB4 is regarded as being one of the 
most potent chemoattractants and activators of leukocytes and plays a major role in 
inflammatory diseases. This calcium ionophore induces adhesion as well as 
chemotactic movement of leukocytes. It is also known to stimulate aggregation and 
the release and generation of superoxide neutrophils (Dahlen et al., 1981; Hoover et 
al., 1984; Sha'afi et al., 1981).
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Lipoxins are any group o f eicosanoids containing a conjugated tetraene structure and 
three hydroxyl groups. Also produced from PUFAs, lipoxins are short-lived 
endogenously-produced eicosanoids involved in signalling the resolution o f 
inflammation following stimulation by IL-4 (Bonnans et a l , 2002). Lipoxins are 
functionally antagonistic to the actions o f leukocytes. They control the entry o f 
neutrophils to inflammatory sites (leukocytes promote neutrophils recruitment), 
reduce vascular permeability and stimulate macrophages to uptake apoptotic 
neutrophils. They exert potent chemoattractant effects on monocytes which play a 
significant role in wound healing (Schwab and Serhan, 2006).
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D jelI  .13: Leukotriene (LT) formation in inflammatory cells and their sites of
action (Henderson, 1994).
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1.5.3 Novel n-3 PUFA Derived Inflammatory Mediators -  Resolvins and
Protectins
Novel oxygenated derivatives of EPA and DHA, the resolvins and protectins, have 
recently been identified as inflammatory mediators possessing both anti-inflammatory 
and immunoregulatory effects (Serhan, 2005b). Mediators derived from EPA are 
classified as the E-series resolvins whilst those derived from DHA are termed 
resolvins or protectins of the D-series (Ariel and Serhan, 2007) (Fig. 1.14). These 
mediators were discovered in a murine model of inflammation (dorsal skin pouch) 
and it was shown that they played an active role in the resolution of the inflammatory 
process (Serhan, 2005a).
Resolvins and protectins invoke their anti-inflammatory and immunoregulatory 
functions at the pico/nano molar range via the removal of inflammatory cells (e.g. 
neutrophils) and neutralisation of some pro-inflammatory prostanoids, thereby, 
allowing restoration o f tissue integrity (Serhan et al., 2004a). As mentioned, both the 
resolvins and protectins are derived from n-3 PUFAs and the presence of aspirin 
greatly facilitates these metabolic pathways (Serhan et al., 2000a, 2000b). The COX- 
2  enzyme is acetylated by aspirin and this allows the introduction of an 18/? 
hydroperoxy-group into the EPA molecule (Serhan and Clish, 2000). Subsequent 
metabolism of the EPA-derived 18/?-hydroperoxy-EPA yields the resolvins, most 
notably resol vin El (55, 12/?, 18/?-trihydroxy-6Z, 8 /s, 10/s, 14Z, 16/s-
eicosapentaenoic acid) (Fig. 1.14) (Serhan and Chiang, 2007).
Formation of DHA-derived 17R and 175 resolvins and protectins (D-series) (Fig. 
1.14) is also facilitated by aspirin via COX-2, although these mediators can also be 
produced in the absence of aspirin, although in that case, they are stereochemically 
different. Neuroprotectins were initially discovered in neural tissues of the brain 
(hence the name) but further research proved that their production is not localised to 
brain tissue. Therefore, they are simply referred to as protectins (Serhan, 2005a). 
Protectins are generated via LOX metabolism and contain conjugated triene structures 
(three conjugated double bonds) (Serhan et al., 2004b). Various protective and anti­
inflammatory properties have also been reported for these compounds, for example it 
has been confirmed that neuroprotectin D1 protects retinal pigment epithelial (RPE)
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cells from oxidative stress-induced apoptosis and, possibly, offers protection to 
neurons. Therefore, this lipid mediator may indirectly contribute to photoreceptor cell 
survival as well (Serhan et al., 2004a, 2004b). By this mechanism, neuroprotectin D1 
may play an important role in age-related macular degeneration (AMD), a leading 
cause o f blindness in the developed world. It has been suggested that, given the role 
of n-3 PUFAs in the generation o f resolvins and protectins, dietary supplementation 
with EPA and DHA in conjunction with aspirin may reduce inflammation associated 
with many chronic diseases including CVD, cancer and arthritis.
Fit. 1.14: Structural representation o f EPA-derived Resolvin El and DHA-
derived Resolvin D l.
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1.5.4 Inflammatory Gene Expression and n-3 Polyunsaturated Fatty
Acids
The collection o f epidemiological, experimental and clinical studies demonstrating a 
protective role o f long chain n-3 PUFAs on inflammatory gene expression is currently 
expanding, with particular attention being paid to the mechanisms as to how n-3 
PUFAs exert their effects on gene expression (Deglon et a l, 1995; Ntambi and Bene, 
2001; Sampath and Ntambi, 2005; Tebbey and Buttke, 1993). It has been 
demonstrated that diets enriched with n - 6  PUFAs stimulate the growth o f different 
cell types and promote metastasis whereas the n-3 PUFAs do not demonstrate such 
effects but, on the contrary, promote curative effects in inflammatory/autoimmune 
diseases (Denys et al., 2005).
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Zhao et al. (2004) reported decreased expression o f TNF-a in a human monocytic cell 
line when the cells were pre-incubated with EPA followed by stimulation with 
bacterial lipopolysaccharide (LPS). This suppression was also demonstrated when 
cells were pre-treated with DHA. Addition o f the n- 6  PUFAs, AA and LA or of the 
monounsaturated acid, oleate, resulted in a decrease in TNF-a expression but to a 
much lesser extent. This study concluded that a significant down-regulation o f TNF-a 
production was specific for n-3 PUFAs (Zhao et al., 2004). A study by de Caterina et 
al. (1994) showed that on increasing the cellular levels of DHA there was a reduction 
in cytokine-induced expression o f endothelial leukocyte adhesion molecules, 
secretion o f inflammatory mediators and leukocyte adhesion to cultured endothelial 
cells. DHA also decreased cytokine-stimulated endothelial cell expression of E- 
selectin and intercellular adhesion molecule- 1 expression o f constitutive surface 
molecules. This effect was shown to be eicosanoid-independent as inhibition of COX 
did not quench this effect indicating that the effect may be based on gene expression 
(de Caterina et al., 1994). Another study reported that fish oil supplementation of 
splenocytes resulted in partial suppression o f virus-induced overproduction of serum 
immunoglobulins (IgG and IgM). The same study also reported that LPS-stimulated 
production o f LTB4 , TNF-a and IL-lp were all suppressed with fish oil 
supplementation. When compared to maize oil, fish oil also resulted in partial 
suppression o f activation o f NFkB (Xi et al., 2001). In a study where the anti­
inflammatory action o f dietary fish oil and calorie restriction was tested in mice the 
authors determined that dietary fish oil (together with a 40% reduction in calorie 
restriction) effectively suppressed age-related inflammatory processes by modulating 
pro-inflammatory COX-2, iNOS gene expression and other related inflammatory 
genes (Kim et al., 2006).
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1.5.4.1 Mechanisms of the Effects of n-3 Polyunsaturated Fattv Acids on 
Gene Expression
The anti-inflammatory effects o f eicosanoids are well documented. However, some 
of the effects exerted by n-3 PUFAs on gene expression are thought to be eicosanoid- 
independent. It is thought that these effects on gene expression are due to n-3 PUFA 
direct effects on intracellular signalling pathways which in turn lead to the activation 
of transcription factor(s) (Fig. 1.15). The most well documented transcription factors 
studied with relation to n-3 PUFAs and gene expression are NFkB and peroxisome 
proliferator-activated receptors (PPAR) which are discussed below. However, these 
are not the sole transcription factors involved. Hepatic nuclear factor-4a (HNF-4a), 
sterol regulatory element binding protein- lc  (SREBP-lc), liver X receptors (LXRs) (a 
and P) and retinol X receptor (RXR) are also documented to be involved in the effects 
of n-3 PUFAs and gene expression (Jump, 2002).
1.5.4.2 Nuclear Factor Kappa-B
Nuclear factor kappa-B (NFkB) is an inactive heterotrimer located in the cytosol of 
most, if not all cells. One o f the three subunits is an inhibitory subunit (IkB). On 
stimulation o f NFkB by a range o f inflammatory stimuli (e.g. LPS), a signalling 
cascade is set in motion activating a protein complex termed IkB kinase. Activated 
IkB kinase results in phosphorylation o f the IkB subunit which dissociates resulting in 
the active heterodimer o f NFkB. The activated heterodimer moves to the nucleus 
where it binds to NFkB response elements and initiates the transcription of various 
inflammatory genes (Christman et al., 1998). The phosphorylated IkB subunit then 
undergoes polyubiquitination, resulting in IkB degradation.
NFkB is thought to be one o f the links between n-3 PUFA and inflammatory gene 
expression. Several studies have documented the ability o f n-3 PUFAs to down- 
regulate the activity o f NFkB. One study reported that feeding mice a fish oil- 
enriched diet resulted in a lower level of NFkB in the nucleus of LPS stimulated 
lymphocytes compared to mice fed a maize oil-enriched diet (Xi et al., 2001). This 
study also demonstrated that fish-oil fed mice had lower levels of NFkB in the 
nucleus than the mice fed maize oil when the mice were infected with murine AIDS.
50
Chen and Zhao (2001) incubated human monocytes with EPA. When the monocytes 
were stimulated by LPS the NFkB response was reduced (see Calder 2002). This 
response was associated with decreased phosphorylation of IkB kinase indicating that 
the EPA effect was elicited on the signalling process leading to the activation o f IkB 
kinase. Another study showed an n-3 PUFA effect at a different step during N FkB 
activation. Pancreatic cells incubated with EPA followed by exposure to TNF-a 
resulted in up-regulated degradation o f IkB. This effect may either be due to 
inhibition o f phosphorylation o f IkB, hence preventing degradation or, alternatively, 
inhibiting the degradation process itself (Ross, 1999). Fig. 1.15 outlines the 
mechanisms by which n-3 PUFAs may regulate inflammatory gene expression via 
NFkB.
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Fig. 1.15: Nuclear factor kappa-B (NFkB) stimulation by lipopolysaccharide
(LPS) and the possible sites where n-3 polyunsaturated fatty acids 
(PUFAs) may regulate inflammatory gene expression. TRL, toll-like 
receptor; CD 14, cluster designation-14; TNF-a, tumour necrosis 
factor-a; IL-lp, interleukin-1P; IL-6 , interleukin-6 ; COX-2, 
cyclooxygenase 2 .
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Increases in n-3 PUFA concentrations may results in less NFkB in the nucleus, 
increased phosphorylation of IkB and degradation of IkB and a reduction in IkB 
kinase activity thereby affecting inflammatory gene expression.
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1.5.43 Peroxisome Proliferator Activated Receptors
Peroxisome proliferator activated receptors (PPARs) belong to the steroid hormone 
nuclear receptor superfamily of ligand-activated transcription factors. There are three 
isoforms of PPARs currently known, PPAR-a, PPAR-p/ 8  and PPAR-y, each of which 
is encoded by a different gene (Daynes and Jones, 2002; Yaqoob, 2003). PPARs are 
key regulators of lipid and glucose homeostasis and are activated by several diverse 
compounds including PUFAs, eicosanoids and hypolipidaemic drugs (Kliewer et a l, 
1997). PPARs are ‘molecular sensors' o f endogenous fatty acids and their 
derivatives. Following binding of a ligand PPAR activate transcription resulting in 
the formation o f a heterodimer coupled to a co-activator (e.g. retinoic acid receptor 
(RXR)). The expression of variety o f genes is under the control of these ligand- 
activated receptors which regulate the expression of a variety of genes (Lefebvre et 
al, 2006).
The two main members of the PPAR family are PPARa and PPARy. PPARa is 
located in the liver and functions in the catabolism of fatty acids whereas PPARy is 
located in adipose tissue and it is involved in the storage of fatty acids. As well as 
being located in the liver and adipose tissue both members can also be found in 
inflammatory cells (Devchand et a l, 1996).
As mentioned previously, gene expression is regulated by PPAR dimerisation with the 
RXR and binding appears to be under regulation by PUFAs and eicosanoids (Kliewer 
et a l, 1997). Devchand et a l, (1996) reported that mice deficient in PPARa had a 
prolonged response to an inflammatory stimulus indicating that PPARa activation 
may have anti-inflammatory properties. Evidence of the ability of n-3 PUFAs in 
conjunction with PPARs to influence gene expression is growing in abundance. 
Several studies indicate that activators of PPARa and y can inhibit the activation of a 
range of inflammatory genes such as TNF-a, iNOS, IL-lp, IL- 6  and COX-2 (Jackson 
et al., 1999; Jiang et a l , 1998; Ricote et a l , 1998).
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Donnellan et al. (2000) demonstrated that feeding mice fish oil increased the 
expression o f PPARa in the liver and PPARy in adipose tissue. Expression of PPAR- 
inducible genes in these tissues were also increased. Therefore, there is a suggestion 
that n-3 PUFAs might act by increasing the level of these anti-inflammatory 
transcription factors in immune cells thus implicating n-3 PUFAs in regulating 
inflammatory gene expression via PPARs.
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1.6 n-3 PUFAs AND OSTEOARTHRITIS
Clinical studies on dietary supplementation with the n-3 PUFAs, EPA and DHA, have 
demonstrated a reduction of many inflammatory symptoms involved in the 
pathogenesis o f RA (Calder and Zurier, 2001, James et a l , 2003). In a population of 
RA patients consuming 2.8 mg o f n-3 PUFAs/day Geusens et al. (1994) reported 
significant clinical benefits together with a reduction in anti-rheumatic medication. 
Nielsen et a l  (1992) investigated the effect o f dietary supplementation o f n-3 PUFAs 
on six clinical parameters in patients o f RA. They reported significant improvement 
in two out o f the six parameters in the experimental group compared to the placebo 
group. In another study, Kremer et a l (1995), investigated whether supplementation 
of n-3 PUFA in a population o f RA patients would result in a reduction of NSAID 
therapy and the biological efficacy o f n-3 PUFAs in this population. Sixty-six 
patients took part in this double blind, placebo-controlled, prospective study. Patients 
were divided into two groups and consumed either a n-3 PUFA supplement or 
placebo whilst taking diclofenac (over-the-counter NSAID). The results indicated 
that the experimental group showed significant improvements in tender joint, morning 
stiffness and scored better on the physician’s and patient’s global arthritis activity 
scale. Also, the levels o f IL-lp were reduced in the n-3 PUFA supplemented group 
(Espersen et al.9 1992). Some, though not all, patients o f the supplementted group 
were also able to discontinue NSAID therapy. As well as these studies, it has been 
documented that EPA and DHA compete with AA for incorporation into the 
phospholipids o f cell membranes (Yaqoob et al., 2000) which, as discussed 
previously, (section 1.5.1, 1.5.2), has advantageous effects in terms of the 
inflammatory response associated with arthritic conditions (Calder, 2001; Sperling, 
1991).
Eicosanoids derived from AA are of the 2-series PGs and TXs and the 4-series LTs 
and hydroxy fatty acids and are considered to be pro-inflammatory. On the other 
hand, metabolism o f EPA by the COX and LOX enzymes systems gives rise to a 
different series o f eicosanoids, the 3-series PGs and TXs and the 5-series of LTs and 
hydroxy fatty acids. The functional significance o f this is that the mediators formed 
from EPA are believed to be less potent and less-inflammatory (Calder, 2005; van der 
Tempel et a l, 1990). Furthermore, as discussed earlier (section 1.5.1, 1.5.2) AA and
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EPA will compete with each other for COX, LOX and other relevant enzymes. 
Supplementation with n-3 PUFAs has been effective in changing the balance of 
eicosanoids produced from pro-inflammatory to less-inflammatory (Calder, 2001; 
Calder and Zurier, 2001; Sperling, 1991).
As previously discussed (section 1.5.1.1), increasing dietary intakes o f n-3 PUFAs 
gives rise to competition between the n-3 and n- 6  PUFAs for enzymes involved in the 
conversion o f 18 carbon fatty acids to AA and EPA. As outlined earlier, (section
1.5.1, 1.5.2) dietary supplementation o f n-3 PUFAs is thought to affect three 
significant pathways involved in the synthesis o f lipid mediators known to play a role 
in the inflammatory response, the COX pathway, the 5-LOX pathway and the 
synthesis o f platelet activating factor (PAF) (James et al., 2000; Sperling, 1991). PAF 
is known to be a potent platelet aggregator and leukocyte activator and strongly 
promotes the metabolism of AA. PAF is not a lipid signalling molecule investigated 
in the course o f this work and, hence, will not be discussed further.
Another benefit o f dietary supplementation o f n-3 PUFAs in terms o f OA is the 
suppressive effects exerted on inflammatory cytokines (Babcock et a l ., 2002; Endres 
et al.y 1989; Priante et al.y 2002; Sundraijun et a l , 2004). TNF-a, IL-1 and IL- 6  are 
the most important cytokines produced by cells o f the immune system (monocytes, 
macrophages and neutrophils) (Wood, 2006). Appropriate amounts o f TNF-a, IL-1 
and IL- 6  are beneficial in combating infection but a disruption in their metabolism 
that yields unnecessary and inappropriate levels are implicated in the pathological 
responses that occur in OA (Simopoulos, 2002). Supplementation with n-3 PUFAs 
has demonstrated suppressive effects on these cytokines, whereas no effect was 
observed with other classes of fatty acids (Endres et al.y 1989; Calder and Zurier, 
2001; Priante et al.y 2002).
In terms of the mechanistic actions of n-3 PUFAs, evidence demonstrates that n-3 
PUFAs may exert effects on inflammatory gene expression through direct actions on 
the intracellular signalling pathways that lead to activation o f one or more 
transcription factors such as nuclear factor kappa B (NF-kB). Previous studies have 
shown that n-3 PUFAs can down-regulate the activity of the nuclear transcription 
factor NF-kB suggesting a direct effect of long-chain n-3 PUFAs on inflammatory
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gene expression through the inhibition o f NF-icB (section 1.5.4.2, Fig. 1 .1 1 ) (Lo et al., 
1999; Novak et a l , 2003).
Therefore, there are numerous mechanisms in which n-3 PUFA supplementation may 
exert protective effects against inflammation such as that seen with OA. As rich 
sources o f n-3 PUFAs (e.g. cod liver) are in decline, the importance o f identifying 
new, viable and long-term sources of n-3 PUFAs is underscored. This would allow 
continued use o f n-3 PUFAs in the dietary treatement of inflammatory diseases such 
as OA whilst also alleviating environmental pressure on the sources o f n-3 PUFAs.
57
1.7 SOURCES OF n-3 PUFAs -  THE ROLE OF AQUACULTURE
Although ALA is present in plants, the conversion o f ALA to the longer chain 
PUFAs, EPA and DHA, is inefficient. Therefore, EPA and DHA are often 
recommended in the diet (section 1.4). The main dietary sources o f such very long 
chain n-3 PUFAs include fish and fish oils (Abrami et a l , 1992). Currently the 
recommended intake for EPA and DHA in the UK are 450 mg EPA and DHA/day 
(Givens and Gibbs, 2008). However, many studies investigating the anti­
inflammatory properties o f n-3 PUFAs use between 3 - 6 g EPA and DHA per day 
and therefore, this amount is often recommended for anti-inflammatory benefits 
(Rayman and Callaghan, 2006). Despite this, these requirements are not often met by 
dietary consumption o f fish, and fish oil capsules are often taken as an adjunct to the 
diet (Rayman and Callaghan, 2006).
However, despite the beneficial effects o f fish and fish oil consumption, over the past 
two decades the marine fishing industry has come under extensive pressure because of 
declining fish stocks caused by over-fishing, mis-management of stocks, inaccurate 
data on time-scales for stock replenishment and government policies (FAO 
Department o f Fisheries, 2004; Myers and Worm, 2003; Rice et al., 2003; Zheng et 
al., 2004). Because o f the problems faced by marine fisheries there has been a 
subsequent increase in the aquaculture industry (FAO Department o f Fisheries, 2004; 
Naylor et al., 2000). A report by the Food and Agriculture Organisation estimated 
that global production o f farmed-fish more than doubled in the last 15 years (Food 
and Agricultural Organisation, 1999). As the world population continues to expand 
and, due to the growing problems encountered by the traditional marine fishing 
industry, the reliance on aquaculture is likely to expand. Aquaculture involves the 
cultivation o f aquatic populations under controlled seawater or fresh water conditions 
and is a tightly regulated industry with growing economic value (SEPA, 2003).
As outlined above, the main source o f n-3 PUFAs is fish and fish oils and, needless to 
say, the aquaculture industry supplies fish for dietary consumption. However, the 
waste materials (e.g. viscera, skin, bones) are commonly disposed of and disposal 
systems are strictly monitored (www.fao.org). Fish waste was extensively used in 
fish feed products but, due to the bovine spongiform encephalopathy (BSE) crisis, a
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review o f disposal regulations restricted the used o f fish waste in numerous products 
(www.defra.gov.uk). Nowadays, the aquaculture industry has to adhere to strict 
regulations regarding waste disposal. A common method of disposal is incineration 
(DEFRA, 2003).
Disposal o f fish waste is seen as a major expense (especially for smaller farms) and, 
in some instances, disposal regulations are not adhered to, resulting in inappropriate 
disposal o f waste products which in turn can have environmental consequences (e.g. 
pollution o f rivers). However, more recently there have been initiatives to utilise 
waste products for several different end products. Work by the Portland Shellfish Inc. 
is one such example. Circa 1999 approximately 3.9 million pounds o f crab waste was 
generated annually. This waste was formerly added to soil fertilizers but a change in 
regulations outlawed this practice. Faced with growing costs for correct waste 
disposal, the Portland Shellfish Inc., invested in research to convert the waste 
products into a marketable gardening product via a composting procedure 
(www.epa. gov/itr/docs/me/me.htm). Despite preliminary difficulties, an appropriate 
system for composting was established and resulted in the development o f a highly 
marketable product o f economic value. There are numerous other examples o f waste 
products being transformed into other viable products, such as in the whey industry.
However, despite success stories such as Portland Shellfish Inc., the aquaculture 
industry commonly disposes o f waste products. For the UK alone, the Fish 
Foundation reports approximately 40,000 tonnes of salmon waste annually. This 
waste contains approximately 30% fat and has a potential market value o f £5 million. 
The fat content o f trout waste is reported to be even greater, approximately 50%. 
Therefore, finding an effective method to transform farmed fish waste into a viable 
product would not only reduce disposal costs and environmental implications but also 
result in the generation of revenue. Due to the abundance o f scientific evidence 
reporting the health benefits o f n-3 PUFAs, fish oil capsules are commonly taken by 
today’s populations. Therefore, an opportunity exists to determine whether farmed 
fish waste could be a plentiful source o f n-3 PUFA for the nutraceutical industry.
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AIMS AND OBJECTIVES:
The overall objective of this project was to assess the potential of offal from an 
example o f a farmed, fresh-water fish species, Oncorhynchus mykiss (rainbow trout), 
as a potential source o f n-3 PUFAs for nutraceutical development. The project was 
divided into three distinct phases as described below.
a) Determination of Lipid and Fattv Acid Composition of Oncorhvnchus 
mvkiss Tissues
Waste by-products from fish farms are currently disposed of at economic cost and this 
process is stringently regulated by government policies. We set out to determine if 
the n-3 PUFA content in farmed fish waste was adequate to allow the offal to be 
processed into products (e.g. dietary supplements) for human/animal consumption. 
We used Oncorhynchus mykiss offal from Crucomey Trout Farm, Abergavenny, to 
test for the levels o f n-3 PUFAs. We set out to report qualitative and quantitative data 
of the complex acyl lipids and fatty acids, with specific interest in EPA and DHA, in 
tissues o f Oncorhynchus mykiss.
b) Determination of the Effect of Storage Time and Extraction Method on 
Lipid Yields from Different Sources of Oncorhvnchus mvkiss Offal
Fish farm waste is generated on a daily basis and normally stored on-site for some 
time prior to treatment and disposal. As the waste is currently not processed, these 
storage conditions are generally not suitable for the storage of lipid-saturated tissues 
because they can result in the oxidation o f the unsaturated compounds especially EPA 
and DHA. We conducted research to determine the effect of storage time on the 
qualitative and quantitative composition o f fish lipids and PUFAs. Also, the effect o f 
processing was determined by comparison of a laboratory-based extraction procedure 
with two adaptations of industrial-based procedures.
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c) Testing of Trout-Derived Oil for Beneficial Effects using an in vitro Model 
of Osteoarthritis
As previously outlined, n-3 PUFAs have been identified as having beneficial effects 
for human health and can alleviate diseases such as arthritis. EPA and DHA have 
previously been suggested to elicit protective effects in patients suffering from 
rheumatoid arthritis and, more recently, for in vitro models of OA. We sought to 
determine if  a trout oil preparation could induce protective effects on a model tissue 
culture system o f OA. Parameters measured included the effect of trout-derived fatty 
acids in comparison to n-3 PUFAs on mRNA levels for degradative and inflammatory 
enzymes known to be involved in OA pathology and on connective tissue 
degradation.
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CHAPTER 2 
General Materials and Methods
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2.0 Lipid Extraction
Lipids are present in tissues in numerous physical forms for example; the non-polar 
lipids (mainly triacylglycerols) tend to be found as part of large deposits in storage 
tissues whereas the more complex lipids tend to be constituents of membranes where 
they are closely associated with proteins. In order to efficiently extract lipids from 
tissues it is necessary to select solvents that will dissolve the lipids present while 
overcoming the interactions between the lipids and other cellular components. When 
correctly done lipid extraction separates cellular lipids from all other cellular constituents 
while preserving these lipids for further analysis.
Total lipid was extracted from all organs by the method of Garbus et al. (1963). This 
method is a modification of an earlier procedure of Bligh and Dyer (1959) and employs 
a two-phase extraction procedure using chloroform/methanol (2:1 by vol.) and a 2 M 
potassium chloride (KC1) salt solution in phosphate buffer. The high salt solution forces 
phospholipids into the organic phase of the extraction mixture and the phosphate buffer 
combines with calcium allowing the extraction of those lipids which are more resistant 
to extraction, such as the phosphoinositides, which are known to form calcium protein 
complexes reducing the extraction efficiency. Specific details (volumes etc) for lipid 
extraction from different tissues are outlined in sections 3.3, 3.4.
2.1 Lipid Analysis
2.1.1 Individual Lipid Class Separation bv Thin Laver Chromatography
Thin-layer chromatography (TLC) is a well-established method used to separate 
complex lipid mixtures into their component lipids. It employs the use of a stationary 
phase which consists o f an adsorbent material, silica gel being the most common. The 
sample to be analysed is applied to the adsorbent which is immobilised onto a glass 
support. The TLC plate is then placed into a chamber containing a particular solvent 
system. As the solvent system migrates on the TLC plate and passes through the 
sample the analytes partition between stationary and moving phases. When using 
silica-based TLC plates the separation o f the individual components is dependent on 
numerous components such as the external polarity of the stationary and moving
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phases. With regard to silica-based plates, the less polar the compound the greater the 
distance travelled by the individual components of the analyte. The distance travelled 
by the analyte is known as the Rf value which is the distance travelled by the 
components divided by the distance travelled by the solvent as measured from the 
origin. Comparison of Rf values is one method used in identifying the components. 
Although other adsorbents can be used, silica gel is the most common. A pore size of 
60 pm was used to separate individual lipids.
Polar and non-polar lipids were separated by (TLC) on silica gel G 60 plates (Merck, 
Germany) which had previously been activated by heating them to 100 °C for 1 h. 
The water content is an important factor in TLC as it determines the polarity of the 
adsorbent. Therefore, in order to decrease the water content and ‘activate’ the plates, 
heating to 100 °C for 1 h was used prior to analysis of the mixture. Appropriate 
solvent systems for the separation of polar and non-polar lipids were used (section
2.1.2, 2.1.3, Table 2.1).
2.1.2 Polar Lipids
Initially, a two-dimensional solvent system was prepared to separate the polar lipids 
present in each extract. Solvent I consisted of the chloroform/methanol/water 
(65:25:4 by vol.) and solvent system II consisted of 
chloroform/acetone/methanol/acetic acid/water (50:20:10:10:5 by vol.). The lipid 
extract was applied as a spot in one comer of the activated TLC plate which was then 
inserted into a TLC chamber which contained solvent system I. When the solvent 
approached the top o f the TLC plate, the plate was removed and any residual solvent 
was allowed to evaporate under nitrogen before the plate was rotated 90° and inserted 
into another TLC chamber containing the second solvent system. When the solvent 
had run to completion the plate was removed. Any residual solvent was evaporated 
and the plates were dried. Plates were then stained with lipid-specific dyes for lipid 
identification (Kates, 1986) or with a non-destructive agent such as 4-amino-3- 
hydroxyl-l-naphthalenesulfonic acid (ANSA) (see section 2.1.4).
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2.13 Non-Polar Lipids
A suitable non-polar two-dimensional solvent system was employed to separate the 
non-polar lipids of a sample. Solvent system I consisted of toluene/hexane/formic 
acid (140/60/1 by vol.) and the solvent system II consisted of hexane/diethyl 
ether/formic acid (60/40/1 by vol.). The same procedure used for the polar lipids was 
also employed here. Identification of lipids was done by co-chromatography using 
authentic non-polar standards (Sigma, UK) and by the use of specific colour reagents 
(Kates, 1986).
As outlined a two-dimensional system was used to identify all lipids present in 
samples. The advantage o f two-dimensional TLC is that only small amount of lipid is 
required for identification purposes. However, once all major polar and non-polar 
lipids in each sample had been appropriately determined a one-dimensional TLC 
system was employed.
2.1.4 Identification of Lipids
Since lipids separated are usually colourless, specific stains were used to locate the 
lipid spots and also to identify individual lipids.
Ninhydrin reagent (0.25 g reagent grade ninhydrin in acetone (100ml), prepared fresh) 
reacts with lipids and phosphatides containing primary amino groups and, therefore, 
was used for the verification of phosphoethanolamine (PE), phosphatidylserine (PS) 
and their lyso derivatives. Where present, these lipids appeared as pink/mauve spots.
A second lipid stain, Dragendorff stain (Beiss, 1964; Wagner and Hoerhammer, 1961) 
(solution I: 2.7 g bismuth nitrate in 100 ml 20% acetic acid; solution II: 10 g KI in 25 
ml water) was used. Before use 20 ml solution I was mixed with 5 ml solution II and 
diluted with 70 ml water). Dragendorff reagent is used to detect choline-containing 
lipids such as PC, lyso-PC and sphingomyelin. It identifies these lipids by binding to 
the quaternary ammonium groups present in their structures giving rise to a 
yellow/orange spot.
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Lipid location was also revealed under UV light. Plates were sprayed with 0.05% 
(w/v) ANSA in methanol and, when examined under UV light, lipid location was 
visible. ANSA is a non-destructive reagent and was employed when further analysis 
of the lipids was required.
A method for charring the lipids present was also undertaken. Plates were removed 
from the TLC chamber, residual solvent was allowed to evaporate and plates were 
then sprayed with sulphuric acid (10%, by vol.) in methanol. The plate was placed on 
a heating block and as the temperature o f the plate increased the lipids were charred 
by the acid and appeared as black spots on the plate. This further enabled the 
visualisation and identification of individual lipids.
In conjunction with the outlined specific colour reagents, known authentic standards 
(Sigma, UK; Nu-Check, USA), were used to confirm identification of lipids. The 
standards were run under identical chromatographic conditions as the sample and 
compared so that identification was achieved by co-chromatography. Once lipids had 
been identified, a non-destructive staining method such as iodine vapour or ANSA 
was used to locate lipids.
2.1.5 One Dimensional Separation -  Polar and Non-Polar Lipids
One-dimensional TLC may be considered as efficient as common two-dimensional 
techniques. A major advantage o f employing a one-dimensional system is that more 
lipid extract may be applied and sufficiently separated thus reducing the number of 
plates needed for lipid separation. It is also a faster technique. As with the two- 
dimensional system an appropriate solvent system needs to be used for efficient 
separation. The solvent systems used are outlined in Table 2.1 (Hamilton and 
Hamilton, 1992).
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Table 2.1: One-dimensional solvent systems used for the routine separation of
polar and non-polar lipid classes by thin-layer chromatography (TLC).
POLAR NON-POLAR
Solvents V olu m e
(m l)
Solven ts V olum e
(m l)
Methyl acetate 25 Hexane 80
Propan-2-ol 25 Diethyl ether 20
Chloroform 25 A cetic acid 2
Methanol 10
0.25% Potassium chloride 9
23 Preparation of Fatty Acid Methyl Esters
Before lipid samples can be analysed by gas liquid chromatography (GLC) it is 
necessary to convert them to volatile derivatives, for example methyl esters. This has 
the added benefit o f improving GLC peak shape and resolution. Acid-catalysed 
esterification and transesterification involves esterifying and transesteritying non- 
esterified fatty acids and 0 -acyl lipids respectively by heating them with an excess of 
anhydrous methanol in conjunction with an acid catalyst.
H+
RCOOR’ + CHjOH ■*----------------► RCOOCH3 + R’OH
RCOOH + CH3OH t ----— ----- ► RCOOCH3 + H20
Choosing the correct derivatization of fatty acids depends on the type of analysis to be 
performed. For GLC analysis, acid-catalysed esterification and transesterification was 
chosen. An aliquot of total lipid extract or individual lipids (separated by TLC) was 
added to 2.5% H2S 0 4 in dry methanol/toluene 2:1 (v/v) (3 ml). A known volume of 
internal standard. C l5:0 in toluene (1 pg/pl), was added. Samples were refluxed at 70 °C
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for 2 h. Care was taken not to avoid any possible decomposition of PUFAs by avoiding 
super heating the samples or storing for inappropriate lengths of time.
To extract the methyl esters, 5% aqueous sodium chloride (3 ml) was added to the 
sample and the methyl esters were extracted with analytical grade petroleum ether (60 -  
80°C fraction) (Fischer, UK) (3 ml x 2) using Pasteur pipettes to separate the layers. The 
extracted petroleum ether layer was washed with 2% aqueous potassium bicarbonate 
which was added to neutralise any residual acid that may be present in the sample. The 
extracted methyl esters were dried with anhydrous sodium sulphate and evaporated 
under nitrogen. Samples were re-dissolved in a known volume of high performance 
liquid chromatography HPLC grade hexane (Fisher Scientific, UK) and transferred to 
glass gas liquid chromatography injection vials (Chromacol Ltd., UK). Samples were 
injected into a Clarus 500 (Perkin Elmer, Connecticut) gas chromatograph (GC) fitted 
with a flame ionising detector (FID) (Perkin-Elmer, Connecticut). A polar capillary 
column (30 m x 0.25 mm) (Elite 225 Perkin Elmer, USA) was used for fatty acid 
analysis.
23  Gas Liquid Chrom atography
GLC is an important technique used to analyse the fatty acid derivatives of lipids. The 
principle is based on vaporising the analyte which is carried by an inert gas known as the 
mobile phase. On reaching the oven the temperature is gradually increased in order to 
increase vapour pressures and allow analysis time to be reduced. As the analyte moves 
through the GLC it passes through the stationary phase, a long cylindrical column with 
an inert polymer bound to it. Capillary columns are most common today as they allow 
greater separation and better resolution in the resulting peaks. The different physical and 
chemical prosperities of the anlayte’s components absorb onto the stationary phase to 
different degrees resulting in different elution times for each component. As the analyte 
leaves the column it is combusted and the resulting ions bombarding the detector are 
recorded giving rise to the resulting chromatograms. The signal recorded relates to the 
proportion of reduced carbon atoms in the flame meaning that the detector is sensitive to 
mass rather than concentration.
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Fatty acid profiles were determined by gas liquid chromatography (GLC). The 
temperature programmed employed was: 170°C for 3 min, followed by heating at 220°C 
at 4°C/miru and finally 220°C for 15 min. The advantage of using a temperature 
programme means that the oven temperature is initially low allowing the elution of the 
more volatile components. The oven temperature is then gradually increased at a 
constant rate allowing an increase in vapour pressure and quicker analytical times as the 
elution of the less volatile components becomes faster with the increased vapour 
pressure. The carrier was nitrogen at a flow rate of 10 ml/min. A split ratio of 20:1 was 
employed. Using a split ratio has the advantage of ensuring rapid delivery of the sample 
into the column. The FAME were identified by comparing retention times (RT) with 
those obtained from a fish oil standard, menhaden oil, (Sigma, UK) as well as specific 
fatty acid standards (Nu-Chek Prep. Inc., USA).
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CHAPTER 3
Lipid and Fatty Acid Composition o f Farmed Fresh-Water
Oncorhvnchus my kiss
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3.0 Introduction
Fish is considered an important global commodity and fish oils, containing PUFAs are 
considered valuable nutritional components. Since it was reported by Bang et al. (1971) 
and Bang and Dyerberg (1980) that a high intake of n-3 PUFAs in the Greenland Eskimo 
population reduced cardiovascular mortality, the scientific interest in n-3 PUFAs has 
developed exponentially. Currently there is an abundance of evidence supporting the 
theory that n-3 PUFAs can have protective roles a variety of disease states, including 
coronary artery disease, most notably sudden cardiac death (Leaf et al., 2003; Metcalf et 
al., 2007), cancer (Chang et al., 1997; Chapkin et al., 2007; Reddy et al., 1991;), 
neurodevelopmental and neurological disorders (Green et al., 2007; Schaefer et al., 
2006), RA (Calder and Zurier, 2001; Leeb et a l,  2006) and a host of other chronic 
inflammatory conditions (Calder and Grimble, 2002). The evidence to support the 
beneficial effects of n-3 PUFAs is so convincing that the American Heart Association 
(AHA) recommends at least two servings of oily fish per week in conjunction with foods 
rich in a-linolenic acid (Kris-Etherton et al., 2002). Also, in the UK, current daily 
recommendations for adults are 450 mg/d EPA and DHA (Givens and Gibbs, 2008).
Much debate exists over the classification of EFAs (Cunnane, 2003). However, despite 
this ongoing debate, it is generally accepted that the 18 carbon n-6 and n-3 fatty acids, 
linoleic and a-linolenic acid, are considered to be EFAs. Both linoleic and a-linolenic 
can be converted to the longer chain PUFAs, AA, EPA and DHA by a series of 
elongation and desaturation steps that occur in the endoplasmic reticulum of the liver 
(Arterbum et al., 2006). However, the rate of conversion from the 18 carbons to the long 
chain PUFAs is extremely limited in humans (Plourde and Cunnane, 2007) and, because 
of this, both EPA and DHA are often classified as EFAs also. Due to this they are 
incorporated into infant formulae to ensure sufficient levels for normal infant 
development (Crawford, 1993).
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The main sources of EPA and DHA in the diet are fish and fish oils. Unlike mammals, 
fish cellular membranes contain low levels of AA but accumulate rather significant levels 
of EPA and DHA (Cejas et al., 2004) and are, therefore, a particularly rich source of 
these long chain PUFAs. However, their quantities are dependent on several parameters 
including species and can be influenced by various environmental factors including the 
diet (Bandarra et al., 2006; Gulliou et al., 1995; Turchini et al., 2006; Visentainer et al., 
2005), sex (Satue and Lopez, 1996), salinity of the environment, (Cordier et al., 2002; 
Innis et al., 1995), surrounding water temperature and season (Hazel, 1979; Luzia et al., 
2003; Senso et al., 2007).
Another important factor which can affect EPA and DHA levels is whether the fish are 
wild or farm-reared (Abrami et al., 1992; George and Bhopal, 1995). Presently, wild fish 
stocks are at historically low levels and it has been estimated that only 10% of big-fish 
(e.g. tuna, swordfish) stocks and large ground-fish (e.g. cod, halibut, skates) remain in the 
seas (Myers and Worm, 2003). The International Council for Exploration of the Sea 
(ICES) have, for some time, being advising governments to implement the closure of 
several fisheries in order to avoid complete eradication of certain fish species 
(www.ices.dk). The Canadian fishing industry is a prime example of how dire the 
situation has become. Over ten years ago several Canadian Atlantic cod populations had 
been reduced to such critical levels that a moratorium was implemented on the fishing 
industry (Myers and Worm, 2003). In the years since this implementation it appears the 
cod stocks together with the fishing industry have yet to recover (Schrank, 2005).
Thus wild fisheries have reached a critical cross-road and for several years the output 
from the traditional fishing industry has stagnated. In accordance with the problems 
faced by wild fisheries the aquaculture industry has risen dramatically in previous years 
(Naylor et al., 2000). One example is that of farm-reared salmon. The output of farm- 
reared salmon now surpasses the landing of wild salmon (Hannesson, 2003) and it is 
estimated that the production of aquaculture has more than doubled in the last two 
decades (Food and Agricultural Organisation, 1999). However, the aquaculture industry 
is not without problems and one such problem encountered by the aquaculture industry is
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the belief that farm-reared fish contained less n-3 PUFAs than their wild counter-parts. 
However, recent findings have found this perception to be inaccurate (Cahu et al.. 2004). 
In fact it has been reported that, in general, fanned fish have higher total lipid levels than 
wild fish and that on an equal weight basis farmed fish fillets provided greater levels of n- 
3 PUFAs (especially EPA and DHA) than wild fish fillets (Cahu et al. 2004). In 
agreement with this idea, it has also been documented that farm-raised salmon and trout 
contain similar levels of EPA and DHA compared to their wild-type counterparts (Kris- 
Etherton et al.. 2002). Moreover, it has been reported that farmed salmon contained more 
than twice the fat as their wild counter-part whereas farmed catfish were noted as having 
five times the fat levels as wild catfish (Nettleton and Exler. 1992). Differences between 
wild and captive fish may be due to dietary manipulation of captive fish which are fed 
nutrient controlled diets (often containing fish lipids) compared to the wild counterparts 
whose diet is predominantly habitat-dependent.
As with marine fisheries, aquaculture produces vast quantities of waste and stringent 
regulations exist on disposal and treatment of aquaculture generated waste 
(www.scotland.gov.uk/Publications/2005/03;www.defra.gov.uk). Treatment and
disposal have large economical and environmental implications for the industry. 
Elementary investigation has shown farmed fish waste to be enriched with valuable n-3 
PUFAs (Kolakowska et al.. 2006) and the logic of disposing of such a rich source of n-3 
PUFAs needs to be revised. The objective of this study was to analyse the various tissues 
of farmed trout (Oncorhynchus mykiss) and components of fish waste and determine if 
the latter would be a suitable source of n-3 PUFAs.
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Chapter 3: Materials & Methods
3.1 Collection and Dissection of Rainbow Trout (Oncorhvnchus mvkiss)
Rainbow trout (Oncorhvnchus mvkiss) fed preformed pellets were obtained from 
Crucomey trout farm. Wales. Fish were killed immediately, covered in ice to prevent 
any degradation and transported back to the laboratory for immediate dissection. On 
arrival at the laboratory the fish were weighed before immediately being dissected.
3.2 Removal of Organs for Analysis
Organs selected for analysis included: liver, muscle, heart, spleen, adipose tissue 
(visceral), brain and eyes. An incision was made behind the pectoral fin and along the 
full length of the underside of the body to the tail fin. Once removed from the fish all 
tissues were rinsed or perfused (heart and liver) with physiological saline (0.9%, w/v) 
and weighed.
33 Extraction of Trout Lipids
Trout lipids were extracted using the Garbus method (Garbus et al., 1963) as previously 
described (section 2.0). Immediately after weighing, the tissues were homogenised in 3 
ml chloroform/methanol (1:2. by vol.) using a mortar and pestle and transferred to 10 ml 
glass tubes. The mortar and pestle were rinsed with 2 ml chloroform/methanol (1:2, by 
vol.) and this was added to the sample. After allowing extraction at room temperature for 
at least 15 minutes, the homogenate was filtered through glass wool in order to remove 
any solid material. Chloroform (2 ml) was added to the extract, followed by 2 ml Garbus 
solution (2 M KC1 in 0.5 M potassium phosphate buffer, pH 7.4) and 2 ml distilled water.
Samples were vortexed and centrifuged on a Baird & Tatlock Auto Bench Centrifuge 
Mark IV for 5 min at 1000 x gav in order to separate the sample into two phases. The 
upper aqueous layer was removed and discarded using Pasteur pipettes. The lower lipid- 
containing layer was transferred to a clean 5 ml glass tube and dried under a stream of 
nitrogen. Lipids were dissolved in a known volume of chloroform and 0.05% (w/v) 
butylated hydroxytoluene was added. All samples were stored at -20°C under nitrogen.
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3.4 Separation of Individual Lipids using Thin Laver Chromatography 
and Preparation of Methyl Esters for Gas Chromatographic 
Analysis
See section 2.1 -  2.3 for standard methods.
3.5 Silver Nitrate Thin Laver Chromatography
Silver nitrate TLC involves the incorporation of silver ions with stationary phase, usually 
the silica gel. This form of TLC is an effective tool to use when it is necessary to 
separate lipids according to the number of c/s-double bonds present in the fatty acids. 
The purpose of employing silver nitrate-TLC was to aid the identification of particular 
fatty acids (20:1 and 22:1). When a lipid sample is applied to the silver ion-TLC 
impregnated plate, complexes between the silver ions and the double bonds of fatty acids 
are formed. Other parameters which influence the separation of fatty acids are whether 
the bonds are in the cis or trans conformation, the position of the double bonds in the 
aliphatic chain as well as the chain length (Christie, 2003). Lipids samples must be 
derivatised (e.g. converted to fatty acid methyl esters (FAMEs)) before silver ion TLC.
Silica gel 60 plates (Merck, Germany) were impregnated with silver nitrate by 
immersing the plates for 1 min into a solution of 4% silver nitrate in methanol/water 
(9/1, by vol). Plates were drained and dried for 2 min in dim light (to prevent the 
oxidation of the silver ions) in a well-ventilated fume hood. Plates were stored 
desiccated in the dark until required.
Two separate solvent systems were used to develop the plates. The first solvent 
system, hexane/diethyl ether (90:10, by vol.) was used to separate saturated, 
monounsaturated and di-unsaturated fatty acids. The second system consisting of 
toluene/ethyl acetate (90:10, by vol.) and was used for appropriate separation of 
PUFAs. To separate the fatty acids, an aliquot of FAMEs was applied to the pre­
activated plate (100°C x 1 h) and the plate was placed in a TLC solvent chamber. 
When the solvent front had reached the top of the plate, plates were removed and dried 
in a stream of cold air. To reveal the location o f the fatty acids, plates were sprayed 
with water and the positions of the separated fatty acid bands compared to standards.
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To elute the fatty acids from the silica gel, hexane/diethyl ether (1:1, by vol.) (6 ml) 
was added to the scraped bands and vortexed. Aqueous 20% sodium chloride (1 ml) 
was added, the tube sealed and the mixture vortexed. It was not necessary to 
centrifuge the samples as the aqueous and lipid layers separated easily. The top 
organic layer was removed to a clean tube. The extraction of fatty acids was repeated 
twice more and the organic layers of each elution combined. Samples were taken to 
dryness under nitrogen and the lipid components were dissolved in a known volume of 
hexane before being analysed by GLC (sections 2.3, 2.4).
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Chapter 3: Results
3.6 Percentage Fatty Acid Composition of Feed for Oncorhvnchus
mvkiss
An abundance of evidence has shown that the fatty acid composition of the diet is 
reflected in the acyl make up of the fish especially when storage TAG is accumulated 
(Bell et al., 1997; Miller et al., 2007; Torstensen et al., 2005). The aquaculture 
system used to produce the Oncorhynchus mykiss used specifically designed food 
pellets to fulfil the nutritional requirements of the fish. According to the 
manufacturer's details these pellets contained approximately 40% crude protein, 15% 
oil, 6% fibre and 6% ash (Benthan Trout Farming Limited, UK) (we assume the 
remainder 33% to be carbohydrate). Based on total acyl composition we determined 
the total lipid content of the feed to be 70 mg fatty acid/g feed. The percentage acyl 
distribution in the feed is illustrated overleaf (Table 3.1).
Individual fatty acids were identified by co-chromatography with known standards 
(Nu-Check Prep.. USA). Some fatty acids were more difficult to identify (20:1 
isomers and 22:1) and were first separated by silver nitrate TLC (section 3.5) to 
determine the degree of unsaturation. Following this co-chromatography was used. 
However, we were only able to identify one of the 20:1 isomers (n-9). The literature 
widely reports the presence of high quantities of 20:1 n-9 and minor levels of 20:1 n- 
11 in fish oils. However, we were unable to confirm the identity of the second 20:1 
isomer as n-11 by co-chromatography or GC-MS although it is highly likely to be the 
n-11 isomer.
The principle saturated fatty acids included 16:0, 14:0 and 18:0. The 
monounsaturated fatty acids, by quanity, were 18:1 n-9 >22:1 > 20:1 n-9 >16:1 n-7 > 
18:1 n-7 > 20:1. The literature states that dietary lipids are reflected in tissue 
compositions so we assumed that these fatty acids would be commonly found in the 
organs analysed. EPA was present at approximately 5% (3.6 mg EPA/g wet weight of 
feed) whilst DHA composed approximately 8% of the acyl composition (5.5 mg 
DHA/g wet weight of feed).
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Table 3.1: Fatty acid analysis of food pellets used in the aquaculture of
Oncorhynchus my kiss. Results as means ± SD. tr., trace (< 0.05).
Fatty Acid Feed
(n=3)
14:0 3.4 ± 0 .1
16:0 12.9 ± 0.6
16:1 n-7 4.3 ± 0 .1
16:2 n-4 0.2 ± tr.
16:3 n-4 0.1 ± tr.
18:0 2.5 ± 0 .1
18:1 n-9 18.0 ± 0.9
18:1 n-7 3.2 ± 0 .1
18:2 n-6 0.3 ± tr.
18:3 n-3 14.4 ± 1.0
18:3 n-4 1.5 ± 0.1
18:4 n-3 1.6 ± 0.1
20:1 n-9 8.7 ± 0.4
20:1 0.4 ± tr.
20:4 n-6 0.2 ± tr.
20:4 n-3 3.7 ± 0 . 2
20:5 n-3 5.2 ± 0.2
22:1 9.4 ±  0.5
22:2 0.3 ±  tr.
22:5 n-3 1.8 ± 0.1
22:6 n-3 7.9 ± 0.3
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3.7 Total Lipid Extracted from Oncorhvnchus mvkiss Tissues
The range of total lipid found in individual tissues of Oncorhynchus mykiss was from 
14 mg/g fresh weight to 190 mg/g fresh weight (Fig. 3.1). As expected, the visceral 
adipose tissue yielded the highest levels of total lipid (190 mg/g fresh weight). Brain 
also contained comparable total levels (180 mg/g fresh weight). Total lipids from the 
eye showed significantly higher levels than the other organs (apart from adipose tissue 
and brain) with approximately 40 mg/g fresh weight. The liver, heart, muscle and 
spleen were found to contain rather similar levels o f total lipid extract ranging from 
approximately 18 mg/g fresh weight for liver and heart to about 15 mg/g fresh weight 
for muscle and spleen.
Fig- 3.1: Total lipid extracted from individual tissues of Oncorhynchus mykiss
(mg lipid/g fresh weight). Results as means ± SD. Adipose = visceral 
adipose tissue.
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3.8 Individual Lipids Found in Oncorhvnchus mvkiss Tissues
3.8.1 Polar Lipids from Oncorhvnchus mvkiss
The principal polar lipids (for identification method see section 2.1.4) found in all 
tissues consisted of phosphatidylcholine (PC), phosphatidylethanolamine, (PE), 
phosphatidylinositol (PI) and phosphatidylserine (PS) with minor levels of 
sphingomyelin (SPH), diphosphatidylglycerol (DPG) and lyso-phosphatidylcholine 
(lyso-PC) also detected in some tissues (Table 3.2). PC was the main lipid found in 
all organs except adipose tissue where it constituted approximately 14% of the total 
polar lipids detected. In all other organs PC represented approximately 50% of the 
total polar lipids present. However, in the spleen PC accounted for only 30% of polar 
lipids. PE was presented in approximately equal distribution, 20%, across all organs 
analysed. In terms of percentage polar lipids, PI was present in the highest amounts 
in adipose tissue, 31%, whereas in all other organs examined PI accounted for 
approximately 11% of the total polar lipids. The spleen did show a slightly elevated 
level of PI, 2.2 mg/g fresh weight (18%). PS was present in all organs at 
approximately 8% although there were two exceptions to this rule. Both adipose 
tissue and spleen displayed almost four times the levels of PS found in the other 
organs, approximately 32%. In both the brain and adipose tissue SPH consisted of 
approximately 12% o f the total polar lipids whereas in all other organs it composed 
approximately 2.5% o f the polar lipids. The heart was seen to have the highest levels 
of DPG, consisting of 8% total polar lipids. This was consistent with the high 
mitochondrial content of heart and the localisation of DPG in the inner mitochondrial 
membrane. Brain and muscle contained approximately 6% and 7% respectively 
whilst DPG was found to compose 4% and 2.5% of liver and spleen polar lipids 
respectively. No DPG was detected in the eye or adipose tissue, two tissues with a 
very low mitochondrial content. The rather unusual polar lipid content of adipose 
tissue may have been due to its relative paucity of internal membranes. Lyso-PC was 
detected in the heart, eye, spleen and liver at the following levels 9%, 6%, 2.5% and 
1.6% respectively. No lyso-PC was detected in the adipose tissue, brain or muscle.
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Table 3.2: Polar acyl lipids detected in various tissues of Oncorhynchus mykiss
(mg fatty acid/g fresh weight). Results as means ± SD n=4. Adipose 
= visceral adipose tissue. Percentages are given in parenthesis, n.d., 
none detected; tr. < 0.05.
mg fatty acid/g fresh wt.
Tissue PC PE PI PS SPH DPG Lyso-PC Total
Adipose 0.6 ± 0 .3 0.5 ± 0 .2 1.3 ± 0 . 2 1.3 ± 0 . 5 0.5 ± 0 .1 n.d. n.d. 4.2
(14) (12) (31) (31) (12) (100)
Brain 1.2 ± 0.3 0.5 ± 0.2 0.3 ± 0 .1 0.3 ± 0 .1 0.3 ± 0 .1 0.2 ± tr. n.d. 2.8
(43) (17) (11) (11) (11) (7) (100)
Eye 7.7 ± 2 .4 3.3 ± 1.1 1.7 ± 0.5 1.3 ± 0 . 5 0.3 ± 0 .1 n.d. 0.6 ± 0.2 14.9
(52) (22) (11) (9) (2) (4) (100)
Heart 2.3 ± 0 .4 1.2 ± 0 .5 0.4 ± 0 .1 0.3 ± 0.3 0.2 ± 0 .1 0.4 ±0 .1 0.5 ± 0.2 5.3
(43) (23) (8) (6) (3) (8) (9) (100)
Liver 6.6 ± 1.4 2.7 ± 0 . 8 1.3 ± 04 0.7 ± 0 .1 0.3 ± 0 .1 0.5 ±0 .1 0.2 ± tr. 12.3
(54) (22) (11) (5) (2) (4) (2) (100)
Muscle 1.5 ± 0 . 4 0.7 ± 0 .3 0.4 ± 0 .1 0.3 ± 0 .1 0.1 ± tr. 0.2 ±0 .1 n.d. 3.2
(47) (22) (13) (9) (3) (6) (100)
Spleen 3.5 ± 1.3 2 .0  ± 0 . 2 2.2 ± tr. 4 .0  ± 1.8 0.2 ± tr. 0.3 ± tr. 0.3 ±0 .1 12.5
(28) (16) (18) (32) (1) (2) (2) (100)
*PC, Phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; SPH, 
sphingomyelin; DPG, diphosphatidylglycerol and lyso-PC, lyso-phosphatidylcholine.
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3.8.2 Non-Polar Lipids from Oncorhvnchus mvkiss
In terms of the non-polar lipids identified, as expected, TAG was the major lipid 
detected representing over 90% of the total non-polar lipids in most tissues (Table 
3.3). The level of TAG in heart tissue was the only exception where approximately 
75% of non-polar lipids consisted o f TAG. The remaining non-polar lipids in heart 
consisted of 12% 1,2-diacylglycerol (1,2 DAG), 9% 1,3-diacylglycerol (1,3 DAG) 
and 9% non-esterified fatty acids (NEFAs).
Table 3.3: Non-polar acyl lipids detected in tissues of Oncorhynchus mykiss (mg
fatty acid/g fresh weight). Results as means ± SD (n=5). Adipose = 
visceral adipose tissue. Percentages given in parenthesis, n.d., none 
detected; tr. < 0.05).
mg fatty acid/g fresh w t
Tissue TAG 1,2 DAG 1,3 DAG NEFA Total
Adipose 131.6 ± 33.7 4.1 ± 2 . 0 4.1 ± 2 .1 n.d. 139.8
(94) (3) (3) (100)
Brain 122.4 ± 59.8 0.6 ± 0 . 2 0.5 ± 0 .1 1.6 ± 0 .7 125.1
(98) (0-5) (0.4) (1.3) (100)
Eye 27.1 ± 10.0 0.1 ± tr. 0.2 ± 0 .1 0.1 ± tr. 27.5
(99) (0.4) (0.7) (0.4) (100)
Heart 2.5 ± 1.2 0.4 ± 0.2 0.3 ± 0 .1 0.3 ±0 .1 3.3
(76) (12) (9) (9) (100)
Liver 2.0 ± 0.3 0.1 ± tr. 0.1 ± tr. n.d. 2.2
(91) (4.5) (4.5) (100)
Muscle 20.2 ± 8.0 0.1 ± tr. 0.1 ± tr. 0.2 ±0 .1 20.6
(98) (0.5) (0.5) (1.0) (100)
Spleen 6.6 ± 1.4 0.1 ± tr. 0.2 ± tr. 0.2 ± tr. 7.1
(93) (1.4) (2.8) (2.8) (100)
*TAG, Triacylglycerol; 1.2-DAG, 1,2 diacylglycerol; 1,3-DAG, 1.3 diacylglycerol; NEFAs, non- 
esterified fatty acids.
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3.5 Acyl Distribution in Phosphatidylcholine from Individual Tissues
of Oncorhvnchus mvkiss
Some notable differences in the fatty acid composition of PC were apparent when the lipid 
was isolated from individual tissues of Oncorhynchus mykiss (Table 3.4). Variable levels of 
the principle saturated fatty acid, palmitic acid (16:0) were observed. PC from brain, heart 
and muscle had the greatest level with approximately 40% 16:0. PC from spleen was seen to 
be composed of 35% palmitic acid whilst the eye and liver demonstrated approximately 
28%. The lowest level of 16:0 was detected in adipose tissue. Elevated levels of palmitoleic 
acid (16:1 n-7) were detected in adipose tissue (6%). Lower levels were observed in the 
brain and eye (approximately 2.3%) while the liver, muscle and spleen demonstrated 
approximately 1.4% 16:1 n-7 in PC. Variable levels of stearic acid (18:0) were also found in 
different tissues. Adipose tissue, brain, eye and liver all contained approximately 8% 18:0. 
PC from heart and spleen contained half o f this amount (4%) while muscle PC only 
contained approximately 2% 18:0. Oleic acid, 18:1 n-9, was the principle monounsaturated 
fatty acid in PC from all tissues except adipose (13%). Highest levels of 18:1 n-9 were 
found in the eye and spleen, 19% and 23% respectively. PC from the remaining tissues was 
composed of approximately 11% 18:1 n-9. The n-6 fatty acid, 18:2, was present in PC from 
all tissues at approximately 3% with the exception of the eye (1.7%). PC present in adipose 
differed significantly from the other tissues in terms of the principle monounsaturated fatty 
acids. The major monounsaturated fatty acids in adipose tissue consisted of eicosaenoic 
acid, 20:1 n-9; oleic acid, 18:1; docosaenoic acid, 22:1 and palmitoleic acid, 16:1 n-7. Both 
20:1 n-9 and 22:1 were found at significantly elevated levels in PC from adipose tissue (15% 
and 8% respectively) compared to other tissues. PC from the remaining organs was 
composed of approximately 2.5% 20:1 although slightly elevated levels were detected in the 
liver, 5%. 22:1 was only found at approximately 1% in all tissues except liver where it 
constituted 2.4% of PC. AA (20:4 n-6) was present in particularly low levels in PC from 
brain, eye and liver (0.4%). In PC from muscle and spleen AA constituted approximately 
1% while no AA was detected in PC from adipose tissue. EPA, (20:5 n-3) was also not 
detected in PC from adipose tissue but was observed at approximately 5% in heart, liver, 
muscle and spleen. However, in both the brain and eye PC contained only 1.5% EPA.
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DHA, 22:6 n-3, was the second most abundant fatty acid detected in all tissues with the 
exception of adipose. DHA was highest in PC from liver and muscle (30%), whereas heart 
and eye contained approximately 25%. Lower levels were observed in the brain and spleen, 
18% and 13% respectively whilst PC from adipose tissue was contained 8% DHA.
3.6 Acyl Distribution in Phosphatidylethanolamine from Individual Tissues
of Oncorhvnchus mvkiss
Differences in the fatty acid profile of PE from individual tissues were also observed (Table 
3.5). In contrast to PC, two principal saturated fatty acids in PE were observed. PE from 
brain contained the highest levels of 16:0 and 18:0 (22% and 18% respectively). Heart and 
muscle PE contained approximately 17% 16:0 while 18:0 was approximately 14% and 8% 
respectively. The eye, liver and spleen PE were composed of approximately 11% 16:0 and 
9% 18:0. The principal monounsaturated fatty acid was 18:1 n-9 (approximately 10%) in PE 
from most tissues although 18:1 n-9 constituted approximately 21% of PE in the eye. 
Adipose tissue was an exception where the principal monounsaturated fatty acids were 20:1 
n-9 and 22:1 (21% and 15% respectively). In all other tissues 20:1 n-9 and 22:1 constituted 
approximately 4% and 1-1.5% although slightly elevated levels of 20:1 n-9 were detected in 
PE from the liver and spleen.
In terms of the PUFAs, in general the principal PUFAs observed in PE in all tissues were 
DHA > 18:2 n-6 > EPA = A A. Organs with the greatest levels of AA in PE included the 
brain, eye and spleen (approximately 3%). Reduced levels were detected in heart and 
muscle (1.5% and 1.2%) and less than 0.5% AA was detected in PE from liver. Similar to 
PC no AA was detected in adipose tissue. EPA was similar to AA in that it too was not 
found in PE from adipose tissue. Approximately 3% EPA was observed in PE from eye, 
heart, muscle and spleen whereas liver PE contained 1.5% EPA. Minor levels of EPA were 
detected in the brain (1%). The highest level of DHA, 40%, was present in PE from muscle, 
followed by approximately 35% DHA in PE from the eye, heart, liver and spleen. About 
10% DHA was detected in PE from both adipose tissue and brain.
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Tabic 3.4: Fatty acid analysis of phosphatidylcholine from individual tissues of Oncorhynchus mykiss. Results as means of %
fatty acids ±SD. tr, trace (< 0.05), n.d., none detected.
Fatty Acid Adipose tissue 
n = 5
Brain 
n = 5
Eye 
n = 4
Heart
n= 3
Liver 
n = 5
Muscle
n=5
Spleen 
n = 5
14:0 0.6 ± 0.3 2.7 ± 0 .5 1.5 ±0 .3 1.4 ±0.1 1.6 ± 0 .2 1.8 ± 0 .6 2.1 ± 1.1
16:0 26.6 ± 7.7 39.5 ±2.1 29.5 ± 1.0 40.4 ± 6.2 27.0 ±4 .3 35.9 ± 5.7 39.3 ± 4.8
16:1 n-7 5.9 ± 0 .4 2.6 ± 0.5 2.1 ±0 .5 0.8 ± 0.3 1.5 ± 0 .4 1.3 ± 0 .2 1.4 ± 0 .2
16:2 n-4 2.2 ± 1.7 0.5 ± 0 .3 0.6 ± 0 .9 0.1 ± tr. 0.4 ± tr. 0.2 ± tr. 0.2 ± tr.
16:3 n-4 2.0 ± 1.0 2.4 ± 0 .5 0.6 ±0.1 0.5 ±0.1 0.4 ± tr. 0.6 ± tr. 0.4 ±0.1
18:0 8.1 ± 1.9 8.3 ± 0 .7 8.5 ± 0 .5 4.4 ± 0 .8 7.0 ± 2.0 2.2 ±0 .3 4.1 ± 0 .4
18:1 n-9 13.0 ±5 .3 11.7 ± 2 .4 18.9 ± 1.2 12.6 ± 1.9 11.5 ± 1.3 9.0 ± 1.4 22.5 ± 1.2
18:1 n-7 n.d. 1.6 ± 0 .4 2.4 ± 0 .2 1.5 ± tr. 3.1 ± 0 .9 2.1 ± 0 .2 3.0 ± 1.8
18:2 n-6 4.3 ± 0 .8 2.3 ± 0.4 1.7 ± 1.0 2.2 ± 0 .3 3.4 ± 0 .7 3.2 ±0 .5 2.7 ± 0 .5
18:3 n-3 n.d. 0.5 ± 0 .2 0.1 ± tr. 0.2 ± tr. 0.1 ±0.1 0.2 ± tr. 0.2 ±0.1
18:3 n-4 1.1 ± 0 .6 0.6 ± 0 .2 0.2 ± tr. 0.4 ±0.1 0.3 ±0.1 0.5 ±0.1 0.1 ±0.1
18:4 n-3 n.d. 0.1 ± tr. 0.2 ± tr. 0.2 ±0.1 0.1 ± tr. 0.4 ±0.1 0.1 ± tr.
20:1 n-9 15.2 ± 3 .8 2.4 ± 0.4 2.0 ± 0 .3 1.9 ± 0 .4 5.2 ± 1.8 1.7 ± 0 .2 2.4 ± 0.4
20:1 n.d. 1.4 ± 0 .3 0.8 ± 0 .2 n.d. n.d. n.d. n.d.
20:4 n-6 n.d. 0.4 ±0.1 0.3 ±0.1 1.6 ± 0 .2 0.4 ± 0.2 1.0 ± 0 .2 1.1 ± 0 .6
20:4 n-3 0.9 ± 0.4 0.5 ± 0.2 3.6 ± 0 .2 0.5 ±0.1 0.7 ± 0.3 0.7 ±0.1 0.4 ± 0.2
20:5 n-3 n.d. 2.2 ± 0.4 1.1 ±0.5 5.6 ± 0.8 4.4 ± 2.2 6.5 ± 1.4 3.9 ± 1.1
22:1 7.5 ± 1.3 1.3 ± 0 .3 0.6 ±0.1 0.3 ±0.1 2.4 ± 1.1 0.7 ± 0.2 0.7 ± 0 .2
22:2 5.7 ±2.1 1.1 ± 0 .2 0.8 ±0.1 0.7 ± 0 .3 0.4 ±0.1 0.5 ±0.1 1.0 ± 0 .2
22:5 n-3 n.d. n.d. n.d. 0.7 ±0.1 1.5 ± 0 .4 1.0 ± 0 .3 0.5 ± 0.2
22:6 n-3 8.1 ± 2.7 18.1 ±2.0 25.3 ± 1.4 23.9 ± 3.6 28.7 ± 3.2 30.5 ± 6.7 13.4 ± 4.0
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Table 3.5: Fatty acid analysis of phosphatidylethanolamine from individual tissues of Oncorhynchus mykiss. Results as means of
% fatty acids ± SD. tr, trace (< 0.05), n.d., none detected.
Fatty Acid Adipose tissue 
n = 5
Brain 
n = 5
Eye 
n = 4
Heart 
n = 3
Liver 
n = 5
Muscle
n=5
Spleen 
n = 3
14:0 0.8 ± 0 .2 2.6 ± 1.0 0.5 ± 0 .2 0.5 ± 0 .2 1.7 ± 0 .2 0.4 ± 0.2 0.3 ±0.1
16:0 12.8 ± 2 .2 21.5 ± 2 .9 9.9 ± 1.6 16.7 ± 2 .9 11.4 ± 1.4 16.6 ± 3 .7 10.4 ± 1.6
16:1 n-7 7.3 ±2.1 5.4 ± 1.4 0.9 ± 0 .4 1.3 ± 0 .4 0.7 ± 0 .3 1.5 ± 0 .5 0.9 ± 0 .3
16:2 n-4 3.2 ± 0 .8 1.6 ± 0 .5 0.3 ± tr. 0.3 ±0.1 0.3 ± tr. 0.2 ± 0 .2 0.3 ±0.1
16:3 n-4 1.7 ± 0 .5 3.5 ± 1.3 1.0 ± 0 .2 1.2 ± 0 .2 0.5 ± tr. 1.1 ± 0 .2 1.0 ± 0 .4
18:0 12.8 ± 2 .2 17.7 ± 1.6 8.8 ± 1.1 13.7 ± 1.9 9.3 ± 2.8 7.9 ± 1.1 8.2 ± 0.6
18:1 n-9 9.3 ± 5.4 10.9 ± 5.1 20.7 ± 2 .5 9.2 ± 1.0 11.8 ± 2 .9 8.8 ± 1.2 12.4 ± 1.8
18:1 n-7 9.3 ± 3 .5 2.7 ± 0 .7 3.1 ± 1.7 4.7 ± 0.6 5.0 ± 0 .9 2.7 ± 0 .5 6.1 ± 0 .9
18:2 n-6 4.9 ± 1.8 3.4 ± 0 .3 3.6 ± 0 .8 4.2 ± 0 .5 4.7 ±1.1 4.2 ± 0 .6 5.4 ± 0 .9
18:3 n-3 n.d. 1.8 ± 0 .6 0.5 ± 0 .2 0.6 ±0.1 0.0 ± tr. 0.6 ±0.1 0.8 ± 0.4
18:3 n-4 n.d. 1.4 ± 0 .3 0.4 ±0.1 0.6 ±0.1 0.3 ±0.1 1.4 ± 1.1 0.5 ± 0.4
18:4 n-3 n.d. n.d. 0.2 ± tr. 0.4 ±0.1 0.3 ± tr. 0.4 ± 0 .2 0.4 ±0.1
20:1 n-9 21.3 ± 6 .8 4.0 ± 0.5 3.8 ± 0 .7 4.6 ± 0.2 8.8 ± 0 .6 3.6 ±2.1 6.5 ± 0.9
20:1 n.d. 1.1 ± 0 .3 n.d. 0.3 ± tr. n.d. n.d. n.d.
20:4 n-6 n.d. 3.0 ± 0.6 2.4 ± 1.2 1.5 ± 0 .3 0.4 ±0.1 1.2 ± 0 .2 3.3 ± 0 .7
20:4 n-3 2.1 ± 0 .7 1.8 ± 0 .5 0.7 ±0.1 0.8 ± 0.4 4.1 ± 1.9 1.2 ± 0 .5 0.3 ± tr.
20:5 n-3 n.d. 1.0 ± 0.4 3.6 ± 0.4 2.5 ± 0.3 1.6 ± 1.9 3.2 ± 0.4 3.2 ± 0.2
22:1 14.5 ± 5 .2 1.0 ±0 .3 0.8 ± 0.2 2.1 ± 0 .4 3.3 ± 1.5 1.7 ± 0 .8 1.6 ± 0 .6
22:2 2.1 ± 0 .4 1.4 ± 0 .4 1.1 ± 0 .6 2.2 ± 1.4 0.7 ±0.1 0.7 ± 0 .2 1.3 ± 0 .3
22:5 n-3 n.d. 1.5 ± 0 .7 1.7 ± 0 .2 1.9 ± 0 .6 0.9 ± 0.2 1.7 ± 0 .5 0.9 ± 0 .2
22:6 n-3 9.9 ± 4.8 12.7 ± 3.0 36.3 ± 2.2 32.5 ± 2.7 35.2 ± 2.2 40.6 ± 6.8 35.7 ± 3.9
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3.7 Acyl Distribution in Phosphatidvlinositol from Individual Tissues of
Oncorhynchus mvkiss
In terms of the saturated fatty acids detected in PI from all tissues 18:0 was consistently 
greater than 16:0, often strikingly so (Table 3.6). This observation is a stark contrast to PC 
(Table 3.4) where 16:0 was the principal saturated fatty acid. Even though 18:0 was the 
principal saturated fatty acid in PE (Table 3.5) the levels of 18:0 observed in PI were much 
greater than found for PE. Adipose tissue had the lowest amounts of saturated fatty acids in 
PI with only 7% 16:0 and 10% 18:0. Moreover, this tissue also had the lowest ratio of 18:0 
to 16:0. PI from the spleen contained approximately seven times more 18:0 than 16:0 while 
there was five times more 18:0 than 16:0 detected in PI from the muscle. The heart 
contained quadruple the amount of 18:0 compared to 16:0. PI from the eye contained treble 
the amount of 18:0 than 16:0 while PI both the liver and brain contained twice as much 18:0 
than 16:0. The principal monounsaturated fatty acid in PI from all tissues except adipose 
was 18:1 n-9. Adipose tissue together with the eye, heart and liver were composed of 
approximately 8% 18:1 n-9. Marginally lower levels were observed in the brain, muscle and 
spleen, approximately 6%. As for the other phosphoglycerides (section 3.5, 3.6) elevated 
levels of 20:1 n-9 and 22:1 were detected in adipose tissue compared to the other tissues 
examined. 20:1 n-9 accounted for 22% of the fatty acid profile of PI in adipose tissue 
compared to the 3% found in other tissues. 22:1 was observed at a level of 27% in adipose 
tissue which was in stark contrast to the approximate 2% found in the other tissues.
In terms of the PUFA content of PI the principal fatty acids were the same in PE and PI 
(Table 3.5, 3.6) although the levels varied. Generally speaking, DHA > 20:4 n-6 > EPA > 
18:2 n-6. PI demonstrated dramatic differences in AA in comparison to the levels detected 
in both PC and PE. Minor levels of AA were observed in both PC and PE in all tissues 
(Tables 3.4, 3.5). However, in PI from liver and spleen the levels of AA were substantial. 
The liver and spleen contained approximately 22.5% AA, dramatically more than that for PC 
or PE (Table 3.4, 3.5) and was twice the level detected in eye and heart and more than six 
times the levels noted in brain and muscle. However, elevated levels of AA compared to PC 
and PE were also detected in PI from eye and heart (11% and 9% respectively). PI from the
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brain and the muscle contained approximately 3.5% AA. Similar to the PC and PE (Tables 
3.4, 3.5) AA was not detected in PI from adipose tissue. The absence of EPA from adipose 
tissue was also observed together with the low levels detected in brain. However, for the 
remaining tissues EPA was detected at approximately 2.5%. DHA was a principal 
component of PI in all tissues, though particular tissues displayed elevated levels. PI from 
muscle was composed of 24% DHA whereas in all remaining tissues DHA accounted for 
approximately 10% of the fatty acid composition of PI, the only exception being adipose 
tissue where DHA constituted 2% of the fatty acids in PI. Overall, PI (Table 3.6) contained 
less DHA than PC and PE (Tables 3.4, 3.5).
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Table 3.6: Fatty acid analysis of phosphatidylinositol from individual tissues of Oncorhynchus mykiss. Results as means of %
fatty acids ± SD. tr., trace (< 0.05); n.d., none detected.
Fatty Acid Adipose tissue 
n = 3
Brain 
n = 4
Eye 
n = 4
14:0 0.5 ± 0 .2 2.0 ± 0 .5 0.7 ± 0 .2
16:0 6.8 ± 2 .8 17.9 ±0 .5 13.0 ± 6 .2
16:1 n-7 5.0 ± 1.8 6.4 ± 1.2 3.5 ± 1.3
16:2 n-4 1.6 ± 0 .6 0.6 ± tr. 1.3 ± 1.2
16:3 n-4 1.0 ±0 .5 2.4 ± 0 .4 1.2 ± 0.1
18:0 9.8 ± 3 .8 32.0 ± 3 .4 35.0 ±2 .5
18:1 n-9 9.7 ± 0 .3 5.9 ± 0 .9 8.1 ± 1.5
18:1 n-7 nd 1.7 ± 0 .5 3.1 ±0.1
18:2 n-6 4.8 ± 1.9 3.1 ± 0 .5 2.7 ± 0.9
18:3 n-3 nd 1.6 ± 0 .2 1.0 ± 0 .7
18:3 n-4 1.4 ± 0 .9 1.2 ± 0 .4 0.7 ± 0.2
18:4 n-3 nd nd nd
20:1 n-9 22.0 ± 11.9 2.6 ± 0.6 3.8 ± 0 .6
20:1 nd 4.1 ± 0 .5 nd
20:4 n-6 nd 2.6 ± 0.8 10.7 ± 5 .4
20:4 n-3 1.5 ± 0 .9 1.5 ± 0 .8 0.9 ± 0.2
20:5 n-3 nd 0.6 ± 0.5 3.2 ± 0.8
22:1 27.2 ± 5 .2 1.0 ± 0 .7 nd
22:2 6.8 ± 1.3 6.4 ± 1.0 2.8 ± 0.3
22:5 n-3 nd nd 0.6 ± 0.5
22:6 n-3 1.8 ± 1.2 6.5 ± 1.39 10.4 ± 3.3
Heart Liver Muscle Spleen
n = 3 s H n=4 n = 3
0.6 ± 0.2 1.9 ±0 .3 0.7 ±0 .5 0.3 ± 0.2
10.7 ± 1.5 7.9 ± 0.4 7.7 ± 1.1 5.0 ± 0 .2
2.0 ± 0.2 0.5 ±0.1 1.6 ± 0.1 2.2 ± 0 .7
0.2 ± tr. 0.8 ± 0 .4 0.2 ± 0.2 0.1 ± tr.
1.1 ±0.1 0.7 ± tr. 1.1 ±0 .3 1.0 ± 0.1
40.7 ± 5.0 34.4 ± 8.9 40.4 ±2 .3 34.0 ± 1.8
7.2 ±0 .5 7.1 ± 0 .9 5.8 ± 0 .9 6.2 ± 0 .7
2.3 ±0.1 1.5 ± 0 .3 1.7 ± 0 .2 1.7 ±0 .5
2.2 ± 0 .6 0.7 ± 0 .4 1.5 ±0 .3 1.9 ± 0 .2
0.6 ± 0 .3 0.7 ±0.1 0.6 ± 0.2 0.5 ±0.1
0.6 ± 0.2 0.4 ± 0.2 0.7 ± 0 .3 0.4 ± 0.4
0.8 ± 0 .4 0.3 ±0.1 0.4 ± 0.4 0.1 ± tr.
3.4 ± 0 .9 3.4 ± 0 .7 2.5 ± 1.4 4.0 ±0.1
0.3 ± tr. nd 0.4 ± 0.3 nd
9.0 ± 0.7 22.9 ± 4.5 3.9 ± 0 .7 21.6 ± 3.1
1.8 ± 0 .8 3.5 ± 0 .7 1.1 ±0.1 0.5 ± 0 .4
1.5 ±  0.3 1.4 ±0.6 3.0 ±0.2 2.6 ± 0.7
2.6 ± 0.8 3.2 ± 2 .2 1.2 ± 0 .6 0.9 ± 0.2
2.6 ± 1.5 0.8 ± 0 .2 0.6 ± 0.2 2.3 ± 1.5
0.4 ±0.1 0.7 ± tr. 1.2 ± 0 .3 2.7 ± 1.8
9.3 ± 2.9 9.5 ±2.1 24.3 ± 5.5 12.2 ±0.5
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3.8 Acyl Distribution in Phosphatidvlserine from Individual Tissues of
Oncorhynchus mvkiss
In terms of the acyl composition of PS, the main saturated fatty acids included 18:0 and 16:0 
(Table 3.6). In all tissues 18:0 was significantly greater than the levels of 16:0. The greatest 
18:0 to 16:0 ratio was observed in spleen where there was four times as much 18:0 as 16:0. 
Liver and muscle contained similar levels o f 16:0 and 18:0 (approximately 12% and 28%, 
respectively). Similar levels of 16:0 were reported in PS from the heart compared to liver 
and muscle but PS from the heart contained approximately 37% 18:0, the highest level of 
18:0 observed in any of the organs examined. The principal monounsaturated fatty acid 
detected in PS from all tissues (with the exception of adipose tissue) was 18:1 n-9. The 
highest level of 18:1 n-9 was observed in PS from the eye (11%) and was seen to be almost 
four times greater than the other principal monounsaturated fatty acid, 16:1. PS from the 
heart, liver and spleen contained approximately 4% 18:1 n-9. Elevated levels of 18:1 n-9 
were observed in PS from muscle (8%) and the ratio of 18:1 n-9 and 16:1 was approximately 
2.7. As previously seen with the other phosphoglycerides (Tables 3.4 -  3.6) 20:1 n-9 and 
22:1 were the dominant monounsaturated fatty acids in PS from adipose tissue (23% and 
19%, respectively).
With regard to the PUFAs, as previously seen (Tables 3.4 -  3.6), DHA was the principal 
PUFA in all tissues apart from adipose tissue. For most tissues the PUFA ranking was DHA 
> AA = 18:2 n-6 = EPA (Table 3.7). AA was highest in PS from brain (6%). PS from the 
heart and muscle contained comparable levels of AA (3%) while lower levels were observed 
in spleen and liver. As seen for PC, PE and PI (Table 3.4 — 3.6) no AA was detected in PS 
from adipose tissue. Also, no AA was observed in PS from the eye. EPA was rather low in 
PS from the muscle, liver, spleen and eye. Slightly higher and comparable levels were found 
in PS in brain and heart (1.2%). As observed for the aforementioned phosphoglycerides 
(Table 3.4 -  3.6), no EPA was detected in PS from adipose tissue. DHA was highest in PS 
from the spleen, eye and liver (approximately 35%). Muscle PS contained 25% DHA while 
the heart contained 16% DHA. The lowest levels of DHA were found in PS from the brain 
and adipose tissue (7% and 2% respectively).
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3.9 Acyl Distribution in Sphingomyelin from Individual Tissues of
Oncorhynchus mvkiss
Sphingomyelin (SPH) was found in all tissues examined (Table 3.8). The main saturated 
fatty acids detected in SPH from all tissues were 16:0 and 18:0. Equal levels of 16:0 and 
18:0 were observed in SPH in adipose tissue, brain, eye and heart. However, lower absolute 
levels of both fatty acids were observed in adipose tissue compared to the other tissues. 
Spleen contained the highest level of 16:0 (33%) while the eye, liver and heart contained 
comparable levels (approximately 24%). Muscle and brain contained approximately 18% 
16:0 in SPH, significantly lower than the spleen, eye, liver and heart (approximately 18%). 
In terms of 18:0, the eye contained the greatest levels (22%). In SPH from the brain, heart, 
liver and spleen 18:0 constituted approximately 18%. Equal proportions of 16:0 and 18:0 
were observed in SPH from adipose tissue (approximately 9%). In terms of the 
monounsaturated fatty acids 18:1 n-9 and 16:1 n-7 were the principal fatty acids. 18:1 n-9 
was present in excess of 16:1 n-7 in SPH from the heart, liver and spleen while comparable 
levels of 18:1 n-9 and 16:1 n-7 were observed in adipose tissue, brain, eye and muscle. 
Adipose tissue was again the exception with 20:1 n-9 and 22:1 being the principal 
monounsaturated fatty acids (28% and 13% respectively).
In terms of the PUFA content of SPH, the main PUFAs in most tissues included DHA > 20:4 
n-3 > 18:2 n-6 > EPA. The highest level of AA were detected in brain and muscle 
(approximately 4%), followed by SPH from the eye (2.4%) with minor levels detected in 
spleen and heart (approximately 1%). No AA was found in SPH from either adipose tissue 
or liver. EPA in SPH from brain, liver and muscle was just over 2%, with very low levels 
detected in the eye, spleen and heart. No EPA was evident in SPH from adipose tissue. 
DHA was found at the greatest level in SPH from the liver and muscle (approximately 13%). 
The spleen, heart and eye contained approximately 6% DHA while the lowest levels were 
present in the eye and adipose tissue (3% and 1% respectively).
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Table 3.7: Fatty acid analysis from phosphatidylserine in individual tissues of Oncorhynchus mykiss. Results as means of % fatty
acids ± SD. tr., trace (< 0.05); n.d., none detected.
Fatty Acid Adipose tissue 
n = 5
Brain 
n = 5
Eye 
n = 3
Heart 
n = 4
Liver 
n = 4
Muscle 
n = 5
Spleen 
n = 3
14:0 0.7 ±0.1 2.6 ± 0.5 0.5 ±0.1 0.8 ± 0.3 0.4 ± 0.2 2.4 ±0.1 0.2 ±0.1
16:0 7.9 ± 3.7 18.6 ±2.1 9.4 ± 0.9 13.5 ± 1.6 11.1 ±2.1 13.1 ±3 .5 7.3 ± 1.3
16:1 n-7 8.2 ± 2.2 7.8 ± 1.5 2.9 ± 0.9 2.6 ± 0.8 0.6 ±0 .3 3.3 ± 1.0 1.2 ± 0 .4
16:2 n-4 1.4 ± 0 .3 0.7 ±0.1 0.5 ±0.1 1.2 ± 0 .7 0.7 ± 0 .3 0.4 ± 0.4 0.3 ±0.1
16:3 n-4 1.4 ±0 .3 2.3 ± 0 .3 1.0 ± 0 .2 0.7 ± 0 .4 1.2 ± 0 .2 1.5 ± 0 .4 1.1 ±0.1
18:0 17.8 ± 9 .6 24.5 ±2.1 27.4 ± 1.6 36.5 ± 3.8 29.0 ± 2.7 27.8 ± 3 .6 29.7 ± 0.7
18:1 n-9 7.7 ± 1.9 6.6 ± 0 .7 10.8 ± 1.3 4.9 ± 1.6 3.5 ± 0 .4 7.8 ± 3.6 4.5 ± 1.2
18:1 n-7 n.d. 2.4 ±1.1 2.9 ± 0.3 2.4 ± 0 .2 2.0 ± 0 .4 2.1 ± 0 .8 3.9 ± 0 .3
18:2 n-6 4.4 ± 0.8 3.2 ± 0 .6 1.8 ± 0.1 1.9 ± 0 .6 0.7 ±0.1 1.8 ± 0 .3 1.3 ± 0 .4
18:3 n-3 1.7 ± 0 .6 2.2 ± 0 .8 0.5 ±0 .1 0.8 ± 0 .2 0.4 ± 0.2 2.0 ± 1.1 0.5 ± 0 .3
18:3 n-4 n.d. 1.6 ± 1.2 1.0 ± 0 .5 1.1 ± 0 .2 0.4 ±0.1 1.1 ± 0 .3 0.6 ±0 .3
18:4 n-3 n.d. 1.2 ± 0 .5 0.5 ±0.1 0.7 ± 0 .3 0.7 ±0.1 0.8 ± 0 .8 0.4 ± tr.
20:1 n-9 22.6 ± 9.2 3.8 ± 0 .7 3.8 ± 0 .3 3.7 ± 0.4 3.7 ± 0 .7 3.8 ± 0 .6 6.8 ± 1.5
20:1 n.d. 0.7 ± 0.6 0.7 ± 0 .2 n.d. n.d. 0.9 ±0.1 n.d.
20:4 n-6 n.d. 5.5 ± 0 .9 n.d. 2.7 ±0.1 1.2 ± 0 .6 2.7 ±0.1 1.0 ± 0 .6
20:4 n-3 1.3 ± 0 .7 1.1 ± 0 .5 0.9 ± 0 .8 0.6 ± 0.7 3.3 ± 1.2 0.5 ± 0.2 0.6 ± 0.3
20:5 n-3 n.d. 1.2 ± 1.0 0.9 ± 0.2 1.2 ± 0 .8 0.7 ± 0.5 0.8 ± 0.4 0.6 ± 0.2
22:1 18.5 ± 7 .6 2.5 ± 1.8 1.9 ± 0 .3 2.7 ± 0 .5 8.0 ±3.1 1.2 ± 0 .5 n.d.
22:2 4.1 ±3.1 n.d. n.d. 5.1 ± 2 .4 0.8 ± 0 .2 1.0 ± 0 .4 n.d.
22:5 n-3 n.d. 4.2 ± 2 .3 n.d. 0.9 ± 0.7 0.8 ± 0 .2 1.8 ± 0 .7 1.2 ± 0 .2
22:6 n-3 1.7 ± 1.5 7.2 ± 3.7 32.6 ± 4.4 15.9 ±2.8 32.1 ± 1.1 24.6 ± 5.8 38.7 ±3.8
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Table 3.8: Fatty acid analysis of sphingomyelin from individual tissues of Oncorhynchus mykiss. Results as means of % fatty
acids ± SD. tr., trace (< 0.05); n.d., none detected.
Fatty Acid Adipose tissue 
n = 4
Brain 
n = 5
Eye 
n = 4
Heart 
n = 4
Liver 
n = 3
Muscle 
n = 3
Spleen 
n = 3
14:0 0.9 ±0.1 2.7 ± 0 .6 2.6 ± 0.9 2.8 ± 1.5 3.5 ± 1.1 1.5 ± 0 .2 4.4 ± 2.9
16:0 9.0 ± 3 .3 18.9 ± 4 .9 22.6 ±7.1 23.6 ± 7.9 26.7 ± 2.2 17.4 ±5 .8 32.5 ±2.1
16:1 n-7 7.9 ± 1.5 7.4 ± 1.6 8.7 ± 0 .7 3.4 ± 1.4 1.8 ± 0 .2 5.3 ± 2.4 3.2 ± 1.0
16:2 n-4 1.2 ± 0 .2 1.0 ± 0 .6 0.9 ± tr. 4.2 ± 0 .4 2.4 ± 0.4 0.5 ± 0.5 0.3 ±0 .3
16:3 n-4 2.3 ± 1.5 1.9 ± 0 .3 2.4 ± 0 .4 1.2 ±0 .3 2.7 ± 0 .8 1.4 ±0 .3 1.3 ± 0 .2
18:0 10.0 ±4 .3 16.7 ± 3 .4 22.1 ± 6 .0 18.7 ± 3 .8 17.5 ±2 .5 10.5 ±6 .3 18.4 ± 1.6
18:1 n-9 5.9 ± 2 .6 6.4 ± 1.9 8.1 ± 2 .8 7.7 ± 5 .7 11.9 ± 3.1 6.0 ± 1.4 9.2 ±2 .3
18:1 n-7 n.d. 2.2 ± 0 .9 1.6 ± 0 .8 1.4 ±0 .5 2.7 ± 0 .2 3.5 ±2 .3 3.3 ± 1.2
18:2 n-6 3.3 ± 1.9 5.2 ± 4 .5 5.2 ± 0 .8 3.8 ± 0 .9 1.7 ± 0 .9 7.5 ± 4 .9 3.6 ± 0 .8
18:3 n-3 n.d. 2.7 ± 1.1 1.8 ± 0 .4 1.3 ± 0 .4 1.3 ± 0 .2 5.4 ± 4.2 0.9 ± 0 .3
18:3 n-4 n.d. 2.3 ± 1.2 1.3 ± 1.1 1.2 ± 0 .9 n.d. 2.1 ± 0 .4 0.8 ± 0.3
18:4 n-3 3.4 ± 2 .7 2.7 ± 0 .9 n.d. 0.9 ± 0.4 n.d. 2.7 ± 1.8 1.0 ± 0 .6
20:1 n-9 31.3 ± 10.8 4.8 ± 0 .7 1.5 ± 0 .5 2.5 ± 1.3 7.4 ± 0 .2 1.6 ± 0 .2 3.9 ± 1.4
20:1 n.d. 5.2 ± 1.4 7.7 ± 0 .7 3.3 ± 0 .7 n.d. 4.6 ± 1.0 n.d.
20:4 n-6 n.d. 3.9 ±2 .1 2.4 ± 0.6 1.1 ± 0 .7 n.d. 3.6 ± 1.7 0.9 ± 0 .2
20:4 n-3 3.8 ± 1.7 2.7 ±1.4 4.2 ± 5 .7 2.9 ± 1.2 2.1 ± 0 .3 3.5 ± 2.4 0.3 ±0 .3
20:5 n-3 n.d. 2.2 ± 1.8 0.4 ±0.1 0.3 ± 0.2 3.5 ± 1.9 1.3 ± 0.5 0.6 ± 0.2
22:1 13.3 ± 5..3 5.9 ± 2 .3 n.d. 4.5 ± 2.4 4.3 ± 0.5 3.4 ± 1.5 4.9 ± 1.6
22:2 6.5 ± 3 .7 4.3 ± 2.7 n.d. 5.2 ±3 .5 n.d. 2.4 ± 0.8 3.1 ± 1.8
22:5 n-3 n.d. n.d. n.d. 4.2 ± 3 .8 n.d. 0.9 ± 0.0 0.5 ± 0 .9
22:6 n-3 1.5 ±0.5 3.3 ± 1.0 7.5 ± 1.3 5.7 ± 3.3 12.3 ± 4.1 14.2 ±8.2 6.7 ±4.1
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3.10 Acyl Distribution in Diphosphatidvlglvcerol from Individual Tissues
of Oncorhynchus mvkiss
Diphosphatidylglycerol (DPG) was detected in the brain, heart, liver, muscle and spleen 
(Table 3.9). As with the other phoshoglycerides analysed (Tables 3.4 -  3.8) 16:0 and 
18:0 were the principal saturated fatty acids. Both fatty acids occurred in approximately 
equal percentages in all tissues but the total saturated fatty acid content varied from 47% 
in brain to 20% in liver. In terms of the mono unsaturated acyl composition of DPG 18:1 
n-9 was the dominant fatty acid ranging from 8% in muscle to 15% in spleen. However, 
18:1 n-7, 16:1 n-7. 20:1 and 22:1 were also significant components of DPG.
The PUFA content of DPG in all tissues consisted of DHA > 18:2 n-6 > EPA = AA = 
20:4 n-3. In contrast to the other phosphoglycerides (Table 3.4 -  3.8) 18:2 n-6 was found 
in appreciable amounts in DPG from most tissues constituting approximately 13% in 
DPG from the heart, liver, muscle and spleen. The levels of AA and EPA were equal in 
DPG from all tissues (approximately 1.5%). DHA was the main PUFA in most tissues. 
Liver DPG was composed of 35% DHA whereas the spleen, muscle and heart contained 
approximately 23% DHA while brain was composed of only 5% DHA. Linoleic acid 
(18:2 n-6) was quite high in most tissues and was the major PUFA in DPG from brain.
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Table 3.9: Fatty acid analysis of diphosphatidylglycerol (cardiolipin) from individual
tissues of Oncorhynchus mykiss. Results as means of % fatty acids ± SD. 
tr., trace (< 0.05); n.d., none detected. No diphosphatidylglycerol was 
detected in the lipid extracts from the adipose tissue and eye.
Fatty Acid Brain
n =  5
Heart 
n = 3
Liver 
n = 4
Muscle 
n = 5
Spleen 
n = 5
14:0 to bo H- © 1.7 ± 0 .3 2.4 ± 0.9 0.9 ± 0 .5 1.7 ± 0 .8
16:0 22.7 ±  2.4 13.2 ± 5.6 10.6 ± 1.8 13.8 ± 3 .3 13.2 ± 4.1
16:1 n-7 6.2  ±  1.7 2.2 ± 0.6 1.9 ± 0 .6 2.9 ± 1.2 4.3 ± 1.2
16:2 n-4 1.0 ± 0 .4 0.4 ±  0.2 1.5 ± 0 .5 0.3 ± 0 .3 0.6 ±  0.3
16:3 n-4 2.5 ± 0 .3 0.6 ± 0 .3 1.8 ± 0 .7 1.1 ± 0 .5 1.1 ± 0 .5
18:0 21.7 ± 1.9 9.9 ± 6.9 6.9 ± 1.4 7.0 ± 1.9 10.0 ± 1.4
18:1 n-9 6.7 ±  1.5 11.3 ± 2 .4 9.3 ±  1.4 7.7 ± 1.7 14.5 ±  1.6
18:1 n-7 3.7 ± 0 .5 4.1 ± 0 .8 3.0 ± 0 .2 6.5 ± 0 .5 6.5 ± 0 .4
18:2 n-6 5.7 ± 0 .9 15.0 ± 2 .3 12.0 ± 1.6 14.8 ± 3 .6 9.9 ± 2.3
18:3 n-3 2.0 ± 0.4 0.7 ± 0 .1 0.7 ± 0 .2 1.3 ± 0 .5 1.1 ± 0 .4
18:3 n-4 2.0 ± 1.2 2.8 ± 0 .3 1.0 ± 0 .4 2.1 ± 0 .3 0.8 ± 0 .3
18:4 n-3 1.7 ± 0 .7 0.9 ± 0 .3 0.4 ± tr. 0.9 ± 0 .6 0.6 ± 0.3
20:1 n-9 3.4 ± 0 . 6 3.1 ± 0 .8 3.8 ± 0 .5 4.5 ± 1.0 5.2 ± 1.1
20:1 5.4 ± 0 .8 0.3 ± 0.2 n.d. 0.9 ± 0 .6 n.d.
20:4 n-6 1.4 ± 0 .7 1.5 ± 0 .7 1.7 ± 0 .5 1.4 ± 0 .9 1.7 ± 0 .8
20:4 n-3 1.3 ± 0 .8 1.3 ± 0 .3 1.3 ± 0 .2 1.2 ± 0 .3 0.7 ± 0.6
20:5 n-3 1.8 ± 0 . 6 1.0 ± 0 .2 1.2 ± 0 . 6 1.0 ± 0 .2 1.3 ±0.5
22:1 1.4 ± 0 .3 3.3 ± 0 .9 5.9 ± 1.4 4.4 ±1.1 1.6 ± 0 .5
22:2 1.9 ± 1.2 1.5 ± 1.2 n.d. 1.1 ±0 .5 4.7 ± 3 .0
22:5 n-3 n.d. 1.0 ± 0 .9 2.0 ± 0.5 0.9 ± 0.3 0.2 ± 0 .5
22:6 n-3 4.9 ± 2.0 24.4 ± 7.5 35.0 ± 4.5 24.5 ± 5.8 20.1 ±3.9
3.11 Acvl Distribution in Lvso-Phosphatidvlcholine from Individual
Tissues of Oncorhynchus mvkiss
Lyso-phosphatidylcholine (lyso-PC) was only detected in eye, heart, liver and spleen 
(Table 3.10). 16:0 and 18:0 were the main saturated fatty acids and the total content of 
saturates in lyso-PC varied from about 30% in the eye to 50% in the liver. 18:0 was the 
principal saturated fatty acid found in the eye and heart (over 20%) while in the liver 16:0 
and 18:0 were found at equal levels. In lyso-PC from the spleen the levels of 16:0 were 
more than twice the level of 18:0 (30% and 12% respectively). The principal 
monounsaturated fatty acids included 16:1 n-7 (except for heart), 18:1 n-9 and n-7 and 
20:1 n-9.
The PUFA content of lyso-PC from the eye was primarily composed of DHA (25%), 18:2 
n-6 (7%), EPA, AA and 16:3 n-4 (approximately 2%). DHA was also the main PUFA 
found in heart, liver and spleen with both A A and EPA constituting approximately 2% of 
the lyso-PC composition.
Differences between PC (Table 3.4) and lyso-PC (Table 3.10) from the same tissues will 
likely reflect the positional distribution of fatty acids and, hence, the selective loss of 
acids from the srt-2 position as lyso-PC is formed.
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Table 3.10: Fatty acid analysis of lyso-phosphatidylcholine from individual organs of
Oncorhynchus mykiss. Results as means of % fatty acids ± SD. tr., trace 
(< 0.05); n.d., none detected. No lyso-phosphatidylcholine was detected 
in adipose tissue, brain and muscle.
Fatty Acid Eye 
n = 4
Heart 
n = 3
Liver 
n = 3
Spleen 
n = 3
14:0 1.6 ± 0 .2 1.6 ± 0 . 9 1.8 ± 0 .8 1.3 ± 0 .6
16:0 13.6 ± 2.2 17.2 ± 8.6 26.2 ± 6.2 30.2 ± 12.2
16:1 n-7 11.0 ± 3.0 6.9 ± 2.8 0.1 ± tr. 4.5 ± 1.0
16:2 n-4 1.3 ± 0 .4 1.5 ± 0 . 9 3.8 ± 0 .8 0.4 ± 0.4
16:3 n-4 2.5 ± 0 .6 1.9 ± 0.1 2.8 ± 0.6 1.3 ± 2 .4
18:0 21.6 ± 7.2 24.7 ± 5.2 22.2 ± 10.0 12.1 ± 7 .7
18:1 n-9 9.0 ± 2 .9 6.4 ± 0.5 7.9 ± 2 .0 3.8 ±2 .3
18:1 n-7 2.2 ± 1.6 6.0 ± 0 . 9 2.9 ± 0.6 3.1 ±0.1
18:2 n-6 6.5 ± 2 .3 4.1 ± 0 . 4 2.6 ± 0.6 1.7 ± 1.0
18:3 n-3 1.9 ± 1.0 1.6 ± 0 .2 1.1 ± 0 .2 0.9 ± 0 .6
18:3 n-4 1.7 ± 0 .4 1.0 ± 0 .2 1.1 ± tr. 0.6 ±0 .5
18:4 n-3 n.d. 1.9 ± 0 .8 n.d. n.d.
20:1 n-9 3.9 ± 1.1 4.3 ± 0.4 7.1 ± 3 .6 5.9 ± 0 .4
20:1 n.d. 1.9 ± 04 n.d. n.d.
20:4 n-6 1.6 ± 0 .2 2.4 ± 1.5 2.2 ± 1.7 1.1 ± 0 .2
20:4 n-3 1.0 ± 0 .9 2.7 ± 1.0 2.7 ± 0 .6 0.7 ± 0 .9
20:5 n-3 2.1 ±0.9 3.6 ± 1.1 2.2 ± 0.8 1.5 ±0.9
22:1 n.d. 4.6 ± 0.9 n.d. n.d.
22:2 n.d. n.d. n.d. n.d.
22:5 n-3 n.d. n.d. n.d. n.d.
22:6 n-3 24.8 ± 8.2 10.3 ±3.7 9.5 ±1.5 11.0 ± 1 .0
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3,12 Acyl Distribution in Triacvlglvcerol from Individual Tissues of
Oncorhynchus mvkiss
The fatty acid composition of the major storage lipid, TAG, is shown in Table 3.11. The 
percentages of acyl components of TAG were similiar between tissues apart from some 
minor discrepancies. The principal saturated fatty acid in each organ was 16:0 which was 
present at approximately 15%. Both 14:0 and 18:0 were the other remaining saturated 
fatty acids and the composition was consistent between individual organs (approximately 
3% and 3.5% respectively). The major monounsaturated fatty acid in TAG from all 
organs was 18:1 n-7 (approximately 26%). Both 20:1 n-9 and 22:1 were also prominent 
components of TAG (12% and 10% respectively) and 16:1 n-7 was present at 
approximately 5% in all tissues. In terms of the PUFAs, 18:2 n-6 was the principal 
PUFA consisting of 10 -  13% in each tissue apart from two exceptions. TAG from both 
the heart and liver contained of 2.7% and 5.1% linolenic acid respectively, significantly 
less than that found in the remaining tissues. EPA was present at approximately 1.5% in 
all tissues although elevated levels were detected in the TAG from the liver (7.5%). 
DHA composed 5% of the TAG fraction in the brain, eye, liver, muscle and eye. TAG 
from adipose tissue and the heart contained only 3% and 2% DHA respectively (Table 
3.11).
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Table 3.11; Fatty acid analysis of triacylglycerols from individual tissues of Oncorhynchus mykiss. Results as means of % fatty
acids ± SD. tr., trace ( < 0.05), n.d., none detected.
Fatty Acid Adipose tissue 
n = 4
Brain 
n = 5
Eye 
n = 5
Heart 
n= 3
Liver 
n = 3
Muscle 
n = 5
Spleen 
n = 4
14:0 2.7 ± 0 .2 3.5 ± 0 .2 3.1 ± 0 .2 2.3 ± 0 .9 3.0 ± 1.6 2.9 ±0 .3 2.2 ± 0 .5
16:0 15.2 ± 0 .8 15.4 ± 1.1 14.4 ± 1.1 19.1 ± 0 .8 18.0 ± 4 .6 16.1 ± 1.2 14.2 ± 0 .8
16:1 n-7 4.0 ± 2 .3 6.4 ± 0 .5 5.4 ±0 .3 5.4 ± 0 .6 4.9 ± 0.8 6.3 ±0 .3 4.4 ± 0.4
16:2 n-4 0.2 ± tr. 0.3 ± tr. 0.3 ± tr. 0.3 ± 0 .2 0.3 ±0.1 0.3 ± tr. 0.2 ± tr.
16:3 n-4 0.5 ±0.1 0.5 ± tr. 0.5 ±0.1 0.7 ± 0 .2 0.5 ± 0.2 0.6 ± tr. 0.6 ± tr.
18:0 3.2 ±0 .3 2.9 ± 0 .2 2.8 ±0 .3 4.9 ± 0 .9 3.7 ± 0 .6 3.0 ±0 .3 3.5 ±0 .3
18:1 n-9 26.2 ± 2.5 27.7 ± 2.4 26.2 ± 0.6 27.2 ± 0.9 29.5 ± 1.9 26.9 ± 0 .8 24.5 ± 2.2
18:1 n-7 5.6 ± 2 .9 0.4 ±0.1 5.0 ± 2.4 5.7 ± 1.7 4.0 ± 0.3 0.3 ± tr. 5.1 ± 2 .6
18:2 n-6 9.9 ± 0 .3 12.2 ± 0 .6 12.4 ± 0 .9 2.7 ± 1.2 5.1 ± 3 .8 12.7 ± 0 .7 10.0 ± 0 .9
18:3 n-3 0.7 ±0.1 1.1 ±0.1 1.2 ± 0.1 0.3 ±0.1 2.7 ± 2 .2 0.9 ±0 .5 0.8 ± 0 .2
18:3 n-4 0.7 ±0.1 1.0 ±0.1 0.9 ± 0 .5 0.5 ± 0 .6 0.3 ± 0 .2 0.6 ±0 .5 0.7 ±0.1
18:4 n-3 0.1 ±0.1 0.3 ±0.1 0.3 ± 0.3 1.4 ± 0 .3 0.6 ±0.1 0.1 ± tr. 0.2 ±0.1
20:1 n-9 12.7 ± 0 .7 10.4 ± 1.1 9.7 ± 0.8 12.7 ± 1.7 11.8 ± 1.5 10.9 ±0.3 13.1 ± 1.4
20:1 0.1 ±0 .1 n.d. n.d. n.d. n.d. 0.1 ±tr. n.d.
20:4 n-6 0.8 ±0.1 0.9 ± 0.2 0.8 ±0.1 0.2 ± 0 .2 0.4 ± 0.2 0.5 ± 0.4 0.4 ± 0.2
20:4 n-3 0.5 ± 0 .2 0.8 ±0.1 0.8 ±0.1 0.5 ± 0 .3 1.2 ± 0 .7 0.9 ± 0.3 1.0 ± 0 .3
20:5 n-3 1.0 ±0.2 1.7 ±0.1 1.9 ± 0.3 1.1 ±0.1 7.3 ±2.1 1.8 ±0.2 1.7 ±0.2
22:1 11.8 ± 1.5 8.6 ± 0 .8 8.1 ± 1.2 12.4 ± 1.5 0.5 ± 0 .5 8.9 ±0 .5 12.1 ± 1.7
22:2 0.5 ±0.1 n.d. n.d. 0.9 ± 0.6 0.9 ± 0.3 0.2 ± tr. 0.6 ± 0.4
22:5 n-3 0.5 ±0.1 0.8 ±0.1 0.8 ±0.1 0.6 ± 0 .5 1.0 ± 0 .4 0.8 ±0.1 0.6 ±0.1
22:6 n-3 2.9 ± 0.6 5.3 ± 0.8 5.5 ± 5.0 2.0 ± tr. 5.8 ± 0.9 5.5 ± 0.8 4.2 ± 0.9
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3.14 Acyl Distribution in 1.2-Diacvlglvcerol from Individual Tissues of
Oncorhynchus mvkiss
The acyl composition of 1,2 diacylglycerol (DAG) was less consistent than what was 
observed for the TAG fraction in each organ (Table 3.12). For 1,2-DAG from most 
tissues the levels of 16:0 and 18:0 were about equal although the specific levels between 
tissues varied quite significantly. The highest levels of 16:0 and 18:0 were found in 
muscle (approximately 27%) whilst the lowest levels were present in heart (9% 16:0 and 
18% 18:0). In terms of the monounsaturated fatty acids, adipose tissue and the eye 
contained approximately equal proportions of 18:1, 20:1 n-9 and 22:1. Brain tissue had 
rather high levels of 22:1 and also contained approximately 9% and 5% of 18:1 and 20:1 
n-9, respectively. The liver, muscle and spleen were composed of equal levels of 18:1 
and 20:1 n-9 and little or no 22:1 was detected. The major PUFA was usually 18:2 n-6 
which comprised approximately 6% of the acyl composition of 1,2-DAG in all tissues. 
Unusually, EPA was highest in 1,2-DAG from adipose tissue (4%) while 1,2-DAG from 
the heart contained approximately 3% EPA. DHA was greatest in the spleen (6%) while 
the liver, heart, eye and adipose tissue contained approximately 4%. 1,2-DAG from both 
muscle and brain had the lowest proportions of 1,2-DAG. AA was found at high levels in
1,2-DAG from liver (14%).
3.15 Acyl Distribution in 1.3-Diacvlglvcerol from Individual Tissues of
Oncorhynchus mvkiss
Table 3.13 outlines the acyl composition of 1,3-DAG. Similar to 1,2-DAG (Table 3.12) 
variations in fatty acyl compositions were detected between tissues. 16:0 comprised 
approximately 17% of 1,3-DAG in most tissues (adipose, 8%) whilst 18:0 varied from 
22% and 20% in muscle and heart to 12% in both the spleen and brain. As seen with 1,2- 
DAG 22:1 n-9 was the dominant monounsaturated fatty acid present in 1,3-DAG from 
the brain (30%) followed by 8% 18:1 and 4% 20:1. Adipose tissue 1,3-DAG contained 
19% 18:1 n-9 and equal proportions of 20:1 n-9 and 22:1. In the eye equal levels of 18:1 
and 22:1 were present (approximately 10%) while 4% was made up of 20:1 n-9. No 22:1
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was detected in 1,3-DAG from the heart and the monounsaturated fatty acids comprised 
16:1 n-7, 18:1 n-9 and 20:1 n-9. The liver 1,3-DAG displayed a significantly high level 
of 20:1 n-9 (12.8%). Muscle and spleen were composed of predominantly equal 
proportions of 16:1, 18:1 and 20:1. O f the PUFA content of 1,3-DAG 18:2 n-6 
comprised approximately 5% in all tissues although a lower proportion was reported for
1,3-DAG from brain (2.6%). EPA was a minor component of 1,3-DAG from all tissues 
with the exception of the liver where it constituted approximately 9% of the acyl 
composition. DHA was significantly elevated in 1,3-DAG from the eye (28%) while in 
the spleen and liver it composed 10% and 6% respectively. 1,3-DAG from adipose tissue 
contained approximately 5%, muscle 4%, heart 3% and 1.2% was found in the brain.
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Table 3.12: Fatty acid analysis of 1,2-diacylglycerol from individual tissues of Oncorhynchus mykiss. Results as means of % fatty
acids ± SD. tr, trace (< 0.05), n.d., none detected.
Fatty Acid Adipose tissue 
n = 4
Brain 
n = 5
Eye 
n = 5
Heart 
n = 4
Liver 
n = 4
Muscle
n=5
Spleen 
n = 5
14:0 0.2 ± 0 .4 4.1 ± 2 .0 1.9 ± 0.4 1.3 ± 0 .4 8.6 ±2.1 3.8 ± 1.2 1.8 ± 0 .2
16:0 11.0 ±7 .5 18.8 ± 0 .7 19.3 ± 3 .3 9.2 ± 6 .5 20.1 ± 2 .7 26.2 ± 4.4 17.0 ± 1.8
16:1 n-7 10.2 ± 1.9 2.0 ± 0 .7 6.5 ±2.1 11.7 ± 4 .3 8.5 ± 1.3 7.2 ± 2.8 10.5 ± 1.6
16:2 n-4 0.2 ± 0 .2 1.7 ±0 .5 2.4 ± 1.7 3.2 ± 0 .3 2.6 ±0 .3 2.6 ± 2.3 2.3 ± 0 .8
16:3 n-4 1.5 ± 0 .2 1.5 ± 0 .5 2.2 ± 0.6 2.6 ± 0 .6 6.4 ± 0.6 2.2 ± 1.5 2.1 ± 0 .6
18:0 16.2 ± 2 .4 18.5 ± 1.9 19.9 ± 6 .2 17.8 ± 4 .7 16.6 ± 3 .2 27.2 ± 8.9 17.6 ±4 .5
18:1 n-9 6.8 ± 2.9 9.0 ± 1.8 10.2 ± 5 .2 4.4 ± 0 .3 5.6 ± 2.7 7.5 ±2 .4 6.4 ± 3 .5
18:1 n-7 2.6 ±1.8 n.d. 1.9 ± 1.3 1.1 ± 2 .3 n.d. n.d. 2.7 ± 0 .6
18:2 n-6 7.4 ±1.1 4.0 ± 0.2 7.3 ± 1.4 6.4 ± 2.0 5.2 ± 1.4 4.1 ± 0 .8 6.7 ± 2 .3
18:3 n-3 2.5 ± 0 .9 1.2 ± 0 .5 1.5 ± 0 .4 5.1 ± 4 .6 3.9 ± 0 .6 2.5 ± 1.4 3.4 ± 2 .0
18:3 n-4 3.8 ± 0 .8 1.2 ± 0 .2 2.4 ± 1.9 3.2 ± 1.6 n.d. 1.7 ± 1.1 2.5 ± 0 .7
18:4 n-3 3.8 ± 2 .6 2.6 ± 1.7 2.0 ± 0.7 2.8 ± 0 .7 0.9 ±0.1 1.6 ± 0 .9 1.7 ± 0 .7
20:1 n-9 9.1 ± 1.4 5.0 ± 3 .2 6.3 ± 2.2 8.4 ± 4 .8 6.6 ± 1.7 5.1 ± 2 .3 5.9 ± 0 .8
20:1 3.6 ± 1.3 3.6 ± 0.6 n.d. n.d. n.d. n.d. n.d.
20:4 n-6 4.1 ± 2 .0 1.2 ± 0 .4 2.4 ± 1.6 2.2 ± 1.8 14.4 ±4 .5 1.9 ± 0 .7 3.3 ± 2 .7
20:4 n-3 0.1 ± tr. 0.9 ± 0.2 1.2 ± 0 .3 2.5 ± 0 .3 n.d. 0.5 ± tr. 3.7 ± 0 .5
20:5 n-3 4.4 ±1.7 0.6 ± 0.3 0.6 ± 0.2 2.9 ± 1.4 n.d. 0.9 ± 0.3 0.2 ± 0.4
22:1 10.9 ± 4 .3 22.6 ± 5.2 9.5 ± 5 .6 1.0 ± 0 .3 n.d. 1.9 ± 1.3 n.d.
22:2 0.1 ±0.1 0.9 ± 0.2 n.d. 6.9 ± 4 .2 n.d. 3.6 ± 2 .2 n.d.
22:5 n-3 0.5 ±0.1 n.d. n.d. 4.9 ± 1.0 n.d. 1.7 ± 1.2 7.4 ± 0 .8
22:6 n-3 3.1 ±1.1 1.4 ±0.5 4.0 ± 1. 3.8 ± 1.9 4.2 ± 0.6 1.3 ± 1.2 5.9 ± 1.0
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Table 3.13: Fatty acid analysis of 1,3-diacylglycerol from individual tissues of
Oncorhynchus mykiss. Results as means of % fatty acids ± SD. tr.,
trace (< 0.05), n.d., none detected.
Eye Heart Liver Muscle Spleen
n = 4 n = 4 n = 4 n = 4 n = 3
Fatty
Acid
14:0 
16:0 
16:1 n-7 
16:2 n-4 
16:3 n-4 
18:0
18:1 n-9 
18:1 n-7 
18:2 n-6 
18:3 n-3 
18:3 n-4 
18:4 n-3 
20:1 n-9 
20:1
20:4 n-6 
20:4 n-3 
20:5 n-3 
22:1 
22:2 
22:5 n-3 
22:6 n-3
Adipose
tissue
n = 4
0.4 ± 0.4
7.7 ± 3.4 
10.1 ± 3.1 
0.6 ± 0.8
2.3 ± 0.7  
18.9 ± 4 .4
10.8 ± 5.7
4.8 ± 1.1
5.6 ± 0 .4
2.6 ± 2 .5
3.0 ± 1.3
3.5 ± 2 .1
9.0 ± 3 .5  
n.d.
1.6 ±  1.0
3.0 ± 0 . 7  
0.3 ±  0.5
7.4 ± 2.4
3.2 ± 2 . 6  
n.d.
5.2 ± 3 .1
Brain 
n = 4
4.1 ± 2.0
18.4 ± 4 . 6
2.5 ± 0.4
1.4 ± 0.6
1.8 ± 0 . 7
12.7 ± 3.4
8.0 ± 4.4  
n.d.
2.6 ± 1.8
1.1 ± 0 . 2
1.1 ± 0.3
1.8 ± 0 .3  
3.6 ± 1.5
3.3 ± 0 . 7
1.5 ± 1.3
2.3 ± 1.5
2.4 ± 1.3
29.7 ± 5.2
1.6 ± 0 .5  
n.d.
1.2 ± 0.7
1.2 ± 0 . 4
14.4 ± 4 . 8
5.1 ± 1.9
1.0 ± 0 .5
1.4 ± 0 .3
18.0 ± 6 .3
8.3 ± 3.9  
n.d.
4.5 ± 2 . 5
1.2 ± 0.8 
0.9 ± 0.5
1.6 ± 1.0
4.0 ± 0.5  
n.d.
0.9 ± 0.0  
2.2  ± 0.1 
0.6 ± 0.1
11.0 ± 2 . 4  
n.d. 
n.d.
27.5 ± 9.2
1.6 ± 0 . 7
17.8 ± 3.9
6.0 ± 2.9
2.8 ± 1.0
2.7 ± 1.2
20.7 ± 3.3 
5.8 ± 1.1
1.7 ± 2 . 2
5.3 ± 1.8
2.4 ± 1.3
1.8 ± 0.8 
1.7 ± 0 . 6
2.9 ± 1.0 
5.2 ± 1.9 
5.6 ± 2 . 7
3.0 ± 1.4
1.0 ± tr. 
n.d. 
n.d.
10.3 ± 1.4
2.9  ±  0.7
4.7 ± 1.4
18.0 ± 4 .0  
7.1 ± 3 .5
1.0 ± 0 .7  
3.9 ± 1.3
16.7 ± 4 .5
7.1 ± 3 .8  
n.d.
4.8 ± 1.8
3.1 ± 1.7 
0.7 ± tr.
n.d.
12.8 ± 5.0 
n.d.
8.0 ± 0 .4
1.1 ± 0.1 
8.7 ±0.1
n.d.
n.d.
4.0 ±  1.0
6.1 ± 0.5
5.1 ± 1.5 
19.9 ±2 .1
9.5 ± 1.5
1.7 ± 0 .0
2.1 ± 0 .3
22.1 ± 6 .4
7.3 ± 2 .6  
n.d.
4.5 ± 1.0
3.6 ± 1.9
2.1 ± 0 .7
2.8 ± 1.2
6.7 ± 0.2 
n.d.
1.1 ± 0.0 
1.1 ± 1.5 
0.9 ± 0.7
1.7 ± tr. 
6.5 ± 2 .0
1.4 ± 2 .0  
3.7 ± 1.7
1.4 ± 0 .5
11.2 ± 4.1
5.5 ± 1.5
2.2  ± 0.2 
2.0  ± 1.1
11.7 ± 4 .9
6.7 ± 3 .7  
2.4 ± 0.9
3.2 ± 1.4
2.3 ± 0 .3  
1.1 ± 0 .7  
0.6 ± 0.2
5.3 ± 2 .3  
n.d.
2.0 ± 0.4
2.0 ± 0.6
1.8 ± 0 . 5  
1.7 ± 0 .9
24.2 ± 5 .4  
4.1 ± 2 .0
10.3 ±4.2
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3.16 Discussion
The dietary intake of fish and fish-derived products has increased dramatically in 
recent years (wAvw.fao.org; www.who.inO due to the acceptance that EPA and DHA 
have beneficial effects on human health and disease (Kris-Etherton et al., 2001; 
Kromann and Green, 1980; Siscovick et al., 2003). However, as the world’s fishing 
stocks are limited and have come under enormous pressure from over-fishing, mis­
management and environmental factors (Schrank, 2005) aquaculture has developed 
into an ever-expanding and profitable industry (Food and Agricultural Organisation, 
1999; Naylor et al., 2000). As the industry continues to develop, the issue of waste 
disposal becomes increasingly more relevant. In this chapter we set out to categorise 
the levels of total and individual lipids (together with their acyl components) in the 
various tissues of farm-reared Oncorhynchus mykiss, many of which could contribute 
to waste.
The impact of diet on the lipid and fatty acid composition of fish has been extensively 
reviewed and it is now accepted that tissue lipid and fatty acid composition are 
reflective of the type of diet consumed (Jeong et al., 2002; Karapanagiotidis et al., 
2007; Miller et al., 2007; Stubhaug et al., 2005). We determined that the principal 
fatty acids found in the diet of the trout used in these experiments included 18:1 n-9 
(18%), 18:3 n-3 (14%), 16:0 (13%), 22:1 (9%), 20:1 n-9 (9%), DHA (8%) and EPA 
(5%). It was therefore not surprising that the acyl composition of the tissues 
examined were predominantly composed o f the aforementioned fatty acids (Tables
3.4 -3 .10 ). Kennedy et al. (2005) observed that fish reared on a diet which contained 
elevated levels of conjugated linolenic acid (CLA) incorporated CLA into tissue lipids 
with a two-fold increase in CLA observed in the liver compared to the flesh. Further 
evidence suggests that replacement of EPA and DHA rich diets with vegetable oil 
diets results in lower tissue concentrations o f EPA and DHA, despite the biosynthetic 
activity that converts 18:3 n-3 to EPA and DHA (Karapanagiotidis et al., 2007). 
Another study which investigated the effect o f feeding diets rich in linseed oil altered 
the fatty acid composition of the muscle and liver resulting in a decrease in the 
concentration of highly unsaturated n-3 PUFAs (EPA, DHA) in the non-polar fraction 
offish flesh, whilst no effect was observed in the polar fraction (Menoyo et al., 2005). 
Menoyo et al. (2005) did however notice an increase in 18:3 n-3 and an accumulation
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of desaturation and elongation products in the liver. Bell et al. (2003) concluded that 
a significant loss in tissue n-3 PUFAs were observed in Atlantic salmon when dietary 
fish oil was replaced with > 66% vegetable oils.
In order for offal from farmed fish to be considered as a potential source of n-3 
PUFAs it was necessary to determine the tissue levels of such fatty acids. In terms of 
total lipid (Fig. 3.1), as expected, the visceral adipose tissue contained the highest 
levels of lipids (19g/100g fresh weight). We found that brain tissue was composed of 
approximately 18 g of total lipid/100 g fresh weight. Previous research has reported 
approximately 7% of total lipid in the brain o f Oncorhynchus mykiss, (Stoknes et al., 
2004). Stoknes et al. (2004) also reported significant differences in the total lipid 
found in brain between species. They reported the lowest levels of total lipid in 
Portuguese and black dogfish brains (3.8% and 3.2%) whereas for salmon they 
reported 7%. It is known that the total lipid content in brain is elevated during 
development and discrepancies may be due to variations in fish development 
(Mourente and Tocher, 1992). Differences in water temperature have also been found 
to affect brain lipid composition (Johnston and Roots, 1964). Differences between 
what we determined as the total lipid content in Oncorhynchus mykiss and what was 
reported by Stoknes et al. (2004) may be explained by the age of the fish and/or 
temperature acclimation. Also, it is widely known that season and farming conditions 
affect levels of lipids (Ackman and Takeuchi, 1986; Argen et al., 1987; Senso et al, 
2007), therefore this may account for differences observed between our data and those 
of Stoknes et al. (2004).
Total lipid in the eye of Oncorhynchus mykiss was determined to be approximately 
3.9 g/100 g fresh weight (4%) (Fig. 3.1). Previous research (Stoknes et al., 2004) 
provided evidence that the eyes of salmon and trout contained particularly high 
amount of lipids compared to several other species (cod, saithe, redfish, Portuguese 
and black dogfish and the leafscale gluper shark). However, we determined the levels 
of total lipid in the eye (4%) of Oncorhynchus mykiss to be much less than the values 
reported by Stoknes et al. (2004) for both trout and salmon (48% and 36% 
respectively). Moreover, our results were more similar to the levels reported for 
Portuguese dogfish.
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The levels of total lipid determined in the liver, heart, muscle and spleen were all 
comparable to each other (18 -  14 mg/g fresh weight) (Fig. 3.1). The levels of total 
lipid reported by Bandarra et al. (2006) in the liver and muscle for Oncorhynchus 
mykiss were 2.8% and 4.1% respectively. The fish used by Bandarra et al. (2006) 
were classified as juveniles whereas the fish used in our experiments were considered 
adult (~2.5 yrs) and differences in age may explain these variations in total lipid 
content in the liver and muscle. Also, another factor that should be taken into account 
is season. Bandarra et al. (2006) do not specify in which season the fish were reared 
and the literature suggests that season has a large effect on lipid accumulation and 
composition in fish (Agren et al., 1987; Senso et al., 2007). Miller et al. (2007) found 
similar levels of total lipid in the muscle o f Atlantic salmon, 17.8 mg/g fresh weight 
to our levels for trout. They also reported that the levels of total lipid were dependent 
on the type of diet consumed. When the fish were subjected to a high fish oil diet 
(24% EPA and 15% DHA) the levels of total lipid in muscle increased significantly. 
However, the use o f such EPA- and DHA-saturated diets have implications in terms 
of the organoleptic qualities o f the flesh for human consumption. Therefore, the 
levels of EPA and DHA are normally lower (the diet used in our analysis consisted of 
approximately 5% EPA and 8% DHA). Our results for total lipid in muscle (1.5%) 
are also consistent with the levels of total lipid reported in the muscle of the 
carnivorous, ffesh-water fish, the zander (Sander lucioperca) analysed during the 
winter months (1.3%) but not during the spring (0.6%), summer (0.8%) or autumn 
(0.6%) (Guler et al., 2007). Differences between total lipid in the muscle of wild and 
farm-reared fish have also been recorded. Rueda et al. (2001) reported that the total 
fat content of sea bream was elevated in the white muscle and liver of reared sea 
bream compared to its wild counterpart. Interestingly, no differences between total 
lipid in muscle and liver of wild and captive sea bream were observed by Cejas et al. 
(2004). As only farm-reared trout were analysed in our experiments it may be 
interesting to compare the levels of total liver and muscle lipid to wild trout of similar 
age. Another factor that may affect total liver lipid is water temperature. Hazel 
(1979) observed that cold-acclimated (5°C) trout (Salmon gairdneri) possessed 
significantly more liver tissue per unit of body weight, and significantly less non­
polar lipid per gram of liver than warm-acclimated (20°C) individuals.
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Total lipid in the heart muscle was determined to be approximately 17.7 mg/g fresh 
weight (1.8%) (Fig. 3.1). Similar levels were reported by Castell et al., (1972). They 
found approximately 2.1% lipid in rainbow trout hearts (Salmo gairdneri) although 
this was dependent on the diet and varied from 2.1% -3.5% .
Individual lipids play a variety o f specific roles in fish biology and oftentimes the 
lipid content of fish can markedly exceed the protein content, indicating the major 
role lipids and their specific acyl components play as sources of metabolic energy in 
fish, growth, reproduction and migration (Kennedy et al., 2005). Specific lipids can 
either be incorporated into cellular membranes of tissues, catabolised to provide 
energy or deposited in adipose tissue as an energy reserve (Tocher, 2003). We 
separated the individual lipid classes and determined that the main non-polar lipid in 
all tissues was TAG (Table 3.2). O f the phosphoglycerides, PC, PE, PI and PS were 
the predominant polar lipids in all tissues. Minor levels of SPH, DPG and lyso-PC 
were also identified in certain tissues (Table 3.1). These particular phospholipids 
were previously reported as the major polar lipids in the total body lipids of rainbow 
trout, Salmo gairdneri (Castledine and Buckley, 1982). As previously discussed, 
(section 3.8.1), significant variations in the percentages of individual phospholipids 
were observed between tissues whereas the TAG was consistently the predominant 
non-polar lipid in all tissues (section 3.8.2).
Similar to the results reported by Castledine and Buckley (1982), we observed 
significant heterogeneity in the acyl constituent and their percentages for the 
individual phosphoglycerides. However, the TAG fraction displayed relatively 
similar fatty acid patterns in each tissue apart from some minor details in liver-derived 
TAG (Table 3.10). The TAG fraction of muscle from one-year old black seabream 
(Rodriguez et al., 2004) was relatively similar to our observations although we 
observed higher levels of 18:1 n-9 in Oncorhynchus mykiss. As previously 
mentioned, fish lipid and acyl composition can be influenced by numerous conditions 
including season, water temperature and habitat. Cejas et al. (2004) determined 
significant differences between the acyl composition of TAG from liver and muscle in 
wild and captive white seabream. In terms of the PUFA content of TAG from the 
liver our findings compare well with the levels of 18:2 n-6 and EPA recorded for 
captive seabream although the the DHA levels were more closely related to the levels
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observed from the wild seabream (Cejas et al., 2004). Some possible explanations for 
this may be due to the age differences, genetics, rearing methods and habitat 
variations between the seabream and Oncorhynchus mykiss.
Overall, as expected, the membrane lipids of Oncorhynchus mykiss demonstrated 
greater levels of EPA and DHA compared to the non-polar lipid fractions. In contrast 
to mammalian-derived membrane lipids, AA was a minor component of membrane 
lipids in most tissues which was consistent with the literature (Cejas et al., 2004; 
Tocher and Sargent, 1987). In comparison to marine fish, fresh-water fish such as 
Oncorhynchus mykiss have the capacity to synthesize the longer chain PUFAs from 
their 18 carbon precursors (Henderson and Tocher, 1987). However, it has been 
reported that the efficiency o f this pathway is not very high and it has been 
established that feeding preformed EPA and DHA results in higher tissue levels of 
EPA and DHA. It was interesting to observe that, despite the diet being composed of 
5% EPA, tissue levels of EPA remained quite low whereas tissue DHA was much 
greater than the 8% DHA that the diet provided. As fish lipid and fatty acid 
composition can be manipulated by dietary intervention as well as seasonal, habitat 
and rearing methods it would be interesting to repeat the analyses to determine the 
effects of each of these parameters. However, the relative enrichement of DHA over 
EPA in trout tissue lipids, compared to diet, suggests that trout have a significant 
capacity to biosynthesise DHA.
To conclude we determined that farmed Oncorhynchus mykiss tissues were a rich 
source o f the valuable n-3 PUFAs and, thus, fish waste could provide these acids, 
especially EPA and DHA for nutraceutical development whilst reducing disposal 
costs and environmental implications.
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CHAPTER 4
Effect on Storage Time and Processing Method on the n-3 
Polyunsaturated Fatty Acid Content o f  Farmed Oncorhynchus mvkiss
Waste Tissues
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4.0 Introduction
Rendering has long been employed in the extraction of lipids from a variety of animal 
products including fish. In brief, rendering means to ‘split open by the process of 
heating’. There are two main forms o f rendering, wet and dry systems. Dry rendering 
involves the removal of vapour once the tissue has been disrupted by steam, whereas 
with wet rendering, heat is applied to melt the fat and the resulting meal and fat still 
contain water after the decanting phase (Woodgate and van der Veen, 2004).
Throughout the fish oil industry wet rendering is commonly employed as the principal 
method for the extraction of fish lipids (Aidos et al., 2003). This involves mincing the 
starting material which is then conveyed through a steam heated continuous cooker 
where it is heated to 100 °C. Such conditions sterilise the fish whilst coagulating 
proteins and disrupting cell membranes facilitates the separation of oil from the dry 
matter. Once rendered, the material moves to a continuous screw-press system where 
most of the liquid is squeezed out to form a press-cake which is removed and sent for 
drying thus separating the solid and liquid phases. The liquid phase (oil, water and 
some dissolved proteins and salts) is passed through a decanter which removes 
dissolved proteins and salts. Such proteins and salts are transported to the drier and 
combined with the press-cake. Liquid from the decanter is fed to separators where the 
oil is removed and enters the refining process. Refining involves several or all of the 
following steps: removal of free fatty acids and some metal contaminants, bleaching, 
winterization (removal of saturated fats by a cold press or filter-type system) and de- 
odourisation. At this stage vitamins which may have been removed during de- 
odourisation may be added back to the oil depending on its final use (Breivik, 2007; 
Gunstone et al., 2007).
In order to compare wet rendering to other methods o f lipid extraction, a laboratory 
scale model of wet rendering was employed. For comparison, we used Garbus 
(laboratory-based) method for lipid extraction. The third method used was a single 
solvent and was based on an alternative procedures used in some industrial processes 
(Gunstone et al., 2007).
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The Bligh and Dyer method of which that of Garbus et al. (1963) is a variant, is 
commonly used with natural tissues and is widely regarded as one of the most 
effective methods for extracting lipids. However, employing this method on an 
industrial scale basis would not prove cost-effective and several problems would be 
encountered. Not only would this method give rise to huge solvent disposal costs it 
would also demand a longer analysis time, specialised equipment, skilled personnel 
and extensive health and safety measures (Johnson and Barnett, 2003). Moreover, 
chloroform is now considered a possible carcinogen and its use in the production of 
food and foodstuff for human and animal consumption is strictly prohibited (Fang et 
al.y 2007; van Vleet and Schnellmann, 2003).
The final system investigated was a single-solvent based method. Petroleum ether 
was the solvent used as it is commonly used in the Soxhlet method for lipid extraction. 
In brief, the Soxhlet method involves the starting material being suspended in a porous 
thimble of a Soxhlet apparatus, for example the Buchi Universal Extraction System, 
(Flawil, Switzerland) where the lipids are extracted by petroleum ether or its vapour 
(Manirakiza et al., 2001). Disadvantages of this method include the lengthy analysis 
time required, poor extraction of polar lipids, large volumes of solvents and in some 
cases, boiling of hazardous solvents (Johnson and Barnett, 2003). Due to such 
complications this method is primarily used as a reference method and, nowadays, is 
less used for the commercial production of oil. The petroleum ether method described 
in this chapter is a modification of the cold Soxhlet method.
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Chapter 4: Materials & Methods
4.1 Collection and Dissection of Oncorhvnchus mvkiss
Rainbow trout were collected fresh from the trout farm on the morning of the 
experiment and transported back to the laboratory stored on ice. For the experiments 
using visceral adipose tissue, the tissue was dissected from the intestinal cavity and 
rinsed in physiological saline. For the experiments using total trout offal as the lipid 
source liver, spleen, eyes, heart, brain and eggs were dissected from the fish, rinsed in 
physiological saline and blended together to ensure complete homogenisation of the 
tissue. The resulting paste was weighed (Extend, Sartorius, USA) and allocated to the 
various lipid extraction methods and time points (0 h, 24 h and 48 h).
For both starting materials, time zero samples were extracted immediately at room 
temperature by each method under investigation whereas samples for the 24 and 48 h 
time points were exposed to the atmosphere and sunlight at room temperature (25 °C) 
in order to mimic the probable offal storage conditions on farms before they were 
extracted.
4.2 Trout Oil Lipid Extraction using a Wet Rendering Method
In order to mimic the conditions employed by industry for the wet rendering 
extraction of fish oils a bench-top apparatus was developed. This consisted o f a 
condenser fitted to a glass chamber where the tissue was suspended on glass-fibre 
membrane (Whatman, UK). The role of the condenser was to prevent evaporation of 
the steam during the rendering process so that the steam was recycled throughout the 
process. Attached to the suspension chamber was the steam source, a glass boiling 
tube containing distilled water (15 ml) and anti-bumping granules (BDH, UK) (Fig. 
4.1). Steam was generated by heating the water using a Bunsen burner. The presence 
of condensed water droplets above the tissue indicated that the steam was in fact 
passing through the glass-fibre membrane and, thus, rendering the tissue.
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Fig. 4.1: Laboratory scale apparatus used for the wet rendering o f trout tissues.
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Steam source (boiling  
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anti-bumping granules)
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■
Condenser to 
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Glass-fibre filter 
containing tissue 
for rendering
Starting material was placed on the moistened glass-fibre filter which was positioned 
inside the suspension chamber. The suspension chamber was located between the 
condenser and the boiling tube and held together using a clamp.
To initiate the rendering process water (15 ml) in the boiling tube was heated using a 
Bunsen burner until a steady flow of steam was moving up through the boiling tube 
and suspension chamber. To prevent evaporation of the steam, cold water was 
continuously passed though the condenser. This process was undertaken for 15 min 
before the apparatus was allowed to cool and the tissue was transferred to a tissue 
separating cloth placed inside a mortar and pestle. Here the tissue was pressed and 
the resulting liquid was transferred to a glass test tube. The water (15 ml) utilised to 
render the material was used to rinse the mortar and pestle and added to the test tube. 
As a final wash, distilled water (2 ml) was used to rinse the mortar and pestle and this 
was combined with the initial water and sample.
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In order to determine that the liquid phase had not become acidic due to the 
generation of free fatty acids during the rendering process the pH was tested with full- 
range pH paper (Whatman, UK). To separate the oil, the sample was centrifuged on a 
Baird & Tatlock Auto Bench Centrifuge Mark IV for 5 min at 1000 x gaV (x2). The top 
lipid layer was removed using a glass pipette and transferred to a glass vial, flushed 
with nitrogen, dissolved in chloroform (1 ml) and stored at -20°C.
4.3 Trout Oil Lipid Extraction using the Garbus Method
Once removed and rinsed in physiological saline, the tissue (adipose tissue or total 
trout offal) was extracted by the Garbus method (Garbus et al., 1963). Depending on 
the amount and type of tissue used as the starting material for lipid extraction different 
amounts of solvents were used.
Samples were homogenised using a mortar and pestle in chloroform/methanol (1:2, by 
vol.) (2.5 ml/g adipose tissue, 5 ml/g total trout offal homogenate) and transferred to a 
glass 10 ml tube via a glass wool filter to remove any residual particles. Mortar and 
pestle were rinsed with chloroform/methanol (1:2, by vol.) and this was combined 
with the sample. Chloroform (2 ml/g adipose tissue, 4 ml/g total trout offal 
homogenate) was then added to sample together with Garbus solution (2 ml/g adipose 
tissue, 4 ml/g total trout offal homogenate) (2 M KC1 in 0.5 M potassium phosphate 
buffer, pH 7.4) and distilled water (1 ml/g adipose tissue, 2 ml/g total trout offal 
homogenate). After thorough mixing, the solutions were allowed to stand for 15 min at 
room temperature to allow the separation of the two phases. The mixture was 
vortexed again and centrifuged on a Baird & Tatlock Auto Bench Centrifuge Mark IV 
for 5 min at 1000 x gaV. The upper aqueous layer was removed and discarded using 
Pasteur pipettes. The lower lipid-containing layer was transferred to a clean 10 ml glass 
tube and dried under a stream of nitrogen. Lipids were dissolved in a known volume of 
chloroform and stored at -20°C. Preliminary data from our laboratory indicated that 
qualtitative extraction was achieved using the volumes outlined.
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4.4 Trout Oil Lioid Extraction using an Industrial Solvent Method
A solvent system based on frequently-used industrial methods for lipid extraction was 
the third method compared in these experiments. Tissue was homogenised in mortar and 
pestle with petroleum ether (3 ml/g adipose tissue, 4 ml/g total trout offal homogenate) 
before being filtered through glass wool into a 10 ml tube. The mortar and pestle were 
rinsed with 2 ml petroleum ether and this was added to the homogenate. Sodium 
chloride (5%) (3 ml/g adipose tissue, 4 ml/g total trout offal homogenate) was added to 
the homogenate and the mixture vortexed followed by centrifugation (x2) on a Baird & 
Tatlock Auto Bench Centrifuge Mark IV for 5 min at 1000 x gay The upper lipid layer 
was removed and brought to dryness under nitrogen before being dissolved in 
chloroform and stored at -20°C.
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Chapter 4: Results
4.5 Effect of Storage Time and Extraction Method on Total Lipid
Extracted from Total Trout Offal
In terms o f total lipid extracted the Garbus extraction proved to be the most efficient 
method employed yielding approximately 38 mg lipid/g tissue homogenate at each 
time point. As for the petroleum ether and rendering methods, both yielded 
approximately 15 mg lipid/g tissue homogenate on initial extraction. With the 
petroleum ether method, the yield increased significantly (p < 0.001) with time 
yielding approximately 32 mg/g tissue homogenate at time 48 h (Fig. 4.2A).
The rendering method also demonstrated significantly increased (p < 0.05) lipid 
yields with storage time -  increasing from 16 mg/g at time zero to 21 mg/g at time 24 
h with a further increase to 25 mg/g at time 48 h (Fig. 4.2A).
At time zero the Garbus method was significantly more effective than both the 
petroleum ether and rendering (p < 0.001) methods. At time 24 h no statistical 
differences were observed in total lipid yield between the Garbus and petroleum ether 
methods but both these methods were significantly different to the rendering method 
(p < 0.001) (Fig. 4.1). The rendering method saw an increase in total lipid yield at 48 
h and due to this no difference was observed with the petroleum ether method but the 
yield was still significantly less that that observed for the Garbus method at 48 h (p < 
0.05). Overall, the Garbus method was consistently more effective at extracting total 
lipid at each time point compared to the petroleum ether and rendering methods. 
Moreover, it gave maximum yield at time zero, in keeping with its efficiency as a 
laboratory method for lipid extraction (Fig. 4.2A).
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4.6 Effect of Storage Time and Extraction Method on Triacvlglvcerol
Yields from Total Trout Offal
The greatest amount of TAG extracted at time zero was 32 mg/g tissue homogenate 
and was achieved by the Garbus method. Both the petroleum ether and rendering 
methods produced approximately one third o f this yield (11 mg/g tissue homogenate) 
(Fig. 4.2B).
No statistically significant changes were observed in TAG yield with the Garbus 
method at each time point. However, the TAG yield produced by the petroleum ether 
method at 24 h and 48 h was significantly different to time zero (p < 0.001). 
However, no differences were observed between 24 and 48 h. The rendering method 
also demonstrated an increase in TAG yield with time. The increase in the TAG 
fraction was significantly different at 48 h compared to time zero (p < 0.05). For both 
the petroleum ether and rendering methods the apparent increase in extraction 
efficiency with time may be attributed to degradation of the tissue structure by 
phospholipases and proteinases during storage.
Overall, the levels o f TAG produced by the Garbus method were shown to be the 
highest and most consistent over time (Fig. 4.2B). Generally speaking, the Garbus 
method was significantly more effective at extracting the TAG fraction compared to 
both the petroleum ether and rendering methods (p < 0.001) at time zero. As seen 
with the extraction o f total lipid, (Fig. 4.2A) Garbus and petroleum ether methods 
were significantly more effective at time 24 h compared to the rendering method (p < 
0.001) but not different from each other. By time 48 h the rendering method was only 
significantly different from the Garbus method (p < 0.05) but had become comparable 
to the petroleum ether method (Fig. 4.2B).
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Fi£^4 .2A: Comparison of the efficiency of extraction by three lipid extraction
methods used to extract total lipid from total trout offal after different 
storage times. Results as means ± SD (n=5). * denotes significance of 
storage time within method, t  denotes significance between methods.
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Fig. 4.2B: Comparison of the efficiency of extraction by three lipid extraction
methods used to extract triacylglycerols from total trout offal after 
different storage times. Results as means ± SD (n=4). * denotes
significance of storage time within method, t  denotes significance 
between methods.
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4.7 Effect of Storage Time and Extraction Method on Non- Esterified
Fattv Acid Yields from Total Trout Offal
Since NEFAs are most likely released by tissue lipases or phospholipases, then higher 
amounts found after storage of the offal at room temperature are to be expected. 
Because the Garbus method of extraction was found to give the highest lipid yields 
(Figs. 4.2A, 4.2B) it was not surprising that the method also gave the highest NEFA 
values (Fig. 4.2C).
After 24 h approximately 0.5 — 1.2 mg NEFA/g tissue homogenate were found, 
depending on the extraction method. Compared to the total lipid yielded (Fig. 4.2A) 
this represented approximately 2%  which might be viewed as an acceptable value for 
an industrially-produced lipid. By 48 h, however, as much as 10% of the total lipid 
extracted by the Garbus method was NEFA, which was an unacceptably high value. 
If these amounts reflect the deterioration in quality of offal stored under typical fish 
farm conditions, then the storage conditions would need modifying.
Fig. 4.2C: Yield of non-esterified fatty acids (mg FFA/g tissue homogenate) over
time in total trout offal evaluated by different extraction methods. 
Results as means ± SD (n=5).
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4.8 Effect of Storage Time and Extraction Method on the Fatty Acid
Profiles of Individual Lipids from Total Trout Offal
The effects of storage time and extraction method on the percentage changes of the 
fatty acid profiles of individual lipids from total trout offal are outlined below (Tables
4.1 -  4.16). EPA and DHA are the most important fatty acids found in fish oil due to 
their biological properties and their levels need to be conserved during processing of 
the oil. Figs 4.3-4.8 represent the effect o f tissue storage time on the levels of these 
fatty acids in the total polar lipid fraction as well as the triacylglycerol and the non- 
esterified fatty acid (NEFA) fractions extracted using the different methods.
The major fatty acids found in the total polar lipid fraction extracted using the Garbus 
method at time zero included DHA > 16:0 > 18:1 n-9 > EPA > 18:2 n-6. Over 
storage time there was a decrease in the percentage of DHA to 21.6% and of EPA to 
2.9% which was coincident with a relative increase in the main monounsaturated fatty 
acids, 16:1, 18:1 n-9, 20:1 n-9, 22:1 and 24:1. These effects were not unexpected as 
the levels of PUFAs are believed to decrease with time, due to deterioration of the 
tissue, resulting in a relative increase in monounsaturated fatty acids (Table 4.2). As 
EPA and DHA are found in greater amounts in the total polar lipids it was necessary 
to look at the relative changes in lipid classes at different times in order to explain the 
decrease in EPA and DHA over time. Table 4.1 outlines the major lipids recovered 
by the three different extraction methods at the three time points examined. For the 
Garbus method the yield o f total polar lipids was greatest at time zero. Moreover, the 
total polar fraction was shown to contain more EPA and DHA than any other lipid 
fraction examined (Tables 4.2, 4.5, 4.8, 4.11 4.14). A reduction in the total polar 
fraction with time partly accounts for the reduction o f total EPA and DHA seen with 
the Garbus method (Figs. 4.3, 4.4).
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Table 4.1 Effect o f tissue storage time and extraction method on total trout offal 
lipids (mg/g tissue homogenate) based on total fatty acid analysis. 
Percentage o f total lipid values are given in parenthesis. Results as 
m eans ± SD (n=4).
GARBUS
TA G MAG DAG NEFA TP
Oh 3 2 . 0  ± 2 .5 0.8 ± 0 . 6 0.3 ± 0 .1 1.2 ± 0 .8 3.0 ± 1.7
(92 ) (1 .2) (0.4) (1.9) (4.9)
24 h 3 0 .1  ± 3.4 1.0 ± 0.3 0.5 ±  0.2 1.4 ± 0 .2 1.9 ± 0 .4
(8 8 .6 ) (2.8) (1.5) (4.3) (5.3)
48 h 2 7 . 4  ± 4 .5 1.2 ± 0 . 4 1.3 ± 0 . 6 4.1 ± 1.9 1.3 ± 0 .3
(7 8 .3 ) (3.2) (3.6) (H.3) (3-7)
PETROLEUM ETHER
TAG MAG DAG NEFA TP
Oh 1 1 .2  ± 2 . 7 0.6  ± 0 . 6 0.2 ±  0.2 1.2 ± 1.3 0.2 ± 0 .1
(9 5 .4 ) (1.7) (0.4) (2.2) (0.3)
24 h 2 6 . 5  ± 1.8 1.0 ± 0 . 6 0.7 ± 0 . 6 1.0 ± 0 .6 0.5 ± 0.2
(9 0 .3 ) (3.3) (2.1) (3.2) (1.7)
48 h 2 5 . 9  ± 4 . 5 0.6  ± 0 . 3 0.7 ± 0 .1 2.7 ± 0 .7 0.7 ± 0 .3
(8 4 .7 ) (2.0) (2.4) (8.7) (2.2)
RENDERING
TAG MAG DAG NEFA TP
Oh 1 0 .9  ± 3 . 8 0.3 ± 0 .1 0.1 ± 0 . 0 0.3 ± 0.2 0.3 ± 0.2
(9 1 .9 ) (2.5) (0.8) (2.0) (2.8)
24 h 1 7 .0  ± 1.3 0.4 ± 0 .1 0.4 ± 0 . 2 1.0 ± 0 .3 0.3 ± 0 .1
(89 .4 ) (1.9) (2.0) (5.1) (1.7)
48 h 1 8 .6  ± 1.7 0.5 ± 0 .1 0.3 ± 0 .1 1.7 ± 0 .8 0.2 ± 0 .1
(87 .5 ) (2.2) (1.2) (8.1) (0.3)
* TAG, triacylglycerol; DAG, diacylglycerol (1,2-DAG and 1,3-DAG combined); 
MAG, monoacylglycerol; NEFA, non-esterified fatty acids; TP, total polar lipid 
fraction.
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The major fatty acids observed in the total polar lipids extracted by the petroleum 
ether method included 18:1 n-9 > DHA > 16:0 > 18:2 n-6 > 18:0 > 16:1 n-7 > 22:1 > 
20:1 n-9 > EPA (Table 4.3). The levels of the monounsaturated fatty acids 20:1 n-9 
and 24:1 extracted with the petroleum ether method increased with time whilst there 
was a decrease in the level of 16:1 n-7. No significant changes in the levels of EPA 
and DHA were detected (Fig. 4.3-4.4).
In order to explain changes in the acyl composition of the total polar fraction 
extracted by the petroleum ether method it is important to consider changes in the 
different lipid fractions (Table 4.1). The total polar lipid fraction was lowest at time 
zero and increased over time (0.3% at time zero to 2.2% at time 48 h). Petroleum 
ether as a non-polar solvent is not considered to be an effective method at extracting 
the more polar lipids. Such an increase can be explained by the effect of storage time 
and tissue degradation. Degradation o f the tissue with time would be expected to 
result in a loss of membrane integrity which in turn could cause the release of 
membrane lipids and fatty acids. Due to this release, the lipids and fatty acids may 
become easier to extract with petroleum ether resulting in an increase of such 
components.
In the total polar lipid fraction extracted by the rendering method from total trout offal 
the major fatty acids consisted o f 18:1 n-9 > 16:0 = DHA > 18:2 n-6 > 20:1 n-9 > 
22:1 > EPA (Table 4.4). No statistically significant changes in percentage fatty acids 
were observed with time. Overall, the pattern of fatty acids in the polar lipid fraction 
was similar to that yielded by the petroleum ether method (Table 4.4). Thus, unlike 
the Garbus method, no significant differences were observed in the percentages of 
EPA and DHA with time (Table 4.4, Figs. 4.3 and 4.4). In general, no major 
differences in the percentage acyl composition of total polar lipids extracted using the 
rendering method were recorded with storage time (Table 4.4). Moreover, the 
percentage of total polar lipids (Table 4.1) did not change from zero h to 48 h (and 
remained low throughout) and the lack o f changes for EPA and DHA may be 
attributed to this.
Comparison of the three methods used to extract total polar lipids showed that the 
Garbus method was best for extracting PUFAs. Petroleum ether is not considered a
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good method for extraction of total polar lipids and because total polar lipids are 
enriched with PUFAs, the lower levels o f DHA and EPA in petroleum ether extracts 
may be due to reduced extraction efficiency.
In terms o f the acyl composition o f the TAG fraction, there was very little variation 
between extraction methods. At time zero for all three extraction methods, the 
principal fatty acids in TAG included 18:1 n-9 > 18:2 n-6 > 16:0 > DHA > 20:1 n-9 = 
22:1 > 18:0 > EPA (Tables 4.5 -  4.7). No apparent changes in the acyl composition 
of the TAG fraction were observed over time with any of the three methods 
examined. This included the long chain PUFAs, EPA and DHA (Figs. 4.5 and 4.6) 
for which no significant changes were detected either with extraction method or with 
storage time. Each method yielded approximately 2% EPA and 8% DHA in the TAG 
fraction at each time point (Tables 4.5 -  4.7).
The major fatty acids in the diacylglycerol (DAG) fraction extracted by the Garbus 
method at time zero were 18:1 n-9 > 16:0 = 18:2 n-6 > 20:1 n-9 = 22:1 > DHA > 18:0 
> EPA > 16:1 n-7. Surprisingly, the levels of EPA and DHA appeared to increase 
with time. This may reflect selective hydrolysis of TAG which may enrich the DAG 
fraction with EPA and DHA. Due to the low levels of DAG present in total trout offal 
it is not unexpected that some o f the minor fatty acids were not detected after lipid 
extraction (Table 4.8).
Very few of the minor fatty acids were detected in the DAG fraction extracted by the 
petroleum ether method at time zero (Table 4.9). However, most of these minor acyl 
components were detected for tissue stored for 24 or 48 h. This effect may be due to 
degradation o f  the tissue over time resulting in a subsequent increase in the DAG 
fraction (Table 4.1). The major fatty acids present in DAG extracted at time zero 
included 18:1 n-9 > 16:0= 18:2 n-6 > 18: 0 > 2 2 : 1  = DHA = 20:1 n-9 > EPA > 16:1 
n-7. There were no obvious and consistent changes in the fatty acid composition of 
the DAG fraction with tissue storage time (Table 4.9).
The DAG fraction extracted by the rendering method (Table 4.10) at time zero was 
similar to that extracted by the petroleum ether method (Table 4.9) in that many minor 
fatty acids were not detected. With time, these components became detectable
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perhaps due to tissue degradation and generation of more DAG. The principal fatty 
acids included 18:1 n-9 > 16:0 = DHA = 22:1 = 20:1 n-9 = 18:2 n-6 > 18:0 > EPA. 
After 48 h of tissue storage, there seemed to be a decrease in the relative proportion of 
EPA and DHA (Table 4.10).
For each extraction method the levels of DAG increased as a function of storage time 
(Table 4.1). DAG is a product of TAG hydrolysis by lipases or of phospholipid 
catabolism from phospholipase C. Activity o f either of these enzymes might be 
expected to increase DAG levels during storage.
The detection of minor fatty acids in the monoacylglycerol (MAG) fraction extracted 
using the three methods under investigation was noticeably better than for DAG 
(Tables 4.11 -  4.13 and 4.8 -  4.10). As seen with previous non-polar lipid fractions 
the major fatty acid found in MAG extracted using three methods was the 
monounsaturated fatty acid, 18:1 n-9. The remaining fatty acids that constituted the 
MAG fraction included 16:0, 18:0, 16:1 n-7, 20:1 n-9, 22:1, 18:2 n-6, EPA and DHA. 
For each method examined, no significant changes were observed in the fatty acid 
profiles over tissue storage time. However, the levels of EPA and DHA were 
observed to be somewhat variable over time, although these changes were not 
significantly different for any o f the three methods (Tables 4.11 -  4.13). Table 4.1 
indicates that, although the MAG fraction tended to increase as a function of storage 
time for each extraction method, any increases were not statistically significant.
No variation due to the extraction method used was detected in the percentage acyl 
composition o f NEFAs generated with time (Tables 4.14 -  4.16, Figs. 4.7 and 4.8). 
The major fatty acids present in the NEFA fraction were consistent and also 
independent of tissue storage time. The approximate levels of the principle fatty acids 
detected at each time point for each method were 18:1 n-9 > DHA > 18:2 n-6 > 16:0 > 
20:1 n-9 > 22:1 > EPA > 18:0 > 16:1 n-7 (Tables 4 .14 -4 .16 ). In terms of percentage 
lipids (based on total fatty acid analysis) the NEFA fraction increased as a function of 
tissue storage time for each extraction method investigated (Table 4.1). However, the 
levels of NEFAs generated were different between extraction methods. The Garbus 
method recovered the greatest amount of NEFAs with time (Table 4.1). However, the 
Garbus method was the most effective method of lipid extraction (Fig. 4.2A, 4.2B)
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and, due to this, greater levels of NEFAs were expected. The petroleum ether and 
rendering methods also saw an increase in NEFA levels with time. After 48 h these 
represented 8-9% of the total lipid (Table 4.1). The rise in percentage levels of 
NEFAs is consistent with tissue degradation and release of fatty acids from complex 
lipids.
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¥ i ^ 4 3 :  EPA values as percentage of total fatty acids in the total polar lipid
fraction of trout offal recovered using three methods of lipid extraction at 
different tissue storage times. Results as means ±SD (n=3). * denotes 
significance of storage time within method. + denotes significance 
between methods.
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Fig- 4.4: DHA values as percentage of total fatty acids in the total polar lipid
fraction of trout offal extracted using three methods of lipid extraction at 
different tissue storage times. Results as means ±SD (n=3). * denotes 
significance of storage time within method, t  denotes significance 
between methods.
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Fie-4.5: EPA values as percentage of total fatty acids in the triacylglycerol
fraction of trout offal extracted using three methods of lipid extraction 
at different tissue storage times. Results as means ±SD (n=3).
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Fig. 4.6: DHA values as percentage of total fatty acids in the triacylglycerol
fraction of trout offal extracted using three methods of lipid extraction 
at different tissue storage times. Results as means ±SD (n=3).
1 0 . 0-1
7.5-
5.0-
2.5-
0 . 0 -
JL
Garbus Pet. E her Rendering
Oh 
24 h 
48 h
Extraction Method
127
Fig. 4.?: EPA values as percentage of total fatty acids in the non-esterified fatty
acid fraction (NEFA) in trout offal extracted using three methods of 
lipid extraction at different tissue storage times. Results as means ±SD
(n=3).
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F»£- 4.8: DHA values as percentage of total fatty acids in the non-esterified free
fatty acid fraction (NEFA) of trout offal extracted using three methods 
of lipid extraction at different tissue storage times. Results as means
±SD (n=3).
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Table 4.2: Percentage fatty acid composition of the total polar lipids from total
trout offal extracted using the Garbus method after different tissue 
storage times. Results as means ± SD (n=3). n.d. = none detected, tr. 
= <0.05.
Fatty Acids T im e zero T im e 24 h Time 48 h
12:0 0.1 ± 0 .1 n.d. n.d.
14:0 0.8 ± 0 .2 0.7 ± 0.2 1.3 ± 0 .6
16:0 18.7 ± 1.0 18.5 ± 1.5 16.6 ± 1.7
16:1 n-7 1.2 ± 0 . 2 1.6 ± 0 . 4 2.0 ± 0.4
16:1 n.d. 0.1 ± 0 .1 0.1 ± 0 .2
17:0 0.2 ± tr. 0.2 ± tr. 0.2 ± 0 .1
17:1 0.2 ± 0 .1 0.2 ± tr. 0.4 ±0 .1
18:0 4.9 ± 0 .3 5.8 ± 0 .5 5.5 ± 0 .5
18:1 n-9 12.1 ± 0.9 16.9 ± 2 . 6 19.2 ± 3 .6
18:1 n-7 0.2 ± 0 .1 0.2 ± 0 .1 0.2 ±0 .1
18:2 n-6 4.7  ± 0 .3 6.4 ±  1.0 7.6 ± 1.2
18:2 n-3 0.1 ± tr. 0 .2 ± tr. 0.2 ± tr.
18:3 n-6 0.6 ± 0 .1 0.8 ± tr. 0.8 ±0 .1
18:3 n-3 0.4 ± 0 .1 0.5 ± 0 .1 0.5 ± tr.
20:0 n.d. 0.2 ± 0.2 0.2 ± tr.
20:1 n-9 2.3 ± 0.2 4.2  ±  1.1 6.1 ± 1.9
20:2 0.8 ± 0 .1 1.0 ± 0 . 2 0.9 ±0 .1
20:3 n-9 0.5 ± 0 .1 0.3 ± 0 . 2 0.6 ± 0 .5
20:4 n-6 1.8 ± 0 .1 1.2 ± 0 . 8 0.9 ± 0 .6
20:4 n-3 0.7 ± 0 .1 0.5 ± 0 .1 0.9 ±0 .1
20:5 n-3 5.2 ±  0.4 3 .9  ±  0.7 2.9 ± 1 .0
22:1 1.3 ± 0 . 2 3.5 ±  1.3 6.2 ± 2.3
22:2 n.d. n.d. n.d.
22:3 tr. n.d. 0.3 ± 0 .1
23:0 0.4 ± 0.4 0.3 ± 0.2 n.d.
22:5 n-3 1.3 ± 0 . 2 1.1 ± 0 .3 0.8 ± 0 .2
22:6 n-3 39.4  ±  1.6 28 .5  ±  4.5 21.6 ± 7 .9
24:0 n.d. tr. ± 0.1 n.d.
24:1 2.3 ± 0 .1 3.0 ± 0 . 6 3.9 ± 0 .3
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Table 4.3: Percentage fatty acid composition of the total polar lipid fraction from
total trout offal extracted using the petroleum ether method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24 h Time 48 h
12:0 n.d. n.d. 0.1 ± 0 .1
14:0 n.d. 1.1 ± 2 .3 2.0 ± 0 .1
16:0 15.7 ± 2 . 4 15.2 ± 5.3 16.8 ± 1.5
16:1 n-7 9.2 ± 3.2 2.1 ± 0 . 6 2.6 ± 0 .7
16:1 n.d. n.d. n.d.
17:0 n.d. 0.2 ± 0.2 0.3 ± 0 .1
17:1 n.d. 0.3 ±  0.4 0.3 ± 0 .1
18:0 9.9 ± 3 . 8 6.0 ± 3 .5 5.4 ± 0.3
18:1 n-9 24.8 ± 2.4 18.3 ± 5.4 22.3 ± 1.3
18:1 n-7 n.d. n.d. 0.1 ± 0 .1
18:2 n-6 10.9 ± 1.1 8.1 ± 1.9 9.1 ± 0 . 2
18:2 n-3 n.d. n.d. 0.1 ± tr.
18:3 n-6 0.6 ± tr. 1.1 ± 0 . 2 1.2 ± 0 .2
18:3 n-3 n.d. 0.3 ± 0 . 2 0.5 ± 0 .2
20:0 n.d. n.d. n.d.
20:1 n-9 4.4 ± 0.9 8.1 ± 2 . 2 8.0 ± 1.5
20:2 n.d. 1.0 ±  0.1 0.7 ± 0.5
20:3 n-9 n.d. 0.4 ±  0.6 0.5 ± 0.2
20:4 n-6 n.d. 0.9 ± 0 . 6 0.9 ± 0 .1
20:4 n-3 n.d. 1.4 ±  1.0 0.8 ± 0.2
20:5 n-3 3.3  ±  1.6 3 .0  ± 0 . 8 2.0 ± 0 . 4
22:1 7.5 ± 1.2 9.3 ± 2 . 9 8.3 ± 1.4
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 n.d. n.d. 3.1 ± 5 .3
22:6 n-3 15.7 ± 3 . 4 19.3 ± 8 . 2 10.7 ± 7 . 9
24:0 n.d. n.d. n.d.
24:1 n.d. 4.3 ± 1.3 3.2 ± 0.4
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Table 4.4 Percentage fatty acid composition of the total polar lipid fraction from 
total trout offal extracted using the rendering method after different 
tissue storage times. Results as means ± SD (n=3). n.d. = none 
detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 n.d. 0.1 ±0.2 n.d.
14:0 1.3 ±0.4 0.8 ±0.5 1.8 ±0.4
16:0 15.8 ±7.3 13.5 ± 1.4 18.6 ±4.2
16:1 n-7 2.0 ± 0.2 2.2 ± 0.4 3.4 ±0.7
16:1 n.d. n.d. n.d.
17:0 0.2 ±0.3 0.2 ±0.1 0.4 ±0.1
17:1 0.2 ± 0.2 0.3 ± tr. 0.9 ± 0.9
18:0 7.1 ± 1.7 5.6 ±0.4 5.5 ±0.7
18:1 n-9 23.5 ± 1.5 23.0 ± 1.4 20.4 ± 4.2
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 10.9 ± 5.6 10.7 ±0.7 9.6 ± 0.5
18:2 n-3 n.d. 0.1 ± tr. 0.3 ±0.1
18:3 n-6 1.6 ±0.8 1.1 ±0.1 1.1 ±0.1
18:3 n-3 1.0 ±0.7 0.8 ± 0.2 0.9 ±0.3
20:0 n.d. 0.1 ±0.1 0.2 ± 0.3
20:1 n-9 9.0 ± 2.9 8.5 ± 1.2 8.7 ±2.0
20:2 0.5 ±0.5 1.2 ±0.2 0.5 ± 0.4
20:3 n-9 0.2 ±0.3 0.3 ± 0.2 0.3 ± 0.2
20:4 n-6 0.5 ± 0.6 0.8 ± 0.2 0.6 ±0.5
20:4 n-3 0.5 ± 0.6 1.3 ±0.3 0.7 ± 0.5
20:5 n-3 2.2 ± 1.2 2.3 ± 0.3 1.9 ±0.4
22:1 8.1 ±2.4 9.6 ± 1.7 8.6 ± 1.9
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 0.5 ± 0.6 0.8 ±0.6 n.d.
22:6 n-3 16.2 ±2.7 14.2 ±3.7 12.2 ±3.4
24:0 0.4 ±0.8 0.1 ±0.2 0.1 ±0.2
24:1 1.9 ± 1.5 2.6 ±0.5 3.6 ±0.9
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Table 4.5: Percentage fatty acid composition of the triacylglycerol fraction from
total trout offal extracted using the Garbus method after different tissue 
storage times. Results as means ± SD (n=3). n.d. = none detected, tr. 
= <0.05.
Fatty Acids T im e zero T im e 24 h Tim e 48 h
12:0 0.1 ± tr. 0.1 ±0.1 tr.
14:0 3.2 ±0.1 3.1 ±0.1 3.0 ±0.1
16:0 13.1 ±0.8 13.2 ±0.9 12.9 ±0.9
16:1 n-7 4.4 ± 0.7 4.4 ± 0.6 4.3 ± 0.6
16:1 0.1 ± tr. 0.1 ± tr. 0.2 ±0.1
17:0 0.2 ± tr. 0.2 ± tr. 0.3 ±0.1
17:1 0.4 ± tr. 0.4 ± tr. 0.3 ± 0.2
18:0 2.7 ± 0.3 2.8 ±0.4 2.7 ± 0.4
18:1 n-9 24.8 ± 1.0 25.8 ± 1.0 25.5 ± 1.1
18:1 n-7 0.3 ± tr. 0.3 ± tr. 0.3 ± tr.
18:2 n-6 15.7 ±0.6 15.5 ±0.7 15.5 ±0.6
18:2 n-3 0.3 ± tr. 0.3 ± tr. 0.3 ± tr.
18:3 n-6 1.7 ±0.1 1.6 ±0.1 1.4 ±0.1
18:3 n-3 1.5 ± 0.1 1.3 ± 0.1 1.4 ±0.1
20:0 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
20:1 n-9 7.7 ± 0.6 8.2 ± 0.6 8.0 ± 0.6
20:2 0.9 ±0.1 0.9 ±0.1 0.9 ±0.1
20:3 n-9 0.3 ± tr. 0.3 ± tr. 0.3 ±0.1
20:4 n-6 0.4 ± tr. 0.3 ±0.1 0.3 ±0.1
20:4 n-3 1.1 ±0.1 1.1 ±0.1 0.9 ± 0.5
20:5 n-3 2.5 ± 0 .1 2.2  ±  0.1 2.4 ± 0 .1
22:1 7.7 ±0.6 8.2 ± 0.6 8.1 ±0.6
22:2 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
22:3 n.d. n.d. 0.1 ±0.1
23:0 0.1 ± tr. 0.2 ± tr. 0.1 ±0.1
22:5 n-3 1.0 ± 0.1 0.8 ±0.1 0.9 ±0.1
22:6 n-3 8 .5  ±  0.7 7.6 ±  0.6 8.5 ±  0.6
24:0 0.1 ±0.1 0.1 ±0.1 0.1 ± tr.
24:1 0.6 ±0.1 0.7 ±0.1 0.7 ±0.1
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Table 4.6: Percentage fatty acid composition of the triacylglycerol fraction from
the total trout offal extracted using the petroleum ether method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
14:0 3.1± 0.2 3.0 ±0.3 3.1 ±0.1
16:0 13.1± 0.8 13.4 ±0.9 13.0 ± 1.0
16:1 n-7 4.5± 0.6 4.4 ± 0.6 4.2 ± 0.7
16:1 0.1± tr. 0.1 ±tr. 0.1 ± tr.
17:0 0.2± 0.1 0.2 ± tr. 0.2 ± tr.
17:1 0.4± 0.1 0.4 ± tr. 0.4 ± tr.
18:0 2.7± 0.3 2.9 ± 0.4 2.7 ±0.3
18:1 n-9 25.4± 1.0 26.2 ± 1.2 25.3 ± 0.8
18:1 n-7 0.3± tr. 0.3 ± tr. 0.3 ± tr.
18:2 n-6 15.7± 0.6 15.2 ±0.6 15.6 ±0.7
18:2 n-3 0.3± tr. 0.3 ± tr. 0.3 ± tr.
18:3 n-6 1.7± 0.1 1.5 ± 0.1 1.7 ±0.1
18:3 n-3 1.4± 0.1 1.3 ± 0.1 1.4 ±0.1
20:0 0.1±tr. 0.1 ± tr. 0.1 ±tr.
20:1 n-9 7.9± 0.6 8.3 ± 0.6 8.3 ± 0.4
20:2 0.9± 0.1 0.9 ±0.1 0.9 ±0.1
20:3 n-9 0.3± tr. 0.3 ±0.1 0.3 ± tr.
20:4 n-6 0.3± tr. 0.3 ±0.1 0.3 ± tr.
20:4 n-3 1.1±0.1 1.0 ±0.1 1.1 ±0.1
20:5 n-3 2.5± 0.1 2.1 ±0.2 1.9 ± 0.6
22:1 7.8± 0.6 8.9 ±0.5 8.3 ± 0.5
22:2 0.1±tr. 0.1 ± tr. 0.1 ± tr.
22:3 tr. tr. 0.2 ± tr.
23:0 0.1±tr. 0.2 ± tr. tr.
22:5 n-3 1.0±0.1 0.8 ±0.1 1.0 ±tr.
22:6 n-3 8.3± 0.4 7.2 ± 0.8 8.2 ± 0.9
24:0 0.1± tr. 0.2 ± tr. 0.2 ± tr.
24:1 0.7± 0.1 0.6 ±0.2 0.7 ± tr.
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Table 4.7: Percentage fatty acid composition of the triacylglycerol fraction from
total trout offal extracted using the rendering method at different tissue 
storage times. Results as means ± SD (n=3). n.d. = none detected, tr. 
= <0.05.
Fatty Acids T im e zero T im e 24 h Tim e 48 h
12:0 tr. tr. 0.1 ± tr.
14:0 2.7 ± 0 .7 2.9 ± 0.2 3.1 ± 0 .1
16:0 13.4 ± 0 .9 13.0 ± 0 .9 13.1 ± 0 .8
16:1 n-7 4 .2  ± 0.8 4.3 ± 0.6 4.2 ± 0.7
16:1 0.1 ± 0 .1 0.1 ± tr. 0.1 ± 0 .1
17:0 0.2 ± tr. 0 .2  ± tr. 0.2 ± tr.
17:1 0.4 ± 0 .1 0 .4  ± tr. 0.4 ± tr.
18:0 2.9 ± 0 .5 2.8 ± 0 .3 2.8 ± 0.3
18:1 n-9 26 .0  ± 0 .9 25 .7  ± 0 .9 25.7 ± 0 .8
18:1 n-7 0.3 ± tr. 0.3 ± tr. 0.3 ±  tr.
18:2 n-6 16.2 ± 1.4 15.5 ± 0 .6 15.4 ± 0 .6
18:2 n-3 0.4  ± 0 .1 0.3 ± tr. 0.3 ±  tr.
18:3 n-6 1.6 ± 0.1 1.7 ± 0.1 1.7 ± 0 .1
18:3 n-3 1.3 ± 0 .2 1.4 ±  0.1 1.4 ± 0 .1
20:0 0.2 ± 0 .1 0.1 ±  tr. 0.1 ±  tr.
20:1 n-9 7.4 ± 1.8 8.2 ±  0.6 8.1 ± 0 .6
20:2 0 .9  ± 0 .1 0 .9  ± 0 .1 0.9 ± 0 .1
20:3 n-9 0 .4  ± 0.2 0.3 ± 0 .1 0.3 ±  tr.
20:4 n-6 0 .6  ± 0 .5 0.3 ± 0 .1 0.3 ± tr.
20:4 n-3 1.1 ± 0 .2 1.4 ± 0 .6 1.1 ±  tr.
20:5 n-3 2 .8  ±  1.2 2 .3  ±  tr. 2.3 ±  0.1
22:1 6.8 ± 2 .5 8.2 ± 0.6 8.1 ± 0 .6
22:2 0.1 ± tr. 0.1 ±  tr. 0.1 ±  tr.
22:3 0.1 ± 0 .2 tr. 0.1 ±  tr.
23:0 0.1 ± 0 .1 0 .2  ±  tr. tr.
22:5 n-3 1.0 ±  0.1 0.9 ± 0 .1 0.9 ± 0 .1
22:6 n-3 8.2 ±  1.5 7 .8  ±  0.5 7.9 ±  0.6
24:0 0.1 ± 0 .1 0.2 ± tr. 0.2 ± tr.
24:1 0.6 ± 0 .2 0.7 ± 0 .1 0.6 ± 0 .1
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Table 4.8: Percentage fatty acid composition of the diacylglycerol (1,2 and 1,3
diacylglycerol) fraction from total trout offal extracted using the 
Garbus method after different tissue storage times. Results as means ± 
SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 n.d. n.d. 0.2 ± tr.
14:0 1.7 ±0.2 0.9 ± 0.2 1.8 ±0.6
16:0 14.7 ± 2.2 11.4 ± 1.8 13.1 ± 1.6
16:1 n-7 2.4 ±0.8 2.1 ±0.1 3.0 ±0.2
16:1 n.d. n.d. n.d.
17:0 n.d. 0.2 ±0.1 0.2 ± tr.
17:1 n.d. 0.4 ± 0.2 0.4 ±0.1
18:0 6.1 ±0.9 4.7 ± 1.1 3.7 ±0.3
18:1 n-9 26.9 ± 2.2 21.1 ±4.8 22.4 ± 2.3
18:1 n-7 n.d. n.d. 2.7 ±2.4
18:2 n-6 13.8 ±0.8 11.1 ± 1.7 12.7 ± 1.3
18:2 n-3 n.d. 0.2 ± tr. 0.3 ± tr.
18:3 n-6 1.3 ±0.9 1.7 ±0.3 1.4 ±0.2
18:3 n-3 1.1 ±0.7 2.4 ± 0.7 1.2 ±0.1
20:0 n.d. 0.2 ± 0.4 n.d.
20:1 n-9 10.3 ± 1.2 9.0 ±2.1 7.4 ± 0.4
20:2 0.2 ± 0.4 1.2 ±0.3 0.9 ±01
20:3 n-9 n.d. 0.1 ±0.2 0.4 ±0.1
20:4 n-6 n.d. 1.1 ±0.3 0.7 ±0.1
20:4 n-3 0.7 ±0.9 2.7 ± 1.3 1.6 ±0.3
20:5 n-3 2.6 ± 0.4 5.3 ± 1.7 3.1 ± 0.2
22:1 10.8 ±0.9 9.6 ±3.1 8.0 ± 0.5
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 n.d. 1.9 ±0.6 1.0 ± 0.1
22:6 n-3 7.5 ± 1.8 12.4 ± 8.6 13.3 ± 1.9
24:0 n.d. n.d. n.d.
24:1 n.d. 0.3 ±0.5 0.6 ± 0.0
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Table 4.9: Percentage fatty acid composition of the diacylglycerol (1,2 and 1,3
diacylglycerol) fraction from total trout offal extracted using the 
petroleum ether method after different tissue storage times. Results as 
means ± SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty A cids T im e zero T im e 24 h Tim e 48 h
12:0 n.d. 0.2 ± tr. 0.1 ± 0 .2
14:0 n.d. 1.3 ± 0 .9 2.4 ± 0.3
16:0 14.8 ± 1.5 11.0 ± 4 .3 13.8 ± 0 .8
16:1 n-7 4.4 ± 2 .1 2.0 ± 0 .5 3.4 ±  1.1
16:1 n.d. n.d. n.d.
17:0 n.d. n.d. n.d.
17:1 1.4 ± 0 .7 0.1 ± 0 .2 0.3 ± tr.
18:0 11.8 ± 2 .6 4.5 ± 1.5 4.6 ± 0.9
18:1 n-9 19.7 ± 5 .0 18.2 ± 4 .1 23.8 ± 0 .8
18:1 n-7 n.d. n.d. 0.1 ± 0 .1
18:2 n-6 12.8 ± 2 .6 11.3 ±  1.9 13.5 ± 0 .4
18:2 n-3 n.d. 0.2 ±  tr. 0.3 ± 0 .1
18:3 n-6 n.d. 1.9 ± 0 .6 1.5 ± 0 .4
18:3 n-3 1.9 ± 0 .4 2.1 ± 0 .2 1.2 ± 0 .2
20:0 n.d. 0.2 ± 0.4 0.2 ± 0.2
20:1 n-9 6.8 ± 1.6 7.3 ± 2.8 8.1 ± 1.0
20:2 n.d. 1.0 ± 0 .3 0.7 ± 0 .5
20:3 n-9 n.d. 0.2 ±  0.3 0.4 ± 0 .1
20:4 n-6 n.d. 0 .9  ±  0.3 0.8 ± 0 .1
20:4 n-3 n.d. 3.1 ± 0 .4 1.4 ± 0 .2
20:5 n-3 5 .9  ±  0.8 5 .8  ± 3 .1 3.0 ± 0.4
22:1 10.4 ± 2 .9 8.5 ± 3 .4 7.8 ±  0.9
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. 0.2 ±  0.4 0.2 ± 0 .1
22:5 n-3 n.d. 1.5 ± 1.3 1.0 ± 0 .1
22:6 n-3 10.1 ±  4.3 18.5 ± 9 .8 11.0 ±  1.5
24:0 n.d. n.d. tr.
24:1 n.d. n.d. 0.5 ± 0 .1
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Table 4.10: Percentage fatty acid composition o f the diacylglycerol (1,2 and 1,3
diacylglycerol) fraction from total trout offal extracted using the 
rendering method after different tissue storage times. Results as means 
± SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 n.d. n.d. n.d.
14:0 1.0 ±0.8 1.0 ±0.5 2.2 ± 0.6
16:0 14.1 ±2.3 13.7 ±2.8 16.7 ±2.4
16:1 n-7 0.5 ±0.8 2.5 ± 1.5 3.2 ± 1.0
16:1 n.d. n.d. n.d.
17:0 n.d. 0.2 ±0.1 1.0 ±0.3
17:1 1.0 ±0.7 0.3 ± 0.2 0.8 ± 0.7
18:0 10.6 ±2.6 6.1 ±2.3 5.0 ±0.8
18:1 n-9 24.0 ±7.1 23.2 ±2.6 25.0 ±2.5
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 10.2 ± 1.6 12.9 ±2.2 11.6 ± 1.7
18:2 n-3 n.d. 0.3 ± 0.2 0.4 ± 0.4
18:3 n-6 0.3 ±0.5 1.6 ±0.2 1.3 ±tr.
18:3 n-3 n.d. 1.7 ±0.3 0.7 ± 0.5
20:0 n.d. 0.1 ±0.1 0.1 ±0.2
20:1 n-9 9.2 ±4.3 7.8 ±2.2 10.3 ± 1.3
20:2 0.3 ± 0.6 1.2 ±0.3 0.5 ± 0.3
20:3 n-9 n.d. 0.3 ± 0.2 0.4 ±0.1
20:4 n-6 n.d. 0.8 ± 0.2 0.4 ± 0.3
20:4 n-3 n.d. 1.7 ±0.7 1.3 ±0.6
20:5 n-3 3.0 ± 1.4 3.4 ± 0.8 1.3 ± 0.9
22:1 12.7 ±2.3 9.0 ± 2.2 10.5 ± 1.0
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 n.d. 1.3 ±0.2 1.6 ±0.3
22:6 n-3 13.2 ±  1.8 12.6 ±2.6 5.8 ± 2.9
24:0 n.d. n.d. n.d.
24:1 n.d. n.d. n.d.
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Table 4.11: Percentage fatty acid composition of the monoacylglycerol fraction
from total trout offal extracted using the Garbus method after different 
tissue storage times. Results as means ± SD (n=3). n.d. = none 
detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 n.d. n.d. n.d.
14:0 2.3 ± 1.5 0.7 ± 0.6 1.5 ±0.7
16:0 16.3 ±7.5 11.0 ± 1.8 12.2 ± 1.7
16:1 n-7 2.8 ± 1.0 2.9 ± 1.4 3.5 ± 1.3
16:1 n.d. n.d. n.d.
17:0 0.3 ± 0.2 0.2 ±0.1 0.2 ± tr.
17:1 0.1 ± tr. 0.2 ± tr. 0.4 ± tr.
18:0 5.4 ± 1.2 5.0 ± 1.1 4.0 ± 0.5
18:1 n-9 22.5± 2.1 25.7 ±2.3 25.0 ± 1.7
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 13.4 ±2.9 14.4 ± 1.7 15.0 ±0.2
18:2 n-3 0.1 ±0.1 0.1 ±0.2 0.3 ±0.1
18:3 n-6 1.7 ±0.3 1.8 ± 0.1 1.8 ± 0.1
18:3 n-3 1.2 ±0.4 1.1 ±0.2 1.3 ±0.1
20:0 0.5 ±0.1 0.4 ± 0.3 tr.
20:1 n-9 7.6 ± 1.1 9.1 ± 1.5 7.7 ± 0.7
20:2 0.9 ± 0.3 1.1 ±0.1 1.0 ±0.1
20:3 n-9 1.1 ±0.7 0.2 ± 0.2 0.4 ±0.1
20:4 n-6 0.9 ±0.5 0.6 ± 0.2 0.8 ± 0.3
20:4 n-3 1.3 ±0.6 1.6 ±0.7 1.2 ± 0.1
20:5 n-3 2.4 ± 0.8 2.2 ± 0.4 2.4 ± 0.4
22:1 6.5 ± 1.0 9.1 ±2.4 7.3 ±0.8
22:2 n.d. 0.1 ±0.2 0.1 ±0.1
22:3 n.d. n.d. 0.3 ±0.1
23:0 n.d. n.d. n.d.
22:5 n-3 0.4 ± 0.4 0.8 ±0.6 1.0 ±0.1
22:6 n-3 11.5 ±5.3 9.9 ± 1.5 12.3 ±2.4
24:0 0.5 ± tr. 0.2 ± 0.5 0.3 ±0.1
24:1 0.7 ±0.1 1.5 ±0.7 0.6 ±0.1
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Table 4.12: Percentage fatty acid composition of the monoacylglycerol fraction from 
toted trout offal extracted using the petroleum ether method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = none 
detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 n.d. n.d. tr.
14:0 0.3 ± 0.5 1.0 ±0.2 2.2 ± 0.3
16:0 13.9 ± 3.7 12.9 ±2.3 13.5 ±0.1
16:1 n-7 5.9 ±3.4 2.7 ± 1.3 3.8 ± 1.4
16:1 n.d. n.d. n.d.
17:0 n.d. 0.2 ± 0.4 0.2 ±0.1
17:1 n.d. 0.2 ± 0.2 0.3 ±0.1
18:0 8.2 ±3.7 4.6 ± 0.6 4.7 ± 1.2
18:1 n-9 25.9 ± 3.1 26.9 ± 1.9 25.3 ± 1.3
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 15.4 ± 1.7 15.5 ±0.1 14.8 ±0.3
18:2 n-3 n.d. 0.2 ± tr. 0.3 ±0.1
18:3 n-6 1.5 ± 1.3 1.9 ±0.1 1.7 ±0.1
18:3 n-3 0.5 ±0.1 1.2 ±0.2 1.2 ±0.2
20:0 n.d. n.d. n.d.
20:1 n-9 6.3 ±2.1 8.3 ± 0.5 7.1 ±0.6
20:2 0.3 ±0.1 1.2 ±0.1 0.9 ±0.1
20:3 n-9 n.d. 0.5 ±0.1 0.4 ±0.1
20:4 n-6 n.d. 0.5 ±0.1 0.7 ± 0.4
20:4 n-3 0.5 ±0.1 1.7 ±0.3 1.1 ±0.1
20:5 n-3 1.5 ±0.4 2.1 ± 0.3 2.2 ±0.2
22:1 7.7 ±2.6 7.9 ± 0.9 7.6 ±0.6
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 0.4 ±0.8 1.2 ±0.2 1.2 ±0.1
22:6 n-3 11.0 ±2.9 9.3 ± 1.9 10.8 ± 1.7
24:0 n.d. n.d. n.d.
24:1 n.d. n.d. n.d.
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Table 4.13: Percentage fatty acid composition of the monoacylglycerol fraction
from total trout offal extracted using the rendering method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 tr. n.d. n.d.
14:0 1.8 ±0.6 0.6 ±0.5 2.2 ± 0.3
16:0 13.1± 1.4 11.1 ± 1.6 14.6 ± 1.9
16:1 n-7 4.1 ± 1.4 2.4 ± 1.2 4.2 ± 1.1
16:1 n.d. n.d. n.d.
17:0 0.2 ± 0.2 0.1 ±0.1 0.8 ±0.1
17:1 0.3 ± 0.2 0.3 ±0.3 0.9 ± 0.8
18:0 4.3 ± 1.0 4.7 ±0.8 4.3 ± 0.7
18:1 n-9 25.9 ±3.8 25.8 ± 1.3 25.6 ± 1.6
18:1 n-7 0.1 ±0.1 n.d. n.d.
18:2 n-6 15.9 ± 1.2 14.6 ± 1.6 14.5 ± 1.4
18:2 n-3 0.2 ±0.1 0.2 ± 0.2 0.2 ± 0.2
18:3 n-6 1.7 ±0.2 1.8 ±0.2 1.8 ± 0.1
18:3 n-3 1.4 ±0.3 1.3 ±0.4 1.3 ±0.1
20:0 n.d. n.d. n.d.
20:1 n-9 8.7 ± 1.1 9.3 ± 2.2 7.5 ± 0.4
20:2 0.7 ±0.5 1.2 ± tr. 0.6 ± 0.4
20:3 n-9 0.3 ± 0.2 0.3 ±0.3 0.5 ± 0.2
20:4 n-6 0.4 ± 0.3 0.8 ± 0.2 0.3 ± 0.3
20:4 n-3 0.7 ±0.5 2.2 ± 1.2 1.3 ±0.6
20:5 n-3 2.1 ±0.2 2.9 ± 0.9 1.9 ± 0.2
22:1 8.1 ±0.7 9.0 ±2.7 6.5 ± 0.3
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 0.6 ±0.4 1.4 ±0.3 0.5 ± 0.4
22:6 n-3 8.7 ± 1.2 11.5 ±0.8 10.1 ± 1.5
24:0 n.d. n.d. n.d.
24:1 0.6 ± 0.4 1.0 ±0.2 0.5 ±0.3
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Table 4.14: Percentage fatty acid composition o f the non-esterified fatty acid
fraction from total trout offal extracted using the Garbus method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 hr Time 48 h
12:0 0.2 ± 0.4 n.d. n.d.
14:0 1.5 ±0.2 1.2 ±0.4 1.8 ±0.4
16:0 14.0 ± 1.9 14.7 ± 1.5 14.4 ±0.8
16:1 n-7 2.4 ± 0.2 2.5 ±0.7 3.3 ±0.7
16:1 n.d. n.d. 0.1 ±0.1
17:0 0.2 ±0.1 0.3 ±0.1 0.2 ± tr.
17:1 0.2 ± 0.2 0.3 ±0.1 0.5 ± tr.
18:0 4.2 ±0.9 4.7 ± 1.2 3.6 ±0.3
18:1 n-9 22.0 ± 1.5 22.5 ± 2.6 22.2 ± 2.3
18:1 n-7 n.d. 0.4 ± tr. 0.3 ± tr.
18:2 n-6 15.6 ± 1.4 14.4 ± 1.9 13.6 ± 1.1
18:2 n-3 0.3 ± 0.2 0.4 ±0.1 0.3 ± tr.
18:3 n-6 1.5 ±0.9 1.1 ±0.7 1.1 ±0.7
18:3 n-3 1.5 ±0.4 1.1 ±0.4 1.3 ±0.2
20:0 n.d. 0.2 ±0.1 0.1 ± tr.
20:1 n-9 4.7 ± 0.4 5.3 ±0.7 5.8 ±0.3
20:2 0.8 ±0.1 1.1 ±0.2 0.9 ±0.1
20:3 n-9 0.5 ±0.1 0.5 ±0.1 0.5 ± tr.
20:4 n-6 1.4 ±0.2 1.3 ±0.3 1.0 ± 0.1
20:4 n-3 1.4 ±0.2 1.1 ±0.6 1.2 ± 0.1
20:5 n-3 4.9 ± 0.8 4.1 ± 0.7 3.9 ± 0.2
22:1 4.4 ± 0.9 5.3 ± 1.4 5.2 ±0.5
22:2 n.d. tr. ± 0.1 0.1 ±tr.
22:3 n.d. n.d. n.d.
23:0 0.2 ±0.5 0.8 ±0.3 0.4 ± tr.
22:5 n-3 1.3 ±0.2 1.2 ±0.2 1.1 ±0.2
22:6 n-3 15.4 ±2.5 15.0 ±3.4 16.5 ±2.8
24:0 n.d. n.d. 0.1 ±0.1
24:1 1.4 ± 1.0 0.5 ±0.1 0.7 ±0.2
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Table 4.15: Percentage fatty acid composition of the non-esterified fatty acid
fraction from total trout offal extracted using the petroleum ether 
method after different tissue storage times. Results as means ± SD 
(n=3). n.d. = none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 hr Time 48 h
12:0 n.d. tr. tr.
14:0 1.4 ±0.8 1.3 ± 1.1 2.8 ±0.2
16:0 13.0 ±2.6 13.8 ±4.4 13.4 ±0.5
16:1 n-7 2.5 ±0.5 3.0 ±0.9 3.5 ±0.9
16:1 n.d. 0.1 ±0.2 tr.
17:0 n.d. 0.2 ±0.1 0.2 ± tr.
17:1 0.6 ±0.7 0.2 ±0.1 0.4 ±0.1
18:0 5.0 ±0.8 5.0 ±1.1 3.2 ± 0.6
18:1 n-9 22.3 ± 3.0 23.1 ±3.9 23.2 ± 0.5
18:1 n-7 0.7 ±0.5 0.2 ± 0.2 0.3 ± tr.
18:2 n-6 16.4 ±2.4 13.4 ±3.3 14.6 ±0.9
18:2 n-3 0.2 ± tr. 0.2 ± 0.2 0.4 ± tr.
18:3 n-6 1.9 ±0.3 1.5 ±0.2 1.6 ± 0.1
18:3 n-3 1.4 ±0.3 1.1 ±0.3 1.4 ±0.2
20:0 n.d. 0.1 ±0.1 1.6 ±0.9
20:1 n-9 4.7 ±0.7 7.2 ±2.5 4.7 ±3.2
20:2 1.4 ±0.7 1.2 ±0.2 0.9 ±0.1
20:3 n-9 0.3 ± 0.3 0.4 ± 0.3 0.6 ± 0.3
20:4 n-6 1.4 ±0.2 0.9 ± 0.6 0.8 ± 0.4
20:4 n-3 1.5 ±0.3 1.9 ± 1.5 1.2 ±tr.
20:5 n-3 5.2 ± 1.2 3.5 ± 0.5 3.9 ±0.3
22:1 4.1 ±0.9 8.5 ±3.5 5.4 ± 0.7
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 0.8 ±0.1 0.9 ± 0.6 1.2 ± 0.1
22:6 n-3 15.2 ±3.1 12.5 ±2.4 14.8 ±1.7
24:0 n.d. n.d. n.d.
24:1 n.d. n.d. n.d.
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Table 4.16: Percentage fatty acid composition of the non-esterified fatty acid
fraction from total trout offal extracted using the rendering method 
after different tissue storage times. Results as means ± SD (n=3). n.d. 
= none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 hr Time 48 h
12:0 n.d. n.d. n.d.
14:0 0.9 ± 0.6 0.9 ± 0.6 1.6 ±0.1
16:0 15.6 ±4.5 13.1 ± 1.1 12.6 ± 1.5
16:1 n-7 1.9 ± 1.1 2.6 ± 1.0 3.1 ±0.8
16:1 n.d. n.d. n.d.
17:0 0.1 ±0.1 0.2 ± tr. 0.3 ± 0.2
17:1 0.2 ± 0.2 0.3 ± 0.2 0.4 ±0.1
18:0 6.8 ± 1.8 4.5 ± 1.4 2.9 ±0.5
18:1 n-9 23.1 ±3.5 20.5 ± 8.5 23.6 ±2.4
18:1 n-7 0.17 ± 0.1 0.2 ± 0.2 0.3 ± 0.2
18:2 n-6 13.8 ±2.2 11.3 ±6.3 14.3 ± 1.4
18:2 n-3 0.1 ±0.2 0.4 ± tr. 0.4 ±0.1
18:3 n-6 1.2 ±0.8 1.7 ±0.2 1.6 ±0.2
18:3 n-3 0.9 ±0.7 1.3 ±0.3 1.3 ±0.2
20:0 n.d. 0.1 ± tr. 0.1 ±0.1
20:1 n-9 6.0 ± 1.2 6.4 ± 1.5 5.3 ± 0.6
20:2 0.7 ± 0.5 1.3 ±0.4 0.9 ±0.1
20:3 n-9 0.3 ±0.3 0.9 ± 0.4 0.5 ±0.1
20:4 n-6 1.0 ±0.7 1.5 ±0.3 1.3 ± 0.1
20:4 n-3 1.1 ±0.8 1.7 ±0.5 1.3 ±0.1
20:5 n-3 3.6 ± 2.5 4.7 ± 0.5 4.6 ± 0.2
22:1 6.0 ±2.7 6.7 ±2.8 4.3 ± 0.3
22:2 n.d. 0.1 ±0.1 tr.
22:3 n.d. n.d. n.d.
23:0 0.2 ± 0.4 1.0 ±0.3 0.6 ± 0.2
22:5 n-3 0.8 ± 1.0 1.5 ±0.3 1.3 ±0.2
22:6 n-3 16.0 ±4.6 17.4 ±2.2 17.5 ±2.4
24:0 n.d. n.d. n.d.
24:1 n.d. n.d. n.d.
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4.9 Effect of Storage Time and Extraction Method on Total Lipid
Extracted from Visceral Adipose Tissue
In order to compare starting materials, visceral adipose tissue was also used as a lipid 
source. It was very uncommon to find subcutaneous adipose tissue whereas visceral 
adipose tissue was present in all fish analysed. In contrast to the trends seen with total 
trout offal (Fig. 4.2B) all three methods used for lipid extraction produced almost 
equal yields of total lipids at each time point (Fig. 4.9). The only exception to this 
trend was seen with the rendering method at which the levels dropped from 
approximately 165 mg lipid/g fresh weight at time zero to 98 mg lipid/g fresh weight 
at 48 h. This decrease in the total lipid extracted was not seen with the other two 
methods where the levels remained stable at about 200 mg/g at each time point (Fig.
4.9).
4.10 Effect of Storage Time and Extraction Method on Triacvlglvcerol
Yields from Visceral Adipose Tissue
For the Garbus method no difference in extraction efficiency was noted between TAG 
yield at 24 h but by 48 h TAG yield had significantly decreased (p < 0.05) compared 
to time zero (Fig. 4.10). No significant differences in TAG yield for the petroleum 
ether method were detected at any o f the three time points examined. The Garbus and 
petroleum ether method produced similar yields of TAGs at each time point. 
However, the rendering method was observed to yield significantly less (p < 0.05) 
TAG than either the Garbus or petroleum ether methods at zero and 48 h. Within the 
rendering experiment the TAG yields were comparable at zero and 24 h but by 48 h a 
significant decrease (p < 0.05) was observed (Fig. 4.10).
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Fig. 4.9: Comparison of the yield of three methods used to extract total lipid
from visceral adipose tissue after different tissue storage times. 
Results as means ± SD (n=3). * denotes significance of storage time 
within method, t  denotes significance between methods.
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Fig. 4.10: Comparison of the yield o f three methods used to extract
triacylglycerols from visceral adipose tissue after different tissue 
storage times. Results as means ± SD (n=3). * denotes significance of 
storage time within method, t  denotes significance between methods.
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In order to explain the effect o f extraction method and tissue storage time on total 
lipid and TAGs extracted from visceral adipose tissue it was important to consider the 
distribution of lipid classes at each time point (Table 4.17). As mentioned previously, 
tissue degradation increases in accordance with increasing storage time. Storage 
conditions employed for the visceral adipose tissue were modelled on the expected 
conditions in which the offal may be stored on farms. Exposure of the tissue to the air 
and sunlight and storage at room temperature are not ideal conditions for lipid-rich 
tissues and would be likely to promote degradation of lipids. The action of 
phospholipases and lipases could reduce the levels of membrane or storage lipids with 
time. In some cases there was a notable increase in breakdown products. Thus, for 
the Garbus method o f extraction a decrease o f 5% in the TAG fraction was associated 
with increases in the MAG and NEFA fractions (Table 4.17).
In terms of the petroleum ether method, the yield of the TAG fraction was similar to 
that found for the Garbus method at all times. Petroleum ether will primarily extract 
non-polar lipids and, as adipose tissue is primarily composed of TAG, it was not 
surprising that the high levels o f TAG were extracted using the petroleum ether 
method (Fig. 4.10). The decrease in TAG observed at 48 h may be associated with 
the increase in degradation products observed over time (Table 4.17) due to the action 
of lipases during storage over time.
The rendering method was significantly different (p < 0.05) from both the Garbus and 
petroleum ether methods at zero and 48 h and produced the lowest yield of TAGs at 
each time point (Fig. 4.10). Due to a decrease in the levels of total lipid extracted at 
time 48 h by the rendering method it was not surprising that the yield of TAGs was 
reduced at time 48 h. In contrast with the Garbus and petroleum ether methods which 
both saw an increase in the minor lipids due to degradation as a function of time the 
minor lipids did not increase significantly with the rendering method (Table 4.17).
Overall, the Garbus and petroleum ether methods gave statistically different yield of 
TAG (p < 0.05) compared to the rendering method at zero and 48 h but not to each 
other (Fig. 4.10)
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Table 4.17 Effect of tissue storage time and extraction method on visceral adipose 
tissue lipids (mg/g tissue homogenate) based on total fatty acid 
analysis. Percentage lipids are given in parenthesis. Results as means 
± SD (n=3). n.d. = none detected.
GARBUS
TAG MAG DAG NEFA TP
Oh 176.9 ± 45.3 n.d. 2 .2  ± 0.7 n.d. 3.0 ± 1.7
(97 .2 ) (1 .2) (1.9)
24 h 173.2 ± 15.7 4.3 ± 1.1 1.7 ± 0 .9 6.4 ± 0.2 4.6 ±  1.6
(91) (2 .3) (0 .9) (3.4) (2.5)
48 h 150.6 ± 11.6 3.1 ± 0 .9 1.9 ± 0 .3 5.1 ± 1.5 2.1 ± 1.1
(92 .5 ) (1 .9) (1 .2) (3.1) (1.3)
PETROLEUM ETHER
TAG MAG DAG NEFA TP
Oh 199.5 ± 16.0 3.4 ± 1.4 2.2 ± 0 .9 0.8 ± 0 .3 1.4 ± 0 .1
(96 .5) (1 .7) (1 .0) (0.3) (0 .7)
24h 144.0 ± 12.9 1.3 ± 0 .3 0 .9  ± 0 .5 4.2 ± 2 .1 1.4 ± 0 .9
(94 .8) (0 .8) (0 .6) (2.8) ( 1 0 )
48 h 161.5 ± 4 .0 3 .9  ± 0 .3 1.8 ± 0 .7 4.6 ± 0.6 2.3 ± 0.2
(94 .2) (1 .9 ) (0 .8) ( 1 8 ) (1.9)
RENDERING
TAG MAG DAG NEFA TP
Oh 107.5 ± 3 8 .6 0.4  ±  0.2 1.6 ± 0 .5 1.8 ± 0 .2 0.9 ± 0 .1
(96) (0 .4 ) (1 .2) (1 6 ) (0.8)
24 h 124.4 ± 5 .9 0.7 ± 0 .3 0.5 ± 0 .1 1.6 ± 0 .8 0.6 ±  0.2
(97 .4) (0 .5 ) (0 .4) (1.2) ( 1 0 )
48h 57.9 ± 2 2 .2 0.5 ± 0.3 0.5 ± 0 .1 1.1 ± 0 .7 0.4 ± 0 .1
(96.3) (0 .8) (0 .1) (1.7) (0 .7)
* TAG, triacylglycerol; DAG, diacylglycerol (1,2-DAG and 1,3-DAG combined); 
MAG, monoacylglycerol; NEFA, non-esterified fatty acids; TP, total polar lipid 
fraction.
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Comparing both types o f starting material, total trout offal and adipose tissue, it is 
quite apparent that, as expected, the levels of both total lipid and TAGs vary 
significantly. In terms o f total trout offal the levels of total lipid extracted (Fig. 4.2A,
4.9) were approximately four and a half times lower than those produced from the 
adipose tissue for the Garbus method. This was also true for the petroleum ether and 
rendering methods although the reduction was even more pronounced, six and seven 
times, respectively (Fig. 4.2A, 4.10).
The levels of TAG produced from the adipose tissue were also far greater than the 
levels produced from total trout offal (Fig. 4.2B, 4.10). Across each method the 
levels of TAGs yielded from adipose tissue were almost five times greater from those 
from total trout offal on a gram fresh weight basis. At time zero for both the 
petroleum ether and rendering methods the differences in TAG levels produced from 
both starting materials were even greater. TAG extracted ffom total offal using the 
Garbus method at time zero produced 32 mg/g tissue homogenate whereas when 
extracted ffom adipose tissue the TAG fraction was almost six times this yield 
(approximately 200 mg/g fresh weight). A similar trend was seen for petroleum ether 
extraction where there was a twenty-fold increase in total offal TAG at time zero and 
an eleven-fold increase was observed with the rendering method when adipose tissue 
was used (Fig. 4.2B, 4.10). Clearly, adipose tissue is an excellent source of TAG and 
can be extracted well by a petroleum ether method.
4.11 Effect of Storage Time and Extraction Method on Non-Esterified
Fattv Acids from Visceral Adipose Tissue
NEFAs generated during the storage and processing o f adipose tissue revealed some 
unexpected results (Fig. 4.11). When fresh visceral adipose tissue was extracted with 
the Garbus method no NEFAs were detected. This was quite unusual as NEFAs were 
detected with both the petroleum ether and rendering methods and were also detected 
with the Garbus method when total trout offal was used (Fig. 4.2C). It would be 
necessary to repeat this experiment to determine NEFAs at time zero as the current 
result may be due to an experimental error such as a problem with the extraction 
procedure or separation of the lipids by TLC. At time 24 and 48 h NEFAs were 
detected with the Garbus method at approximately 5 mg/g fresh weight.
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NEFAs were detected with both the petroleum ether and rendering methods at each 
time point analysed. There was a steady increase in the NEFA fraction with the 
petroleum ether method over time increasing from 0.6 mg/g fresh weight to 4.3 mg/g 
fresh weight by time 48 h.
These trends were not consistent with the changes in NEFAs observed from total trout 
offal. When total trout offal was used as the starting material NEFAs were detected at 
time zero, increased over 24 h with a further, more pronounced increase observed by 
time 48 h. There was no apparent plateau effect observed as seen in the adipose tissue 
experiments (Figs. 4.2C, 4.11).
Appreciable amounts of NEFAs were found at time zero for the rendering method and 
did not change significantly at 24 h or 48 h. This pattern was also seen in the NEFA 
fraction from total trout offal (Figs. 4.2C, 4.11).
Fig. 4.11: Yield of non-esterified fatty acids (mg NEFA/g tissue homogenate) over
storage time in visceral adipose tissue evaluated by different extraction 
methods. Results as means ± SD (n=3).
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4.12 Effect of Storage Time and Extraction Method on the Fatty Acid
Profiles of Individual Lipids from Visceral Adipose Tissue
Percentage changes in fatty acid profiles for individual lipids from adipose tissue 
extracted by the three methods employed are outlined in Tables 4 .18-4.33.
Total polar lipids appeared to demonstrate the greatest changes in fatty acid profiles 
on tissue storage. For the total polar lipids extracted using the Garbus method the 
major fatty acids included: 18:1 n-9 > 16:0 = DHA > 22:1 = 18:2 n-6 = 20:1 n-9 > 
18:0 > 16:1 n-7 = EPA (Table 4.18). A decrease in the percentages of EPA and DHA 
was observed over time and this correlated to a corresponding increase in the major 
monounsaturated fatty acids 16:1, 18:1 n-9, 20:1 n-9 and 22:1 (Table 4.18). This 
effect had also been observed in the total polar lipid fraction extracted from total trout 
offal using the Garbus method (Table 4.2).
For the total polar lipids extracted using the petroleum ether method the major fatty 
acids detected were 18:0 >18:1 n-9 > 16:0 > 20:1 n-9 > DHA > 22:1 > 18:2 n-6 and 
16:1 n-7 (Table 4.19). The levels o f DHA and EPA present in the total polar lipids 
extracted by the petroleum ether method at time zero were found at approximately 
half the yield as seen with the Garbus extraction. There was a noticeable increase in 
both EPA and DHA at time 24 h and this may be due to tissue degradation which 
allowed better lipid extraction. As previously mentioned, petroleum ether primarily 
extracts non-polar lipids such as TAGs. However, at time 24 h tissue deterioration 
may have led to the breakdown o f cell membranes and the subsequent release of EPA 
and DHA from membrane phospholipids allowing increased efficiency of extraction 
and may explain the slightly elevated levels reported at time 24 h. However, both 
these fatty acids are reduced even further by time 48 h. This may be due to oxidation 
and degradation over time (Table 4.19). In accordance with this relative increases in 
the percentages of the monounsaturated fatty acids, 18:1 n-9, 20:1 n-9 and 22:1 were 
observed at time 48 h (Table 4.19).
The efficiency of extraction of the total polar lipid fraction extracted using the 
rendering method was less than both the Garbus and petroleum methods (Table 4.20). 
This meant that minor fatty acids in the total polar lipids could not be detected at time
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zero. However, over time many o f these acids became detectable, an effect which 
may be due to tissue breakdown thus allowing better penetration of the cells and, 
henceforth, their membrane lipids. The major fatty acids detected included: 18:1 n-9 
> 20:1 n-9 > 16:1 n-7 > 16:0 > 18:1 n-7 > 22:1 > 18:2 n-6 > EPA and DHA. One 
obvious difference between this method and the Garbus and petroleum ether method 
is the poor extraction of DHA and the large percentage of monoenoic fatty acids such 
as 16:1, 20:1 n-9 and 22:1. Over time the levels o f saturated fatty acids were seen to 
increase, particularly 12:0, 14:0, 16:0, 18:0 and 20:0. Some of the monounsaturated 
fatty acids actually decreased with time, 16:1, 18:1 n-9 and 20:1 n-9 (Table 4.20).
Overall, in terms o f DHA percentage in the total polar lipid fraction the Garbus 
method was significantly more effective than either the petroleum ether or the 
rendering methods (p < 0.05 and p < 0.001 respectively). The petroleum ether 
method was also significantly more effective (p < 0.05) compared to the rendering 
method (Fig. 4.12).
Fig. 4.12: EPA values as percentage of the total fatty acids in the total polar
lipids of visceral adipose tissue extracted using three methods of lipid 
extraction after different tissue storage times. Results as means ±SD 
(n=3). * denotes significance o f storage time within method, t
denotes significance between methods.
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Fig. 4.13: DHA values as percentage of total fatty acids the total polar lipids of
visceral adipose tissue extracted using the three methods of lipid 
extraction after different tissue storage times. Results as means ±SD 
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In terms of the effect of storage time and extraction method on the acyl composition 
of the TAG fraction no obvious differences were noted (Tables 4.22 -  4.24). The 
major fatty acids detected with each method were: 18:1 n-9 > 16:0 = 18:2 n-6 > 22:1 
= 20:1 n-9 = DHA > 16:1 n-7 > 14:0 = EPA (Tables 4.22 -  4.24). Despite EPA and 
DHA being highly unsaturated and, therefore, more prone to degradation the levels of 
both these fatty acids remained constant over time. Independent of the method used 
approximately 2% EPA and 8% DHA was detected at each time point (Figs. 4.14, 
4.15).
For the DAG fraction, the same main fatty acids were detected for each extraction 
method examined although the relative proportions o f fatty acids differed (Tables 4.25 
-  4.27). The major fatty acids detected by the Garbus method included: 18:1 n-9 > 
16:0 > 18:2 n-6 > 20:1 n-9 = 22:1 = DHA = 18:0 whereas for DAG extracted using 
the petroleum ether method the predominant fatty acids were: 18:1 n-9 > 18:0 > 20:1 
n-9 = 16:0 > 22:1 > 18:2 n-6 > DHA. Overall no significant changes in the acyl 
composition were detected with time for the Garbus or petroleum ether methods. For 
the rendering method many of the minor fatty acids were not detected at time zero but 
this improved with time (Table 4.27). This may be due to the degradation of the 
tissue over time allowing for easier extraction o f lipids including catabolic 
intermediates such as DAG. Interestingly the percentages of 12:0, 14:0, 16:0, 18:0 
increased with time while 16:1 n-7 decreased. An effect of storage time on the acyl 
composition was not found in the DAG fraction extracted by the Garbus or petroleum 
ether methods (Tables 4.25, 4.26).
The MAG fraction was not detected at time zero with the Garbus method and little 
variability in its acyl composition was recorded with time (Table 4.28). The principle 
fatty acids included: 18:1 n-9 > 16:0 = 18:2 n-6 > 20:1 n-9 = 22:1 > DHA > 16:1 n-7 
and 18:0 (Table 4.28). Some changes were detected in the MAG fraction when the 
petroleum ether method was used (Table 4.29). The principle fatty acids were similar 
to those detected with the Garbus method but increases in the percentages of 16:0, 
18:1 n-9, and 18:2 n-6 were detected with time. The percentage of 18:0 decreased 
with time while no apparent changes were observed for either EPA or DHA (Table 
4.29). A similar decrease was observed for 18:0 in the MAG fraction extracted using 
the rendering method (Table 4.30). Similar to the effect seen in DAG when the
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rendering method was used the levels of the saturated fatty acids, 12:0 14:0 and 16:0 
increased with time. In terms o f EPA and DHA, no significant changes were 
observed over time (Table 4.30).
NEFAs were not detected at time zero with the Garbus method. However, as 
previously mentioned this was quite unexpected (Fig. 4.11). NEFAs were detected at 
time zero for both the petroleum ether and rendering methods and also with the 
Garbus method when total trout offal was used (Fis. 4.11). It would be advisable to 
repeat the Garbus extraction of adipose tissue at time zero and it is likely that NEFAs 
were not detected due to a problem with the extraction method or separation of lipids 
byTLC.
The major fatty acids found in the NEFA fraction derived using all three extraction 
methods included: 18:1 n-9>  18:2 n-6 > 16:0 >20:1 n-9 > DHA >22:1 > 18:0 > 16:1 
n-7 and EPA. There was no significant effect o f time on the fatty acid composition of 
the NEFA fraction derived with all three methods (Tables 4.31 -  4.33). In terms of 
EPA and DHA some minor differences were noted between methods. No changes in 
EPA and DHA were observed between 24 and 48 h whilst with the petroleum ether 
method both EPA and DHA had increased by 24 h with no further increases observed 
at 48 h. The rendering method saw an increase in EPA at 24 h but DHA was seen to 
increase at 48 h (Table 4.31 -4 .3 3  and Figs. 4.16, 4.17).
Comparing the results obtained with adipose tissue to those produced from total trout 
offal some similarities are observed. With both starting materials, the total polar 
lipids displayed the greatest changes in terms o f fatty acid profiles. The levels of EPA 
and DHA in total polar lipids decreased in a time-dependent fashion for both starting 
materials (Tables 4.2 -  4.4 and 4.18 -  4.20). The method that produced the greatest 
levels of EPA and DHA ffom both tissue sources at all times was the Garbus method 
(Tables 4.2 -  4.4 and 4.18 -  4.20).
For the major lipid class, TAG, the consistency o f the fatty acid profiles as a function 
of time was maintained independent o f the starting material used (Tables 4.5 -  4.7 and 
4.22 -  4.24 ). Also, the percentage levels o f both EPA and DHA from the TAG 
fraction, about 2% and 8% respectively was independent of lipid source (Tables 4.5 -  
4.7 and 4.22 -  4.24).
Overall, as expected, the yield of both total lipid and TAG was far greater ffom 
adipose tissue compared to the total trout offal (Fig. 4.2A, 4.2B, 4.12, 4.13). 
However, despite higher yields of both total lipid and TAG the levels of one of the 
most important fatty acids, DHA, was significantly and more consistently greater in 
all lipids derived from total trout offal (Tables 4.1 -  4.16, 4.18 -  4.25). EPA levels 
were detected at approximately 2% in all lipids ffom both sources (Tables 4.1 -  4.16, 
4.18 -  4.25). In terms of method, the Garbus method proved to be significantly more 
effective in yielding both total lipid and TAG from total trout offal (Fig. 4.2A, 4.2B). 
It also demonstrated increased efficiency in the extraction of the minor fatty acids at 
time zero compared to the other two methods investigated (Tables 4.1 -  4.16). When 
adipose tissue was used as the starting material all three methods demonstrated equal 
efficiency of extraction at zero and 48 h although a significant decrease at 48 h for the 
rendering method was observed for total polar and TAG extraction (Figs. 4.12, 4.13). 
Generation of oxidation products (Figs. 4.3 -  4.11) associated with storage time were 
noted to increase with time when both total trout offal and adipose tissue were used 
although, as previously mentioned, (section 4.11), some discrepancies were observed 
in terms of NEFAs ffom adipose tissue at time zero for the Garbus method.
Fig. 4.14: EPA values as percentage of total fatty acids in the triacylglycerol
fraction of visceral adipose tissue using three methods of lipid 
extraction after different tissue storage times. Results as means ± SD
(n=3).
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Fig. 4.15: DHA values as percentage values of total fatty acids in the
triacylglycerol fraction of visceral adipose tissue using three methods 
of lipid extraction after different tissue storage times. Results as means
± SD (n=3).
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Fig. 4.16: EPA values as percentage of total fatty acids in the non-esterified fatty
acid (NEFA) fraction of visceral adipose tissue using three methods of 
lipid extraction after different tissue storage times. Results as means ± 
SD (n=3). Unexpectedly, NEFAs were not detected in adipose tissue 
at time zero with the Garbus method which may be due to an 
experimental error.
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FjJLi .17: DHA values as percentage of total fatty acids in the non-esterified fatty
acid (NEFA) fraction of visceral adipose tissue extracted using three 
methods of lipid extraction after different tissue storage times. Results 
as means ± SD (n=3). Unexpectedly, NEFAs were not detected in 
adipose tissue at time zero with the Garbus method which may be due 
to an experimental error.
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Table 4,18: Percentage fatty acid composition of the total polar lipids from visceral
adipose tissue extracted using the Garbus method after different tissue 
storage times. Results as means ± SD (n=3). n.d. = none detected, tr. 
= <0.05.
Fatty A cids T im e zero T im e 24  h Tim e 48 h
12:0 0.2 ± 0 .1 0.1 ± 0 .1 0.2 ± 0.2
14:0 1.3 ±0.1 0 .6  ± 0 .6 1.3 ± 0 .8
16:0 16.7 ± 0 .9 14.0 ± 3 .8 14.3 ± 2 .3
16:1 n-7 2.3 ± 0.2 2 .0  ± 0 .6 3.2 ± 1.4
16:1 0.5 ± 0 .3 0.7  ± 0.2 1.0 ± 0 .6
17:0 0.3 ± tr. 0.3 ± 0 .1 0.3 ± 0 .1
17:1 0.3 ± 0 .1 0.3 ± 0 .1 0.4 ± 0.2
18:0 5.7 ± 0 .3 6.8 ± 0 .1 5.3 ± 1.5
18:1 n-9 20.5 ± 0 .5 21 .7  ±  0.1 23.8 ± 0 .7
18:1 n-7 n.d. n.d. 0.1 ± 0 .2
18:2 n-6 7.3 ± 1.3 7.3 ±  0.4 9.0 ± 1.2
18:2 n-3 0.2 ± 0 .1 0 .2  ± tr. 0.2 ± tr.
18:3 n-6 0.6 ± 0.2 0 .7  ±  0.2 0.9 ± 0.2
18:3 n-3 0.7 ± 0.2 0 .6  ± 0 .2 1.1 ± 0 .5
20:0 0.4 ± 0.3 0.3 ± 0 .1 0.2 ± 0.2
20:1 n-9 6.2 ± 1.2 8.8 ± 1.6 9.5 ±  0.5
20:2 0.7 ± 0.2 0 .9  ± 0.2 0.8 ± 0 .1
20:3 n-9 1.1 ± 0 .2 0.7 ± 0 .1 0.4 ± 0.2
20:4 n-6 1.7 ± 0 .2 1.7 ± 0 .3 1.1 ± 0 .6
20:4 n-3 0.8 ± tr. 0 .7  ± 0 .3 0.6 ± 0 .1
20:5 n-3 3.6  ±  0 .5 2 .7  ±  0 .5 2.2 ±  0.6
22:1 7.8 ±  1.6 10.5 ± 2 .4 10.9 ± 0 .7
22:2 n.d. n.d. n.d.
22:3 0.1 ± tr. 0.2  ±  0.2 0.2 ±  0.2
23:0 0.4 ± tr. 0.2  ± 0 .1 0.1 ± 0 .1
22:5 n-3 0.8 ± 0 .1 0.7 ± 0 .1 0.7 ± 0 .1
22:6 n-3 16.1 ± 4 .5 12.0 ±  1.9 9.2 ±  3.2
24:0 n.d. n.d. n.d.
24:1 4 .0  ± 0 .2 5.5 ± 1.2 3.1 ± 2 .3
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Table 4.19: Percentage fatty acid composition of the total polar lipids from visceral
adipose tissue extracted using the petroleum ether method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24 h Tim e 48 h
12:0 0 .2  ± 0.3 0.5 ±  0.2 n.d.
14:0 0.5 ± 0 .4 1.0 ± 0 .5 0.6 ± 0.4
16:0 12.0 ± 5.5 16.2 ± 1.5 13.9 ± 1.5
16:1 n-7 5.2 ± 2 .9 2.2 ± 0.6 1.6 ± 0 .5
16:1 n.d. 1.7 ±  1.5 1.9 ± 1.4
17:0 0.8 ± 0 .4 0.4 ± 0 .1 0.5 ± 0 .1
17:1 0.1 ± 0 .2 0.3 ± 0 .1 0.2 ± 0.2
18:0 17.6 ± 3 .2 10.6 ± 2 .8 12.7 ± 2 .2
18:1 n-9 23 .7  ± 8 .6 20.0  ± 1.9 25.0 ± 0.6
18:1 n-7 n.d. 0.1 ± 0 .1 n.d.
18:2 n-6 5.5 ± 1.0 6.5 ±  1.4 8.3 ± 0.7
18:2 n-3 n.d. 0.2 ±  0.2 0.1 ± 0 .1
18:3 n-6 0 .7  ± 0 .6 0.6 ± 0 .1 0.9 ± 0 .1
18:3 n-3 1.8 ± 0 .4 1.1 ± 0 .6 1.3 ± 0 .2
20:0 0.1 ± 0 .2 1.3 ±  1.6 n.d.
20:1 n-9 10.4 ± 1.9 7.9 ±  3.0 12.3 ±  0.2
20:2 0.3 ± 0 .0 0.8 ± 0 .1 0.7 ± 0 .1
20:3 n-9 0.3 ± 0 .0 0.7 ±  0.2 0.4 ± 0 .1
20:4 n-6 2 .2  ± 0 .4 1.8 ± 0 .2 0.5 ± 0 .2
20:4 n-3 0 .3  ± 0 .5 0.7 ± 0 .1 0.5 ± 0.5
20:5 n-3 1.3 ±0.3 2.4  ±  1.9 0.9 ±  0.2
22:1 7.3 ± 1.5 6.5 ± 2 .5 11.4 ± 1.0
22:2 0 .2  ± 0 .4 0.2 ±  0.2 n.d.
22:3 n.d. n.d. n.d.
23:0 0.5 ± 0 .8 0.1 ±  tr. n.d.
22:5 n-3 n.d. 0.4 ±  0.5 0.3 ± 0.2
22:6 n-3 7 .5  ± 1.5 12.0 ± 5 .7 3.8  ± 0 .7
24:0 n.d. 0.2 ±  0.3 n.d.
24:1 1.9 ± 1.8 3.7 ± 0 .6 2.2 ± 0.4
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Ttble 4.20: Percentage fatty acid composition o f the total polar lipids from visceral
adipose tissue extracted using the rendering method after different 
tissue storage times. Results as means ± SD (n=3). n.d. = none 
detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24  h Time 48 h
12:0 n.d. 1.9 ± 0 .3 6.0 ± 1.8
14:0 0 .6  ± 0.9 4 .2  ± 2.4 4.2 ± 0.9
16:0 10.4 ± 1.5 17.3 ± 1.9 17.8 ±2 .1
16:1 n-7 10.9 ± 1.4 7.7 ± 1.7 2.2 ± 0.5
16:1 n.d. 0.7 ± 0 .8 0.1 ± 0 .2
17:0 1.2 ± 0 .3 0.7 ± 0.8 0.6 ± 0.2
17:1 n.d. 0.6 ± 0 .5 0.5 ± 0.8
18:0 1.7 ± 0 .8 5.5 ± 2 .7 11.8 ± 1.6
18:1 n-9 29 .4  ± 4.6 19.2 ± 6 .3 21.0 ± 3 .7
18:1 n-7 9.8 ± 4 .5 1.2 ± 0 .1 n.d.
18:2 n-6 4 .4  ± 1.3 8.0 ± 4 .0 7.7 ± 2 .5
18:2 n-3 n.d. 0.1 ± 0 .1 0.2 ± 0.3
18:3 n-6 0 .4  ±  0.6 0.7 ±  0.6 0.8 ± 0 .7
18:3 n-3 4 .0  ± 0.7 1.3 ± 0 .3 1.9 ± 0 .7
20:0 n.d. n.d. 3.3 ± 0.4
20:1 n-9 15.4 ±  1.3 13.2 ± 2 .7 9.6 ± 0.9
20:2 n.d. n.d. 0.5 ± 0.2
20:3 n-9 n.d. n.d. 0.7 ± 0.7
20:4 n-6 0.2 ± 0.8 0.7 ± 0 .6 0.1 ± 0 .7
20:4 n-3 tr. 1.1 ± 0 .5 0.5 ± 0.2
20:5 n-3 3.2  ±  0 .9 1.5 ±  0.6 0.6 ± 0 .3
22:1 5.4 ± 1.5 8.2 ± 2 .5 7.7 ± 1 .4
22:2 n.d. 0.9 ±  0.6 0.3 ± 0.2
22:3 n.d. n.d. n.d.
23:0 n.d. n.d. n.d.
22:5 n-3 n.d. 0.2 ±  0.3 0.2 ± 0.3
22:6 n-3 1.9 ±  1.5 4.0 ±  0.5 3.6 ± 1 .1
24:0 n.d. 0.8 ± 0 .5 n.d.
24:1 n.d. 0.5 ± 0 .9 0.5 ± 0.3
NB; there is no Tab e 4.21.
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Table 4.22: Percentage fatty acid composition of the triacylglycerol fraction from
visceral adipose tissue extracted using the Garbus method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fatty A cids T im e zero T im e 24 h Tim e 48 h
12:0 tr. 0.1 ± tr . 0.1 tr.
14:0 3.5 ± tr. 3.4 ± 0 .2 3.3 ± 0 .1
16:0 14.0 ± 0 .4 13.7 ± 0 .4 13.5 ± 0 .4
16:1 n-7 5.0 ± 0 .1 5.2 ± 0.2 5.3 ± 0.2
16:1 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
17:0 0.2  ± tr. 0 .2  ± 0 .1 0.2 ± tr.
17:1 0.5 ± tr. 0.5 ± tr. 0.4 ±  tr.
18:0 2.5 ± 0 .6 2.8 ± 0 .3 2.7 ± 0 .4
18:1 n-9 26.3 ± 0.7 26 .4  ± 0.5 26.0 ± 1.4
18:1 n-7 0.5 ± 0.9 0.5 ±  0.9 0.8 ± 0 .8
18:2 n-6 9.5 ± 3 .8 13.9 ± 0.1 14.1 ± 0 .1
18:2 n-3 4 .9  ± 2 .8 0 .4  ±  0.4 0.4 ±  tr.
18:3 n-6 1.4 ± tr . 0 .9  ± 0 .7 1.0 ± 0 .8
18:3 n-3 1.1 ± 0 .9 1.3 ± 0 .2 1.5 ± 0 .1
20:0 0.4  ± 0 .1 0.3 ± 0 .1 0.2 ±  tr.
20:1 n-9 8.1 ± 0 .1 8.5 ±  0.2 8.2 ±  0.2
20:2 0 .8  ± tr. 0 .8  ±  tr. 0.8 ± tr.
20:3 n-9 0 .4  ± tr. 0 .4  ± tr. 0.4 ± tr.
20:4 n-6 0 .4  ±  tr. 0 .4  ±  tr. 0.4 ±  tr.
20:4 n-3 1.0 ±  0.1 0.9 ± tr. 0.9 ± 0 .1
20:5 n-3 2.2 ±0.1 2.0 ± 0.1 2.1 ± tr.
22:1 8.2 ± 0.3 8.6 ± 0 .3 8.0 ± 0 .1
22:2 0.1 ± tr. 0.5 ±  0.6 0.1 ± tr.
22:3 0.1 ± tr. n.d. 0.1 ± tr.
23:0 0.2 ±  tr. 0 .2  ± tr. 0.2 ± tr.
22:5 n-3 0.6  ± 0.4 0.7  ± 0.4 0.9 ±  tr.
22:6 n-3 7.5 ± 0.7 6.6 ± 0.8 7.6 ± 0.7
24:0 0.1 ± tr. 0.1 ± tr . 0.1 ± 0 .1
24:1 0.8 ± 0 .1 0.7 ± 0 .1 0.7 ± 0 .1
NB; there is no Tab e 4.21
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Table 4.23: Percentage fatty acid composition o f the triacylglycerol fraction from
visceral adipose tissue extracted using the petroleum ether method 
after different tissue storage times. Results as means ± SD (n=3). n.d. 
= none detected, tr. = <0.05.
Fatty Acids Time zero Time 24 h Time 48 h
12:0 tr. tr. tr.
14:0 3.1 ± 0 .3 3.7 ± 0 .3 2.5 ± 1.0
16:0 13.1 ± 0 .1 13.9 ± 1.0 13.7 ± 0 .5
16:1 n-7 5.6 ± 0 .6 5.9 ± 0 .2 5.5 ± 0.4
16:1 0.1 ± tr. 0.1 ± tr. 0.1 ± tr.
17:0 0.1 ± tr. 0 .2  ±  tr. 0.2 ± tr.
17:1 0 .2  ± tr. 0.5 ±  tr. 0.5 ± tr.
18:0 2.3 ± 0 .3 2.1 ± 0 .2 1.9 ± 0 .8
18:1 n-9 26 .4  ± 0.3 24.5 ±  2.9 27.3 ± 0 .1
18:1 n-7 0.4  ±  tr. 0 .6  ± 0 .5 1.4 ± 0 .9
18:2 n-6 14.0 ± 0 .3 14.0 ± 0 .9 13.9 ± 0 .7
18:2 n-3 0.4  ± tr. 0 .4  ±  tr. 0.4 ± 0 .1
18:3 n-6 1.5 ±  tr. 1.0 ± 0 .8 1.4 ± 0 .1
18:3 n-3 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0 .2
20:0 0.5 ± tr. 0.3 ± 0 .1 0.2 ± tr.
20:1 n-9 8.5 ± 0 .2 8.7 ±  0.6 8.6 ± 0.2
20:2 0.8  ±  tr. 0.8 ± 0 .1 0.8 ± tr.
20:3 n-9 0.4  ± tr. 0 .4  ± tr. 0.4 ±  tr.
20:4 n-6 0.4 ±  tr. 0 .4  ±  tr. 0.4 ± tr.
20:4 n-3 1.0 ± tr. 1.0 ±  0.1 0.9 ± 0 .1
20:5 n-3 2.3 ±0.1 2.1 ± 0.2 2.0 ±0.2
22:1 7.7 ± 0.2 8.9 ± 1 .1 8.0 ± 0.3
22:2 0.1 ± tr. 0.1 ±  tr. 0.1 ±  tr.
22:3 0.1 ± tr. 0.1 ± tr . 0. 1± tr.
23:0 0.2 ± tr. 0.2 ± tr. 0.1 ±  tr.
22:5 n-3 0.7 ± 0 .5 0.9  ± 0 .1 0.8 ± 0 .1
22:6 n-3 7.8 ± 0.5 7.1 ± 1.2 6.8 ± 0.2
24:0 0.1 ± tr. 0.1 ± tr. 0.1 ±tr.
24:1 0.7 ± tr. 0 .7  ±  0.2 0.7 ± 0 .1
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Table 4.24: Percentage fatty acid composition of the triacylglycerol fraction from
visceral adipose tissue extracted using the rendering method at 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05.
Fstty A cids T im e zero T im e 24 h Tim e 48 h
12:0 tr. 0.1 ± tr. 0.1 ± tr.
14:0 3.2 ± 0 .3 3.3 ± 0 .2 3.1 ± 0 .4
16:0 14.0 ± 0 .9 13.6 ± 0 .2 13.9 ± 0 .2
16:1 n-7 5.6 ± 0.6 5.4 ± 0 .1 5.0 ± 0 .2
16:1 0.1 ± tr. 0 .2  ± 0.2 0.1 ± tr.
17:0 0.2 ± tr. 0 .2  ± tr. 0.2 ±  tr.
17:1 0.5 ± tr. 0 .2  ± tr. 0.3 ±  0.2
18:0 2 .6  ± 0.5 2.7 ± 0 .3 3.0 ± 0 .1
18:1 n-9 27 .0  ± 0 .5 27 .9  ± 0 .1 27.1 ± 0 .3
18:1 n-7 0.3 ± tr. 0.3 ±  tr. 0 .2  ±  0.2
18:2 n-6 13.7 ± 0 .3 14.0 ± 0 .2 1 14.1 ± 0 .1
18:2 n-3 0.3 ± tr. 0 .4  ± tr. 0.4 ±  tr.
18:3 n-6 1.4 ± tr. 0 .9  ±  0.7 0.9 ± 0.7
18:3 n-3 1.4 ± 0.1 1.4 ± 0 .2 0.9 ± 0.7
20:0 tr. 0.2 ±  tr. 0.2 ±  tr.
20:1 n-9 8.5 ± 0.4 8.5 ± 0 .3 8.5 ±  0.3
20:2 0.8 ± tr. 0 .8  ±  tr. 0.9 ± 0 .1
20:3 n-9 0.4 ± tr. 0 .4  ± 0 .1 0.5 ±  tr.
20:4 n-6 0 .4  ± tr. 0.3 ± 0 .1 0.4 ± tr.
20:4 n-3 1.0 ± 0 .2 0 .9  ± 0 .1 0.9 ± 0 .1
20:5 n-3 2 .0  ± 0 .1 2.1 ± 0 .1 2.0 ±  tr.
22:1 8.0 ± 0 .2 7.9 ± 0 .3 8.4 ± 0.3
22:2 0.1 ±  tr. 0.1 ±  tr. 0.1 ±  tr.
22:3 tr. 0.1 ± 0 .1 0.1 ± 0 .1
23:0 0.1 ± 0 .1 0.1 ± tr. 0.1 ± 0 .1
22:5 n-3 0.8 ± 0 .1 0.9 ± tr. 0.9 ±  tr.
22:6 n-3 6.8  ±  1.1 6 .4  ±  0.6 6.8 ±  0.1
24:0 0.1 ± 0 .1 0.1 ± 0 .1 0.1 ±tr.
24:1 0.7 ± 0 .1 0.6 ± 0 .1 0.8 ± 0 .1
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Table 4.25: Percentage fatty acid composition o f the diacylglycerol (1,2- and 1,3
diacylglycerol) fraction from visceral adipose tissue extracted using the 
Garbus method after different tissue storage times. Results as means ± 
SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24  h Tim e 48 h
12:0 0.3 ± 0 .1 0.4  ± 0 .3 0.2 ± 0 .1
14:0 2.0  ± 0.4 1.8 ± 0 .6 1.2 ± 0 .4
16:0 15.5 ± 0 .4 13.3 ± 0 .2 12.2 ± 1.7
16:1 n-7 3.5 ± 0 .4 2.8 ± tr. 2.8 ± 0 .3
16:1 0.3 ± 0 .1 0.2 ±  tr. 0.5 ± 0.5
17:0 0.3 ± tr. 0.3 ± 0 .1 0.2 ± tr.
17:1 0.5 ± 0 .1 0 .6  ± tr. 0.5 ± 0 .1
18:0 4 .4  ± 0.2 5.0 ± 1.4 4.4 ± 0.9
18:1 n-9 27 .3  ±  0.6 24.3 ±  1.9 25.2 ±  2.9
18:1 n-7 n.d. n.d. 0.1± 0.2
18:2 n-6 12.1 ± 0 .3 11.8 ± 0 .5 11.6 ± 0 .6
18:2 n-3 0.3 ± 0 .1 0.4 ±  tr. 0.4 ±  0.2
18:3 n-6 0.8 ± 0 .5 1.0 ± 0 .7 0.8 ± 0 .8
18:3 n-3 1.0 ± tr . 1.8 ± 0 .5 1.8 ± 0 .9
20:0 0.2 ± 0.2 n.d. n.d.
20:1 n-9 9.5 ± 0.4 8.9 ± 0 .7 9.4 ± 1.2
20:2 0 .8  ± 0 .1 0.6  ± tr. 0.6 ± 0 .1
20:3 n-9 0 .4  ± 0 .1 0.5 ± 0 .1 0.4 ± tr.
20:4 n-6 1.4 ± 0 .1 1.1 ± 0 .2 1.1 ± 0 .3
20:4 n-3 0 .7  ±  0.2 1.2 ± 0 .2 1.1 ± 0 .2
20:5 n-3 2.1 ±  tr. 3 .8  ±  1.0 3.4 ± 1 .3
22:1 n-9 8.5 ± 0 .5 8.3 ± 0 .9 8.7 ± 1.0
22:2 n.d. 0.2 ± 0 .3 0.2 ± 0.3
22:3 0 .6  ± 0 .3 0.6 ±  tr. 0.9 ± 0.4
23:0 0.5 ±  0.4 0.5 ±  tr. 0.3 ±  0.4
22:5 n-3 0 .6  ± tr. 1.1 ± 0 .2 1.2 ± 0 .4
22:6 n-3 5.8  ± 1 .0 8 .8  ± 1.1 9.9 ± 1.9
24:0 0.3 ± 0 .3 n.d. 0.1 ± 0 .1
24:1 0.8 ± 0 .4 0.8 ± 0 .8 1.0 ± 0 .1
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Table 4.26: Percentage fatty acid composition of the diacylglycerol (1,2- and 1,3
diacylglycerol) fraction from visceral adipose tissue extracted using the 
petroleum ether method after different tissue storage times. Results as 
means ± SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty A cids T im e zero T im e 24 h Tim e 48 h
12:0 0.7 ± 0 .1 0.8 ± 0.3 0.3 ± 0.3
14:0 1.2 ± 0 .7 2.1 ± 0 .5 0.7 ± 0.7
16:0 10.7 ± 5.7 14.8 ± 1.0 13.9 ± 0 .8
16:1 n-7 1.6 ± 0 .3 3.7 ± 1.8 1.6 ± 0 .4
16:1 3.3 ± 0 .6 0.1 ± 0 .1 3.9 ± 1.2
17:0 0 .6  ± 0.5 0.4 ± 0 .1 0.7 ± 0.2
17:1 0.5 ± 0 .5 0.2 ± 0 .1 0.7 ± 0 .1
18:0 15.0 ± 5.2 9.2 ± 2.2 15.0 ± 3 .2
18:1 n-9 21.3  ± 3 .2 24 .6  ±  0.6 21.2 ± 2 .4
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 8.8 ±  1.8 10.3 ± 0 .8 7.4 ± 1.2
18:2 n-3 n.d. 0.3 ±  0.2 0.1 ± 0 .2
18:3 n-6 1.1 ± 0 .1 1.0 ± 0 .2 1.1 ± 0 .5
18:3 n-3 1.6 ± 0 .9 2.2 ±  0.5 2.0 ± 0.4
20:0 n.d. n.d. n.d.
20:1 n-9 12.0 ± 0 .5 10.4 ±  1.3 12.4 ± 1.0
20:2 1.4 ± 1.1 0.8 ± 0.2 0.4 ± 0.4
20:3 n-9 0 .9  ±  0.2 0.4 ± 0 .1 0.1 ± 0 .2
20:4 n-6 0 .6  ±  tr. 1.3 ± 0 .2 1.7 ± 0 .6
20:4 n-3 0 .6  ±  0.5 0.8 ±  0.4 1.3 ± 0 .5
20:5 n-3 1.2 ± 0 .1 1.3 ±  0.5 0.5 ± 0.5
22:1 10.9 ± 5.1 9.4 ± 1.2 10.6 ± 1.0
22:2 n.d. 0.2 ±  0.3 n.d.
22:3 n.d. 0 .4  ±  0.3 0.3 ± 0.2
23:0 n.d. n.d. n.d.
22:5 n-3 0 .5  ± 0 .4 0.6 ±0.1 0.1 ± 0 .2
22:6 n-3 5.5  ± 2 .1 4 .8  ±  1.1 2.7 ±  0.4
24:0 n.d. 0.2 ± 0.3 n.d.
24:1 n.d. 0.6 ±  0.7 1.1 ± 0 .9
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Table 4.27: Percentage fatty acid composition o f the diacylglycerol from visceral
adipose tissue using the rendering method of extraction after different 
tissue storage times. Results as means ± SD. n.d. = none detected, tr. 
= <0.05.
Fatty Acids T im e zero T im e 24 h Tim e 48 h
12:0 n.d. 5.5 ± 2 .7 4.0 ± 1.3
14:0 n.d. 2 .8  ± 0 .1 3.1 ± 0 .4
16:0 12.6 ± 1.5 15.7 ± 4 .6 14.2 ±  1.0
16:1 n-7 9.1 ± 1.3 2.5 ± 0 .8 2.4 ± 0 .3
16:1 n.d. 1.7 ± 0 .7 0.1 ± 0 .2
17:0 0.8  ± 0.2 0.7 ± 0.4 0.4 ± 0.4
17:1 n.d. 1.4 ±  1.6 1.8 ±  1.6
18:0 1.5 ± 0 .3 4 .7  ± 2 .0 5.0 ± 1.2
18:1 n-9 23 .7  ± 5 .3 21 .9  ± 5.1 22.0 ± 1.9
18:1 n-7 14.6 ± 8.2 n.d. n.d.
18:2 n-6 6.0  ± 1.8 9.6 ±  1.8 8.9 ± 0.9
18:2 n-3 n.d. 0 .4  ± 0 .1 0.1 ± 0 .1
18:3 n-6 0.4 ± 0 .4 2.1 ±  1.5 1.4 ± 0 .1
18:3 n-3 2.9  ± 1.8 1.3 ± 0 .9 1.8 ± 1.3
20:0 0.4  ±  0.3 0.1 ±  tr. 0.4 ±  0.7
20:1 n-9 14.2 ± 2 .9 11.0 ± 3 .0 14.3 ± 2 .6
20:2 0.3 ±  0.3 0.1 ± 0 .2 0.5 ±  0.9
20:3 n-9 n.d. 0 .6  ± 0 .8 0.3 ±  0.5
20:4 n-6 n.d. 0.4 ±  0.4 0.7 ± 0 .1
20:4 n-3 0.5 ± 0 .5 0 .9  ± 0.3 0.5 ± tr.
20:5 n-3 2 .7  ±  0 .9 1.3 ±  0.3 3.5 ± 1 .2
22:1 7.7 ± 1.9 7.5 ± 2 .8 8.2 ± 0 .9
22:2 n.d. 2.7 ±  1.8 0.9 ± 0.6
22:3 n.d. n.d. 0.1 ± tr.
23:0 n.d. n.d. n.d.
22:5 n-3 n.d. 0.4 ± 0.3 0.2 ± 0.3
22:6 n-3 2.4  ± 0 .1 4 .3  ±  0.2 3.4 ±  0.4
24:0 n.d. 0 .4  ±  0.4 0.2 ± 0.3
24:1 n.d. 0.2 ± 0.2 2.0 ± 0.7
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Table 4.28: Percentage fatty acid composition of the monoacylglycerol fraction
from visceral adipose tissue extracted using the Garbus method after 
different tissue storage times. Results as means ± SD (n=3). n.d. = 
none detected, tr. = <0.05. No MAG was detected at time zero.
Fatty Acids T im e 24  hr T im e 48  h
12:0 0.3 ± 0 .1 0.3 ± 0 .1
14:0 1.9 ± 0 .2 1.7 ± 0 .5
16:0 13.8 ± 0 .5 14.3 ± 0.6
16:1 n-7 5.0 ± 0 .2 4 .9  ±  1.4
16:1 0.2 ± tr. 0.3 ± 0 .1
17:0 0.2 ± tr. 0.3 ± 0 .1
17:1 0.3 ±0.1 0 .6  ± tr.
18:0 4.5 ± 0.9 4 .4  ±  0.4
18:1 n-9 27 .8  ± 0 .3 27 .6  ±  1.1
18:1 n-7 n.d. n.d.
18:2 n-6 13.9 ± 0 .3 13.7 ± 0 .5
18:2 n-3 0.3 ± 0 .1 0.3 ± tr.
18:3 n-6 1.4 ± 0 .1 1.0 ± 0 .6
18:3 n-3 1.4 ± 0 .2 1.3 ± 0 .2
20:0 0.1 ± 0 .1 n.d.
20:1 n-9 8.8 ± 0 .4 8.7 ± 0 .2
20:2 0.8 ± 0 .2 0.7 ± 0 .1
20:3 n-9 0.5 ± 0 .1 0.4 ±  tr.
20:4 n-6 0.5 ± 0 .4 0.5 ± 0 .1
20:4 n-3 0 .9  ± 0 .1 0.7 ± 0 .1
20:5 n-3 1.6 ± 0 .2 1.5 ± 0 .1
22:1 7.3 ± 0 .5 8.1 ± 1.0
22:2 0.1 ± 0 .2 n.d.
22:3 0.2 ± 0.2 0.1 ± 0 .1
23:0 0.1 ± 0 .2 n.d.
22:5 n-3 0.8 ± 0 .1 0.7 ± 0 .1
22:6 n-3 6.9 ±  0.4 7.3 ± 1 .0
24:0 n.d. n.d.
24:1 0.6 ± 0 .1 0.5 ± 0 .1
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Table 4.29: Percentage fatty acid composition o f the monoacylglycerol fraction
from visceral adipose tissue extracted using the petroleum ether 
method after different tissue storage times. Results as means ± SD 
(n=3). n.d. = none detected, tr. = <0.05.
Fatty A cids T im e zero T im e 24  h Tim e 48 h
12:0 n.d. 0 .6  ±  0.3 0.1 ±tr.
14:0 n.d. 2 .0  ± 0 .8 0.5 ± 0.2
16:0 7.4 ± 1.7 14.3 ± 1.1 12.5 ± 1.0
16:1 n-7 4 .2  ± 2 .3 5.1 ±0.2 2.4 ± 0.3
16:1 n.d. 0 .2 ± 0 .1 0.2 ± 0.2
17:0 0 .6  ± 0.5 0.4 ± tr. 0.4 ± 0 .1
17:1 0 .6  ± 0.9 0.5 ±  0.2 0.2 ± 0 .1
18:0 19.1 ± 3 .6 7.4 ±  1.3 9.3 ± 2 .1
18:1 n-9 21 .9  ± 2 .6 25.1 ± 0 .5 27.3 ± 2.0
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 9.2 ±  1.9 13.5 ± 0 .2 13.4 ± 0 .8
18:2 n-3 n.d. 0.3 ± 0 .1 0.2 ± 0.2
18:3 n-6 1.0 ± 0 .3 1.4 ±  tr. 1.4 ± 0 .1
18:3 n-3 2.1 ±  1.3 1.5 ± 0 .2 1.4 ± 0 .3
20:0 n.d. n.d. n.d.
20:1 n-9 11.9 ± 0.1 8.4 ± 0.6 10.3 ± 0 .3
20:2 0 .6  ± 0 .6 0.7 ± tr. 0.8 ± 0 .1
20:3 n-9 0.2 ± 0.3 0.5 ± tr. 0.4 ± 0 .1
20:4 n-6 3.0 ± 2 .3 0.9 ± 0 .5 0.4 ± 0.2
20:4 n-3 1.0 ± 0 .9 1.0 ± 0 .1 1.2 ± 0 .4
20:5 n-3 1.3 ± 0 .5 1.7 ±  tr. 1.5 ±  0.2
22:1 8.0 ± 2 .0 6.1 ±  tr. 7.8 ± 0.6
22:2 n.d. n.d. n.d.
22:3 n.d. n.d. n.d.
23:0 n.d. 0.1 ± 0 .1 0.2 ± 0.3
22:5 n-3 0.3 ± 0 .5 0.5 ±  0.4 0.7 ± tr.
22:6 n-3 6.8  ± 1.3 7.8 ± 1 .1 7.3 ±  0.2
24:0 n.d. n.d. n.d.
24:1 0 .8 +  0.1 0.5 ± 0 .1 0.2 ± 0.3
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Ttblc 430: Percentage fatty acid composition of the monoacylglycerol from
visceral adipose tissue over time using the rendering method of 
extraction after different tissue storage times. Results as means ± SD. 
n.d. = none detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24 h Tim e 48 h
12:0 n.d. 2.1 ± 0 .5 2.7 ± 0.7
14:0 0.1 ± 0 .2 4 .2  ± 2.9 2.8 ± 0 .7
16:0 9.2 ± 1.3 14.8 ± 2 .1 15.8 ± 2 .7
16:1 n-7 4 .6  ± 1.5 9.1 ± 4 .5 3.7 ± 1.4
16:1 0.3 ± 0 .5 1 .0 ±  1.3 n.d.
17:0 0.5 ± 0.4 0.2 ± 0.2 0.6 ± 0.2
17:1 0.2 ± 0 .3 0.3 ± 0.3 0.7 ± 0.3
18:0 16.4 ± 5.5 5.1 ± 3 .1 6.6 ± 2 .7
18:1 n-9 19.4 ± 1.9 20 .6  ± 8.3 21.5 ± 1.4
18:1 n-7 n.d. n.d. n.d.
18:2 n-6 8.1 ± 1.0 10.3 ± 3 .3 10.7 ± 0 .6
18:2 n-3 0.2 ± 0 .3 0.3 ± 0.2 0.1 ± 0 .2
18:3 n-6 1.1 ± 0 .2 1.2 ± 0 .2 0.7 ± 0.2
18:3 n-3 2.2 ± 0 .7 2.5 ±  0.2 1.6 ± 1.2
20:0 0.5 ± 0 .1 0.2 ±  tr. 0.7 ±  0.4
20:1 n-9 10.5 ± 0 .9 10.7 ± 2 .0 11.0 ± 3 .2
20:2 0.5 ± 0 .5 0.3 ±  tr. 0.2 ± 0.3
20:3 n-9 0.3 ± 0 .5 0.5 ± 0 .6 0.8 ±  tr.
20:4 n-6 2 .7  ± 0 .6 0.4 ±  0.4 1.1 ± 0 .8
20:4 n-3 1.5 ± 0 .2 1.5 ± 1.1 0.5 ± 0 .5
20:5 n-3 1.7 ± 0 .5 1.8 ±  0.5 3.4 ± 2.2
22:1 7.9 ± 2 .0 6.0 ± 1.1 7.3 ± 1.5
22:2 n.d. 1.3 ± 0 .9 n.d.
22:3 n.d. n.d. n.d.
23:0 4 .2  ± 0 .8 n.d. n.d.
22:5 n-3 0.5 ± 0 .5 0.5 ± 0.4 0.2 ± 0.3
22:6 n-3 5.6 ±  1.8 5.2 ±  2.4 4.9 ±  0.3
24:0 n.d. n.d. n.d.
24:1 1.1 ± 0 .9 0.4 ± 0.4 2.6 ± 0.9
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Table 4.31: Percentage fatty acid composition of the non-esterified fatty acid
fraction (NEFA) from visceral adipose tissue extracted using the 
Garbus method after different tissue storage times. Results as means ± 
SD (n=3). n.d. = none detected, tr. = <0.05. Unexpectedly, no NEFA 
fraction was detected at time zero possibly due to an experimental 
error.
F itty  Acids T im e 24 hr T im e 48 h
12:0 0.2 ± tr. 0.2 ± 0 .1
14:0 1.0 ± 0 .3 1.2 ± 0 .2
16:0 12.4 ± 0.2 13.6 ± 0 .7
16:1 n-7 3.7 ± 0 .3 3.5 ± 1 .1
16:1 0.2 ± tr. 0.5 ± 0 .3
17:0 0.2 ± tr. 0.2 ± tr.
17:1 0.4 ± 0 .1 0.4 ± tr.
18:0 3.8 ± 0 .2 4.4 ±  1.1
18:1 n-9 29.5 ± 2 .1 27 .0  ± 2 .5
18:1 n-7 0.7 ± 0 .6 0.4 ±  tr.
18:2 n-6 14.0 ± 1.1 13.7 ± 0 .9
18:2 n-3 0.4 ± 0.2 0.4 ±  tr.
18:3 n-6 0.8 ± 0 .5 1.1 ± 0 .1
18:3 n-3 1.0 ± 0.1 1.0 ± 0 .2
20:0 0.2 ±  0.2 0.3 ± 0 .1
20:1 n-9 7.4 ±  0.6 7.0 ± 0 .5
20:2 1.0 ± 0 .3 1.0 ± 0 .2
20:3 n-9 0.7 ± 0.2 0.7 ± 0 .1
20:4 n-6 1.4 ± 0 .3 1.7 ± 0 .4
20:4 n-3 1.2 ± tr . 1.0 ± 0 .2
20:5 n-3 3.1 ± 0 .6 3.1 ±  0.4
22:1 6.3 ± 0.8 5.5 ± 0 .6
22:2 0.1 ± 0 .1 0.2 ± 0.3
22:3 0.5 ± 0 .6 0.8 ± 0.4
23:0 1.3 ± 1.1 1.0 ± 0 .9
22:5 n-3 0.9 ± 0 .1 0.8 ± 0 .2
22:6 n-3 6.6 ±  1.9 8.3 ±  2.2
24:0 0.4 ± 0.3 0.3 ± 0.3
24:1 0.8 ± 0 .3 0 .7  ± 0 .2
Table 4.32: Percentage fatty acid composition of the non-esterified fatty acid
fraction from visceral adipose tissue extracted using the petroleum 
ether method after different tissue storage times. Results as means ± 
SD (n=3). n.d. = none detected, tr. = <0.05.
Fatty A cids T im e zero T im e 24 h Tim e 48 h
12:0 0.7 ± 0 .5 0.2 ± tr. 0.1 ± 0 .2
14:0 1.9 ± 0 .4 0.9 ± 0.2 1.0 ± 0.1
16:0 14.0 ± 1.2 11.8 ± 0 .8 12.9 ± 1.2
16:1 n-7 2.1 ± 0 .3 3.8 ± 0 .3 3.4 ± 1.3
16:1 n.d. 0.2 ±  tr. 0.3 ± tr.
17:0 0.5 ± 0 .1 0.2 ± tr. 0.3 ± 0 .1
17:1 0.2 ± 0.0 0.4 ± 0 .1 0.4 ± 0 .1
18:0 10.6 ± 2 .1 4.8  ± 0.6 5.6 ± 1.8
18:1 n-9 22 .8  ± 1.5 24.1 ± 1.4 25.4 ± 0 .4
18:1 n-7 n.d. 0.2 ±  0.2 0.1 ± 0 .1
18:2 n-6 10.9 ± 0 .8 12.9 ± 1.5 12.7 ± 1.1
18:2 n-3 0.5 ± tr. 0 .4  ± 0 .1 0.3 ± 0 .1
18:3 n-6 0.7 ± 0 .3 0 .6  ± 0 .5 1.1 ± 0 .1
18:3 n-3 1.1 ± 0 .9 1.5 ± 0 .2 1.3 ± 0 .2
20:0 0.3 ± 0.2 0.4 ±  tr. 0.2 ±  0.2
20:1 n-9 8.3 ± 0 .1 6.8 ± 0 .1 8.1 ± 0 .9
20:2 0 .6  ±  tr. 1.0 ± 0 .2 0.8 ± 0 .1
20:3 n-9 0.4 ± 0 .1 0.8 ± 0 .1 0.6 ± 0 .1
20:4 n-6 0.9  ± 0 .4 1.8 ± 0 .3 1.4 ± 0 .2
20:4 n-3 0.8 ± tr. 1.3 ± 0 .2 1.1 ± 0 .2
20:5 n-3 2.2 ± 0 .1 4.2 ±  0.6 3.1 ± 0.9
22:1 6.5 ± 0 .5 5.3 ± 0 .6 6.8 ± 0.9
22:2 tr. tr. n.d.
22:3 tr. 1.5 ±  1.5 2.2 ± 0.4
23:0 4.6  ± 0 .8 0.8 ± 1.3 n.d.
22:5 n-3 0.8 ± 0.2 1.2 ± tr . 1.0 ± 0 .2
22:6 n-3 6.9  ±  0.5 12.0 ±  1.7 8.6 ± 0 .6
24:0 1.0 ± 0 .9 0.6 ± 0.5 0.8 ± 0.2
24:1 0 .9  ± 0 .3 0.6 ± 0.2 0.7 ± 0 .2
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Table 433: Percentage fatty acid composition o f the non-esterified fatty acid
fraction from visceral adipose tissue extracted using the rendering 
method of extraction after different tissue storage times. Results as 
means ± SD. n.d. = none detected, tr. = <0.05.
Fatty Acids T im e zero T im e 24  b Time 48 h
12:0 n.d. 1.4 ±0.9 0.8 ± 0 .3
14:0 0.1 ± 0 .1 2.5 ±1.1 1.4 ± 0 .5
16:0 9.2 ± 1.3 14.3 ±2.5 13.2 ± 0 .7
16:1 n-7 4 .6  ± 1.5 3.2 ±2.8 2.8 ± 1.4
16:1 0.3 ± 0 .3 0 .2  ±0.2 0.6 ± 0.8
17:0 0.5 ± 0 .4 1.0 ±0.2 0.3 ± 0 .1
17:1 0.2 ± 0.3 0.3 ±0.3 0.5 ± 0 .1
18:0 16.4 ± 5.5 5.1 ±0.2 4.2 ± 0 .1
18:1 n-9 19.4 ± 1.9 20 .6  ±8.3 24.9 ± 1.2
18:1 n-7 n.d. 2.1 ±0.2 0.1 ± 0 .1
18:2 n-6 8.1 ± 0 .4 10.6 ±3.2 12.7 ± 0 .9
18:2 n-3 0.2 ± 0.3 0.3 ±0.2 0.6 ± 0 .1
18:3 n-6 1.1 ± 0 .2 2 .7  ±2.6 1.0 ± 0 .6
18:3 n-3 2.2 ± 0.7 1.7 ±0.9 1.1 ± 0 .9
20:0 0.5 ± 0 .1 0.3 ±0.3 0.5 ± 0.6
20:1 n-9 10.5 ± 0 .9 11.4 ± 5 .3 8.4 ±  1.5
20:2 0.5 ± 0.4 0.8 ± 0 .7 1.0 ± 0 .1
20:3 n-9 0.3 ±  0.4 0.5 ± 0 .5 0.7 ± 0 .1
20:4 n-6 2 .7  ± 0 .5 1.5 ± 0 .7 1.5 ± 0 .3
20:4 n-3 1.5 ± 0 .2 0.9 ± 0 .8 1.0 ± 0 .2
20:5 n-3 1.7 ± 0 .5 2 .8  ±  0.9 3.3 ±  0.6
22:1 7.9 ± 2 .0 6.1 ±  1.8 6.2 ± 0.9
22:2 n.d. 1.0 ±  1.5 n.d.
22:3 n.d. n.d. 1.5 ± 1.1
23:0 4 .2  ± 0 .1 0.3 ± 0.5 0.6 ± 0 .1
22:5 n-3 0.5 ± 0 .5 0.6 ±  0.3 1.0 ± 0 .2
22:6 n-3 5 .6  ±  1.8 6.1 ±  1.0 9.5 ±  1.3
24:0 0.8 ± 0.3 1.0 ± 0 .8 0.3 ± 0 .3
24:1 1.1 ± 0 .9 0 .6  ±  0.6 0.6 ± 0.3
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4.13 Discussion
It has been well documented that different methods of lipid extraction give rise to 
different yield of lipids (Ewald et al., 1998; de Boer, 1998; Randall et a l , 1991). 
However, very few publications exist which report specific details on the most 
commonly-used commercial method of lipid extraction, rendering. Due to a lack of 
information on the rendering method, we set out to compare extraction efficiencies 
between the commercially-used rendering method and what can be regarded as the 
best method of lipid extraction, the Garbus method, together with a variation of the 
Soxhlet method.
The Garbus method is an adaptation o f the Bligh and Dyer procedure and is a reliable 
method for lipid extraction and offers the unique advantage of extracting the more 
difficult-to-extract lipids such as highly charged phospholipids (e.g. higher inositides) 
(Christie, 2003). In keeping with its reputation we determined that the yields of both 
total lipid and TAG were significantly and, more consistently, greater with the Garbus 
method than either of the other two methods o f extraction examined (Figs. 4.2A, 4.2B, 
4.12, 4.13). However, despite the Garbus method being generally considered a ‘gold 
standard' in lipid extraction it is not used commercially due to toxicity and cost- 
related issues (Fang et a l , 2007). Previous research has been undertaken to determine 
a method which reports comparable yields to that of the chloroform/methanol-based 
Garbus method. Gunnlaugsdottir and Ackman (1993) investigated the efficiency of 
extraction of two chloroform/methanol/water methods, Bligh and Dyer (of which the 
Garbus is a variant) and Smith-Ambrose-Knobl compared to a hexane/isopropanol 
method. They determined that the hexane/isopropanol method was a less effective 
method of lipid extraction compared to the chloroform/methanol/water-based 
methods. It was also reported that the hexane/isopropanol method was far less 
efficient in extracting the more polar lipid classes (Gunnlaugsdottir and Ackman, 
1993). These conclusions reflect our findings for the Garbus and petroleum ether 
methods in terms of total lipid, TAG yield and extraction of the acyl components of 
lipids from total trout offal (Figs. 4.2A, 4.2B, Tables 4.2 -  4.16).
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When total trout offal was employed as the starting material, the Garbus method 
yielded the maximum amount o f total lipid (approximately 36.5 mg/g tissue 
homogenate) at each time point examined whereas the petroleum ether method gave a 
total lipid yield of 14.5 mg/g tissue homogenate at time zero. However, the yield from 
the petroleum ether method increased with tissue storage time and reached comparable 
yields with the Garbus method after 24 h. Yield of TAG as well as yield of the minor 
acyl constituents improved with time (Figs. 4.2A, 4.2B, Tables 4.3, 4.9, 4.12, 4.15). 
Similar to Gunnlaugsdottir and Ackamn (1993) we also found that the more polar 
lipids were poorly extracted with the petroleum ether method and hypothesised that an 
increase in the total polar fraction was more reflective of tissue degradation and the 
subsequent release of complex lipids rather than an increase in method effectiveness 
(Aidos et al., 2003b).
Ewald et al. (1998) also investigated the differences between the Bligh and Dyer and 
the Soxhlet extraction methods on muscle from various fish species including salmon, 
herring, cod and Northern pike. The solvent system used for the Soxhlet method was 
acetone/hexane (10:7, by vol.) and they found that the method of Bligh and Dyer 
resulted in a greater yield of total lipid compared to the Soxhlet method. For salmon 
they reported significantly higher yields o f total lipid with the Bligh and Dyer method 
(12.8%) compared to the Soxhlet method (11.72%). Our results correspond with the 
trend observed by Ewald et al (1998) (i.e. our Garbus method resulted in a greater 
yield of total lipid, 3.8%, compared to the petroleum ether method, 1.5%, (a Soxhlet 
variant) used in our experiments). Manirakiza et al. (2001) also compared variations 
of the Bligh and Dyer method to different solvents used with the Soxhlet method and 
reported higher total lipid yields with the Bligh and Dyer method and its variants 
rather than with the Soxhlet. The Bligh and Dyer method and its variants achieved 
recoveries of approximately 72 mg/g fresh wt. of total lipid from fish flour (dried and 
powdered fish used for animal/fish food stuffs) whereas the standard Soxhlet method 
using acetone hexane (1:4, by vol.) gave approximately 51 mg/g fresh wt. of total 
lipid. As different starting materials were used in the present study and that of 
Manirakiza et al. (2001), it was to be expected that the levels of total lipid yield would 
be significantly different. Nevertheless, the trend is similar. We determined that for
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the total trout offal at time zero the total lipid yield with the Garbus method was about 
twice that seen with the petroleum ether method (Fig. 4.2A).
Inter-method differences observed when total trout offal was used were not found 
when the starting material was visceral adipose tissue (Figs. 4.9, 4.10). At time zero 
and 24 h no disparities between methods were observed but by 48 h the level of 
efficiency for the rendering method had decreased and was significantly different from 
both the Garbus and petroleum ether methods (Figs. 4.9, 4.10). Since adipose tissue is 
heavily dominated by TAG accumulating in lipid droplets, the comparability of the 
extraction methods probably reflects this. Very little literature is available on the use 
of specific tissues such as adipose tissue in terms of monitoring efficiency of different 
methods of lipid extraction.
Commercial production o f fish oil is most commonly achieved by a rendering method 
which relies on the use o f steam to rupture cells and liberate the oil, followed by a 
series of purification steps (Aidos et al., 2003a; Pigott and Tucker, 1990). Due to this, 
a model system of rendering was employed to determine yield from this method in 
terms of total lipid, TAG, acyl composition and EPA and DHA levels. We found that 
the yield from total lipid and TAG extraction increased with tissue storage time when 
total trout offal was used (Figs. 4.2A, 4.2B). However, no differences were observed 
when visceral adipose tissue was used as a starting material (Figs. 4.9, 4.10). Visceral 
adipose tissue is primarily used as a storage depot for fatty acids catabolised for 
energy metabolism (Henderson and Tocher, 1987). It is predominantly composed of 
die non-polar lipid TAG and we observed that TAG-enriched adipose tissues produced 
greater yields of both total lipid and TAG with rendering compared to the 
phospholipid-enriched tissues in total trout offal homogenate (Figs. 4.2A, 4.2B, 4.9, 
4.10).
Despite the rendering process being predominantly used for commercial production of 
fish oils, surprisingly very little literature is available on lipid yields or acyl 
composition of rendering-derived lipids. From our analysis we determined that total 
lipids yields depended on both starting material and time of analysis when the 
rendering method was used (Figs. 4.2A, 4.9). When total trout offal was used the total 
lipid yield increased from 15.9 mg/g fresh weight of homogenate to 25 mg/g by 48 h. 
We hypothesised that the increase in yield was probably due to degradation of the
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tissue over time by proteinases etc. which would break up the tissue structure thus 
allowing for easier extraction of complex lipids (Aidos et al., 2003b). Despite this 
increase in total lipid yield at 48 h the rendering method remained significantly less 
efficient compared to the Garbus method (Fig. 4.2A). However, when visceral 
adipose tissue was used as the starting material the rendering method demonstrated 
equal extraction capacity to that o f the Garbus and petroleum ether methods at both 
zero and 24 h. Nevertheless, total lipid and TAG yield decreased at 48 h and this may 
be due to degradation such as the susceptibility o f the TAG fraction for catabolism by 
lipases (Athenstaedt and Daum, 2006).
In terms of acyl composition of the lipid classes extracted, we observed that for both 
starting materials (total trout offal and visceral adipose tissue) there was a general 
trend for a relative increase in the monounsaturated fatty acids in most lipids with 
tissue storage time (Tables 4.2 -  4.16, 4.18 -  4.33). As previously mentioned (section 
4.8, 4.12) the principal monounsaturated fatty acids consisted of 16:1, 18:1, 20:1 and 
22:1 in all lipids derived from either starting material. Aidos et al. (2003b) also 
reported these fatty acids to be the principal fatty acids determined in herring 
byproducts. Total trout offal contained a high amount of DHA whilst EPA was 
equally distributed between the trout offal-derived and visceral adipose tissue-derived 
lipids (Figs. 4.3 -  4.6, 4 .1 2 -4 .1 5 , Tables 4.2 -  4.16, 4.18 -  4.33). In terms of acyl 
composition the TAG fractions demonstrated very little changes with time whilst acyl 
changes with time were quite distinct for the total polar lipid fractions especially with 
regard to DHA which generally decreased significantly with increased storage time 
(Tables 4 .2 -4 .1 6 , 4 .1 8 -4 .3 3 ).
Overall, the Garbus method o f lipid extraction was found to be the most consistent and 
produced much better yields of total and individual lipids compared to the petroleum 
ether and rendering methods when the phospolipid-rich tissues were used. Petroleum 
ether and rendering proved equally as efficient for tissues stored for 24 h, but as 
mentioned earlier, a decrease in rendering efficiency was observed at 48 h. Some of 
the literature reports that steam-based methods of lipid extraction method yield lower
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levels of saturated fatty acids and higher yields of PUFAs (Aidos et a l, 2001; Aidos et 
al., 2002a) but this finding was not confirmed in our experiments. Our findings 
demonstrated that, the rendering method is a less efficient method than the Garbus and 
a petroleum ether-based derivative o f the Soxhlet method of lipid extraction. 
However, despite this, rendering can be employed to produce sufficient levels of lipid 
yield for commercial production o f fish oil with very little toxicity implications. EPA 
and DHA in total trout offal are present in high enough quantities to make the use of 
such material a suitable source for fish oil production. However, EPA and DHA are 
highly unsaturated and, as we have observed, they become degraded over time 
especially in the phospholipid fractions. In order to preserve the levels some 
adjustment to farm storage conditions may be advisory. Also, from our analysis we 
can conclude that a combination o f total trout offal as used here (liver, spleen, eyes, 
heart, brain) and visceral adipose tissue would be a more effective source for the 
production of trout oils rich in PUFAs.
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CHAPTER 5
Effect o f Polyunsaturated Fatty Acid Supplementation on Cartilage 
Deeradation in a Model System for Osteoarthritis
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5.0 Introduction
An abundance o f evidence exists on the ability o f long chain n-3 PUFAs, specifically 
EPA and DHA, to alter the inflammatory response in a multitude of diseases (Calder,
2002, 2005; Kris-Etherton et al., 2001; Simopoulos, 2002). RA, an autoimmune 
disease, is one such condition where the long chain PUFAs found in fish oil, are 
thought to ameliorate particular symptoms, both physical and biochemical (Leeb et a l ,
2003, 2006) associated with the disease. As previously detailed (section 1.5.1.1) the 
long chain PUFAs, EPA and DHA, are incorporated into the phospholipids of cellular 
membranes at the expense of the n - 6  fatty acid, AA. AA is a precursor for a range of 
inflammatory mediators such as prostaglandin E2  and leukotriene B4  (Fig. 1.8) both of 
which are considered key mediators in arthritis (Goggs et al., 2005). The n-3 PUFA 
derived mediators are believed to be less inflammatory than those derived from AA. 
Replacement of AA with EPA and DHA in the phospholipids of cell membrane of 
cells results in competition for the COX and LOX enzyme systems and, thereby, gives 
rise to smaller amounts o f the more inflammatory prostanoids (Calder, 2003). An 
abundance of literature reports on the relationship of n-3 PUFAs with rheumatoid 
arthritis (Goldberg and Katz, 2007; James et a l , 2003; James and Cleland, 1997; 
Kremer, 2000) but there is relatively little evidence on the effects of n-3 PUFAs in 
OA.
Development of OA results in a progressive degeneration and erosion of cartilage over 
time (section 1.3). In brief, catabolism and subsequent loss of cartilage aggrecan, 
collagen and chondrocyte death results in a compromised ECM coupled with joint 
inflammation (Sarzi-Puttini et a l , 2005). In the early stages of the disease, 
progressive loss of joint integrity is primarily due to the actions of proteinases, 
specifically aggrecanases (Sandy et a l ,  1992). The aggrecanases, of which there are 
two main specific iso forms, ADAMTS-4 and ADAMTS-5 (Section 1.13), cleave 
aggrecan within the IGD at the peptide bond Glu3 7 3 -Ala3 7 4  resulting in a compromised 
ECM (Flannery et a l ,  1992). As joint destruction continues, MMPs become more 
involved in the erosion of the ECM. Within the IGD of aggrecan the Asn3 4 1 -Phe3 4 2  
peptide bond is cleaved by MMPs (van Meurs et a l ,  1999). Two of the major MMPs 
involved in joint degradation are MMP-3 and MMP-13. MMP-3 is thought to activate 
collagenases which in turn degrade the collagen matrix of the ECM. MMP-13 is
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considered to be involved in destruction of collagen type II which some consider to be 
the key marker of irreversible joint damage (Cawston, 1998).
The role of lipid metabolism in the pathogenesis and progression of arthritis has been 
under investigation for some time (James and Cleland, 1997; Lippiello, 1990; 
Lippiello et al., 1991). Lippiello et al. (1991) determined that elevated levels of lipids 
in synovial fluid could be attributed to arthritic modifications of articular cartilage and 
the synovial membrane. This study also concluded that patients presenting with 
osteoarthritis had elevated concentrations o f serum fatty acids. Previous studies have 
suggested that prostaglandin synthesis in chondrocytes is affected by fatty acids and 
that linoleate may promote reduced collagen type II synthesis in avian chondrocytes 
(Lippiello, 1990; Watkins et al., 1996). There is also an age-related association 
between lipid accumulation and osteoarthritic pathogenesis. Evidence indicates an 
increase in lipid accumulation (and AA in particular) in human articular cartilage 
which may induce some of the changes observed in chondrocyte metabolism during 
osteoarthritis (Lippiello, 1990).
Due to the abundance o f evidence suggesting a link between n-3 PUFAs in the 
pathogenesis of rheumatoid arthritis we wanted to elucidate whether such beneficial 
effects could also be observed in OA. The object of this chapter was to investigate the 
effects of EPA, DHA and a fish oil preparation, from trout, on protein degradation and 
mRNA levels of inflammatory and degradative proteins in an in vitro model of OA.
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Chapter 5: Materials & Methods
5.1 Preparation and Culture of Cartilage Explants
Metacarpophalangeal joints of 7 day-old calves were obtained from the local abattoir, 
washed thoroughly and sprayed with virusolue (Microsol laboratory disinfectant, 
Anachem) before the skin was removed from the limb.
The synovial joint was opened in a Class I laminar flow hood. Full depth cartilage 
was cut away from the bone using sterile conditions and placed in Dulbecco’s- 
modified Eagle’s medium (DMEM; Gibco Life Technologies, UK) containing 50 
pg/ml gentamicin (Gibco Life Technologies, UK) and 10% foetal calf serum (FCS) 
(Gibco Life Technologies, UK) for 36 h at 37°C in a humidified atmosphere of 5% 
CO2 and 95% O2 . Explants were washed in DMEM (x 3) and fresh DMEM plus 10% 
FCS was added to explants for a further incubation o f 36 h.
52  Preparation of Fatty Acid Solutions
Fatty acids (EPA, DHA) (99% minimum purity) (Nu-Check Prep, USA) were 
dissolved in appropriate volumes o f dimethyl sulfoxide (DMSO) (Sigma, UK) to give 
stock concentration o f 20 mg/ml. The fatty acid stock was diluted in de-lipidised FCS 
(Pan-Biotech, Germany) to yield a working solution of 1 mg/ml. Aliquots of the 
stock solution and the fatty acid working solutions were derivatised by 
transesterification and the resulting FAMEs were analysed on GLC in order to 
confirm the final concentrations (sections 2.3, 2.4). The required fatty acid 
concentrations (10- 300 pg/ml) were prepared in DMEM from the working solutions.
53 Supplementation of Explants with Polyunsaturated Fatty Acids
Following the stabilisation period (36 h), cultured explants were washed (x3) in 
scrum-free DMEM and one explant was placed in each individual well of a sterile 24- 
well plate (Greiner, UK) in 1ml DMEM with or without fatty acid-DMSO working 
solution (10 -  300 fig/ml). Supplemented explants were incubated for 12 h to allow
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uptake and incorporation o f the fatty acids into the chondrocyte membranes, under 
aforementioned conditions (section 5 . 1 ).
5.4 Inflammatory Stimulation of Explants
Following fatty acid-supplementation (12 h) the media was removed and the explants 
washed (x3) in serum-free DMEM to remove any residual fatty acids. Interleukin-1 
alpha (IL-la) (10 ng/ml) (Pepro Tech Inc, UK) was added to the explants and 
incubated in aforementioned conditions for a further 72 h. IL-la, an inflammatory 
cytokine, is regularly used to generate inflammation and cartilage degradation in vitro 
(Flannery et al., 1999).
Following incubation with IL -la, the explants were weighed and stored in RNAlater9 
(1 ml) (Sigma, UK) at -20°C until needed for RNA extraction. RNA later9 is an 
aqueous, non-toxic tissue and cell storage reagent that stabilizes and protects cellular 
RNA by rapidly permeating tissues and immediately inactivating RNases, thus 
maintaining RNA integrity.
5.5 Hydrolysis (Saponification) of Lipids
For some experiments (section 5.3.3) trout oil was used to supplement the explants. In 
Older to allow a comparison with the PUFA supplementation, it was necessary to 
hydrolyse the trout oil before dissolving it in the DMSO-delipidised FCS complex.
Hydrolysis of lipids can be achieved by heating them in a solution of aqueous ethanolic 
alkali and allowing them to reflux. The cleaved fatty acids remain water-soluble in 
alkali conditions and, in order to extract them, acidification of the solution is required. 
Upon acidification the NEFAs can then be extracted using an organic solvent. If desired, 
non-saponifiable and water-soluble components can be recovered by using additional 
steps.
A solution of 0.1 M potassium hydroxide (KOH) in 90% aqueous ethanol was prepared 
fresh. The lipid sample was placed in a stoppered tube to which the 0.1 M KOH was 
added (0.25 ml KOH per milligram of lipid sample; up to 6  mg). The lipid was refluxed
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at 50°C for 3 h. Acidification of the sample was completed by adding hydrochloric acid 
( 6  M). The pH of the solution was checked using full range pH paper (Whatman, UK). 
Once acidified, water (2 ml) was added to the mixture and the non-esterified fatty acids 
were extracted in iso-hexane(2-methylpentane):diethyl ether (1:1, by vol.) (Fischer, UK). 
The extracted organic layers were passed through short columns of anhydrous sodium 
sulphate (Sigma, UK) to remove any residual water. The columns of anhydrous sodium 
sulphate had previously been washed with iso-hexane (2 -methylpentane):diethyl either 
(1:1, by vol). Extraction of the lower aqueous layer was repeated (x2) to ensure 
complete extraction of NEFAs. The resulting NEFAs were washed thoroughly in 
potassium hydrogen carbonate (KHCO3 ) and water to completely remove any residual 
acid that was present after the extraction procedure. Samples were taken to dryness 
under N2 , re-dissolved in HPLC hexane (Fischer, UK) and stored at -20°C.
5.6 Preparation of Trout Oil-Derived NEFAs for Supplementation of
Explant Cultures
Once the trout oil had been hydrolysed and the NEFAs extracted, an aliquot was 
derivatised by transesterification and the concentration determined by GLC. Once 
quantified the trout oil-derived NEFAs were prepared in DMSO-delipidised FCS as 
previously described (section 5.2) and the final concentrations were confirmed by 
GLC (section 2.2 and 2.3). Explant cultures were then supplemented with 10 -  300 
pg of hydrolysed trout oil-derived NEFAs for 12 h.
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5.7 Dismembration of Cartilage Explants for RNA Extraction
This procedure was employed in order to reduce the cartilage explants to a fine 
powder prior to RNA extraction. The method involved snap freezing the tissue 
followed by vigorous shaking o f the tissues in the presence of a steel ball which 
resulted in the explant being pulverised to a fine powder.
The cartilage explants were removed from KNAlater® (Sigma, UK) snap-frozen in 
liquid nitrogen and placed into a pre-cooled (liquid nitrogen) dismembrator vessel 
together with a steel ball. The vessel was secured into the dismembrator (Mikro- 
Dismembrator U, B-Braun Biotech International) and freeze-milled for 1 min at 2000 
rpm. Upon completion, Tri reagent (Sigma, UK) (1 ml) was added to the vessel and 
the Tri reagent-explant powder was transferred to a sterile 1.5 ml micro-centrifuge 
tube (Coming, USA). Tri-reagent combines phenol and guanidine thiocyanate in a 
mono-phase solution which facilitates rapid and effective inhibition of RNase activity.
5.8 RNA Isolation
Molecular biology grade chloroform (0.2 ml) was added to milled cartilage samples in 
Tri-reagent (1 ml). Samples were vortexed and left at room temperature for 15 min. 
Samples were then centrifuged on a Sanyo Hawk 15/05 refrigerated bench-top 
centrifuge at 13,200 rpm for 15 min. The upper phase was transferred to a sterile 1.5 
ml tube containing 375 pi of 70% molecular biology grade ethanol (Fischer, UK). 
Total RNA was isolated using RNeasy mini-columns and reagents (Qiagen, UK) 
according to the manufacture’s protocol and eluted in sterile water. Samples were 
then frozen at -80 °C until needed for reverse transcription of RNA.
The RNeasy columns used in this particular kit separate RNA, based on the binding 
properties of a silica gel-based membrane. Upon transferring the tissue to the spin 
column, total RNA binds to the membrane whilst contaminants are removed by a 
series of buffer washes. RNA is then eluted in RNase-free, sterile water. Using the 
RNeasy kit allows all RNA molecules greater than 200 nucleotides to be extracted.
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To determine RNA purity the ratio o f absorbance at 260 and 280 nanometres (nm) 
was determined. Satisfactory RNA preparations give a ratio between 1.6 and 2.2 for 
260/280 nm absorption. Values outside this range indicated significant contamination 
(by, for example, protein) and such RNA extracts were not used further.
RNA extraction from articular cartilage is known to be more difficult than from many 
other tissues due complicating factors including low cell content and a high 
proportion of negatively charged proteoglycans which elute with RNA.
5.9 Oligonucleotide Primer Design
A primer is a short synthetic oligonucleotide designed to have a sequence which is the 
reverse complement o f a region o f target DNA to which it can anneal at a specific 
temperature. Several parameters were taken into account in designing oligonucleotide 
primers. Each primer was approximately 20 base pairs in length and had a GC 
content between 40-60%. In addition, the melting temperatures for primers were 
preferred in the range between 50-65°C. The primers were also assessed for primer- 
dimer formation. Primer-dimers are the product o f non-specific annealing and primer 
elongation. Possible sites for self-complementarities increase the risk of primer-dimer 
formation and, therefore, care was taken to ensure the ends of primer sequences were 
not complementary. Sequences o f primers corresponding to the genes of interest were 
developed using Genbank (the National Institute of Health (NIH) genetic sequence 
database) and these primer sequences are outlined in Table 5.0. Oligonucleotide 
primer products were sequenced by the DNA Sequencing Core Unit at Cardiff 
University.
Table 5.0: Oligonucleotide sequences for primers used for reverse-transcription 
polymerase chain reaction (RT-PCR). In the sequence for ADAMTS-5, 
Y denotes a mixture of G and C.
Protein S eq u e n c e  o f  P r im ers (F o r w a r d /R e v e r se ) P rod uct O p tim a l C ycle
S ize (bp) tem p  (°C ) N u m b er
GAPDH 5' TGG CAT CGT GGA GGG ACT TAT 3' 299 59.9 28
(Bovine) 5* GAC GCC TGC TTC ACC ACC TTC -v *.>
COX-1 5* GCC C A A  CAC TTC ACC CAT CAG 3' 287 59.0 32
(Bovine) 5* CCA GGA AGC AGC CCA A AC ACT 3*
COX-2 5* GCT CTT CCT CCT GTG CCT GAT 3' 229 52.3 32
(Bovine) 5* CAT GGT TCT TTC CCT TAG TGA 3'
ADAMTS-4 5* TGG ATC CCG AGG AGC CCT GGT -v * 151 54.2 28
(Bovine) 5* TGG CGG TCA GCG TCG TAG TCC 3'
ADAMTS-5 5* GGC CTC TCC C A T G A Y  G AT TCC 3' 498 62.2 28
(Hainan) 5' TGA GCG AGA A C A  CTG GCC CCA
MMP-3 5' CTT TTG GCG A A A  ATC TCT CAG 3' 404 50.0 28
(Bat) 5* AAA G AA ACC CAA ATG CTT CAA 3'
MMP-13 5' TTC TGC CAC ACG CTT TTC CTC 3 ’ 273 53.0 35
(Bat) 5' GGT TGG GGT CTT CAT CTC CTG 3 ’
IU 5* TGC AGT CTT CA A ACG AGT GG 3* 378 54.0 28
(Bovine) 5' ACA TTC AAG CCA CAT AGC CA 3'
INF-a 5' ACG TCA TTC ATC ACT TTC ATG AGT TC * 310 44.0 35
(Bovine) 5' TCT TCT CAA GCC TCA AGT AAC AAG T 3'
CCOX-I 5 ’ TCC GAT TGA C AT TAT AGC C 3 ’ 204 48.0 21
(Bovine) 5* AAC CTA A AT ACA ACC TCC TTC 3'
CCOX-II 5' GAG GAG ACT AAC ATT CGG AT 3' 290 48.0 22
(Bovine) 5* GAA GTA GAG ACA ATC TGA ACC 3'
GAPDH. glyceraldehyde-3-phosphate dehydrogenase; COX-1, cyclooxygenase-1; 
COX-2, cyclooxvgenase-2; ADAMTS-4, aggrecanases-1; ADAMTS-5, aggrecanases- 
2; MMP-3. matrix metalloproteinase-3; MMP-13, matrix metalloproteinase-13; IL-6, 
interleukin-6; TNF-u. tumour necrosis factor-a; CCOX-1, cytochrome c oxidase 
subunit I; CCOX-2 cytochrome c oxidase subunit II.
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5.10 Reverse Transcription Polymerase Chain Reaction
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was used 
to investigate the effect o f particular fatty acids on the levels of mRNA for various 
inflammatory genes and ECM proteinases involved in OA.
Complementary DNA (cDNA) was synthesised by reverse transcription using 
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (Promega, UK). 
MMLV reverse transcriptase uses single-stranded RNA as a template in the presence 
of a primer to synthesise a complementary DNA strand. The reaction mixture also 
contained 5 x RT buffer (250 mM Tris-HCl (pH 8.3), 375 mM KC1, 15 mM MgCl2, 
50 mM DTT), RNasin (RNase inhibitor) (Promega, UK), random hexamers , (50 
ng/pl) (Abgene, UK) and dNTPs (100 mM) (Promega, UK).
PCR amplification was undertaken using specific oligonucleotide primers (MWG, 
Germany) which corresponded to the genes o f interest (Table 5.0). Initially, the 
annealing temperatures generated during primer design were used but, in some 
instances, unspecific bands appeared for some primers. When this problem was 
encountered, conditions were optimised for each primer set to ensure a single product 
| band of the correct size. MgCl2 concentration gradients (10, 15, 20, 25, 30 mM) as 
i well at temperature gradients were employed to select the correct conditions for
\ primers. MgCl2 is necessary in PCR reactions as Taq polymerase requires a divalent
|
ion as a co-factor and also affects the stringency o f binding (lower concentrations 
i  provide more stringent conditions thus increasing exact matching of base priming and 
amplification). In order to maintain the PCR reaction in the logarithmic phase, cycle 
numbers were optimised for each primer sequence (Table 5.0).
Based on these optimisation experiments, the following conditions for PCR were 
devised. Following initial denaturation o f the cDNA at 95 °C for 5 min, amplification 
involved 20 -  35 cycles o f 1 min at 94 °C, 1 min at the appropriate annealing 
temperature (Table 5.0), 1 min at 72 °C and a final extension step of 10 min at 72 °C. 
PCR products were visualised on 2% wt./vol. agarose (Bioline, UK) gels (containing 
2%ethidium bromide (Sigma, UK)) under UV light.
187
5.11 Determination of Explant Metabolism
To assess the metabolic state of cartilage explants a commercially available lactate 
assay kit (Trinity Biotech, UK) was used to determine the concentration of lactate 
released into the culture media from the explants during incubation.
The principle behind this assay lies with measuring a glycolysis end product -  lactic 
acid. Lactic acid is metabolised to pyruvate and hydrogen peroxide (H2O2) by lactate 
oxidase. In the presence of the H2O2 formed, peroxidase catalyses the oxidative 
condensation of chromogen precursors to produce a coloured dye which is measured 
at 540 nm. The increase in absorbance at 540 nm is directly proportional to the 
lactate concentration of the sample. Changes in the levels of lactate in the media were 
taken to reflect changes in chrondrocyte metabolism and, thus, were thought to be 
indicative of chrondrocyte viability.
Anaerobic Lactate
glvcolvsis _ . . .  oxidase  ^ „  , . „  ^
Glucose   — s-------- ► Lactic acid -------------------------► Py ruvate + H2O2
_  ^  Peroxidase __ _  ^  .H 2O 2 + Chromogens -----------------------► H 2 O + Colour
Lactate standards (0-400 pg/ml) were prepared and 5 pi of these standards or 
appropriately diluted media samples were added to individual wells of a 96-well plate. 
Lactate reagent was prepared according to the manufacturer instructions and 250 pi of 
reagent was added to each well. Samples were left to incubate for 10 min at room 
temperature before the absorbance at 540 nm was determined using a microplate 
reader (Opsys MR, Dynex technologies, UK).
188
5.12 Dimethvlmethvlene Blue Assay
Determination of proteoglycan degradation was monitored using the 
dimethylmethylene blue (DMMB) assay which quantifies the levels of sulphated 
glycosaminoglycans (GAG) released by the cartilage into the culture media (Famdale 
e/a/., 1982) . The sulphated GAGs released from cartilage bind to the DMMB dye 
forming a complex. Generation of this complex gives rise to a metachromatic shift in 
the absorbance (i.e., colour changes from pink to blue).
Standards of chondroitin sulphate C derived from shark cartilage were prepared (0 -  
40 pg/ml) and placed in a 96-well plate together with the appropriately diluted media 
samples. DMMB solution (200 pi) (32 mg 1,9-DMMB, 20 ml ethanol, 59 ml 1 M 
sodium hydroxide, 7 ml 98% formic acid and made up to 2 1 with water) was added 
and the absorbance immediately determined at 525 nm due to the instability of the 
sulphated glycosaminoglycan-DMMB complexes which start to aggregate, and 
eventually precipitate, as soon as the dye is added to the mixture (Famdale et al., 
1986).
Statistical analysis for both GAG and lactate assay results was carried out using one­
way ANOVA (post hoc Tukey Test) using SPSS for windows XP.
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Chapter 5: Results
5.13 Endogenous Acyl Composition of Total Polar Lipids in Bovine 
Articular Cartilage
To investigate the uptake and incorporation o f supplemented fatty acids, typical 
compositions of explants were determined. The acyl composition of total polar lipids 
in bovine articular cartilage from the metacarpophalangeal joint was analysed to 
determine the percentage levels o f AA, EPA and DHA (Tables 5.1 -  5.3). The major 
saturated fatty acids included 18:0 and 16:0 with minor traces of 2 0 :0 , 2 2 : 0  and 24:0. 
The principal monounsaturated fatty acid was 18:1 n-9 with minor traces of 18:1 n-7, 
16:1 n-7, 20:1 n-9, 22:1 and 24:1. AA constituted approximately 5% of the total acyl 
composition whilst EPA and DHA were found at 0.8% and 1.5% respectively. 
Relatively high levels o f the unusual n-9 fatty acid, eicosatrienoic acid (20:3), have 
been previously reported as a major acyl component of total polar lipids from foetal 
bovine articular cartilage (Adkisson et al., 1991). Here, eicosatrienoic acid was 
detected at approximately 3% o f the total fatty acids (see control values in Tables 5.1 
-5.3).
5.14 Incorporation of q-Linolenic. Eicosapentaenoic and 
Docosahexaenoic Acids into Total Polar Lipids of Bovine Explant 
Cultures and the Resulting Effect on the Percentage of 
Arachidonic Acid
Supplementation of articular cartilage with various doses (10 -  100 pg/ml) of a- 
linolenic acid, EPA and DHA resulted in dose-dependent increases in the respective 
fetty acids compared to controls (Fig. 5.1). a-Linolenic acid was found at 
Ipproximately 0 .2 % in non-treated cartilage and, following supplementation, the 
levels increased to 11.5% with 100 pg a-linolenic acid. Supplementation with 50 and 
1 0 0  pg/ml resulted in a statistically significant increase compared to control levels (p 
<0.001) (Fig. 5.1).
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EPA was detected at approximately 0.6% in control explants but following 
supplementation with 1 0 -1 0 0  pg/ml, a dose-dependent increase in EPA (p < 0.001) 
was observed. A final concentration o f EPA in polar lipids following 100 pg/ml was 
approximately 13%. The incorporation o f EPA following supplementation resulted in 
a dose-dependent increase which was statistically significant when compared to 
control at all doses. DHA was detected at approximately 1.6% in control cultures. 
Similar to the trends seen with a-linolenic acid and EPA there was a dose-dependent 
increase observed with DHA supplementation (Fig. 5.1). With 100 pg/ml DHA the 
final concentration of DHA detected was significantly greater (p < 0.001) than 
controls (approximately 10.8%) (Fig. 5.1). Some variation was observed with 50 pg 
of DHA (Table 5.3) and it would be advisable to repeat the experiment because of this 
variation.
Incorporation of the n-3 fatty acids, a-linolenic acid, EPA and DHA into the total 
polar lipids of chondrocytes was primarily accompanied by a selective decrease in the 
percentage of 18:1 n-9 (Tables 5.1 -  5.3). With 100 pg/ml ALA there was a 7% 
decrease in 18:1 n-9 (7%) together with a minor decrease in the minor fatty acids 
(Table 5.1). EPA supplementation (100 pg/ml) resulted in a 12% increase in EPA 
accompanied by decreases in 18:1 n-9 (10%) and AA (1.5%). As well as this, a 2.1% 
increase in DHA was also observed. This increase in DHA following EPA 
supplementation may have been due to chondrocytes metabolism of EPA to the more 
tmsaturated DHA (Table 5.2). Following 100 pg/ml DHA supplementation there was 
a 10% increase in DHA of the total polar lipid fraction and a concomitant decrease in 
18:1 n-9 (10%). A minor reduction in AA (1.2%) was also observed (Table 5.2).
The uptake of trout oil was not investigated as, in the absence of a specific marker 
acid or radio-labelled fatty acid, the relative uptake of individual fatty acids from the 
trout oil mixture would have been very difficult to interpret. Also, the individual 
levels of EPA and DHA in trout oil (7.5 pg/ml EPA and 31.5 pg/ml DHA) (Table 5.4) 
were significantly lower than the doses o f a-linolenic acid, EPA and DHA used for 
the uptake experiments.
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Fig-LI Increases in the percentage of a-linolenic (ALA), eicosapentaenoic 
(EPA) and docosahexaenoic acid (DHA) into chondrocyte polar lipids 
following supplementation of cartilage explants with 10-100  pg/ml of 
the respective fatty acid preparations. Results as means ± SD (n=4).
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Table S.l Percentage acyl composition o f total polar lipids extracted from bovine
articular cartilage following supplementation with 10 -  100 pg/ml a-
linolenic acid. Results as means ± SD (n=4).
Fatty
Acids
~MkO
16:0 
16:1 n-7 
16:1 
17:0 
17:1 
18:0 
18:1 n-9 
18:1 n-7 
18:2 n-6 
18:2 n-3 
18:3 n-6 
18:3 n-3 
20:0 
20:1 n-9 
20:3 n-9 
20:4 n-6 
20:4 n-3 
20:5 n-3 
22:0 
22:1 n-9 
22:2 
22:5 n-3 
22:6 n-3 
24:0 
24:1
Control
0.5 ± 0.1
12.4 ± 1.0 
0.9 ± tr.
1.5 ± 0.3
1.6 ± 0.1
2.4 ± 0.3
15.4 ± 0.1
35.0 ± 1.9
7.0 ± 0 . 1
1.4 ± 0.1 
0.2 ± 0.3
1.8 ± 0 . 3  
0.2 ± 0.1 
0.5 ± 0.2  
0.8 ± tr.
2.9 ± 1.9
4.9 ± 0.4 
0.2 ± tr. 
0.8 ± tr.
1.3 ± 0.1 
0.4 ± 0.2
1.6 ± 0.1
2.3 ±0 . 1
1.5 ±0.2
1.0 ± 0.2
1.6 ± 0.4
10 pg/ml
0.3 ± 0.0
7.6 ± 2.2  
0.5 ± 0.1
1.0 ± 0.6 
0.9 ± 0.7
1.6 ± 0.2
17.7 ± 1.4
29.4 ± 0.7
6.3 ± tr.
1.0 ±0 . 1
tr.
1.9 ± 0 . 3
1.3 ± 0 .2
1.2 ± 0 . 3  
0 .6 ± 0 . 5
4.1 ± 0 . 3
6.5 ± 0.6 
0.5 ± 0 . 1  
0.9 ±0.1
1.4 ± 0.3 
0.5 ± 0 . 3
1.9 ± 0 . 7
3.7 ± 0 . 7
2.6 ± 0.6
3.3 ± 0.6
3.4 ± 0.2
25 pg/ml
0.2 ± tr.
6.5 ± 1.7 
0.4 ± 0 . 1
1.1 ± 0 . 9
1.4 ± 0 . 3
1.7 ± 0 . 5
16.6 ± 1.3
28 .7  ± 1.3
4 .8 ± 3 . 2
1.0 ± 0 . 3  
0.2 ± 0.2
1.4 ± 0 . 4
2.3 ± 0.5
1.1 ± 0.6
1.1 ± 0.1
4 .8 ± 0 . 3
6.5 ± 0.4 
0 .6  ± 0.3 
0.7 ± 0.4
1.8 ± 0.1 
0.5 ± 0.4
2.3 ±  0.5
3.8 ± 0 . 1
2.6 ± 0.1
3.7 ± 0 . 6
4.1 ± 0 . 6
5 0  pg/ml
0.2 ± tr.
11.1 ±2.3 
0.7 ± 0.3
1.0 ±0.5
1.8 ± 0.1
2.2 ± 0.3
17.2 ±0.9
32.1 ±4.2
n.d.
0.7 ±0.1 
0.1 ± 0.1
1.6 ± 0.2
6.2 ± 0.8 
0.6 ± 0.1
1.0 ±0.3
4.4 ± 0.9
5 .6  ±  1.1 
0.5 ±0.2
1.1 ± 0 .3
1.7 ±0.7 
0.7 ±0.1
1.7 ±0.3
2.7 ±0.5
1.7 ±  0 .3  
1.6 ± 0.4
1.8 ±0.4
100 pg/ml
0.3 ± tr. 
10.0 ± 2.0 
0.6 ± 0.1
1.1 ±0 . 5
1.6 ± 0.1
2.2 ± 0.3
15.1 ±0 .3
28.4 ± 1.0
3.4 ± 3 . 0  
0.9 ±0.1  
0.3 ± tr.
1.3 ±tr.
11.5 ± 1.1
1.0 ± 0 . 4  
0.8 ± 0.1
3.7 ± 0 . 2
4.8 ± 0.2
1.0 ± 0 . 5  
0.9 ± 0.1
1.6 ± 0 . 3  
0.7 ±0 .1
1.4 ±0.1
2.4 ±0 .1
1.5 ±tr.
1.6 ± 0.1
1.8 ± 0.1
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Table 5.2 Percentage acyl composition o f total polar lipids extracted from bovine
articular cartilage following supplementation with 10 -  100 pg/ml
EPA. Results as means ± SD (n=4).
Fatty
Acids
Control 10 tig/ml 25 iig/ml 50 jig/ml 100 |ig/ml
14:0 1.0 ± 0 . 2 0.8 ± 0 . 3 0.8 ± 0 . 3 0.7 ± 0 . 3 0.7 ± 0 . 3
16:0 18.8 ± 1.4 14.3 ± 3.0 11.1 ± 6 . 4 14.2 ± 1.4 12.8 ± 2 . 5
16:1 n-7 1.4 ± 0.1 1.2 ± 0.3 0.9 ± 0 . 5 1.0 ± 0 . 3 3.1 ± 4 . 8
16:1 2.5 ±0 . 1 1.9 ± 0 . 5 1.2 ± 0 . 5 1.3 ± 0 . 4 0.9 ± 0.3
17:0 2.0 ± tr. 1.1 ± 0.5 1.8 ± 0 . 3 1.8 ± 0.1 1.9 ± 0 . 2
17:1 2.5 ± tr. 2 .0 ± 0.4 2.0 ± 0.3 2.1 ± 0 . 2 1.7 ± 0 . 2
18:0 17.7 ± 0 . 4 14.8 ± 1.1 14.9 ± 1.2 15.3 ± 0 . 8 15.7 ± 1.1
18:1 n-9 31.9 ± 1.2 31.7 ± 1.7 26.0 ± 2.0 24.9 ± 1.7 22.0 ± 2 . 7
18:1 n-7 n.d. 5 .0 ± 3.3 1.3 ± 2 . 5 6.1 ± 0 . 9 5.5 ± 1.0
18:2 n-6 0.8 ± 0.1 1.3 ± 0 . 2 0.7 ± 0 . 1 0.9 ± 0.2 0.8 ± 0.2
18:2 n-3 0.2 ± tr. 0.4 ± 0.1 0.2 ± 0.2 0.4 ±0 . 1 0.3 ± 0 . 1
18:3 n-6 2.1 ± 0.4 0 .9  ± 0 . 2 1.4 ± 0 . 7 1.2 ± 0.1 1.1 ± 0 . 2
18:3 n-3 0.2 ± tr. 0.4 ± 0.2 0.3 ±0.1 0.3 ± tr. 0.3 ± tr.
20:0 0.6 ±0 . 1 0.6 ± 0.1 1.5 ± 0 . 3 1.1 ±0 .1 0.8 ± 0.4
20:1 n-9 0.5 ± tr. 1.1 ± 0.2 1.6 ± 0.1 0.9 ±  tr. 0.8 ±  tr.
20:3 n-9 3.5 ±0 . 1 4.3 ± 0 . 5 3.8 ± 0 . 6 2.6 ± 0.3 2.3 ± 0 . 5
20:4 n-6 6.2 ± tr. 4.5 ± 1.0 6.7 ± 0.8 4.5 ± 0.5 4.8 ± 0.5
20:4 n-3 0.2 ± tr. 0.5 ± 0.2 0.8 ± 0.2 0.4 ±  tr. 0.5 ±  tr.
20:5 n-3 0.5 ±0.1 2.1 ± 0 .4 7.6 ± 1.2 10.1 ± 0.6 12.9 ± 0.4
22:0 1.1 ±0 . 1 1.4 ± 0.2 1.2 ± 0 . 4 1.0 ±  tr. 1 . 0 ± 0 . 1
22:1 0.4 ± tr. 0.7 ± 0 . 7 1.5 ± 1.2 0.7 ± 0 . 1 0.7 ± 0 . 1
22:2 1.4 ± 0 . 7 1.4 ± 0 . 3 1.9 ± 0 . 3 1.8 ± 0 . 3 1.7 ± 0 . 1
22:5 n-3 0.2 ± tr. 0 .6  ± 0 . 3 1.5 ± 0 . 6 0.3 ± tr. 0.4 ± 0 . 1
22:6 n-3 1.1 ±0.1 4.1 ± 1.5 3.9 ± 1.1 2.7 ± 0.3 3.2 ± 0.3
24:0 1.4 ± 0 . 1 1.4 ± 1.7 2.3 ± 1.4 1.8 ± 0 . 2 2.0 ± 0 . 1
24:1 1.0 ± 0.1 1.6 ± 1.3 3.3 ± 2 . 2 1.9 ± 0 . 3 2.1 ± 0 . 3
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Table S 3  Percentage acyl composition o f total polar lipids extracted from bovine
articular cartilage following supplementation with 10 -  100 pg/ml
DHA. Results as means ± SD (n=3).
Fatty
Acids
Control 10 pg/ml 25 pg/ml 50 pg/ml 100 pg/ml
14:0 0.7 ± 0 . 3 1.4 ± 0 . 3 0.4 ± 0.2 0.7 ± 0.3 0 .9  ±  0.2
16:0 15.6 ± 3.7 13.9 ± 3.9 14.8 ± 1.7 12.2 ± 4 . 4 13.2 ± 2 . 2
16:1 n-7 1.1 ± 0 . 3 1.7 ± 0 . 3 1.4 ± 0 . 1 0.9 ± 0.2 0 .9  ± 0.2
16:1 2.0 ± 0.6 2.4 ± 0.4 2.3 ± 0 . 4 2.1 ± 0 . 8 1.9 ± 1.3
17:0 1.8 ± 0 . 2 1.7 ± 0 . 6 2.0 ± 0 . 7 1.5 ± 0 . 8 1.7 ± 0 . 6
17:1 2.5 ± 0.2 2.7 ± 0 . 4 3.1 ± 1.0 2.3 ± 0.4 2.3 ± 0.6
18:0 16.6 ± 1.3 13.6 ± 4 . 5 15.4 ± 3.5 14.6 ± 4 . 9 12.8 ±8 . 1
18:1 n-9 33.5 ± 2 . 2 30.4 ± 6 . 1 30.6 ± 3 . 3 29.9 ± 3 . 0 23 .6  ± 5.9
18:1 n-7 3.5 ±0 . 1 5.2 ±  1.5 0.7 ± 1.5 5.4 ±  1.0 5.2 ± 2 . 3
18:2 n-6 1.1 ± 0.4 0.9 ± 0.5 0.3 ± 0.2 0.8 ±0 . 1 0 .6  ± 1.1
18:2 n-3 0.2 ± 0.2 1.6 ± 0.7 1.6 ± 0 . 7 2.7 ± 0 . 6 1.9 ± 0 . 8
18:3 n-6 1.9 ± 0 . 4 1.0 ± 0.2 0.4 ± 0 . 1 0.3 ±0 .1 0 .6  ± 0.3
18:3 n-3 0.2 ±0.1 0.5 ±0.1 0.6 ±0.1 0.5 ± 0.2 0.3 ± 0.2
20:0 0.6 ±0 .1 0.9 ± 0 . 7 1.1 ± 0 . 2 1.1 ± 0 . 9 1.0 ± 0 . 7
20:1 n-9 0.7 ± 0.2 0.5 ± 0 . 1 0.6 ± 0 . 1 0.6 ±0 .1 0.5 ± 0.2
20:3 n-9 3.2 ± 1.2 3.4 ± 0 . 8 3.8 ± 2 . 2 . 3.3 ±2 . 1 2.8 ± 1.1
20:4 n-6 5.6 ± 0.8 5.0 ± 1.3 5.1 ± 1.7 7.0 ±0.1 4.4 ± 1.3
20:4 n-3 0.2 ± tr. 0 .6 ± 0 . 7 0.2 ± 0 . 1 0.1 ± tr. 0 .2  ± 0.2
20:5 n-3 0.7 ±0.1 1.0 ±0 .3 1.0 ±0.1 1.1 ±0.5 0.7 ± 0.3
22:0 1.2 ± 0 . 2 0.8 ± 0.4 0.9 ±  0.3 0.9 ± 0.3 1.1 ± 0 . 4
22:1 0.4 ±0 . 1 0.1 ± 0 . 2 0.1 ± 0 . 1 0.2 ±0 .1 0 .2  ± 0 . 1
22:2 1.5 ± 0 . 4 0.1 ± 0 . 4 1.6 ± 0 . 2 2.3 ± 0 . 3 1.7 ± 0 . 7
22:5 n-3 1.3 ± 1.1 1.5 ± tr. 2.5 ± 0 . 2 3.1 ±  1.2 1.4 ± 0 . 4
22:6 n-3 1.3 ±0.2 2.4 ±0.1 4.5 ± 1.1 2.6 ±2.1 10.8 ±3.4
24:0 1.2 ± 0 . 3 3.6 ± 1.4 1.7 ± 0.1 1.5 ± 0 . 8 2 .0 ±  1.2
24:1 1.3 ± 0 . 4 1.5 ± 0.6 1.8 ± 0 . 8 1.9 ± 0 . 9 2.5 ± 0 . 3
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5.15 Glycosaminoglvcan Release from PUFA-Supplemented and
Interleu kin-1« Stimulated Explants
The DMMB assay (section 5.12) for sulphated glycosaminoglycans (GAGs) has been 
accepted as a quick and effective method for measuring the release of sulphated 
GAGs from articular cartilage (Famdale et al., 1986). M edia collected from bovine 
explant cultures supplemented with increasing doses o f  EPA (Fig. 5.3, 5.4), DHA 
(Fig. 5.5) and trout oil (Fig. 5.6) prior to stimulation with IL -la  were analysed. The 
effect of the 18 carbon a-linolenic acid was not investigated for two specific reasons, 
(a) it is not a major component o f trout oil and (b) previous research from our 
laboratory demonstrated that it has little, if  any, effect on GAG release (Zainal, 2005).
5.15.1 Effect o f EPA Supplementation on Glycosaminoglvcan Release
The addition of IL -la (10 ng/ml) resulted in a significant increase (approximately 6  
fold) in the levels of GAG released from articular cartilage compared to the controls 
minus IL -la  (Figs. 5.3, 5.4). In contrast, the addition o f  DMSO (1.5%) did not result 
in any significant change in GAG release compared samples without DMSO. In 
addition, as expected, no alterations were observed following supplementation with 
EPA in controls (minus IL-la).
Supplementation of EPA 10-100 pg/ml (Fig 5.3 A-C) for 12 h resulted in some 
reductions o f GAG release stimulated by the presence o f  IL -la . Compared to DMSO 
+ IL-la, explants supplemented with 1 0 -1 0 0  pg/ml EPA gave significant effects. In 
Fig. 5.3A the results for GAG release showed reductions at 100 and 50 pg/ml (p < 
0.001) and also at 25 pg/ml (p < 0.05) compared to DMSO + IL-la. Significant 
reductions in GAG release in Fig. 5.3B were observed with only 100 pg/ml (p < 
0.05). Significant reductions in GAG release was observed at all doses in Fig. 5.3C 
(25 -  100 pg/ml p < 0.001 and 10 pg/ml p < 0.05). To investigate whether a further 
reduction in GAG release could be elicited, increased doses of EPA were employed 
(Fig. 5.4A-C).
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Supplementation of bovine explant cultures with 200-300 pg/ml EPA (Fig. 5.4) for 12 
h demonstrated more pronounced effects compared to cultures supplemented with 1 0 - 
100 pg/ml (Fig. 5.3). Significant reduction of GAG compared to DMSO + IL -la was 
observed with 25 pg/ml (p < 0.05) and 50-300 pg/ml (p < 0.001) in Fig. 5.4A. The 
experiment shown in Fig. 5.4B showed progressive reduction in GAG release at 50 
pg/ml and above. In the experiment shown in Fig. 5.4C GAG reduction was only 
significant at 200 pg/ml and 300 pg/ml (p < 0.001) but not at the lower doses.
Though differences exist between individual experiments there appeared to be a dose- 
dependent trend in the reduction o f IL -la  stimulated GAG release from bovine 
articular cartilage following supplementation with 10-100 pg/ml EPA (Fig. 5.3). 
Moreover, the protection offered by 200-300 pg/ml EPA further reduced the levels of 
GAG release to those seen in control cultures (Fig. 5.4A-C). These effects compare 
well with previous work from our laboratory which also reported a decrease of GAG 
release from both bovine explant and monolayer cultures following supplementation 
with EPA (Hurst 2004, Zainal, 2005). However, it should be noted that both Hurst 
(2004) and Zainal (2005) reported significant reductions in GAG release at lower 
concentrations (1 0 -2 5  pg/ml) o f EPA.
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Fie- 53: GAG analysis of medium from three independent experiments using
bovine explant cultures, supplemented with or without 10-100 pg/ml EPA for 12 h, ± 
10 ng/ml interleukin-la (IL-la) for 72 h. (Means ± SD; n=12). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
Fig- 5.4: GAG analysis of medium from three independent experiments using
bovine explant cultures, supplemented with or without 10-300 pg/ml EPA for 12 h, ± 
10 ng/ml interleukin-la (IL-la) for 72 h. (Means ± SD; A n=12; B, C n=6). The 
significance of changes was tested using ANOVA post hoc Tukey test compared to 
DMSO + IL-la.
5.15.2 Effect of DHA Supplementation on Glycosaminoglvcan Release
Since EPA and DHA are the two most important long chain PUFAs in fish oil and are 
both thought to possess ‘anti‘-inflammatory properties (Serhan and Chiang, 2007; 
Tziomalos et al.. 2007), the effect o f DHA supplementation on bovine explant 
cultures was also examined (Fig. 5.5).
Again, following stimulation with IL -la, GAG release increased significantly 
(approximately 5-fold) compared to controls (Fig. 5.5). Control levels of GAG 
release were comparable to the levels seen with EPA supplementation (Figs. 5.3 and
5.4) and. as previously seen for EPA (Figs. 5.3 and 5.4), no obvious effect on GAG 
release was noted with DHA supplementation or the addition of DMSO (1.5%) (Fig.
5.5). DHA supplementation was carried out for 12 h.
A statistically significant decrease in GAG release following IL-la stimulation was 
found for 10-300 pg/ml DHA (p < 0.001) compared to DMSO alone in the first 
experiment (Fig. 5.5A). For the second experiment, DHA was effective at 50-300 
pg/ml (Fig. 5.5B) whereas in the third experiment statistically significant reductions 
in GAG release were found with 200 and 300 pg/ml DHA (Fig. 5.5C). In all 
experiments, the levels of GAG release were reduced by 200-300 pg/ml DHA to 
control (no IL-la) levels.
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Fig* 5.5: GAG analysis of medium from three independent experiments using
bovine explant cultures, supplemented with or without 10-300 pg/ml DHA for 24 h, ± 
10 ng/ml interleukin-la (IL-la) for 72 h. (Means ± SD; n=6). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
5.15.3 Effect o f Trout Oil Supplementation on Glycosaminoglvcan Release
Having established the effect o f purified n-3 PUFAs on GAG release in the explants 
following stimulation with IL -la. we needed to investigate how trout oil preparations 
would perform. The trout oil used contained a range of fatty acids (Table 5.4) 
including both EPA (7.5 pg/ml) and DHA (31.5 pg/ml), together with several n-6 
PUFAs which would be expected to be more pro-inflammatory than the n-3 PUFAs 
(Calder. 2005). Linoleic acid was the main n-6 PUFA.
The results for the three experiments using trout oil supplementation are shown in Fig. 
5.6. In all cases, a statistically significant reduction in GAG release was noted for the 
IL-la treated explants pre-treated with trout oil. For the second and third 
experiments, variability in the DMSO alone controls meant that only higher 
concentrations of trout oil gave statistically significant results. Nevertheless, the data 
for the three experiments were consistent in that (a) trout oil did not affect the no IL- 
la treated controls and (b) lowering of the GAG release induced by IL-1 a was 
achieved at low levels of trout oil and was not much increased (if at all) by the higher 
doses of this preparation. Clearly, the overall reduction of GAG release seen at high 
concentrations was less for trout oil than for EPA or DHA supplementation (Figs. 5.3,
5.4 and Fig. 5.5 respectively).
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Table 5.4 Percentage acyl composition of the trout oil preparation used to
supplement bovine explant cultures. Results as means ± SD (n=3), tr.
<0.05.
Fatty Acids % acyl  composit ion
12:0 0.1 ± tr.
14:0 1.7 ± tr.
16:0 11.3 ± 0.1
16:1 n-7 3.3 ± 0.3
16:1 0.2 ± tr.
17:0 0.1 ± tr
17:1 0.1 ±tr.
18:0 3.1 ±0 . 1
18:1 n-9 22.0 ± 1.5
18:1 n-7 2.7 ±0 . 1
18:2 n-6 15.0 ±0 .1
18:2 n-3 0.4 ±0 .1
18:3 n-6 1.6 ± 0 . 2
18:3 n-3 0.7 ± 0 . 5
20:0 0.2 ± tr.
20:1 n-9 8.8 ± 0 .1
20:2 0.2 ± tr.
20:3 n-9 1.1 ± tr.
20:4 n-6 0.5 ±tr.
20:4 n-3 1.1 ± tr.
20:5 n-3 2.5 ± 0 . 1
22:1 10.2 ± 0 . 2
22:2 0.3 ± tr.
22:3 0.2 ± tr.
23:0 0.1 ± tr.
22:5 n-3 1.1 ± tr.
22:6 n-3 10.5 ± 0 . 2
24:0 0.2 ± tr.
24:1 0.8 ± tr.
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Fig- GAG analysis of medium from three independent experiments using
bovine explant cultures, supplemented with or without 10-300 pg/ml trout oil for 24 h, 
± 10 ng/ml interleukin-1 a (IL-la) for 72 h. (Means ± SD; n=6). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
5.16 Effect of Fatty Acid Supplementation on the Metabolic State of
Explant Cultures
Respiration in chondrocytes located in articular cartilage is predominantly anaerobic 
and rates of lactate production (and secretion) are commonly used as a measure of cell 
or explant metabolic state (Beecher et al., 2007; Ilic et al., 2003; Munteanu et al., 
2000). Lactate levels in explant cultures supplemented with various doses of EPA, 
DHA or trout oil were measured by the lactate oxidase/peroxidase method (Section 
5.12 methods).
Lactate production in explant cultures supplemented with EPA, DHA or trout oil are 
shown in Figs. 5.7 -  5.10. No significant effects were observed between test 
conditions (+ IL-la) and control (minus IL -la) for any of EPA, DHA or the trout oil 
preparation. DMSO, EPA. DHA and trout oil did not elicit any significant effects on 
lactate production either (Figs. 5.7 -  5.10). The only exception to this was seen in 
Fig. 5 .1C where 25 jig EPA + IL -la  was significantly different to the test conditions 
control + IL -la and DMSO + IL -la  (p < 0.05). For the same experiment 10 and 25 
gg EPA - IL -la were significantly different to control and DMSO -  IL-la. As seen 
i for the GAG analysis (Figs. 5.3 -  5.6) variability between experiments was also 
observed in terms of lactate production (Figs. 5.7 -  5.10). Nevertheless, there were no 
consistent effects of any treatment, showing that metabolism (as judged by lactate 
release) was generally not affected.
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Fig-5-7: Lactate analysis of medium from three independent experiment using
bovine explant cultures, supplemented with or without 10-100 pg/ml EPA for 24 h, 
±10 ng/ml interleukin-la (IL-la) for 72 h. (Means ± SD; n=6). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
Fig- 5.8: Lactate analysis of medium from three independent experiments using
bovine explant cultures, supplemented with or without 10-300 pg/ml EPA for 24 h, ± 
10 ng/ml interleukin-la (IL-la) for 72 h. (Means ± SD; n=6). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
Fig- S.9: Lactate analysis o f medium from three independent experiment using
bovine explant cultures, supplemented with or without 10-300 pg/ml DHA for 24 h, ± 
10 ng/ml interleukin-la (IL -la) for 72 h. (Means ± SD; n=6). The significance of 
changes was tested using ANOVA post hoc Tukey test compared to DMSO + IL-la.
Fig» 5J0** Lactate analysis of medium from bovine explant cultures, 
supplemented with or without 10-300 pg/ml trout oil for 24 hs, ±10 ng/ml interleukin- 
la (IL-la) for 72 hs. (Means ± SD; n=6). The significance of changes was tested 
using ANOVA post hoc Tukey test compared to DMSO + IL-la.
A 7 5 -,
+ IL-1a * IL-la
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5.17 Effect of Fatty Acid Supplem entation on mRNA Levels of
Inflam m atory and D egradative Proteins Involved in Osteoarthritis
As previously mentioned, (section 5.9), oligonucleotide primers were designed for a 
number of genes involved in both inflammation and degradation of articular cartilage. 
One of the most well documented effects of n-3 PUFAs on inflammatory processes is 
the down-regulation of COX-2. COX-2 is the inducible form of the COX isoforms 
and we observed up-regulation o f COX-2 mRNA levels following incubation with IL- 
la (Figs. 5.11 -  5.13) compared to controls. Explants supplemented with 10 -  300 pg 
EPA demonstrated a reduction in mRNA levels at 50 -  300 pg/ml whereas with DHA 
reductions were only observed with 200 -  300 pg/ml (compare Figs. 5.11 with 5.12). 
Following supplementation with 10 -  300 pg trout oil fatty acids no reduction in 
mRNA levels for COX-2 were observed. This may be due to the presence of other 
fatty acids in the trout oil mixture. Also, the levels of EPA and DHA (7.5 pg/ml and
31.5 pg/ml respectively) may have been present in too low a concentration to elicit an 
effect on COX-2 mRNA levels.
With regards to the constitutively-expressed COX-1 no statistically significant 
changes in mRNA levels were observed with either IL -la  or EPA, DHA or trout oil 
derived fatty acid supplementation (Figs. 5.11 -  1.13). It is believed that n-3 PUFAs 
elicit their effect on the inducible isoform, COX-2, at the level of transcription rather 
than at the protein level.
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Fig 5.11: mRNA levels for cyclooxygenase 1 (COX-1) and cyclooxygenase 2
(COX-2) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine 
articular cartilage. RNA was isolated from explants supplemented with 10-300 pg/ml 
EPA for 12 h. Quantification by densitometry was carried out and gene expression 
levels were corrected for GAPDH loading (Means ± SEM; n=3). The gels shown are 
from a representative experiment.
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mRNA levels for cyclooxygenase 1 (COX-1) and cyclooxygenase 2 
(COX-2) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine 
articular cartilage. RNA was isolated from explants supplemented with 10-300 pg/ml 
DHA for 12 h. Quantification by densitometry was carried out and gene expression 
levels were corrected for GAPDH loading (Means ± SEM; n=4 COX-2, n=3 COX-1). 
The gels shown are from a representative experiment.
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Fig. 5.13: mRNA levels for cyclooxygenase-1 (COX-1) and cyclooxygenase-2
(COX-2) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine 
articular cartilage. RNA was isolated from explants supplemented with 10-300 pg/ml 
trout oil fatty acids (containing 7.5 pg/ml EPA and 31.5 pg DHA) for 12 h. 
Quantification by densitometry was carried out and gene expression levels were 
corrected for GAPDH loading (Means ± SEM; n=4). The gels shown are from a 
representative experiment.
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As previously detailed (sections 1.6, 5.0), both aggrecanases and MMPs are involved 
in the destruction o f articular cartilage. We investigated the effects that 
supplementation of EPA, DHA and trout oil fatty acids may have on expression of the 
two main aggrecanases, ADAMTS-4 and ADAMTS-5, and two specific MMPs, 
MMP-3 and MMP-13 (Figs. 5.14 -  5.16) which are thought to be important in 
cartilage degradation. Basal levels of both the aggrecanases and MMPs were 
observed in control tissue. Following incubation with IL-la mRNA levels for these 
genes were increased.
Supplementation with 200 -  300 pg EPA and DHA appeared to reduce the levels of 
mRNA for ADAMTS-4 though this was not significant (Figs. 5.14, 5.15). The effects 
of EPA appeared to be more pronounced (though not significant) with ADAMTS-5 
where downregulation was observed with 50 -  300 pg EPA (Fig. 5.14). An effect of 
DHA supplementation on ADAMTS-5 was only observed at the higher doses, 200 -  
300 pg DHA (Fig. 5.15) but again this was not significant. No effect on mRNA levels 
for either ADAMTS-4 or ADAMTS-5 were found following supplementation with 10 
-  300 pg trout oil fatty acids (Fig. 5.16).
With regards to the MMPs, MMP-3 mRNA levels were more readily reduced 
following supplementation with EPA and DHA compared to MMP-13 (Figs. 5.14, 
5.15). The level of MMP-3 mRNA appeared reduced with 10 -  300 pg EPA and 50 -  
300 pg DHA (Figs. 5.14, 5.15) although this was not significant. The mRNA levels 
for the principal collagenolytic MMP, MMP-13, appeared to be reduced with 100 -  
300 pg EPA (though not significantly) whereas no effect on MMP-13 was detected 
following DHA supplementation (Figs. 5.14 -  5.15). As previously seen with the 
aggrecanases, no effects on mRNA levels for MMP-3 or MMP-13 were detected 
following trout oil fatty acid supplementation (Fig. 5.16).
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Fig. 5.14: mRNA levels for aggrecanase-1 (ADAMTS-4) and aggrecanases-2
(ADAMTS-5), matrix metalloproteinase 3 and 13 (MMP-3 and MMP-13) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine articular cartilage. 
RNA was isolated from explants supplemented with 10-300 pg/ml EPA for 12 h. 
Quantification by densitometry was carried out and gene expression levels were 
corrected for GAPDH loading (Means ± SEM; n=3). The gels shown are from a 
representative experiment.
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Fig. 5.15: mRNA levels for aggrecanase-1 (ADAMTS-4) and aggrecanases-2
(ADAMTS-5), matrix metalloproteinase 3 and 13 (MMP-3 and MMP-13) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine articular cartilage. 
RNA was isolated from explants supplemented with 10-300 pg/ml DHA for 12 h. 
Quantification by densitometry was carried out and gene expression levels were 
corrected for GAPDH loading (Means ± SEM; n=3). The gels shown are from a 
representative experiment.
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Fig. 5.16: mRNA levels for aggrecanase-1 (ADAMTS-4) and aggrecanases-2
(ADAMTS-5), matrix metalloproteinase 3 and 13 (MMP-3 and MMP-13) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine articular cartilage. 
RNA was isolated from explants supplemented with 10-300 pg/ml trout oil fatty acids 
(containing 7.5 pg/ml EPA and 31.5 pg DHA) for 12 h. Quantification by 
densitometry was carried out and gene expression levels were corrected for GAPDH 
loading (Means ± SEM; n=4). The gels shown are from a representative experiment.
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IL- 6  is an inducible cytokine and its role in arthritis has been under investigation for 
some time. However, the results o f previous studies detailing the effects on n-3 
PUFAs on IL- 6  are divided (for review see Sijben and Calder, 2007). We observed 
an upregulation of mRNA levels for IL- 6  following IL-la treatment compared to 
controls (Figs. 5 .1 7 -5 .1 9 ).
Supplementation of EPA resulted in a dose-dependent decrease in IL- 6  mRNA levels 
with 10 -  300 pg/ml. Even though the effects were more pronounced at the higher 
doses this was not significant (Fig. 5.17). DHA treatment of explants also appeared to 
reduce mRNA levels although only at the higher doses, 200 -  300 pg/ml (Fig. 5.18). 
With regards to the supplementation o f trout oil fatty acids, no significant effects were 
observed (Fig. 5.19).
The effect of trout oil supplementation was also investigated with regard to TNF-a 
and cytochrome C oxidase subunits I and II. TNF-a is implicated in the pathogenesis 
of arthritis (Farahat et al.. 1993) and the literature reports a potential role of n-3 
PUFAs on the reduction o f TNF-a mRNA levels (Moghaddami et al., 2007). 
However, as with IL-6 , there is some debate on the relationship of n-3 PUFAs and 
TNF-a. Incubation with IL -la  resulted in an increase in TNF-a mRNA expression 
but no consistent effect was observed with trout oil fatty acid supplementation at any 
dose (Fig. 5.19). It may be o f interest to further investigate the role of n-3 PUFAs on 
TNF-a following supplementation with pure EPA or DHA.
The role of mitochondria in degenerative disease is widely recognized (Maneiro et al.,
2003) and the cytochrome c oxidase complex has been implicated in pathogenesis of 
RA (Henderson et a l 1978). It is thought that the level of the mitochondrial 
respiratory chain, of which cytochrome c oxidase is a component, decreases in OA 
although this is still a controversial area (Maneiro et al., 2003). We investigated 
whether supplementation o f trout oil had any effect on the mRNA levels for subunit I 
and II of the cytochrome c oxidase complex. We observed no effect on either subunit 
I or II at any dose o f trout oil (Fig. 5.20). Moreover, addition of IL-la did not appear 
to change levels of these mRNAs.
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Fig. 5.17. mRNA levels for interleukin- 6  (IL-6 ) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in bovine articular cartilage. RNA was isolated from 
explants supplemented with 10-300 pg/ml EPA for 12 h. Quantification by 
densitometry was carried out and gene expression levels were corrected for GAPDH 
loading (Means ± SEM; n=3). The gels shown are from a representative experiment.
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Fig. 5.18: mRNA levels for interleukin- 6  (IL-6 ) and glyceraldehyde-3 -phosphate
dehydrogenase (GAPDH) in bovine articular cartilage. RNA was isolated from 
explants supplemented with 10-300 pg/ml DHA for 12 h. Quantification by 
densitometry was carried out and gene expression levels were corrected for GAPDH 
loading (Means ± SEM; n=3). The gels shown are from a representative experiment.
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Fig. 5.19: mRNA levels for interleukin- 6  (IL-6 ) and tumour necrosis factor-a
(TNF-a) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine 
articular cartilage. RNA was isolated from explants supplemented with 10-300 pg/ml 
trout oil fatty acids (containing 7.5 pg/ml EPA and 31.5 pg/ml DHA) for 12 h. 
Quantification by densitometry was carried out and gene expression levels were 
corrected for GAPDH loading (means ± SEM; n=4). The gels shown are from a 
representative experiment.
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Hg. 5.20: mRNA levels for cytochrome c oxidase subunit I and subunit II and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in bovine articular cartilage. 
RNA was isolated from explants supplemented with 10-300 pg/ml trout oil fatty acids 
containing (7.5 pg/ml EPA and 31.5 pg/ml DHA) for 12 h. Quantification by 
densitometry was carried out and gene expression levels were corrected for GAPDH 
loading (means ± SEM; n=4). The gels shown are from a representative experiment.
Cyto. C Oxidase I 204 bp
Cyto. C Oxidase II 290 bp
GAPDH 299 bp
From the results o f our analysis o f mRNA levels of both inflammatory and 
dcgradative proteinases it is apparent that supplementation with EPA or DHA can 
have potential benefits. However, supplementation with fish oil, containing a mixture 
of fatty acids, had no apparent effect o f on mRNA levels of the genes studied despite a 
significant reduction in the levels of GAG released. It is possible that n-3 PUFAs 
supplied by the fish oil may be inducing a protective effect through genes not 
examined here or by a different mechanism other than gene transcription. Also, the 
dose of n-3 PUFAs may be too low to elicit an effect of gene expression.
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5.18 Discussion
The association between the age and deposition o f lipids in articular cartilage has been 
accepted for quite some time (Bonner et al., 1975) and the accumulation of both intra- 
and extracellular lipid is considered a normal occurrence due to the presence of such 
lipids in disease-free tissue (Collins et al., 1965). However, some studies suggest that 
excessive lipid accumulation may be linked to certain pathological conditions such as 
degenerative or traumatic arthritis (Lippiello, 1990). Other research has examined the 
beneficial role of dietary lipids in articular cartilage, for example, in C-57 mice a diet 
rich in saturated fatty acids was reported to induce age-dependent osteoarthrosis in the 
animals which was subsequently alleviated by the inclusion of 3% linoleic acid in the 
diet (Silberberg et al., 1965; Silberberg and Silberberg, 1950). However, despite an 
association between lipids, fatty acids and cartilage, a possible relationship between 
initiation and progression of disease has yet to be fully investigated (Lippiello, 1990). 
Epidemiological studies also confer support for the role of n-3 PUFAs in arthritic 
diseases. The Japanese population have a high prevalence of the alleles which confer 
susceptibility for RA (Iikuni et al., 2006) but the occurrence of the disease is lower 
than Western populations (Rayman and Callaghan, 2006). The high intake of fish oils 
has been suggested to offer protection against RA (Calder and Zurier, 2001). Also, 
the Inuit population is renowned for its high fat diet and low rate of CVD. It is 
believed that, despite the high fat diet consumed, its enrichment with n-3 PUFAs 
offers protection again CVD (Bang and Dyerberg, 1980; James et a l, 2003). 
Intervention studies where n-3 PUFA supplementation was administered to patients 
with RA reported significant improvement in some or all of the following parameters, 
morning stiffness, tender and/or swollen joints, pain, grip strength and clinical 
assessment of disease activity (Kremer, 2000; Kremer et al., 1995; MacLean et al.,
2004). Therefore, due to an abundance of evidence documenting the effect of n-3 
PUFAs on inflammation (Sijben and Calder, 2007) and arthritis, we investigated the 
possible protective effects of n-3 PUFA supplementation on a bovine in vitro model of 
OA.
In order to establish the effect o f n-3 PUFAs on the degradative mechanisms involved 
in OA (GAG release and mRNA gene expression levels, sections 5.15 -  5.17) we first 
investigated the acyl composition o f total polar lipids from articular cartilage explants
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(section 5.13). Due to the metabolism of AA, EPA and DHA by the COX and LOX 
pathways and the generation o f eicosanoids, resolvins and their specific role in 
inflammation we were specifically interested in determining the levels of these fatty 
acids in the total polar lipid fractions (Table 5.1). In control cultures, we determined 
AA at approximately 5%, whilst EPA and DHA were determined at approximately
0.8% and 1.5% respectively. A previous study also investigated the acyl composition 
of total polar lipids in articular cartilage from a number of species (Adkisson et al., 
1991). Adkisson et al. (1991) determined AA, EPA and DHA composed 
approximately 5.1%, 0.4% and 1.7% o f the acyl composition of total polar lipids in 
articular cartilage from foetal calf. Our results support these findings. The levels of 
these fatty acids detected in articular cartilage from newborn pig were less than those 
observed in foetal calf although a similar trend was reported (i.e., AA was present at 
significantly higher levels than EPA and DHA). An interesting point was observed by 
Adkisson et al. (1991) with regard to the abundance of an unusual n-9 fatty acid, 20:3. 
20:3 n-9 is often seen in animals that have been subjected to EFA deficiency but is 
normally present in minor amounts, if  at all, in most tissues (Holman, 1960). 
Adkisson et al. (1991) reported 5.12% 20:3 n-9 in foetal calf and 6.35% in newborn 
pig cartilage. Our analysis reported approximately 3% 20:3 n-9 in the total polar 
lipids of bovine articular cartilage (Table 5.1). Other tissue levels of AA are 
considerably greater than those recorded in articular cartilage (approximately 8 % in 
muscle, 13% in liver, 14% in kidney and 8 % in serum) and several theories to explain 
the low levels of AA and elevated levels o f 20:3 n-9 have been proposed (Adkisson et 
al., 1991).
Previous studies, both in vivo and in vitro, have demonstrated that it is possible to 
enrich cells in n-3 PUFAs (Kew et al., 2004; Kishida et al., 2006; Martin-Chouly et 
al., 2000; Yaqoob et al., 2000). From the analysis of the total polar lipids from 
control cartilage we determined the principal n-3 PUFAs, a-linolenic acid, EPA and 
DHA to be minor components (Table 5.1). Due to the avascular nature of cartilage 
there was a concern that perhaps the uptake and incorporation of supplemented PUFA 
may be compromised. However, following supplementation with various 
concentrations of these PUFAs the polar lipid levels of all three fatty acids increased 
in a dose-dependent fashion (Fig. 5.1). Previous research has demonstrated the uptake 
and incorporation of PUFAs into cellular lipids. Incubation of L929 murine
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fibrosarcoma cells supplemented with 0 - 5 0  pM DHA showed a dose-dependent 
increase in DHA from 2.2% (percentage o f total fatty acids) in control cultures to 
21.6% DHA with 50 pM (Kishida et al., 2006). Kishida et al. (2006) also reported a 
significant increase in EPA (as a percentage of total fatty acids) following 24 h 
supplementation with 25 and 50 pM DHA. As no a-linolenic acid was present this 
increase in EPA may have been due to retro-conversion of DHA. As expected, there 
was a concomitant reduction in the percentage o f 16:1 n-7, 18:1 n-9, 22:5 n-3 and AA 
following DHA supplementation. As previously mentioned, although the effect of a- 
linolenic acid was not investigated on GAG and mRNA expression levels (section 
5.15, 5.17), we did investigate the uptake and incorporation of a-linolenic acid into 
total polar lipids (section 5.14.). a-Linolenic acid can be elongated and desaturated to 
yield the longer chain n-3 PUFAs, EPA and DHA, although the efficiency of this 
pathway is thought to be extremely low with only approximately 5% of a-linolenic 
acid being converted to EPA and < 0.5% a-linolenic acid converted to DHA in most 
tissues (Plourde and Cunnane, 2007). Despite this low conversion rate we were 
interested to see if increasing the levels o f a-linolenic acid might lead to a significant 
increase in EPA or DHA. However, no increase in the longer chain PUFAs was found 
(Table 5.1).
Both EPA and DHA supplementation increased significantly their percentages in the 
total polar lipid fraction. However, some variation was observed with 50 pg of DHA 
(Table 5.3) and it would be advisable to repeat the experiment because of this 
variation. It is believed that incorporation o f n-3 EPA and DHA would diminish the 
levels of AA present (Babcock et al., 2000) but we found no reduction in AA 
following supplementation with a-linolenic acid, EPA or DHA (Tables 5.1 -  5.3). 
Despite AA being the preferred substrate for COX metabolism (Smith, 2005), EPA 
competes with A A for the active site of the COX enzyme (Calder, 2001) and the 
resulting prostanoids are known to be less inflammatory compared to the n- 6  derived 
prostanoids (Calder, 2002). Due to the significant increase of both EPA and DHA in 
the total polar fraction of articular cartilage chondrocytes we hoped that a reduction in 
degradative and inflammatory mediators would be observed following incubation with 
IL-la (sections 5.15, 5.17).
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Culturing cartilage explants is a well-established method for investigating the 
inflammatory processes involved in arthritis and had been used extensively to test 
anti-arthritic treatments (Caterson et a l, 2000). Destruction of GAG chains that form 
the ECM is considered to be a useful marker of disease progression (Famdale et al., 
1986). An osteoarthritic state can be mimicked in vitro by subjecting explants to a 
catabolic agent such as IL -la  (IL -lp  is used for human cartilage), TNF-a, retinoic acid 
or oncostatin-M (Caterson et al., 2000; Kozaci et al., 2005). Following 
supplementation with IL -la  for 72 h we observed a significant increase in aggrecan 
catabolism and a subsequent and significant release in GAG compared to the controls 
(Figs. 5.3 -  5.6). However, explants supplemented with 10 -  300 pg EPA/DHA or 
trout oil demonstrated significant reductions in GAG release compared to controls + 
IL-la (Figs. 5.3 -  5.6). Our findings are supported by previous studies on both bovine 
explant and monolayer cultures where supplementation with EPA and, to a lesser 
extent, DHA also demonstrated a significant reduction in GAG release following 
treatment with IL -la  (Hurst, 2004; Zainal, 2005). However, in contrast to Hurst
(2004) and Zainal (2005), greater concentrations of PUFAs or trout oil were required 
to elicit a similar effect on GAG reduction. Hurst (2004) observed significant 
reduction in GAG release with approximately 10 pg EPA but little, if any, reduction 
was observed at this dose in our experiments (Figs. 5.3 -  5.6). However, the methods 
used by Hurst (2004) and Zainal (2005) were different from those used in our 
experiments. Hurst and Zainal used fatty acid-free bovine serum albumin and Tyrode 
HEPES buffer to solubilise the PUFA whereas in our experiments each PUFA or trout 
oil-derived fatty acids were dissolved in DMSO and delipidised FBS. As bovine 
serum albumin is a large protein o f approximately 60,000 kDa and due to the 
avascular nature of cartilage we were concerned that delivery of the fatty acid (which 
occurs by diffusion through the ECM) may be hindered due to the large size of the 
protein-fatty acid complex. With regard to the DMSO method, previous research has 
reported that DMSO may possess some anti-microbial, analgesic and anti­
inflammatory effects (Smith et al., 2000). Prior to implementing the DMSO method, 
preliminary experiments were conducted to determine any possible effects DMSO 
alone may have on the explants. We observed no effects of DMSO alone (Figs. 5.3 -  
5.6). Also, the level o f DMSO (1.5%) that the explants were exposed to was low and 
well within the range normally used for mammalian tissues.
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With regard to the effects o f PUFA or trout oil supplementation on the IL -la 
stimulated release o f GAG from explants, significant variations were recorded (Figs. 
5.3 -  5.6). A dose-dependent decrease in GAG reduction was recorded although 
biological variation was also observed. A specific example was supplementation with 
the trout oil preparation (Figs. 5.6 A-C). These three experiments were carried out 
simultaneously under the same culture conditions. The trout oil fatty acid preparation 
(Table 5.4) was the same in all three independent experiments. Despite similar culture 
conditions and the same fatty acid preparations the results varied significantly between 
animals. Fig. 5.6A demonstrated significant reduction of GAG release at each 
concentration of trout oil (10 -  300 pg/ml) whereas significant reductions in GAG 
release were only observed at 100 -  300 pg/ml in Fig. 5.6B and in Fig. 5.6C at 50 and 
300 pg/ml. We hypothesised that such differences were due to biological variation 
and may suggest that some animals/persons may respond better to n-3 
supplementation than others. Given that the levels of EPA and DHA (7.5 and 31.5 
pg/ml respectively) were much less in the trout oil fatty acid preparation and taking 
into account the levels o f n- 6  PUFAs (together with other classes of fatty acids) such 
significant reductions in GAG release were surprising (Fig. 5.6).
As previously mentioned, (section 5.16), the metabolic state of the explants was 
determined by measuring the amount o f lactate produced. This assay has been widely 
used to determine the metabolic state o f explants (Ilic et al., 2003; Kozaci et al., 2005; 
Smith et al., 2000). Using the lactate assay we determined no adverse effects of either 
IL-la, PUFA or trout oil supplementation on explant metabolic state. However, it 
should be noted that a threshold level o f lactate production below which explants are 
deemed non-viable is not reported in the literature and hence, this method is only a 
crude measure for measuring explant metabolic state, despite its widespread use.
At the time these experiments began no specific assay for determining explant 
viability was available. Some researchers have investigated certain methods for 
determining explant viability such as dye-exclusion assays and the MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method. Due to the nature o f 
the explants, (thickness of tissues, network of the ECM, low cell content) 
complications for both these assays deemed them inappropriate. However, a recent 
breakthrough (Caterson and Hughes Laboratory, Cardiff University) has permitted a
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variant of the MTT assay to be used on explants in culture. The method is currently 
being optimised but such a technique to determine explant viability, rather than 
metabolic state, would be a much more effective tool for this research. Measuring cell 
metabolic state is a rather rudimentary method and effects on cell senescence may lead 
to a mis-interpretation of results. Therefore, it would be advisable to repeat the 
experiments mentioned in section 5.15 and determine cell viability using the MTT 
assay.
The role of n-3 PUFAs in the autoimmune disease, RA, had been reviewed 
extensively in the literature and most conclude that sufferers of RA can benefit from 
fish oil supplementation (James and Cleland, 1997; Volker and Garg, 1996). 
However, little evidence is available on the potential role of n-3 PUFAs in OA despite 
the role of inflammation in the pathogenesis of the disease. The role of cytokines, 
particularly IL-la/p, IL-6 . IL-10, TNF-a, in the inflammatory process is well 
documented (Wood, 2006) and inflammation is known to be a key mediator of 
aggrecan destruction and, hence, cartilage degradation. MMPs and aggrecanases have 
been identified as the key catabolic enzymes involved in cartilage destruction 
(Caterson et al., 2000). As previously mentioned (section 1.3, 1.3.1) the MMP and 
aggrecanase families are composed o f multiple enzymes and during our research we 
focused on MMP-3, MMP-13, ADAMTS-4 and ADAMTS-5 as these are thought to 
be the main, (or some o f the main) enzymes involved in OA (Flannery, 2006).
Supplementation with EPA and DHA was observed to reduce the levels of mRNA for 
MMP-3, ADAMTS-4 and ADAMTS-5 in a dose-dependent fashion (section 5.17). 
However, these reductions can only be interpretated as a trend as significance was not 
reached and we would recommend the use of quantitative PCR for future 
investigations. Despite MMP-13 being the principle collagenolytic MMP responsible 
for cleavage of collagen type II in cartilage no effect on MMP-13 was observed 
following supplementation with n-3 PUFAs (Fig. 5.14, 5.15). The trends observed in 
our data support those o f Zainal (2005) and Hurst (2004) who also observed a 
decrease in mRNA for these enzymes with increasing doses of EPA, and to a lesser 
extent DHA. However, with regard to trout oil fatty acid supplementation which had 
not been investigated previous to this study, we observed no reduction in the 
expression of mRNA for the aforementioned proteinases (Figs. 5.16) despite the
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decrease in the release of GAGs. This indicated that other MMPs and/or aggrecanases 
may also be involved in the breakdown of cartilage in bovine explant cultures. It is 
known that MMP-28 and ADAMTS-16 are both upregulated in OA together with 
MMP-2, -9, -16. ADAMTS-2. -14,-12 (Davidson et al., 2006). Additional research to 
elucidate whether such enzymes are affected by n-3 PUFA supplementation would be 
useful.
With regard to mRNA levels o f the inflammatory genes, COX-2, IL- 6  and TNF-a, 
some interesting results were observed. COX-2 is often referred to as the inducible 
isoform of the COXs and the expression of COX-2 is often induced by the action of 
certain cytokines such as IL -la  as observed here. EPA and DHA both reduced the 
levels of mRNA for COX-2 (Figs. 5.11, 5.12). Previous studies have also 
demonstrated a reduction in COX-2 following incubation with long chain n-3 PUFAs. 
When HT-29 colon cancer cells were incubated with n-3 PUFAs the protein levels of 
COX-2 were reduced (Calviello et a l, 2007). Singh et al. (1997) reported that the 
feeding of high levels o f fish oil exerted anti-neoplastic effects on an animal model of 
carcinogenesis by down-regulating COX-2 expression whereas a diet rich in n- 6  
PUFAs promoted colon tumourgenesis. Another study investigating the effect o f fish 
oil on an in vitro model of colorectal cancer also observed a down-regulation of COX- 
2 (Llor et al., 2003). Also, a decrease in COX-2 mRNA expression following 
supplementation with EPA and DHA on bovine monolayer chondrocytes was recorded 
by Hurst (2004) and Zainal (2005) although the concentrations which elicited these 
effects were lower than reported here (Figs. 5.5, 5.14) (see previous paragraph).
COX-1 expression is increased during development and is thought to be constitutively 
expressed in most tissues (Spencer et al., 1999). Such constitutive expression is 
thought to be due, at least in part, to the relative stability of both COX-1 mRNA and 
its protein levels (Smith, 2008). From our experiments we observed constitutive 
expression of COX-1 although the addition of IL -la appeared to moderately 
upregulate its mRNA expression compared to controls (Figs. 5.11 -  5.13). Previous 
research has demonstrated no effect o f n-3 PUFAs on COX-1 mRNA levels. When 
Sprague-Dawley rats were fed diets rich in either n- 6  PUFAs (safflower oil) or n-3 
PUFAs (menhaden oil) for three weeks no effects on COX-1 mRNA were observed 
whereas the mRNA for COX-2 was induced in rats fed the high n- 6  diet but not the n-
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3 rich diet (Badawi et al., 1998). Moreover, Zainal (2005) also found no effect of n-3 
PUFA supplementation on COX-1 mRNA levels in bovine monolayer cultures.
IL- 6  is a multi-factorial cytokine involved in the regulation of inflammatory and 
immunoregulatory responses and is inducible by numerous inflammatory agents such 
as IL-1, TNF-a and interferon gamma (IFN-y) (Gueme et al, 1990). IL- 6  is 
implicated in both OA and RA and has been detected in the synovial fluid of such 
patients. Previous research has determined that chondrocytes possess the ability to 
synthesise IL- 6  in response to both physiological and inflammatory stimuli (Bender et 
a l 1990). We observed upregulation of IL- 6  mRNA following incubation with IL-la 
(Figs. 5.17 -  5.19). Pre-treatment with n-3 EPA and DHA reduced the levels of 
mRNA (though significance was not reached) although no effects were observed 
following treatment with trout oil (Figs. 5 .1 7 -5 .1 9 ). A reduction in IL- 6  has been 
previously reported with dietary n-3 PUFAs. In a community-based study it was 
found that circulating n-3 PUFAs independently associated with lower levels of IL- 6  
and increased levels of its soluble receptor (IL-6 r) (Ferrucci et al., 2006). An 
abundance of literature describes the relationship n-3 PUFAs and IL-6 , however, 
although some studies report a decrease in IL- 6  production, overall the results are 
quite disparate and further investigation is needed (for review see Sijben and Calder, 
2007).
When explants were supplemented with trout oil-derived fatty acids the effect of 
supplementation on TNF-a was also investigated (Fig. 5.19). TNF-a is an inducible 
mediator of inflammation, produced by numerous cells including neutrophils, 
macrophages and lymphocytes and has been identified as a key component of both OA 
and RA (Farahat et al., 1993). Following incubation with IL-la we observed an 
increase in mRNA levels of TNF-a but no significant reduction was found with trout 
oil-derived fatty acid supplementation (Fig. 5.19). We hypothesised that this may be 
due to the presence of other classes o f fatty acids (saturated, n- 6  PUFAs etc) or may 
indeed indicate that the n-3 PUFAs do not decrease mRNA levels for TNF-a. Similar 
to previous research on IL-6 , the literature is split over the relationship between n-3 
PUFAs and TNF-a. Some authors report an increase in TNF-a production (in vitro) 
following feeding of n-3 PUFA-rich diets (Hardardottir and Kinsella, 1991, 1992). 
Also, when peritoneal macrophages were incubated with n-3 PUFAs in vitro an
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increase in the secretion of TNF-a was reported. However, when n-3 PUFAs were 
incubated with RAW 264.7 macrophages a reduction in TNF-a was observed 
(Skuladottir et al., 2007). Such discrepancies in the literature indicate that further 
research is necessary to elucidate the effect o f n-3 PUFAs on TNF-a.
There is no question o f the beneficial role o f n-3 PUFA in inflammation, although a 
clear understanding o f the precise mechanisms by which their ‘anti’-inflammatory 
effects are produced is still being investigated. From our research we conclude that 
significant uptake of n-3 PUFAs is achievable in explant cultures and that such uptake 
and incorporation can have beneficial effects on the pathogenesis of OA. Pure EPA 
and DHA supplementation compared to trout oil fatty acids have greater benefits both 
on GAG destruction and mRNA levels. Due to this, it may be more advantageous to 
purify EPA and DHA from trout oil rather than using mixtures of the full range of 
fatty acids extracted from trout tissues.
231
CHAPTER 6
General Discussion
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Chapter 6: General Discussion
The possible relationship between fish oil derived-n-3 PUFAs, EPA and DHA, and 
human health and disease was first mentioned as far back as the 18th century when it 
was reported in the London Medical Journal that administering 1-3 tablespoons of cod 
liver oil 2-4 times daily had beneficial effects in cases of “obstinate chronic 
rheumatisms, sciaticas of long standing, and in those cases of premature decrepitude” 
(Percival, 1783). Since then, there has been a significant progress made in 
understanding the biology o f n-3 PUFAs and their protective effects in both health and 
disease.
Fish are the major source for the long chain PUFAs, EPA and DHA. However, as 
previously mentioned, the supply o f n-3 PUFAs from marine fishing industries is in 
rapid decline for several reasons (e.g. mis-management of stocks, inaccurate 
predictions for stock replenishment) which has led to a significant decline in certain 
species of fish (Schrank, 2005). Cod stocks are one such example, although many 
other fish species are currently in danger o f eradication (Pauly et al., 2002). In 
contrast to the decline of marine fish species, over the past two decades there has been 
a significant increase in the production of farmed fish. Currently, the aquaculture 
industry is playing, and is forecast to continue to play, a significant role in global fish 
production. A meeting o f the Food and Agriculture Organisation Committee on 
Fisheries (FAO COFI) underscored the importance of the aquaculture industry in 
complementing the traditional fishing industry, by reducing the pressure on marine 
fish species and providing a sustainable source of fish, and, subsequently, providing 
n-3 PUFAs, for human consumption (www.fao.org/focus/e/fisheries/sustaq .htm; 
Naylor et al., 2000).
Fish farming in the UK is governed by strict regulations with regard to treatment and 
disposal of waste products (www.defra.gov.uk/fish/fishfarm/waste.htmL The 
objective of this work was to determine if waste products from one of the most 
commonly reared fish species, Oncorhynchus my kiss, could be a potential source of 
n-3 PUFAs for the nutraceutical industry.
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In chapter three we set out to investigate the lipid and acyl composition of the waste 
products from Oncorhynchus mykiss reared on a controlled-fed, fresh-water fish farm. 
Current regulations for disposal o f fish waste are particularly stringent and incur 
significant costs to the industry (www.defra.gov.uk/fish/fishfarm/waste.htm). 
Therefore turning the waste products into a sustainable source of n-3 PUFAs would 
not only have beneficial effects in reducing costs to the aquaculture industry, it would 
also lead to a reliable and plentiful source of n-3 PUFAs for nutraceutical 
development. However, in order for the offal to be considered for this role, it is 
essential that it contains adequate levels of n-3 PUFAs. As discussed previously, 
(section 3.6), the farm-reared Oncorhynchus mykiss used in these experiments were 
fed controlled diets containing all the necessary nutrients for growth and development. 
Initially, we examined the levels of fatty acids contained in the diet. This was 
important to determine, as it is now accepted that tissue levels of lipids and fatty acids 
are reflective of those consumed in the diet (Bell et al., 1997; Jeong et al., 2002; 
Miller et al., 2007). According to our analysis EPA and DHA comprise 5% and 8 % of 
the fatty acyl groups in the lipids in the preformed pellets (Table 3.1). However, we 
found that the actual tissues levels o f both these n-3 PUFAs varied quite significantly 
depending on tissue and lipid species. The main non-polar lipid, TAG, contained a 
generally similar ratio o f EPA and DHA in all tissues, 2% and 5% respectively 
(although EPA in the liver was 7% and DHA in the heart and adipose tissue was 
slightly lower that the other tissues). We reported that, as expected for membrane 
constituents, the polar lipids contained significantly greater levels of the n-3 PUFAs 
compared to the non-polar lipids, particularly with respect to DHA. From our analysis 
we determined that collectively, the waste products from farm-reared Oncorhynchus 
mykiss contain sufficiently high levels of n-3 PUFAs, particularly DHA, for them to 
be used potentially in nutraceutical development.
However, despite Oncorhynchus mykiss waste containing high levels of the n-3 
PUFAs, EPA and DHA, the storage and processing of this waste material needed to be 
investigated to determine if these processes had adverse effects on the levels o f these 
PUFAs. During processing of the farmed fish, the waste by-products are stored on site 
for quite some time. Due to the fact that this waste is currently disposed of and not 
processed further, it is often stored under adverse conditions (e.g. exposure to sunlight, 
unregulated temperatures and lengthy storage time). These conditions are not ideal for
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the storage of tissues containing high levels of lipids, especially highly unsaturated 
molecules. In chapter three, we outlined the lipid and acyl composition of waste 
tissues from Oncorhynchus mykiss but it should be noted that this investigation was 
earned out on fresh tissues. In chapter four we investigated the effect of storage time 
and processing method on two different starting materials (total waste and adipose 
tissue) in order to determine if  (a) storage conditions resulted in excessive tissue 
degradation and subsequent loss of n-3 PUFAs and (b) the effect different processing 
procedures on lipid and fatty acid yields.
In terms of the two different starting materials used, the total trout offal fraction 
yielded significantly more polar lipids compared to the adipose tissue fraction which 
was enriched in TAG. This was not unexpected, as from our initial studies (chapter 
three), adipose tissue contained low levels of total polar lipids. If total waste from 
farm-reared Oncorhynchus mykiss was to be used as a source of n-3 PUFAs we would 
recommend that all waste products should be combined to increase the yield of EPA 
and DHA.
In terms of storage o f the waste, (chapter four), it seemed that increased storage time 
resulted in tissue degradation probably due to the loss of membrane integrity and the 
action of phospholipases and other catabolising enzymes. In certain regards this effect 
was advantageous. For example, both the lipid and acyl yields from the petroleum 
ether and rendering methods increased with time, resulting in more successful 
extraction from the tissues. However, a disadvantage of increased storage time was 
the increased generation o f NEFAs. As EPA and DHA are the essential PUFAs found 
in fish tissues their concentration needed to be maintained in order for the tissues to 
have a use for nutraceutical development. These PUFAs are highly unsaturated and 
increased storage times, which resulted in increased NEFAs and also reduced the 
proportions of EPA and DHA in tissues due to the latters’ susceptibility for oxidation. 
Therefore, if farm-reared fish offal was to be employed as source of n-3 PUFAs, its 
storage conditions need to be reconsidered: for example, on-site storage of offal 
should be stored under cool (refrigerated) conditions and out of direct sunlight.
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With regard to processing o f fish waste, the Garbus method was determined to be the 
most effective method at each time point (section 4.5, 4.6). As discussed previously, 
(section 4.8), petroleum ether is a non-polar solvent and, therefore, predominantly 
extracts TAGs whilst the extraction o f non-polar lipids was quite inefficient. The 
rendering method is commonly used for large scale industrial extraction of fish lipids 
(Gunstone et a l, 2007). Although we observed that the rendering method was not as 
efficient as either the Garbus or the petroleum ether method, reasonable levels of EPA 
and DHA were extracted. A major advantage that the rendering method offers over 
the Garbus and petroleum ether methods is the reduction of toxicity issues (through 
the use of solvents) which makes the rendering method ideal for the production of 
products for human and animal consumption. With regard to the effect of storage time 
and rendering we found that increased storage time increased the efficiency of lipid 
extraction. However, in accordance with increased storage time the production of 
NEFAs also increased, although the level o f NEFAs did not reach the levels seen with 
either the Garbus or petroleum ether method. We hypothesised that this was primarily 
due to the greater levels o f total lipid extracted with the Garbus and petroleum ether 
methods rather than a ‘protective’ effect of the rendering method against NEFA 
generation (Figs. 4.2A, 4.2C, 4.9, 4.11).
With regard to the acyl composition o f individual lipids from the trout waste, there 
were apparent differences between the results reported in chapter three and chapter 
four (Tables 3.4 -  3.13, 4.2 -  4.26 and 4.18 -  4.33). The acyl composition for 
individual lipids outlined in chapter four are for multiple tissues pooled together, 
whilst in chapter three the lipid and acyl composition are given for specific lipids from 
individual organs. However, another important factor which may contribute to 
differences in the fatty acid profiles is season. As previously discussed, (section 3.16), 
season has a large bearing on both the lipid and fatty acid composition o f fish 
(Ackman and Takeucki, 1986; Agren et al., 1987; Senso et a l, 2007). The fish used 
in chapter three were caught in late November whilst those used in chapter four were 
caught in April. One example o f the effect o f season is the level of unsaturated fatty 
acids found in membrane lipids. In the colder months, membrane polar lipids are 
often more highly saturated than in the warmer months in order to maintain ‘fluidity’ 
of the membranes to compensate for the decrease in water temperature (Johnston and 
Roots, 1964) (Tables 3.4 -  3.13, 4.3 -  4.26, and 4.16 -  4.33).
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The results from both chapter three and four permitted us to conclude that farm-reared 
Oncorhynchus mykiss waste is a rich source of n-3 PUFAs. However, we advise that 
if minor adjustments were made with regard to storage of the waste tissues, (e.g. 
refrigeration), the levels of n-3 PUFAs could be maintained for a possible 48 h. We 
can advise this as, from our analysis, offal stored at room temperature and exposed to 
direct sunlight was stable for at least 24 h (after 48 h elevated levels of NEFAs were 
detected. With regard to the processing o f such waste tissues, the rendering method, 
albeit not as efficient as laboratory-scale lipid extraction procedures, could be 
employed as an effective method of lipid extraction. Bearing in mind that our model 
rendering system was a small scale, laboratory-based system which was not an exact 
model of the industrial process, we still achieved adequate yields of total lipids, total 
TAG, individual lipid separations and adequate recovery of EPA and DHA. Given 
that an industrial scale rendering system could be more reproducible (e.g. a steamed, 
twin screw presses are commonly employed to ensure complete disruption, 
homogenisation and rendering o f tissues (Gunstone et a l , 2007)), we hypothesise that 
in a large scale system, the yield of EPA and DHA would be even greater than what 
we reported here.
Following on from the previous chapters, we wanted to determine if processed trout 
oil from Oncorhynchus mykiss waste could elicit beneficial effects on a model tissue 
culture system for OA. The bovine tissue culture system employed as a model for OA 
is widely used as a well-established method and stimulation of the tissue with an 
inflammatory cytokine (e.g. IL -la) is regarded as a good model to mimic the 
inflammatory state seen in osteoarthritic tissues (Caterson et al, 2000; Hughes et al., 
1998). As mentioned earlier in this chapter, fish oil has long been implicated with 
alleviating the symptoms of arthritic disease. Arthritis is a major problem in 
developed countries and places an enormous burden on national health care systems as 
well as the devastating effects on quality of life for sufferers of the disease (Lawrence 
et a l 2007; Helmick et al., 2007; Reginster, 2002). Pharmacological treatments for 
OA focuses on alleviating the pain and discomfort associated with the disease but no 
treatment that addresses the pathology currently exits. The pharmacological 
treatments for OA often result in unwanted side effects (e.g. classical NSAIDS may 
result in gastric discomfort or, in more extreme cases, ulceration of the gastric lining 
(section 1.5.1)) (DeWitt, 1999). Dietary intervention has been reported to have
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beneficial effects in reducing the inflammation found in patients with rheumatoid 
arthritis (Rayman and Callaghan, 2006) and, more recently, evidence is emerging that 
sufferers of OA may also benefit from dietary intervention (Hurst, 2004; Zainal,
2005).
In chapter five we investigated the effect of EPA, DHA and trout oil-derived fatty acid 
supplementation on a tissue culture model of OA. In terms of EPA, DHA (and a- 
linolenic acid) supplementation (section 5.14) we found that the levels of these n-3 
PUFA were dose-dependently increased in membrane lipids from bovine articular 
cartilage during incubation. Uptake and incorporation of these PUFAs, did not 
however, result in a specific decrease in the levels of AA but did alter the percentages 
of oleic acid, 18:1 n-9. This result indicated that, during the time of the experiment, n- 
3 PUFA supplementation did not significantly affect the metabolism of AA. We then 
investigated whether the increase in n-3 PUFAs was enough to induce a protective 
effect on IL-la-stimulated GAG degradation. As previously detailed, (section 1.3) 
aggrecanase cleavage of GAG side chains is induced by IL-la (Hughes et al, 1998). 
The release of these GAGs was measured by a colorimetric assay which determined 
that incubation with IL -la  significantly up-regulated GAG release compared to 
controls. Pre-incubation with varying doses of EPA and DHA (section 5.15), 
particularly at the higher doses, was seen to significantly reduce IL-la stimulated 
GAG release, therefore, offering protection against cartilage degradation which agreed 
with previous work from Hurst (2004) and Zainal (2005). However, it should be 
noted that we used a DMSO method to add PUFAs, in contrast to the technique used 
by Hurst (2004) and Zainal (2005).
Having determined that supplementation of both EPA and DHA offered articular 
cartilage protection against aggrecan destruction we decided to examine the effects 
that n-3 PUFAs may exert on mRNA levels for specific proteinases or ‘inflammatory’ 
proteins thought to be involved in the degradation of cartilage and the associated 
inflammation seen in the pathogenesis of OA. The higher doses of EPA and DHA 
used in the supplementation resulted in a decrease in COX-2 mRNA, a key enzyme 
involved in inflammation (section 1.5.1). As discussed earlier, (section 5.18), other 
investigators have also reported a down regulation of COX-2 mRNA following 
treatment with EPA and/or DHA (Calviello et al., 2007; Llor et al., 1994; Singh et al.,
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1997). A reduction in COX-2 mRNA expression and the generation of n-3 PUFA- 
derived eicosanoids would have the advantage of shifting the inflammatory response 
from one that was pro-inflammatory (n- 6  PUFA-derived eicosanoids) to less 
inflammatory (section 1.5.1.1).
In addition to investigating the effects of n-3 PUFA supplementation on inflammatory 
markers such as COX-2, we also looked at mRNA levels for proteinases involved in 
the loss of ECM integrity. As detailed in section 1.3 and 1.3.1, aggrecanases and 
MMPs are extensively involved in cartilage degradation (Caterson et a l , 2000). Pre­
incubation of articular cartilage prior to IL -la  stimulation, led to a decrease in mRNA 
expression for two o f the principle aggrecanases, ADAMTS-4 and -5, as well as 
MMP-3. However, mRNA for the principle collagenolytic enzyme, MMP-13 was not 
affected by supplementation with either EPA and/or DHA. We hypothesised that a 
reduction in the mRNA levels o f ADAMTS-4 and -5 could be responsible, at least in 
part, for the protection seen with regard to GAG release (section 5.15 and 5.17).
Once we had determined that pre-incubation o f EPA and DHA in an in vitro model of 
OA resulted in protective effects with regard to protein release and gene expression, 
we employed the same in vitro tissue culture model to test the trout-derived fatty 
acids. As outlined in Table 5.4, the trout oil preparation contained approximately 
2.5% EPA and 10.5% DHA as well as a range of other fatty acids. Interestingly, we 
also observed a significant decrease in GAG release with various doses of the trout oil 
preparation (Figs. 5.6A-C). Biological variation was quite apparent as all cultures 
shown in the aforementioned figures were treated with the same culture materials and 
the same trout oil fatty acid preparation. The only difference between experiments 
was the tissue source (individual animals were used per experiment). This in turn 
suggested that perhaps, more control over the tissue used (e.g. specific cow breed, 
dietary history) might give more consistent and, perhaps, higher responses to fatty acid 
supplementation than others. This hypothesis has been previously reported in the 
literature. Hagfors et al. (2005) reported responders and non-responders in a 
population of Swedish rheumatoid arthritic patients with regards to dietary 
intervention and clinical improvements. Also, there are reports that some persons 
respond better to pharmacological treatment than others (e.g. chemotherapy and breast 
cancer patients). Hence, it is plausible that tissues from some individuals may also
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respond differently to supplementation also. Indeed, one can see this result in the data 
shown in Figs. 5.6A-C.
With regard to supplementation with trout-derived fatty acids and mRNA expression, 
we did not find any significant changes in relation to mRNA levels for inflammatory 
genes (e.g. COX-2) or the matrix proteinases (e.g. ADAMTS-5) (see Figs. 5.13, 5.16, 
5.19 and 5.20) despite a clearly significant reduction in GAG release (Fig. 5.6 A-C). 
However, mRNA was the only parameter we measured with respect to gene 
expression. Enzyme activity levels were not measured and, moreover, the balance of 
fatty acids would be affected by the presence of a range of n- 6  and saturated fatty 
acids also being present in the trout oil preparation. In comparison with the high 
levels of EPA and DHA, 300 pg/ml of the trout oil preparation only contained 7.5 
EPA and 31.5 fig/ml DHA which, together with the other fatty acids present, may not 
have been sufficient to elicit a reduction of the mRNA levels. Furthermore, Zainal
(2005) noted that EPA was the most effective n-3 PUFA in tissue culture systems to 
test for OA and this component was rather low in the trout oil mixture. Moreover, as 
outlined in section 1.5.4.1, n-3 PUFA are known to elicit protective effects by 
mechanisms other than gene expression (Jump, 2002). Therefore, it may be possible 
that the trout oil-derived mixture may be exerting protective effects, such as on GAG 
release, via a different mechanism rather than solely regulating gene expression. 
Needless to say, these possibilities need to be investigated further as the mechanisms 
involved are still far from understood. The nature of OA also brings into question the 
role of other members o f the aggrecanase and MMP families. Currently research is 
ongoing to determine which members of these families may be involved in the 
pathogenesis and progression o f OA or may offer protection from this debilitating 
disease (Davidson et al., 2006).
From our investigation, we can recommend farmed Oncorhynchus mykiss waste to be 
a rich source of n-3 PUFAs and hypothesise that other varieties of farmed fish (e.g. 
salmon, which are particularly rich in n-3 PUFAs) may be used as an alternative 
source of n-3 PUFAs. Given the financial costs for the treatment and disposal of 
farmed fish waste, combined with the environmental issues associated with waste 
disposal, we recommend that the use of farmed fish by-products should be 
readdressed. Given the estimated value of salmon waste alone (£5 million annually in
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the UK) and the abundance o f n-3 PUFAs in Oncorhynchus mykiss we predict that 
utilising waste products for the generation of n-3 PUFAs would be a profitable 
exercise which would reduce disposal costs for the aquaculture industry and the 
associated environmental risks, whilst generating profit from a current waste product. 
From our research, we can recommend that minor modifications for the on-site storage 
of waste which would maintain the levels of n-3 PUFAs should be investigated. Not 
only would the aquaculture industry profit from this exercise but the nutraceutical 
industry would also reap benefit. As outlined earlier, the aquaculture industry is 
rapidly expanding and this would guarantee a plentiful supply of waste products with 
high n-3 PUFA content. Not only this, but the current method for lipid extraction, 
rendering, is an appropriate method to guarantee adequate yield of lipid as well as n-3 
PUFAs, EPA and DHA.
Due to the abundance o f research on the beneficial effects of n-3 PUFAs, not solely in 
terms of arthritis (evidence now suggests the importance of n-3 PUFAs in foetal 
development, neurological and psychiatric disorders, cancer, CVD and other 
inflammatory conditions) (Calder, 2004; de Vriese et al., 2003; Koletzko et al, 2001 
Tokudome et al., 2006), the demand for n-3 PUFA nutraceuticals will continue to rise 
and, therefore, transforming a current waste product into a reliable source of n-3 
PUFAs would have multi-factorial advantages.
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